



(86) **Date de dépôt PCT/PCT Filing Date:** 2014/10/10
(87) **Date publication PCT/PCT Publication Date:** 2015/04/16
(85) **Entrée phase nationale/National Entry:** 2016/04/04
(86) **N° demande PCT/PCT Application No.:** US 2014/060036
(87) **N° publication PCT/PCT Publication No.:** 2015/054572
(30) **Priorités/Priorities:** 2013/10/10 (US61/889,460);
2014/08/07 (US62/034,619); 2014/09/18 (US62/052,366);
2014/10/09 (TW103135318); 2014/10/09 (JO289/2014)


(51) **Cl.Int./Int.Cl. C07D 239/94** (2006.01),
A61K 31/517 (2006.01), **A61P 35/00** (2006.01),
C07D 215/46 (2006.01), **C07D 215/54** (2006.01),
C07D 231/56 (2006.01), **C07D 237/28** (2006.01),
C07D 401/04 (2006.01), **C07D 401/12** (2006.01),
C07D 403/04 (2006.01), **C07D 403/10** (2006.01),
C07D 403/12 (2006.01), ...

(71) **Demandeur/Applicant:**
ARAXES PHARMA LLC, US

(72) **Inventeurs/Inventors:**
LI, LIANSHENG, US;
FENG, JUN, US;
WU, TAO, US;

(54) **Titre : INHIBITEURS DE K-RAS G12C**

(54) **Title: INHIBITORS OF KRAS G12C**



Oncogene	Tumor Type	Cumulative Mutation Frequency (All Tumors)
Bcr-Abl	90% CML	<1%
EGFR	10% NSCLC	<5%
ALK	5% NSCLC	<1%
B-Raf	66% Melanoma	<5%
Flt3	25% AML	<1%
PI3k α	25% Breast; 25% Endometrial; 15% CRC	15-20%
K-Ras	>80% Pancreatic; >40% colon >20% lung	~20%

FIG. 3

(57) **Abrégé/Abstract:**

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R^1 , R^{2a} , R^{3a} , R^{3b} , R^{4a} , R^{4b} , G^1 , G^2 ,

(51) **Cl.Int./Int.Cl. (suite/continued)** **C07D 409/04** (2006.01), **C07D 409/14** (2006.01), **C07D 417/10** (2006.01)

(72) **Inventeurs(suite)/Inventors(continued)**: REN, PINGDA, US; LIU, YI, US; LIU, YUAN, US; LONG, YUN OLIVER, US

(74) **Agent**: NORTON ROSE FULBRIGHT CANADA LLP/S.E.N.C.R.L., S.R.L.

(57) **Abrégé(suite)/Abstract(continued)**:

L¹, L², m¹, m², A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 April 2015 (16.04.2015)



(10) International Publication Number
WO 2015/054572 A1

- (51) International Patent Classification:

C07D 239/94 (2006.01)

C07D 403/10 (2006.01)

C07D 403/12 (2006.01)

C07D 237/28 (2006.01)

C07D 215/46 (2006.01)

C07D 409/04 (2006.01)

C07D 215/54 (2006.01)

C07D 409/14 (2006.01)

C07D 231/56 (2006.01)

C07D 417/10 (2006.01)

C07D 401/04 (2006.01)

A61K 31/517 (2006.01)

C07D 401/12 (2006.01)

A61P 35/00 (2006.01)

C07D 403/04 (2006.01)
- (21) International Application Number:

PCT/US2014/060036
- (22) International Filing Date:

10 October 2014 (10.10.2014)
- (25) Filing Language:

English
- (26) Publication Language:

English
- (30) Priority Data:


61/889,46010 October 2013 (10.10.2013)US

62/034,6197 August 2014 (07.08.2014)US

62/052,36618 September 2014 (18.09.2014)US
- (71) Applicant: ARAXES PHARMA LLC [US/US]; 11119 North Torrey Pines Road, Suite 125, La Jolla, California 92037 (US).
- (72) Inventors; and
- (71) Applicants : LI, Liansheng [CN/US]; 13569 Arroyo Dale Lane, San Diego, California 92130 (US). FENG, Jun [US/US]; 6160 Quail Run Street, San Diego, California 92130 (US). WU, Tao [CN/US]; 2355 Terraza Guitara, Carlsbad, California 92009 (US). REN, Pingda [CN/US]; 5534 Havenridge Way, San Diego, California 92130 (US). LIU, Yi [US/US]; 4841 Barlows Landing Cove, San Diego, California 92130 (US). LIU, Yuan [CN/US]; 3871 Camino Lindo, San Diego, California 92122 (US). LONG, Yun, Oliver [US/US]; 10763 Santa Tomasa Avenue, San Diego, California 92127 (US).
- (74) Agents: HARWOOD, Eric, A. et al.; Seed Intellectual Property Law Group PLLC, Suite 5400, 701 Fifth Avenue, Seattle, WA 98104-7064 (US).

[Continued on next page]

(54) Title: INHIBITORS OF KRAS G12C



(57) Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R¹, R^{2a}, R^{3a}, R^{3b}, R^{4a}, R^{4b}, G¹, G², L¹, L², m¹, m², A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Oncogene	Tumor Type	Cumulative Mutation Frequency (All Tumors)
Bcr-Abl	90% CML	<1%
EGFR	10% NSCLC	<5%
ALK	5% NSCLC	<1%
B-Raf	66% Melanoma	<5%
Flt3	25% AML	<1%
PI3kα	25% Breast; 25% Endometrial; 15% CRC	15-20%
K-Ras	>80% Pancreatic; >40% colon >20% lung	~20%

FIG. 3

WO 2015/054572 A1



(81) Designated States *(unless otherwise indicated, for every kind of national protection available):* AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available):* ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

INHIBITORS OF KRAS G12C

BACKGROUND

Technical Field

The present invention is generally directed to novel compounds and
5 methods for their preparation and use as therapeutic or prophylactic agents, for example
for treatment of cancer.

Description of the Related Art

RAS represents a group of closely related monomeric globular proteins
of 189 amino acids (21 kDa molecular mass) which are associated with the plasma
10 membrane and which bind either GDP or GTP. RAS acts as a molecular switch. When
RAS contains bound GDP, it is in the resting or off position and is "inactive". In
response to exposure of the cell to certain growth promoting stimuli, RAS is induced to
exchange its bound GDP for a GTP. With GTP bound, RAS is "switched on" and is
able to interact with and activate other proteins (its "downstream targets"). The RAS
15 protein itself has a very low intrinsic ability to hydrolyze GTP back to GDP, thus
turning itself into the off state. Switching RAS off requires extrinsic proteins termed
GTPase-activating proteins (GAPs) that interact with RAS and greatly accelerate the
conversion of GTP to GDP. Any mutation in RAS which affects its ability to interact
with GAP or to convert GTP back to GDP will result in a prolonged activation of the
20 protein and consequently a prolonged signal to the cell telling it to continue to grow and
divide. Because these signals result in cell growth and division, overactive RAS
signaling may ultimately lead to cancer.

Structurally, RAS proteins contain a G domain which is responsible for
the enzymatic activity of RAS - the guanine nucleotide binding and the hydrolysis
25 (GTPase reaction). It also contains a C-terminal extension, known as the CAAX box,
which may be post-translationally modified and is responsible for targeting the protein
to the membrane. The G domain is approximately 21-25 kDa in size and it contains a
phosphate binding loop (P-loop). The P-loop represents the pocket where the
nucleotides are bound in the protein, and this is the rigid part of the domain with

conserved amino acid residues which are essential for nucleotide binding and hydrolysis (Glycine 12, Threonine 26 and Lysine 16). The G domain also contains the so called Switch I (residues 30-40) and Switch II (residues 60-76) regions, both of which are the dynamic parts of the protein which are often represented as the “spring-loaded” mechanism because of their ability to switch between the resting and loaded state. The key interaction is the hydrogen bonds formed by Threonine-35 and glycine-60 with the γ -phosphate of GTP which maintain Switch 1 and Switch 2 regions respectively in their active conformation. After hydrolysis of GTP and release of phosphate, these two relax into the inactive GDP conformation.

10 The most notable members of the RAS subfamily are HRAS, KRAS and NRAS, mainly for being implicated in many types of cancer. However, there are many other members including DIRAS1; DIRAS2; DIRAS3; ERAS; GEM; MRAS; NKIRAS1; NKIRAS2; NRAS; RALA; RALB; RAP1A; RAP1B; RAP2A; RAP2B; RAP2C; RASD1; RASD2; RASL10A; RASL10B; RASL11A; RASL11B; RASL12; 15 REM1; REM2; RERG; RERGL; RRAD; RRAS and RRAS2.

Mutations in any one of the three main isoforms of RAS (HRAS, NRAS, or KRAS) genes are among the most common events in human tumorigenesis. About 30% of all human tumors are found to carry some mutation in RAS genes. Remarkably, KRAS mutations are detected in 25-30% of tumors. By comparison, the rates of oncogenic mutation occurring in the NRAS and HRAS family members are much lower (8% and 3% respectively). The most common KRAS mutations are found at residue G12 and G13 in the P-loop and at residue Q61.

G12C is a frequent mutation of KRAS gene (glycine-12 to cysteine). This mutation had been found in about 13% of cancer occurrences, about 43% of lung cancer occurrences, and in almost 100% of MYH-associated polyposis (familial colon cancer syndrome). However targeting this gene with small molecules is a challenge.


Accordingly, while progress has been made in this field, there remains a need in the art for improved compounds and methods for treatment of cancer, for example by inhibition of KRAS, HRAS or NRAS. The present invention fulfills this need and provides further related advantages.

BRIEF SUMMARY

In brief, the present invention provides compounds, including stereoisomers, pharmaceutically acceptable salts, tautomers and prodrugs thereof, which are capable of modulating G12C mutant KRAS, HRAS and/or NRAS proteins.

- 5 In some instances, the compounds act as electrophiles which are capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS, HRAS or NRAS G12C mutant protein. Methods for use of such compounds for treatment of various diseases or conditions, such as cancer, are also provided.

10 In one embodiment, compounds having the following structure (I) are provided:



(I)

or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein R¹, R^{2a}, R^{3a}, R^{3b}, R^{4a}, R^{4b}, G¹, G², L¹, L², m¹, m², A, B, W, X, Y, Z and E are as
15 defined herein. Pharmaceutical compositions comprising one or more of the foregoing compounds of Structure (I) and a pharmaceutically acceptable carrier are also provided in various other embodiments.

In other embodiments, the present invention provides a method for treatment of cancer, the method comprising administering an effective amount of a
20 pharmaceutical composition comprising any one or more of the compounds of structure (I) to a subject in need thereof.

Other provided methods include a method for regulating activity of a KRAS, HRAS or NRAS G12C mutant protein, the method comprising reacting the KRAS, HRAS or NRAS G12C mutant protein with any one of the compounds of
25 structure (I). In other embodiments, a method for inhibiting proliferation of a cell population, the method comprising contacting the cell population with any one of the compounds of structure (I) is also provided.

In other embodiments, the invention is directed to a method for treating a disorder mediated by a KRAS, HRAS or NRAS G12C mutation in a subject in need thereof, the method comprising:

determining if the subject has a KRAS, HRAS or NRAS G12C mutation;
5 and

if the subject is determined to have the KRAS, HRAS or NRAS G12C mutation, then administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising any one or more compounds of structure (I).

In still more embodiments, the invention is directed to a method for
10 preparing a labeled KRAS, HRAS or NRAS G12C mutant protein, the method comprising reacting the KRAS, HRAS or NRAS G12C mutant with a compound of structure (I), to result in the labeled KRAS, HRAS or NRAS G12C protein.

These and other aspects of the invention will be apparent upon reference to the following detailed description.

15 BRIEF DESCRIPTION OF THE DRAWINGS

In the figures, identical reference numbers identify similar elements. The sizes and relative positions of elements in the figures are not necessarily drawn to scale and some of these elements are arbitrarily enlarged and positioned to improve figure legibility. Further, the particular shapes of the elements as drawn are not
20 intended to convey any information regarding the actual shape of the particular elements, and have been solely selected for ease of recognition in the figures.

Fig. 1 illustrates the enzymatic activity of RAS.

Fig. 2 depicts a signal transduction pathway for RAS.

Fig. 3 shows some common oncogenes, their respective tumor type and
25 cumulative mutation frequencies (all tumors).

DETAILED DESCRIPTION

In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments of the invention.

However, one skilled in the art will understand that the invention may be practiced without these details.

Unless the context requires otherwise, throughout the present specification and claims, the word “comprise” and variations thereof, such as,
 5 “comprises” and “comprising” are to be construed in an open, inclusive sense, that is as “including, but not limited to”.

Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present
 10 invention. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

Unless defined otherwise, all technical and scientific terms used herein
 15 have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. As used in the specification and claims, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.

“Amidiny” refers to a radical of the form $-(C=NR_a)NR_bR_c$, wherein R_a , R_b and R_c are each independently H or C_1 - C_6 alkyl.

20 “Amino” refers to the $-NH_2$ radical.

“Aminylsulfone” refers to the $-S(O)_2NH_2$ radical.

“Carboxy” or “carboxyl” refers to the $-CO_2H$ radical.

“Cyano” refers to the $-CN$ radical.

“Guanidiny” refers to a radical of the form $-NR_d(C=NR_a)NR_bR_c$,
 25 wherein R_a , R_b , R_c and R_d are each independently H or C_1 - C_6 alkyl.

“Hydroxy” or “hydroxyl” refers to the $-OH$ radical.

“Imino” refers to the $=NH$ substituent.

“Nitro” refers to the $-NO_2$ radical.

“Oxo” refers to the $=O$ substituent.

30 “Thioxo” refers to the $=S$ substituent.

“Alkyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which is saturated or unsaturated (*i.e.*, contains one or more double and/or triple bonds), having from one to twelve carbon atoms (C₁-C₁₂ alkyl), preferably one to eight carbon atoms (C₁-C₈ alkyl) or one to six carbon atoms (C₁-C₆ alkyl), and which is attached to the rest of the molecule by a single bond, *e.g.*, methyl, ethyl, *n*-propyl, 1-methylethyl (*iso*-propyl), *n*-butyl, *n*-pentyl, 1,1-dimethylethyl (*t*-butyl), 3-methylhexyl, 2-methylhexyl, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Alkyl includes alkenyls (one or more carbon-carbon double bonds) and alkynyls (one or more carbon-carbon triple bonds such as ethynyl and the like). “Amidinylalkyl” refers to an alkyl group comprising at least one amidinyl substituent. “Guanidinylalkyl” refers to an alkyl group comprising at least one guanidinyl substituent. Unless stated otherwise specifically in the specification, an alkyl, amidinylalkyl and/or guanidinylalkyl group is optionally substituted.

“Alkylene” or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, which is saturated or unsaturated (*i.e.*, contains one or more double and/or triple bonds), and having from one to twelve carbon atoms, *e.g.*, methylene, ethylene, propylene, *n*-butylene, ethenylene, propenylene, *n*-butenylene, propynylene, *n*-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain is optionally substituted.

“Alkylcycloalkyl” refers to a radical of the formula -R_bR_d where R_b is cycloalkyl chain as defined herein and R_d is an alkyl radical as defined above. Unless stated otherwise specifically in the specification, a alkylcycloalkyl group is optionally substituted.

“Alkoxy” refers to a radical of the formula -OR_a where R_a is an alkyl radical as defined above containing one to twelve carbon atoms. “Amidinylalkyloxy”

refers to an alkoxy group comprising at least one amidinyl substituent on the alkyl group. “Guanidinylalkoxy” refers to an alkoxy group comprising at least one guanidinyl substituent on the alkyl group. “Alkylcarbonylaminylalkoxy” refers to an alkoxy group comprising at least one alkylcarbonylaminyl substituent on the alkyl group. “Heterocyclalkoxy” refers to an alkoxy group comprising at least one heterocycl substituent on the alkyl group. “Heteroarylalkoxy” refers to an alkoxy group comprising at least one heteroaryl substituent on the alkyl group. “Aminylalkoxy” refers to an alkoxy group comprising at least one substituent of the form $-NR_aR_b$, where R_a and R_b are each independently H or C_1 - C_6 alkyl, on the alkyl group. Unless stated otherwise specifically in the specification, an alkoxy, amidinylalkoxy, guanidinylalkoxy, alkylcarbonylaminyl, heterocyclalkoxy, heteroarylalkoxy and/or aminylalkoxy group is optionally substituted.

“Alkoxyalkyl” refers to a radical of the formula $-R_bOR_a$ where R_a is an alkyl radical as defined above containing one to twelve carbon atoms and R_b is an alkylene radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxyalkyl group is optionally substituted.

“Alkoxy carbonyl” refers to a radical of the formula $-C(=O)OR_a$ where R_a is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy carbonyl group is optionally substituted.

“Aryloxy” refers to a radical of the formula $-OR_a$ where R_a is an aryl radical as defined herein. Unless stated otherwise specifically in the specification, an aryloxy group is optionally substituted.

“Alkylaminyl” refers to a radical of the formula $-NHR_a$ or $-NR_aR_a$ where each R_a is, independently, an alkyl radical as defined above containing one to twelve carbon atoms. A “haloalkylaminyl” group is an alkylaminyl group comprising at least one halo substituent on the alkyl group. A “hydroxylalkylaminyl” group is an alkylaminyl group comprising at least one hydroxyl substituent on the alkyl group. A “amidinylalkylaminyl” group is an alkylaminyl group comprising at least one amidinyl substituent on the alkyl group. A “guanidinylalkylaminyl” group is an alkylaminyl

group comprising at least one guanidinyll substituent on the alkyl group. Unless stated otherwise specifically in the specification, an alkylaminyl, haloalkylaminyl, hydroxylalkylaminyl, amidinylalkylaminyl and/or guanidinyllalkylaminyl group is optionally substituted.

5 “Aminylalkyl” refers to an alkyl group comprising at least one aminyl substituent ($-NR_aR_b$ wherein R_a and R_b are each independently H or C_1 - C_6 alkyl). The aminyl substituent can be on a tertiary, secondary or primary carbon. Unless stated otherwise specifically in the specification, an aminylalkyl group is optionally substituted.

10 “Aminylalkylaminyl” refers to a radical of the formula $-NR_aR_b$ wherein R_a is H or C_1 - C_6 alkyl and R_b is aminylalkyl. Unless stated otherwise specifically in the specification, an aminylalkylaminyl group is optionally substituted.

“Aminylalkoxy” refers to a radical of the formula $-OR_aNH_2$ wherein R_a is alkylene. Unless stated otherwise specifically in the specification, an aminylalkoxy group is optionally substituted.

15 “Alkylaminylalkoxy” refers to a radical of the formula $-OR_aNR_bR_c$ wherein R_a is alkylene and R_b and R_c are each independently H or C_1 - C_6 alkyl, provided one of R_b or R_c is C_1 - C_6 alkyl. Unless stated otherwise specifically in the specification, an alkylaminylalkoxy group is optionally substituted.

20 “Alkylcarbonylaminyl” refers to a radical of the formula $-NH(C=O)R_a$ where R_a is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylcarbonylaminyl group is optionally substituted. An alkenylcarbonylaminyl is an alkylcarbonylaminyl containing at least one carbon-carbon double bond. An alkenylcarbonylaminyl group is optionally substituted.

25 “Alkylcarbonylaminylalkoxy” refers to a radical of the formula $-OR_bNH(C=O)R_a$ where R_a is an alkyl radical as defined above containing one to twelve carbon atoms and R_b is alkylene. Unless stated otherwise specifically in the specification, an alkylcarbonylaminylalkoxy group is optionally substituted.

30 “Alkylaminylalkyl” refers to an alkyl group comprising at least one alkylaminyl substituent. The alkylaminyl substituent can be on a tertiary, secondary or

primary carbon. Unless stated otherwise specifically in the specification, an alkylaminylalkyl group is optionally substituted.

“Aminylcarbonyl” refers to a radical of the formula $-C(=O)R_aR_b$ where R_a and R_b are each independently H or alkyl. Unless stated otherwise specifically in the specification, an aminylcarbonyl group is optionally substituted.

“Alkylaminylcarbonyl” refers to a radical of the formula $-C(=O)NR_aR_b$, where R_a and R_b are each independently H or alkyl, provided at least one of R_a or R_b is alkyl. Unless stated otherwise specifically in the specification, an alkylaminylcarbonyl group is optionally substituted.

“Aminylcarbonylalkyl” refers to a radical of the formula $-R_cC(=O)NR_aR_b$, where R_a and R_b are each independently H or alkyl and R_c is alkylene. Unless stated otherwise specifically in the specification, an aminylcarbonylalkyl group is optionally substituted.

“Aminylcarbonylcycloalkylalkyl” refers to a radical of the formula $-R_cC(=O)NR_aR_b$, where R_a and R_b are each independently H or alkyl and R_c is cycloalkyl. Unless stated otherwise specifically in the specification, an aminylcarbonylcycloalkyl group is optionally substituted.

“Aryl” refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring. For purposes of this invention, the aryl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems. Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, *as*-indacene, *s*-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the term “aryl” or the prefix “ar-” (such as in “aralkyl”) is meant to include aryl radicals that are optionally substituted.

“Aralkyl” refers to a radical of the formula $-R_b-R_c$ where R_b is an alkylene chain as defined above and R_c is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an aralkyl group is optionally substituted.

“Arylalkyloxy” refers to a radical of the formula $-OR_b-R_c$ where R_b is an alkylene chain as defined above and R_c is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an arylalkyloxy group is optionally substituted.

5 “Arylalkylaminyl” refers to a radical of the formula $-N(R_a)R_b-R_c$ where R_a is H or C_1-C_6 alkyl, R_b is an alkylene chain as defined above and R_c is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an arylalkylaminyl group is optionally substituted.

10 “Carboxyalkyl” refers to a radical of the formula $-R_b-R_c$ where R_b is an alkylene chain as defined above and R_c is a carboxy group as defined above. Unless stated otherwise specifically in the specification, carboxyalkyl group is optionally substituted.

15 “Cyanoalkyl” refers to a radical of the formula $-R_b-R_c$ where R_b is an alkylene chain as defined above and R_c is a cyano group as defined above. Unless stated otherwise specifically in the specification, a cyanoalkyl group is optionally substituted.

“Cycloalkyl” or “carbocyclic ring” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond. Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbornyl, decalyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. A “cycloalkenyl” is a cycloalkyl comprising one or more carbon-carbon double bonds within the ring. Unless otherwise stated specifically in the specification, a cycloalkyl (or cycloalkenyl) group is optionally substituted.

30 “Cyanocycloalkyl” refers to a radical of the formula $-R_b-R_c$ where R_b is cycloalkylene chain and R_c is a cyano group as defined above. Unless stated otherwise specifically in the specification, a cyanocycloalkyl group is optionally substituted.

“Cycloalkylaminylcarbonyl” refers to a radical of the formula –
 $C(=O)NR_aR_b$, where R_a and R_b are each independently H or cycloalkyl, provided at
 least one of R_a or R_b is cycloalkyl. Unless stated otherwise specifically in the
 specification, n cycloalkylaminylcarbonyl group is optionally substituted.

5 “Cycloalkylalkyl” refers to a radical of the formula $-R_bR_d$ where R_b is an
 alkylene chain as defined above and R_d is a cycloalkyl radical as defined above. Unless
 stated otherwise specifically in the specification, a cycloalkylalkyl group is optionally
 substituted.

“Fused” refers to any ring structure described herein which is fused to an
 10 existing ring structure in the compounds of the invention. When the fused ring is a
 heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure
 which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring is
 replaced with a nitrogen atom.

“Halo” or “halogen” refers to bromo, chloro, fluoro or iodo.

15 “Haloalkyl” refers to an alkyl radical, as defined above, that is
 substituted by one or more halo radicals, as defined above, *e.g.*, trifluoromethyl,
 difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl,
 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise
 specifically in the specification, a haloalkyl group is optionally substituted.

20 “Halolkoxy” refers to a radical of the formula $-OR_a$ where R_a is a
 haloalkyl radical as defined herein containing one to twelve carbon atoms. Unless
 stated otherwise specifically in the specification, a haloalkoxy group is optionally
 substituted.

“Heterocyclyl” or “heterocyclic ring” refers to a stable 3- to
 25 18-membered non-aromatic ring radical which consists of two to twelve carbon atoms
 and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen
 and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl
 radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include
 fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the
 30 heterocyclyl radical is optionally oxidized; the nitrogen atom is optionally quaternized;
 and the heterocyclyl radical is partially or fully saturated. Examples of such

heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperaziny, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperaziny, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholyl, thiamorpholyl, 1-oxo-thiomorpholyl, and 1,1-dioxo-thiomorpholyl. Unless stated otherwise specifically in the specification. “Heterocyclyloxy” refers to a heterocyclyl group bound to the remainder of the molecule via an oxygen bond (-O-). “Heterocyclylaminyl” refers to a heterocyclyl group bound to the remainder of the molecule via a nitrogen bond (-NR_a-, where R_a is H or C₁-C₆ alkyl). Unless stated otherwise specifically in the specification, a heterocyclyl, heterocyclyloxy and/or heterocyclylaminyl group is optionally substituted.

“N-heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, a N-heterocyclyl group is optionally substituted.

“Heterocyclylalkyl” refers to a radical of the formula -R_bR_e where R_b is an alkylene chain as defined above and R_e is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom. Unless stated otherwise specifically in the specification, a heterocyclylalkyl group is optionally substituted.

“Heterocyclylalkyloxy” refers to a radical of the formula -OR_bR_e where R_b is an alkylene chain as defined above and R_e is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom. Unless stated otherwise specifically in the specification, a heterocyclylalkyloxy group is optionally substituted.

“Heterocyclylalkylaminyl” refers to a radical of the formula -N(R_c)R_bR_e where R_b is an alkylene chain as defined above and R_e is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the

heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom, R_c is H or C_1-C_6 alkyl. Unless stated otherwise specifically in the specification, a heterocyclylalkyloxy group is optionally substituted.

“Heteroaryl” refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring. For purposes of this invention, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[*b*][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothieryl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-*a*]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indoliziny, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1*H*-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e. thienyl). “Heteroaryloxy” refers to a heteroaryl group bound to the remainder of the molecule via an oxygen bond (-O-). “Heteroarylaminy” refers to a heteroaryl group bound to the remainder of the molecule via a nitrogen bond (-NR_a-, where R_a is H or C_1-C_6 alkyl). Unless stated otherwise specifically in the specification, a heteroaryl, heteroaryloxy and/or heteroarylaminy group is optionally substituted.

“N-heteroaryl” refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the

rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an *N*-heteroaryl group is optionally substituted.

“Heteroarylalkyl” refers to a radical of the formula $-R_bR_f$ where R_b is an alkylene chain as defined above and R_f is a heteroaryl radical as defined above. Unless
5 stated otherwise specifically in the specification, a heteroarylalkyl group is optionally substituted.

“Heteroarylalkyloxy” refers to a radical of the formula $-OR_bR_f$ where R_b is an alkylene chain as defined above and R_f is a heteroaryl radical as defined above,
10 and if the heteroaryl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom. Unless stated otherwise specifically in the specification, a heteroarylalkyloxy group is optionally substituted.

“Heteroarylalkylaminyl” refers to a radical of the formula $-NR_cR_bR_f$ where R_b is an alkylene chain as defined above and R_f is a heteroaryl radical as defined
15 above, and if the heteroaryl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom, and R_c is H or C_1 - C_6 alkyl. Unless stated otherwise specifically in the specification, a heteroarylalkyloxy group is optionally substituted. “Hydroxylalkyl” refers to an alkyl group comprising at least one hydroxyl substituent. The $-OH$ substituent may be on a primary, secondary or tertiary
20 carbon. Unless stated otherwise specifically in the specification, a hydroxylalkyl group is optionally substituted. “Hydroxylalkylaminyl” is an alkylaminyl groups comprising at least one $-OH$ substituent, which is on a primary, secondary or tertiary carbon. Unless stated otherwise specifically in the specification, a hydroxylalkylaminyl group is optionally substituted.

25 “Thioalkyl” refers to a radical of the formula $-SR_a$ where R_a is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group is optionally substituted.

The term “substituted” used herein means any of the above groups (*e.g.*, alkyl, alkylene, alkylcycloalkyl, alkoxy, amidinylalkyloxy, guanidinylalkyloxy,
30 alkylcarbonylaminylalkyloxy, heterocyclylalkyloxy, heteroarylalkyloxy, aminylalkyloxy, alkoxyalkyl, alkoxycarbonyl, haloalkylaminyl, hydroxylalkylaminyl,

amidinylalkylaminyl, guanidinylalkylaminyl, aminylalkyl, aminylalkylaminyl, aminylalkoxy, alkylaminylalkoxy aryloxy, alkylaminyl, alkylcarbonylaminyl, alkylaminylalkyl, aminylcarbonyl, alkylaminylcarbonyl, alkylcarbonylaminylalkoxy, aminylcarbonylalkyl, aminylcarbonylcycloalkylalkyl, thioalkyl, aryl, aralkyl, arylalkyloxy, arylalkylaminyl, carboxyalkyl, cyanoalkyl, cycloalkyl, cycloalkyloxy, cycloalkylaminyl, cyanocycloalkyl, cycloalkylaminylcarbonyl, cycloalkylalkyl, haloalkyl, haloalkoxy, heterocyclyl, heterocyclyloxy, heterocyclylaminyl, *N*-heterocyclyl, heterocyclylalkyl, heterocyclylalkyloxy, heterocyclylalkylaminyl, heteroaryl, *N*-heteroaryl, heteroarylalkyl, heteroarylalkyloxy, heteroarylalkylaminyl, hydroxylalkylaminyl and/or hydroxylalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, *N*-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyl diarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. "Substituted" also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, "substituted" includes any of the above groups in which one or more hydrogen atoms are replaced with -NR_gR_h, -NR_gC(=O)R_h, -NR_gC(=O)NR_gR_h, -NR_gC(=O)OR_h, -NR_gSO₂R_h, -OC(=O)NR_gR_h, -OR_g, -SR_g, -SOR_g, -SO₂R_g, -OSO₂R_g, -SO₂OR_g, =NSO₂R_g, and -SO₂NR_gR_h. "Substituted also means any of the above groups in which one or more hydrogen atoms are replaced with -C(=O)R_g, -C(=O)OR_g, -C(=O)NR_gR_h, -CH₂SO₂R_g, -CH₂SO₂NR_gR_h. In the foregoing, R_g and R_h are the same or different and independently hydrogen, alkyl, alkoxy, alkylaminyl, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, *N*-heterocyclyl, heterocyclylalkyl, heteroaryl, *N*-heteroaryl and/or heteroarylalkyl. "Substituted" further means any of the above groups in which one or

more hydrogen atoms are replaced by a bond to an aminyl, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylaminyl, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, *N*-heterocyclyl, heterocyclylalkyl, heteroaryl, *N*-heteroaryl and/or heteroarylalkyl group. In addition, each of the foregoing
5 substituents may also be optionally substituted with one or more of the above substituents.

“Electrophile” or “electrophilic moiety” is any moiety capable of reacting with a nucleophile (e.g., a moiety having a lone pair of electrons, a negative charge, a partial negative charge and/or an excess of electrons, for example a –SH
10 group). Electrophiles typically are electron poor or comprise atoms which are electron poor. In certain embodiments an electrophile contains a positive charge or partial positive charge, has a resonance structure which contains a positive charge or partial positive charge or is a moiety in which delocalization or polarization of electrons results in one or more atom which contains a positive charge or partial positive charge. In
15 some embodiments, the electrophiles comprise conjugated double bonds, for example an α,β -unsaturated carbonyl or α,β -unsaturated thiocarbonyl compound.

The term “effective amount” or “therapeutically effective amount” refers to that amount of a compound described herein that is sufficient to effect the intended application including but not limited to disease treatment, as defined below. The
20 therapeutically effective amount may vary depending upon the intended treatment application (in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target
25 cells, e.g. reduction of platelet adhesion and/or cell migration. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.

30 As used herein, “treatment” or “treating” refer to an approach for obtaining beneficial or desired results with respect to a disease, disorder or medical

condition including but not limited to a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the
5 underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder. In certain embodiments, for prophylactic benefit, the compositions are administered to a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may
10 not have been made.

A “therapeutic effect,” as that term is used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing,
15 halting, or reversing the progression of a disease or condition, or any combination thereof.

The term “co-administration,” “administered in combination with,” and their grammatical equivalents, as used herein, encompass administration of two or more agents to an animal, including humans, so that both agents and/or their metabolites are
20 present in the subject at the same time. Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both agents are present.

“Pharmaceutically acceptable salt” includes both acid and base addition salts.

25 “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid,
30 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid,

camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, *p*-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.

“Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, *N*-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.

The terms “antagonist” and “inhibitor” are used interchangeably, and they refer to a compound having the ability to inhibit a biological function of a target protein, whether by inhibiting the activity or expression of the protein, such as KRAS, HRAS or NRAS G12C. Accordingly, the terms “antagonist” and “inhibitors” are defined in the context of the biological role of the target protein. While preferred antagonists herein specifically interact with (e.g. bind to) the target, compounds that inhibit a biological activity of the target protein by interacting with other members of the signal transduction pathway of which the target protein is a member are also specifically included within this definition. A preferred biological activity inhibited by an antagonist is associated with the development, growth, or spread of a tumor.

The term “agonist” as used herein refers to a compound having the ability to initiate or enhance a biological function of a target protein, whether by inhibiting the activity or expression of the target protein. Accordingly, the term “agonist” is defined in the context of the biological role of the target polypeptide. While preferred agonists herein specifically interact with (e.g. bind to) the target, compounds that initiate or enhance a biological activity of the target polypeptide by interacting with other members of the signal transduction pathway of which the target polypeptide is a member are also specifically included within this definition.

As used herein, “agent” or “biologically active agent” refers to a biological, pharmaceutical, or chemical compound or other moiety. Non-limiting examples include a simple or complex organic or inorganic molecule, a peptide, a protein, an oligonucleotide, an antibody, an antibody derivative, antibody fragment, a vitamin derivative, a carbohydrate, a toxin, or a chemotherapeutic compound. Various compounds can be synthesized, for example, small molecules and oligomers (e.g., oligopeptides and oligonucleotides), and synthetic organic compounds based on various core structures. In addition, various natural sources can provide compounds for screening, such as plant or animal extracts, and the like.

“Signal transduction” is a process during which stimulatory or inhibitory signals are transmitted into and within a cell to elicit an intracellular response. A modulator of a signal transduction pathway refers to a compound which modulates the activity of one or more cellular proteins mapped to the same specific signal transduction

pathway. A modulator may augment (agonist) or suppress (antagonist) the activity of a signaling molecule.

An “anti-cancer agent”, “anti-tumor agent” or “chemotherapeutic agent” refers to any agent useful in the treatment of a neoplastic condition. One class of anti-cancer agents comprises chemotherapeutic agents. “Chemotherapy” means the administration of one or more chemotherapeutic drugs and/or other agents to a cancer patient by various methods, including intravenous, oral, intramuscular, intraperitoneal, intravesical, subcutaneous, transdermal, buccal, or inhalation or in the form of a suppository.

The term “cell proliferation” refers to a phenomenon by which the cell number has changed as a result of division. This term also encompasses cell growth by which the cell morphology has changed (e.g., increased in size) consistent with a proliferative signal.

The term “selective inhibition” or “selectively inhibit” refers to a biologically active agent refers to the agent’s ability to preferentially reduce the target signaling activity as compared to off-target signaling activity, via direct or indirect interaction with the target.

“Subject” refers to an animal, such as a mammal, for example a human. The methods described herein can be useful in both human therapeutics and veterinary applications. In some embodiments, the subject is a mammal, and in some embodiments, the subject is human.

“Mammal” includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.

“Radiation therapy” means exposing a subject, using routine methods and compositions known to the practitioner, to radiation emitters such as alpha-particle emitting radionuclides (e.g., actinium and thorium radionuclides), low linear energy transfer (LET) radiation emitters (i.e. beta emitters), conversion electron emitters (e.g. strontium-89 and samarium-153-EDTMP, or high-energy radiation, including without limitation x-rays, gamma rays, and neutrons.

An “anti-cancer agent”, “anti-tumor agent” or “chemotherapeutic agent” refers to any agent useful in the treatment of a neoplastic condition. One class of anti-cancer agents comprises chemotherapeutic agents. “Chemotherapy” means the administration of one or more chemotherapeutic drugs and/or other agents to a cancer patient by various methods, including intravenous, oral, intramuscular, intraperitoneal, intravesical, subcutaneous, transdermal, buccal, or inhalation or in the form of a suppository.

“Prodrug” is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound described herein (e.g., compound of structure (I)). Thus, the term “prodrug” refers to a precursor of a biologically active compound that is pharmaceutically acceptable. In some aspects, a prodrug is inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam). A discussion of prodrugs is provided in Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein. The term “prodrug” is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject. Prodrugs of an active compound, as described herein, are typically prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of a hydroxy functional group, or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound and the like.

The term “in vivo” refers to an event that takes place in a subject’s body.

The invention disclosed herein is also meant to encompass all pharmaceutically acceptable compounds of structure (I) being isotopically-labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{13}N , ^{15}N , ^{15}O , ^{17}O , ^{18}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , ^{36}Cl , ^{123}I , and ^{125}I , respectively. These radiolabelled compounds could be useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action, or binding affinity to pharmacologically important site of action. Certain isotopically-labelled compounds of structure (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, *i.e.* ^3H , and carbon-14, *i.e.* ^{14}C , are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.

Substitution with heavier isotopes such as deuterium, *i.e.* ^2H , may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements, and hence are preferred in some circumstances.

Substitution with positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of structure (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Preparations and Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.

The invention disclosed herein is also meant to encompass the *in vivo* metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes compounds produced by a process comprising administering a

compound of this invention to a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically identified by administering a radiolabelled compound of the invention in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.

“Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

Often crystallizations produce a solvate of the compound of the invention. As used herein, the term “solvate” refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent. In some embodiments, the solvent is water, in which case the solvate is a hydrate. Alternatively, in other embodiments, the solvent is an organic solvent. Thus, the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms. In some aspects, the compound of the invention is a true solvate, while in other cases, the compound of the invention merely retains adventitious water or is a mixture of water plus some adventitious solvent.

“Optional” or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted aryl” means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.


A “pharmaceutical composition” refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, *e.g.*, humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.

“Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent,

preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.

5 The compounds of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that are defined, in terms of absolute stereochemistry, as (*R*)- or (*S*)- or, as (*D*)- or (*L*)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and
10 optically pure forms. Optically active (+) and (-), (*R*)- and (*S*)-, or (*D*)- and (*L*)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate
15 (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centres of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both *E* and *Z* geometric isomers. Likewise, all tautomeric forms are also intended to be included.

20 The present invention includes all manner of rotamers and conformationally restricted states of a compound of the invention. Atropisomers, which are stereoisomers arising because of hindered rotation about a single bond, where energy differences due to steric strain or other contributors create a barrier to rotation that is high enough to allow for isolation of individual conformers, are also included.
25 As an example, certain compounds of the invention may exist as mixtures of atropisomers or purified or enriched for the presence of one atropisomer. Non-limiting examples of compounds which exist as atropisomers include the following compounds:



A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another.

A “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present invention includes tautomers of any said compounds.


The chemical naming protocol and structure diagrams used herein are a modified form of the I.U.P.A.C. nomenclature system, using the ACD/Name Version 9.07 software program and/or ChemDraw Ultra Version 11.0.1 software naming program (CambridgeSoft). For complex chemical names employed herein, a substituent group is typically named before the group to which it attaches. For example, cyclopropylethyl comprises an ethyl backbone with a cyclopropyl substituent. Except as described below, all bonds are identified in the chemical structure diagrams

herein, except for all bonds on some carbon atoms, which are assumed to be bonded to sufficient hydrogen atoms to complete the valency.

Compounds

In an aspect, the invention provides compounds which are capable of selectively binding to and/or modulating a G12C mutant KRAS, HRAS or NRAS protein. The compounds may modulate the G12C mutant KRAS, HRAS or NRAS protein by reaction with an amino acid. While not wishing to be bound by theory, the present applicants believe that, in some embodiments, the compounds of the invention selectively react with the G12C mutant KRAS, HRAS or NRAS proteins by forming a covalent bond with the cysteine at the 12 position of a G12C mutant KRAS, HRAS or NRAS protein. By binding to the Cystine 12, the compounds of the invention may lock the switch II of the G12C mutant KRAS, HRAS or NRAS into an inactive stage. This inactive stage may be distinct from those observed for GTP and GDP bound KRAS, HRAS or NRAS. Some compounds of the invention may also be able to perturb the switch I conformation. Some compounds of the invention may favor the binding of the bound KRAS, HRAS or NRAS to GDP rather than GTP and therefore sequester the KRAS, HRAS or NRAS into an inactive KRAS, HRAS or NRAS GDP state. Because effector binding to KRAS, HRAS or NRAS is highly sensitive to the conformation of switch I and II, the irreversible binding of these compounds may disrupt KRAS, HRAS or NRAS downstream signaling.

As noted above, in one embodiment of the present invention, compounds having activity as modulators of a G12C mutant KRAS, HRAS or NRAS protein are provided, the compounds have the following structure (I):



(I)

or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:

A is CR¹, CR^{2b}, NR⁷ or S;

- B is a bond, CR¹ or CR^{2c}
- G¹ and G² are each independently N or CH;
- W, X and Y are each independently N, NR⁵ or CR⁶;
- Z is a bond, N or CR⁶, or Z is NH when Y is C=O;
- 5 L¹ is a bond or NR⁷;
- L² is a bond or alkylene;
- R¹ is H, cyano, halo, CF₃, C₁-C₆alkyl, C₁-C₆alkylaminyl, C₃-C₈ cycloalkyl, C₁-C₆alkenyl or C₃-C₈cycloalkenyl, heterocyclyl, heteroaryl, aryloxy, heteroaryloxy or aryl;
- 10 R^{2a}, R^{2b} and R^{2c} are each independently H, halo, hydroxyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₃-C₈ cycloalkyl, heteroaryl or aryl;
- R^{3a} and R^{3b} are, at each occurrence, independently H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R^{3a} and R^{3b} join to form a carbocyclic or heterocyclic ring; or R^{3a} is H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R^{3b} joins with R^{4b} to form a carbocyclic or heterocyclic ring;
- 15 R^{4a} and R^{4b} are, at each occurrence, independently H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R^{4a} and R^{4b} join to form a carbocyclic or heterocyclic ring; or R^{4a} is H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R^{4b} joins with R^{3b} to form a carbocyclic or heterocyclic ring;
- 20 R⁵ is, at each occurrence, independently H, C₁-C₆ alkyl or a bond to L¹;
- R⁶ is, at each occurrence, independently H, oxo, cyano, cyanoalkyl, amino, aminylalkyl, aminylalkylaminyl, aminylcarbonyl, aminylsulfonyl, -CO₂NR^aR^b, wherein R^a and R^b, are each independently H or C₁-C₆ alkyl or R^a and R^b join to form a carbocyclic or heterocyclic ring, alkylaminyl, haloalkylaminyl, hydroxylalkylaminyl, amindinylalkyl, amidinylalkoxy, amindinylalkylaminyl, guanidinylalkyl,
- 25 30

- guanidinyloxy, guanidinyllalkylaminyl, C₁-C₆ alkoxy, aminyloxy,
 alkylcarbonylaminylalkoxy, C₁-C₆ alkyl, heterocyclyl, heterocycloxy,
 heterocyclalkyloxy, heterocyclaminyl, heterocyclalkylaminyl, heteroaryl,
 heteroaryloxy, heteroarylalkyloxy, heteroarylaminyl, heteroarylalkylaminyl, aryl,
 5 aryloxy, arylaminyl, arylalkylaminyl, arylalkyloxy or a bond to L¹;
 R⁷ is H or C₁-C₆ alkyl;
 m¹ and m² are each independently 1, 2 or 3;
 ==== indicates a single or double bond such that all valences are satisfied;
 and
 10 E is an electrophilic moiety capable of forming a covalent bond with the
 cysteine residue at position 12 of a KRAS, HRAS or NRAS G12C mutant protein,
 wherein at least one of W, X, Y or Z is CR⁶ where R⁶ is a bond to L¹, and
 provided that when R¹, R^{2a}, R^{2b} and R^{2c} are all independently selected
 from H and halo, then X and Z are both N and at least one of R^{3a}, R^{3b}, R^{4a} or R^{4b} is not
 15 H, and provided that at least one of R^{2a}, R^{2b} or R^{2c} is not H when R¹ is pyridyl.
 In some other embodiments of compound (I):
 A is CR¹, CR^{2b}, NR⁷ or S;
 B is a bond, CR¹ or CR^{2c}
 G¹ and G² are each independently N or CH;
 20 W, X and Y are each independently N, NR⁵ or CR⁶;
 Z is a bond, N or CR^{6a} or Z is NH when Y is C=O;
 L¹ is a bond or NR⁷;
 L² is a bond or alkylene;
 R¹ is heterocyclyl, heteroaryl or aryl;
 25 R^{2a}, R^{2b} and R^{2c} are each independently H, halo, hydroxyl, C₁-C₆ alkyl,
 C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₃-C₈ cycloalkyl, heteroaryl or aryl;
 R^{3a} and R^{3b} are, at each occurrence, independently
 H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalkyl,
 aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or
 30 aminylcarbonyl; or R^{3a} and R^{3b} join to form a carbocyclic or heterocyclic ring; or R^{3a} is
 H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalkyl,

aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R^{3b} joins with R^{4b} to form a carbocyclic or heterocyclic ring;

R^{4a} and R^{4b} are, at each occurrence, independently

H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalkyl,

5 aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R^{4a} and R^{4b} join to form a carbocyclic or heterocyclic ring; or R^{4a} is H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R^{4b} joins with R^{3b} to form a carbocyclic or heterocyclic ring;

10 R^5 is, at each occurrence, independently H, C₁-C₆ alkyl or a bond to L¹;

R^6 is, at each occurrence, independently H, oxo, cyano, cyanoalkyl, amino, aminylalkyl, aminylalkylaminyl, aminylcarbonyl, aminylsulfonyl, -CO₂NR^aR^b, wherein R^a and R^b, are each independently H or C₁-C₆ alkyl or R^a and R^b join to form a carbocyclic or heterocyclic ring, alkylaminyl, haloalkylaminyl, hydroxylalkylaminyl,

15 amindinylalkyl, amidinylalkoxy, amindinylalkylaminyl, guanidinylalkyl, guanidinylalkoxy, guanidinylalkylaminyl, C₁-C₆ alkoxy, aminylalkoxy, alkylaminylalkoxy alkylcarbonylaminylalkoxy, C₁-C₆ alkyl, heterocyclyl, heterocyclylalkoxy, heterocyclylalkoxy, heterocyclylaminyl, heterocyclylalkylaminyl, heteroaryl, heteroarylalkoxy, heteroarylalkoxy, heteroarylalkylaminyl, heteroarylalkylaminyl, aryl, arylalkoxy, arylaminyl, arylalkylaminyl, arylalkoxy or a bond to L¹;

R^{6a} is H, alkyl or a bond to L¹;

R^7 is H or C₁-C₆ alkyl

m^1 and m^2 are each independently 1, 2 or 3;

==== indicates a single or double bond such that all valences are satisfied;

25 and

E is an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS, HRAS or NRAS G12C mutant protein,

wherein at least one of W, X, Y or Z is CR⁶ where R⁶ is a bond to L¹ or at least one of W, X or Y is NR⁵, wherein R⁵ is a bond to L¹, and

30 provided that least one of R^{2a}, R^{2b} or R^{2c} is not H when R¹ is pyridyl.

In some of the foregoing embodiments, R^1 is aryl. In other embodiments, R^1 is heterocyclyl. In still other embodiments, R^1 is heteroaryl, provided that least one of R^{2a} , R^{2b} or R^{2c} is not H when R^1 is pyridyl. In some other embodiments, C_1 - C_6 haloalkyl is CF_3 .

5 In some embodiments of the compound of structure (I), the bond between W and X is a double bond. In other embodiments, the bond between Y and Z is a double bond. In more embodiments, the bond between A and B is a double bond. In still more embodiments, the bonds between W and X, Y and Z and A and B are each double bonds.

10 In some other embodiments, Z is a bond, N or CR^6 . In some embodiments, Z is a bond, N or CR^{6a} , wherein R^{6a} is H, alkyl or a bond to L^1 . In other embodiments Z is NH when Y is C=O

In some more embodiments of the foregoing compound of structure (I):

A is CR^1 , CR^{2b} , NR^7 or S;

15 B is a bond, CR^1 or CR^{2c}

G^1 and G^2 are each independently N or CH;

W, X and Y are each independently N, NR^5 or CR^6 ;

Z is a bond, N or CR^6 ;

L^1 is a bond or NR^7 ;

20 L^2 is a bond or alkylene;

R^1 is H, cyano, halo, heterocyclyl, heteroaryl, aryloxy or aryl;

R^{2a} , R^{2b} and R^{2c} are each independently H, halo, hydroxyl, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl C_3 - C_8 cycloalkyl or aryl;

R^{3a} and R^{3b} are, at each occurrence, independently

25 H, -OH, -NH₂, -CO₂H, halo, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkynyl, hydroxylalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R^{3a} and R^{3b} join to form a carbocyclic or heterocyclic ring; or R^{3a} is H, -OH, -NH₂, -CO₂H, halo, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkynyl, hydroxylalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or
30 aminylcarbonyl, and R^{3b} joins with R^{4b} to form a carbocyclic or heterocyclic ring;

R^{4a} and R^{4b} are, at each occurrence, independently

H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R^{4a} and R^{4b} join to form a carbocyclic or heterocyclic ring; or R^{4a} is

5 H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R^{4b} joins with R^{3b} to form a carbocyclic or heterocyclic ring;

R^5 and R^7 are each independently H or C₁-C₆ alkyl;

10 R^6 is, at each occurrence, independently H, oxo, cyano, cyanoalkyl, amino, aminylcarbonyl, alkylaminyl, C₁-C₆ alkoxy, C₁-C₆ alkyl or a bond to L¹;

m^1 and m^2 are each independently 1, 2 or 3;

==== indicates a single or double bond such that all valences are satisfied;

and

15 E is an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS, HRAS or NRAS G12C mutant protein,

wherein at least one of W, X, Y or Z is CR⁶ where R^6 is a bond to L¹, and

provided that when R^1 , R^{2a} , R^{2b} and R^{2c} are all independently selected from H and halo, then X and Z are both N and at least one of R^{3a} , R^{3b} , R^{4a} or R^{4b} is not H, and provided that at least one of R^{2a} , R^{2b} or R^{2c} is not H when R^1 is pyridyl.

20 In some other embodiments of the foregoing compound of structure (I):

A is CR^{2b}, NR⁷ or S;

B is a bond or CR^{2c}

G¹ and G² are each independently N or CH;

W, X and Y are each independently N, NR⁵ or CR⁶;

25 Z is a bond, N or CR⁶;

L¹ is a bond or NR⁷;

L² is a bond or alkylene;

R^1 is cyano, C₁-C₆alkyl, C₁-C₆alkylaminyl, C₃-C₈ cycloalkyl, C₁-C₆alkenyl or C₃-C₈ cycloalkenyl, heterocyclyl or aryl;

30 R^{2a} , R^{2b} and R^{2c} are each independently H, halo, C₁-C₆alkyl or C₃-C₈ cycloalkyl;

R^{3a} and R^{3b} are, at each occurrence, independently H, -OH, -NH₂, -CO₂H, halo, cyano, hydroxylalkyl, aminylalkyl, cyanoalkyl, carboxyalkyl or aminylcarbonyl; or R^{3a} and R^{3b} join to form a carbocyclic or heterocyclic ring; or R^{3a} is H, -OH, -NH₂, -CO₂H, halo, cyano, hydroxylalkyl, aminylalkyl, cyanoalkyl, carboxyalkyl or aminylcarbonyl, and R^{3b} joins with R^{4b} to form a carbocyclic or heterocyclic ring;

R^{4a} and R^{4b} are, at each occurrence, independently H, -OH, -NH₂, -CO₂H, halo, cyano, hydroxylalkyl, aminylalkyl, cyanoalkyl, carboxyalkyl or aminylcarbonyl; or R^{4a} and R^{4b} join to form a carbocyclic or heterocyclic ring; or R^{4a} is H, -OH, -NH₂, -CO₂H, halo, cyano, hydroxylalkyl, aminylalkyl, cyanoalkyl, carboxyalkyl or aminylcarbonyl, and R^{4b} joins with R^{3b} to form a carbocyclic or heterocyclic ring;

R^5 and R^7 are each independently H or C₁-C₆alkyl;
 R^6 is, at each occurrence, independently H, cyano, amino, alkylaminyl, C₁-C₆alkoxy, C₁-C₆alkyl or a bond to L¹;
 m^1 and m^2 are each independently 1, 2 or 3;
 === indicates a single or double bond such that all valences are satisfied;
 and


E is an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS, HRAS or NRAS G12C mutant protein, wherein at least one of W, X or Y is CR⁶ where R⁶ is a bond to L¹.

In still other embodiments of the foregoing compound of structure (I), R¹ is H, cyano, halo, heterocyclyl, heteroaryl, aryloxy or aryl.

The structure of E is not particularly limited provided it is capable of forming a covalent bond with a nucleophile, such as the cysteine residue at position 12 of a KRAS, HRAS or NRAS G12C mutant protein. Accordingly, moieties which are capable of reaction with (*e.g.*, by covalent bond formation) a nucleophile are preferred. In certain embodiments, E is capable of reacting in a conjugate addition manner (*e.g.*, 1.4-conjugate addition) with an appropriately reactive nucleophile. In some embodiments, E comprises conjugated pi bonds such that delocalization of electrons results in at least one atom (*e.g.*, a carbon atom) having a positive charge, partial

positive charge or a polarized bond. In other embodiments, E comprises one or more bonds wherein the electronegativity of the two atoms forming the bonds is sufficiently different such that a partial positive charge (*e.g.*, by polarization of the bond) resides on one of the atoms, for example on a carbon atom. E moieties comprising carbon-halogen
 5 bonds, carbon-oxygen bonds or carbon bonds to various leaving groups known in the art are examples of such E moieties.

In certain embodiments of the foregoing, E has the following structure:



wherein:


- 10 $\equiv$ represents a double or triple bond;
 Q is $-\text{C}(=\text{O})-$, $-\text{C}(=\text{NR}^{8'})-$, $-\text{NR}^8\text{C}(=\text{O})-$, $-\text{S}(=\text{O})_2-$ or $-\text{NR}^8\text{S}(=\text{O})_2-$;
 R^8 is H, C_1 - C_6 alkyl or hydroxylalkyl;
 $\text{R}^{8'}$ is H, $-\text{OH}$, $-\text{CN}$ or C_1 - C_6 alkyl; and
 when $\equiv$ is a double bond then R^9 and R^{10} are each independently H,
 15 cyano, carboxyl, C_1 - C_6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, or hydroxylalkyl or R^9 and R^{10} join to form a carbocyclic or heterocyclic ring;
 when $\equiv$ is a triple bond; then R^9 is absent and R^{10} is H, C_1 - C_6 alkyl, aminylalkyl, alkylaminylalkyl or hydroxylalkyl.

In certain embodiments when $\equiv$ is a double bond then R^9 and R^{10} are
 20 each independently H, cyano, C_1 - C_6 alkyl, aminylalkyl, alkylaminylalkyl, or hydroxylalkyl or R^9 and R^{10} join to form a carbocyclic or heterocyclic ring.

In some of the foregoing embodiments, Q is $-\text{C}(=\text{O})-$, $-\text{NR}^8\text{C}(=\text{O})-$, $-\text{S}(=\text{O})_2-$ or $-\text{NR}^8\text{S}(=\text{O})_2-$.

In some other of the foregoing embodiments, Q is $-\text{C}(=\text{NR}^{8'})-$, wherein
 25 $\text{R}^{8'}$ is H, $-\text{OH}$, $-\text{CN}$ or C_1 - C_6 alkyl. For example, in some embodiments $\text{R}^{8'}$ is H. In other embodiments, $\text{R}^{8'}$ is $-\text{CN}$. In other embodiments, $\text{R}^{8'}$ is $-\text{OH}$.


In some embodiments, the compound has the following structure (I'):



(I'),

wherein R' is R¹ and R'' is R^{2c} or R' is H and R'' is R¹.

5 In other embodiments, the compound has the following structure (I'a):



(I'a)

wherein:

$\equiv$ represents a double or triple bond;

10 Q is $-\text{C}(=\text{O})-$, $-\text{C}(=\text{NR}^{8'})-$, $-\text{NR}^8\text{C}(=\text{O})-$, $-\text{S}(=\text{O})_2-$ or $-\text{NR}^8\text{S}(=\text{O})_2-$;

R⁸ is H, C₁-C₆alkyl or hydroxylalkyl;

R^{8'} is H, -OH, -CN or C₁-C₆alkyl;

when $\equiv$ is a double bond then R⁹ and R¹⁰ are each independently H, cyano, carboxyl, C₁-C₆alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, heteroaryl
15 or hydroxylalkyl or R⁹ and R¹⁰ join to form a carbocyclic or heterocyclic ring;

when $\equiv$ is a triple bond then R⁹ is absent and R¹⁰ is H, C₁-C₆alkyl, aminylalkyl, alkylaminylalkyl or hydroxylalkyl; and


R' is R¹ and R'' is R^{2c} or R' is H and R'' is R¹.

In some of the foregoing embodiments of compound (I'a), Q is $-\text{C}(=\text{O})-$, $-\text{NR}^8\text{C}(=\text{O})-$, $-\text{S}(=\text{O})_2-$ or $-\text{NR}^8\text{S}(=\text{O})_2-$.
20


In some other of the foregoing embodiments of compound (I'a), Q is $-\text{C}(=\text{NR}^{8'})-$, wherein R^{8'} is H, -OH, -CN or C₁-C₆alkyl. For example, in some

embodiments $R^{8'}$ is H. In other embodiments, $R^{8'}$ is $-\text{CN}$. In other embodiments, $R^{8'}$ is $-\text{OH}$.

In still more embodiments of the foregoing compounds, the compound has one of the following structures (I'b), (I'c), (I'd) or (I'e):




10 In still more embodiments, the compound has one of the following structures (I'f), (I'g), (I'h) or (I'i):



In some embodiments of the compounds of structures (I'f), (I'g), (I'h) or (I'i), R^1 is aryl and R^{2c} and R^{2b} are independently selected from H and halo, for example in some further embodiments R^1 is aryl and R^{2c} and R^{2b} are independently selected from halo.


5 In different embodiments, the compound has one of the following structures (I'j), (I'k), (I'l) or (I'm):



10


In some embodiments of the compounds of structures (I'j), (I'k), (I'l) or (I'm), R^1 is aryl and R^{2a} and R^{2b} are independently selected from H and halo, for example in some further embodiments R^1 is aryl and R^{2a} and R^{2b} are independently selected from halo.

15 In other embodiments, the compound has the following structure (I''):



(I''),

wherein R' is R^1 and R'' is R^{2c} or R' is H and R'' is R^1 . For example, in some embodiments the compound has the following structure (I''a):



wherein:

$\equiv$ represents a double or triple bond;

5 Q is $-\text{C}(=\text{O})-$, $-\text{C}(=\text{NR}^{8'})-$, $-\text{NR}^8\text{C}(=\text{O})-$, $-\text{S}(=\text{O})_2-$ or $-\text{NR}^8\text{S}(=\text{O})_2-$;

R^8 is H, C_1 - C_6 alkyl or hydroxylalkyl;

$\text{R}^{8'}$ is H, $-\text{OH}$, $-\text{CN}$ or C_1 - C_6 alkyl;

when $\equiv$ is a double bond then R^9 and R^{10} are each independently H, cyano, carboxyl, C_1 - C_6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, heteroaryl
10 or hydroxylalkyl or R^9 and R^{10} join to form a carbocyclic or heterocyclic ring;



when $\equiv$ is a triple bond then R^9 is absent and R^{10} is H, C_1 - C_6 alkyl, aminylalkyl, alkylaminylalkyl or hydroxylalkyl; and

R' is R^1 and R'' is R^{2c} or R' is H and R'' is R^1 .



In some of the foregoing embodiments of compound (I''a), Q is $-\text{C}(=\text{O})-$, $-\text{NR}^8\text{C}(=\text{O})-$, $-\text{S}(=\text{O})_2-$ or $-\text{NR}^8\text{S}(=\text{O})_2-$.
15

In some other of the foregoing embodiments of compound (I''a), Q is $-\text{C}(=\text{NR}^{8'})-$, wherein $\text{R}^{8'}$ is H, $-\text{OH}$, $-\text{CN}$ or C_1 - C_6 alkyl. For example, in some embodiments $\text{R}^{8'}$ is H. In other embodiments, $\text{R}^{8'}$ is $-\text{CN}$. In other embodiments, $\text{R}^{8'}$ is $-\text{OH}$.

20 In other embodiments, the compound has one of the following structures (I''b), (I''c), (I''d) or (I''e):




(I''b)



(I''d)


(I''e)

In other embodiments, the compound has one of the following structures (I''f), (I''g), (I''h) or (I''i):




5

In some different embodiments, the compound has one of the following structures (I'j), (I'k), (I'l) or (I'm):




10



In other various embodiments, the compound has the following structure


5 (I'''):



wherein A is NH or S.

For example, in some embodiments, the compound has the following

10 structure (I'''a):



wherein:

$\equiv$ represents a double or triple bond;

15 Q is $-\text{C}(=\text{O})-$, $-\text{C}(=\text{NR}^8)-$, $-\text{NR}^8\text{C}(=\text{O})-$, $-\text{S}(=\text{O})_2-$ or $-\text{NR}^8\text{S}(=\text{O})_2-$;

R⁸ is H, C₁-C₆alkyl or hydroxylalkyl;

$R^{8'}$ is H, -OH, -CN or C_1 - C_6 alkyl; and

when $\equiv$ is a double bond then R^9 and R^{10} are each independently H, cyano, carboxyl, C_1 - C_6 alkyl, alkoxy carbonyl, aminylalkyl, alkylaminylalkyl, heteroaryl or hydroxylalkyl or R^9 and R^{10} join to form a carbocyclic or heterocyclic ring;

5 when $\equiv$ is a triple bond then R^9 is absent and R^{10} is H, C_1 - C_6 alkyl, aminylalkyl, alkylaminylalkyl or hydroxylalkyl; and


A is NH or S.

In some of the foregoing embodiments of compound (I'''a), Q is Q is -C(=O)-, -NR⁸C(=O)-, -S(=O)₂- or -NR⁸S(=O)₂-.


10 In some other of the foregoing embodiments of compound (I'''a), Q is -C(=NR^{8'})-, wherein $R^{8'}$ is H, -OH, -CN or C_1 - C_6 alkyl. For example, in some embodiments $R^{8'}$ is H. In other embodiments, $R^{8'}$ is -CN. In other embodiments, $R^{8'}$ is -OH.

In other embodiments, the compound has one of the following structures

15 (I'''b), (I'''c), (I'''d) or (I'''e):




20 In still more embodiments, the compound has one of the following structures (I'''f), (I'''g), (I'''h) or (I'''i):




5 In certain embodiments of any of the foregoing, at least one of G^1 or G^2 is N. In other embodiments, at least one of W, X or Y is N or NR^5 . In other embodiments, at least one of W, X or Y is N and at least one of W, X or Y is CR^6 . For example, in some embodiments two of W, X and Y are N and one of W, X and Y is CR^6 .

10 In some embodiments, at least one of W, X or Y is N or NR^5 , wherein R^5 is a bond to L^1 . In some other embodiments, at least one of W, X or Y is N or CR^6 , wherein R^6 is a bond to L^1 .

For example, in some different embodiments, the compound has one of the following structures:





(I'p)

wherein:

$\equiv$ represents a double or triple bond;

5 Q is $-\text{C}(=\text{O})-$, $-\text{C}(=\text{NR}^8)-$, $-\text{NR}^8\text{C}(=\text{O})-$, $-\text{S}(=\text{O})_2-$ or $-\text{NR}^8\text{S}(=\text{O})_2-$;

R^8 is H, C_1 - C_6 alkyl or hydroxylalkyl;


$\text{R}^{8'}$ is H, $-\text{OH}$, $-\text{CN}$ or C_1 - C_6 alkyl;

when $\equiv$ is a double bond then R^9 and R^{10} are each independently H, cyano, carboxyl, C_1 - C_6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, heteroaryl or hydroxylalkyl or R^9 and R^{10} join to form a carbocyclic or heterocyclic ring; and

when $\equiv$ is a triple bond then R^9 is absent and R^{10} is H, C_1 - C_6 alkyl, aminylalkyl, alkylaminylalkyl or hydroxylalkyl.

In some embodiments of the compounds of structures (I'n), (I'o) or (I'p), R^1 is aryl or heteroaryl and R^{2a} and R^{2b} are independently selected from H and halo, for example in some further embodiments R^1 is aryl or heteroaryl and R^{2a} and R^{2b} are independently selected from halo, such as chloro and fluoro. In some embodiments, R^1 is aryl or heteroaryl, R^{2a} is chloro and R^{2b} is fluoro. In other embodiments R^1 is aryl or heteroaryl, one of R^{2a} or R^{2b} is halo, such as chloro or fluoro, and the other one of R^{2a} or R^{2b} is H. In other embodiments of the foregoing, R^6 is H, cyano, cyanoalkyl, amino, or C_1 - C_6 alkyl.

In other different embodiments, the bond between W and X Y and Z are both single bonds. For example, in some embodiments the compound has one of the following structures (I''''a) or (I''''b):



wherein:

$\equiv$ represents a double or triple bond;

5 Q is $-\text{C}(=\text{O})-$, $-\text{C}(=\text{NR}^{8'})-$, $-\text{NR}^8\text{C}(=\text{O})-$, $-\text{S}(=\text{O})_2-$ or $-\text{NR}^8\text{S}(=\text{O})_2-$;

R⁸ is H, C₁-C₆alkyl or hydroxylalkyl;


R^{8'} is H, -OH, -CN or C₁-C₆alkyl;

when $\equiv$ is a double bond then R^9 and R^{10} are each independently H, cyano, carboxyl, C_1 - C_6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, heteroaryl or hydroxylalkyl or R^9 and R^{10} join to form a carbocyclic or heterocyclic ring; and

when $\equiv$ is a triple bond then R⁹ is absent and R¹⁰ is H, C₁-C₆alkyl, aminylalkyl, alkylaminylalkyl or hydroxylalkyl.

In some embodiments of the compounds of structures (I''''a) or (I''''b), R¹ is aryl or heteroaryl and R^{2a} and R^{2b} are independently selected from H and halo, for example in some further embodiments R¹ is aryl or heteroaryl and R^{2a} and R^{2b} are independently selected from halo, such as chloro and fluoro. In some embodiments, R¹ is aryl or heteroaryl, R^{2a} is chloro and R^{2b} is fluoro. In other embodiments R¹ is aryl or heteroaryl, one of R^{2a} or R^{2b} is halo, such such as chloro or fluoro, and the other one of R^{2a} or R^{2b} is H. In other embodiments of the foregoing, R⁶ is H, cyano, cyanoalkyl, amino, or C₁-C₆ alkyl.

In yet more of any of the foregoing embodiments, E has the following structure:



wherein:

25 Q is $-\text{C}(=\text{O})-$, $-\text{C}(=\text{NR}^{8'})-$, $-\text{NR}^8\text{C}(=\text{O})-$, $-\text{S}(=\text{O})_2-$ or $-\text{NR}^8\text{S}(=\text{O})_2-$;

R⁸ is H, C₁-C₆alkyl or hydroxylalkyl;


$R^{8'}$ is H, -OH, -CN or C_1 - C_6 alkyl; and

R^9 and R^{10} are each independently H, cyano, C_1 - C_6 alkyl, aminylalkyl, alkylaminylalkyl, or hydroxylalkyl or R^9 and R^{10} join to form a carbocyclic or heterocyclic ring.

5 In some of the foregoing embodiments, Q is $-C(=O)-$, $-NR^8C(=O)-$, $-S(=O)_2-$ or $-NR^8S(=O)_2-$.

In some other of the foregoing embodiments, Q is $-C(=NR^{8'})-$, wherein $R^{8'}$ is H, -OH, -CN or C_1 - C_6 alkyl. For example, in some embodiments $R^{8'}$ is H. In other embodiments, $R^{8'}$ is -CN. In other embodiments, $R^{8'}$ is -OH.

10 In still other of any of the foregoing embodiments, E has the following structure:



wherein:

Q is $-C(=O)-$, $-NR^8C(=O)-$, $-S(=O)_2-$ or $-NR^8S(=O)_2-$;

15 R^8 is H, C_1 - C_6 alkyl or hydroxylalkyl; and

R^{10} is H, C_1 - C_6 alkyl, aminylalkyl, alkylaminylalkyl or hydroxylalkyl.

In some embodiments of any of the compounds described herein, C_1 - C_6 haloalkyl is CF_3 (e.g., when one or more of R^{2a} , R^{2b} or R^{2c} is C_1 - C_6 haloalkyl).

20 In some embodiments m^1 is 1. In other embodiments m^1 is 2. In still more embodiments, m^1 is 3. In different embodiments, m^2 is 1. In some other embodiments, m^2 is 2. In yet still more embodiments, m^2 is 3.

In some other particular embodiments of any of the foregoing compounds, m^1 is 1, and m^2 is 1. In other embodiments, m^1 is 1 and, m^2 is 2. In still other embodiments m^1 is 2, and m^2 is 2. In more embodiments, m^1 is 1, and m^2 is 3.

25 In any of the foregoing embodiments, G^1 and G^2 are each independently selected from N and CH. In some embodiments, at least one of G^1 or G^2 is N. In some embodiments, each of G^1 and G^2 are N. In some embodiments, each of G^1 and G^2 are N and m^1 and m^2 are each 2. In some other embodiments, at least one of G^1 or G^2 is CH. In other embodiments, each of G^1 and G^2 are CH.

Without wishing to be bound by theory, Applicants believe correct selection of the R^1 substituent may play a part in the compounds' inhibitory activity (e.g., against KRAS, HRAS or NRAS G12C). In some embodiments, R^1 is aryl or heterocyclyl (e.g., heteroaryl or aliphatic heterocyclyl), each of which is optionally substituted with one or more substituents. In some embodiments, R^1 is capable of reversible interaction with KRAS, HRAS or NRAS G12C mutant protein. In some embodiments R^1 has high affinity towards KRAS, HRAS or NRAS and is highly specific towards G12C KRAS, HRAS or NRAS. In some embodiments R^1 is capable of hydrophobic interaction with KRAS, HRAS or NRAS G12C. In some embodiments R^1 is able to form hydrogen bonds with various residues of G12C KRAS, HRAS or NRAS protein.

In other of the foregoing embodiments, R^1 is heterocyclyl, heteroaryl or aryl.


In certain embodiments of any of the foregoing, R^1 is aryl. For example, in some embodiments R^1 is phenyl. In other embodiments, R^1 is naphthyl. In some of these embodiments, R^1 is unsubstituted aryl, such as unsubstituted phenyl or unsubstituted naphthyl. In other embodiments, R^1 is substituted with one or more substituents. In some of these embodiments, the substituents are selected from halo, cyano, hydroxyl, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and C_3 - C_8 cycloalkyl. In other more specific embodiments, the substituents are selected from fluoro, chloro, bromo, hydroxyl, methoxy and cyclopropyl.


In other embodiments, the R^1 substituents are selected from halo, cyano, cyano C_1 - C_6 alkyl, cyano C_3 - C_8 cycloalkyl, hydroxyl, C_1 - C_6 alkyl, C_1 - C_6 alkylcycloalkyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, C_1 - C_6 haloalkoxy, C_1 - C_6 alkylaminyl, C_1 - C_6 alkylcarbonylaminyl, C_1 - C_6 hydroxylalkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxyalkyl, aminylsulfone, aminylcarbonyl, aminylcarbonyl C_1 - C_6 alkyl, aminylcarbonyl C_3 - C_8 cycloalkyl, C_1 - C_6 alkylaminylcarbonyl, C_3 - C_8 cycloalkylaminylcarbonyl, C_3 - C_8 cycloalkylalkyl and C_3 - C_8 fusedcycloalkyl and heteroaryl.

In still other embodiments, the R^1 substituents are selected from fluoro, chloro, bromo, cyano, hydroxyl, hydroxylmethyl, methoxy, methoxymethyl, ethyl, isopropyl, trifluoromethyl, aminylcarbonyl and cyclopropyl.


In still more embodiments, the R^1 substituents are selected from fluoro, chloro, bromo, cyano, hydroxyl, hydroxymethyl, methoxy, methoxymethyl, methyl, ethyl, isopropyl, difluoromethyl, trifluoromethyl, aminylcarbonyl and cyclopropyl.

In certain embodiments, R^1 has one of the following structures:







5 In other of the foregoing embodiments, R^1 has one of the following structures:



10 In still other embodiments, R^1 has one of the following structures:







In some different embodiments of any of the foregoing, R¹ is heteroaryl.

- 5 In certain embodiments, R¹ comprises oxygen, sulfur, nitrogen or combinations thereof. In some of these embodiments, R¹ comprises sulfur or nitrogen. In certain
embodiments, R¹ is thiophenyl, pyridinyl, pyridinonyl, pyrimidinyl, benzooxazolyl,
benzoxisoxazolyl, benzodioxazolyl, benzoimidazolyl, quinolinyl, quinolinonyl,
dihydroquinolinonyl, tetrahydroquinolinyl, quinazolinyl, indazolyl, indolinonyl,
10 benzothiophenyl or dihydrobenzodioxinyl.

In some embodiments, R¹ is substituted or unsubstituted indazolyl. In some of these embodiments the indazolyl is substituted with one or more C₁-C₆ alkyl, C₁-C₆ alkoxy and/or halo groups. For example, in some embodiments, the indazolyl is substituted with one or more methyl, methoxy, chloro and/or fluoro groups.


- 15 For example, in some embodiments R^1 is pyridinyl. In some
embodiments R^1 is unsubstituted pyridinyl, for example unsubstituted pyridin-4-yl or
unsubstituted pyridin-3-yl. In other embodiments R^1 is thiophenyl. In some
embodiments R^1 is unsubstituted thiophenyl, for example unsubstituted thiophen-2-yl.

In other embodiments, R¹ is substituted with one or more substituents.


- 20 For example, in some embodiments, the substituents are selected from halo, C₁-C₆alkyl, C₁-C₆alkoxy, or C₂-C₆alkenylcarbonylaminy. In some of these embodiments, the substituents are selected from halo and C₁-C₆alkyl. In other embodiments, the substituents are selected from fluoro, chloro, amino and methyl. For example, in more


specific embodiments, the substituents are selected from chloro and methyl. In other embodiments at least one R1 substituent is fluoro.

In some embodiments, R¹ has one of the following structures:




In certain embodiments, R¹ has one of the following structures:






In some of the foregoing embodiments, R^1 has one of the following

5 structures:



In still other embodiments, R^1 is aliphatic heterocyclyl. In some
embodiments the aliphatic heterocyclyl comprises oxygen and/or nitrogen. In some
further embodiments, R^1 is morpholinyl. For example, in some embodiments R^1 has the
10 following structure:



In various embodiments of the foregoing, R^1 is unsubstituted.

In some of the foregoing embodiments, R^{2a} is H. In other embodiments,
 R^{2a} is halo, for example in some embodiments R^{2a} is chloro or fluoro. In still other
15 embodiments of the foregoing, R^{2a} is C_1 - C_6 alkyl. For example, in some embodiments
 R^{2a} is C_3 - C_8 cycloalkyl, such as cyclopropyl.

In other embodiments of the foregoing compounds, R^{2b} and R^{2c} , when
present, are H. In different embodiments, R^{2b} and R^{2c} , when present, are each
independently halo. In yet other embodiments, R^{2b} , when present, is halo. In more
20 embodiments, R^{2c} , when present, is halo. In certain of the foregoing embodiments, halo
is chloro or fluoro.


The Q moiety is typically selected to optimize the reactivity (i.e., electrophilicity) of E. In certain of the foregoing embodiments, Q is $-C(=O)-$. In other embodiments, Q is $-S(=O)_2-$. In still more embodiments, Q is $-NR^8C(=O)-$. In still more different embodiments, Q is $-NR^8S(=O)_2-$.

5 In some of the immediately foregoing embodiments, R^8 is H. In other of these embodiments, R^8 is hydroxylalkyl, for example in some embodiments the hydroxylalkyl is 2-hydroxylalkyl.

In some embodiments, Q is $-C(=NR^{8'})-$, wherein $R^{8'}$ is H, $-OH$, $-CN$ or C_1-C_6 alkyl. For example, in some embodiments $R^{8'}$ is H. In other embodiments, $R^{8'}$ is $-CN$. In other embodiments, $R^{8'}$ is $-OH$.


In some of any one of the foregoing embodiments, at least one of R^9 or R^{10} is H. For example, in some embodiments each of R^9 and R^{10} are H.

In other of the foregoing embodiments, R^{10} is alkylaminylalkyl. In some of these embodiments, R^{10} has the following structure:




In other embodiments, R^{10} is hydroxylalkyl, such as 2-hydroxylalkyl.

In some other different embodiments of the foregoing embodiments, R^9 and R^{10} join to form a carbocyclic ring. For example, in some of these embodiments the carbocyclic ring is a cyclopentene, cyclohexene or phenyl ring. In other embodiments, the carbocyclic ring is a cyclopentene or cyclohexene ring. In other embodiments, the carbocyclic ring is a phenyl ring, for example a phenyl ring having the following structure:




In some of any of the foregoing embodiments E is an electrophile capable of bonding with a KRAS, HRAS or NRAS protein comprising G12C mutation. In some embodiments, the electrophile E is capable of forming an irreversible covalent bond with a G12C mutant KRAS, HRAS or NRAS protein. In some cases, the electrophile E may bind with the cysteine residue at the position 12 of a G12C mutant


KRAS, HRAS or NRAS protein. In various embodiments of any of the foregoing, E has one of the following structures:




In other embodiments of any of the foregoing, E has one of the following structures:



In different embodiments, E has one of the following structures:



In some cases E has one of the following structures:



wherein:

- 5 R^8 is H or C_1 - C_6 alkyl;
 R^9 is H, cyano or C_1 - C_6 alkyl, or R^9 joins with R^{10} to form a carbocycle;
 R^{10} is H or C_1 - C_6 alkyl or R^{10} joins with R^9 to form a carbocycle and
 R^{10a} is H or C_1 - C_6 alkyl.

- 10 In some embodiments E is . In some embodiments E is .

In some of any of the foregoing embodiments, L^1 is a bond. In other embodiments, L^1 is NR^7 . For example, in some of these embodiments, R^7 is C_1 - C_6 alkyl. In other embodiments, L^1 is NH.

- 15 L^2 can be selected to provide proper spacing and/or orientation for the E group to form a bond with the KRAS, HRAS or NRAS protein. In some of the foregoing embodiments, L^2 is a bond. In other of the foregoing embodiments, L^2 is alkylene. In some embodiments, the alkylene is substituted/ In other embodiments the alkylene is unsubstituted. For example, in some embodiments L^2 is CH_2 or CH_2CH_2 .

- 20 In certain embodiments, R^{3a} and R^{3b} are, at each occurrence, independently H, -OH, - NH_2 , - CO_2H , halo, cyano, hydroxylalkyl, aminylalkyl, cyanoalkyl, carboxyalkyl or aminylcarbonyl, and R^{4a} and R^{4b} are, at each occurrence, independently H, -OH, - NH_2 , - CO_2H , halo, cyano, hydroxylalkyl, aminylalkyl, cyanoalkyl, carboxyalkyl or aminylcarbonyl.

- 25 In other of the foregoing embodiments, R^{3a} and R^{4a} are, at each occurrence, independently H, -OH, hydroxylalkyl, cyano, or aminylcarbonyl and R^{3b} and R^{4b} are H.

In certain other embodiments, R^{3a} and R^{4a} are H and R^{3b} and R^{4b} are, at each occurrence, independently H, -OH, -NH₂, -CO₂H, halo, cyano, hydroxylalkyl, aminylalkyl, cyanoalkyl, carboxyalkyl or aminylcarbonyl.

In any of the foregoing embodiments, at least one of R^{3a} , R^{3b} , R^{4a} or R^{4b} is H. In some embodiments, each of R^{3a} , R^{3b} , R^{4a} and R^{4b} are H.


In some embodiments, R^{3a} is -OH, -NH₂, -CO₂H, halo, cyano, hydroxylalkyl, aminylalkyl, cyanoalkyl, carboxyalkyl or aminylcarbonyl, and R^{3b} , R^{4a} and R^{4b} are H.

In other embodiments, R^{4a} is -OH, -NH₂, -CO₂H, halo, cyano, hydroxylalkyl, aminylalkyl, cyanoalkyl, carboxyalkyl or aminylcarbonyl, and R^{3a} , R^{3b} and R^{4b} are H.

In other embodiments, R^{3a} is H, -OH, -NH₂, -CO₂H, halo, cyano, hydroxylalkyl, aminylalkyl, cyanoalkyl, carboxyalkyl or aminylcarbonyl, and R^{3b} joins with R^{4b} to form a carbocyclic or heterocyclic ring;

In still more embodiments, R^{4a} is H, -OH, -NH₂, -CO₂H, halo, cyano, hydroxylalkyl, aminylalkyl, cyanoalkyl, carboxyalkyl or aminylcarbonyl, and R^{4b} joins with R^{3b} to form a carbocyclic or heterocyclic ring.


In other embodiments, R^{3a} and R^{3b} join to form a carbocyclic or heterocyclic ring. In other embodiments, R^{4a} and R^{4b} join to form a carbocyclic or heterocyclic ring.

In still other embodiments, R^{3a} or R^{4a} is aminylcarbonyl. For example, in certain embodiments, the aminylcarbonyl is . In other embodiments, R^{3a} or R^{4a} is cyano. In other embodiments, R^{3a} or R^{4a} is -OH. In other embodiments, R^{3a} or R^{4a} is hydroxylalkyl, for example hydroxymethyl.

In some embodiments, R^6 is, at each occurrence, independently H, oxo, cyano, cyanoalkyl, aminyl, aminylalkyl, aminylalkylaminyl, aminylcarbonyl, aminylsulfonyl, -CO₂NR^aR^b, wherein R^a and R^b, are each independently H or C1-C6 alkyl or R^a and R^b join to form a carbocyclic or heterocyclic ring, alkylaminyl, haloalkylaminyl, hydroxylalkylaminyl, amindinylalkyl, amidinylalkoxy, amindinylalkylaminyl, guanidinylalkyl, guanidinylalkoxy, guanidinylalkylaminyl, C₁-

C₆ alkoxy, aminylalkoxy, alkylcarbonylaminyalkoxy, C₁-C₆ alkyl, heterocyclyl, heterocyclyloxy, heterocyclylalkyloxy, heterocyclylaminy, heterocyclylalkylaminy, heteroaryl, heteroaryloxy, heteroarylalkyloxy, heteroarylaminy, heteroarylalkylaminy, aryl, aryloxy, arylaminy, arylalkylaminy, arylalkyloxy or a bond to L¹.


5 Each of the foregoing R⁶ moieties may be substituted with one or more substituents. For example, in some embodiments the one or more substituents are aminyl (e.g., substituted or substituted), alkylcarbonyl aminyl, hydroxyl, haloalkyl or heterocyclyl (e.g., substituted or substituted aliphatic heterocycle or substituted or substituted heteroaryl). For example, in some embodiments, the R⁶ moiety is C₁-C₆
10 alkyl, C₁-C₆ alkoxy or alkylaminy, which is further substituted with alkylcarbonylaminy, hydroxyl, -CN or haloalkyl. For example, in some embodiments, R⁶ has one of the following structures:



15 wherein X is a bond, -O- or -NR-; each R is independently H or C₁-C₆alkyl and n is an integer from 0 to 6.


Various different R⁶ moieties are included in the scope of the compounds. For example, in various embodiments, R⁶ is H. In other embodiments, R⁶ is -CN. In more embodiments, R⁶ is methoxy.

20 In various other embodiments, R⁶ is aminylalkyl, aminylalkyloxy or aminylalkylaminy. For example, in some embodiments R⁶ has the following structures:




wherein X is a bond, -O- or -NR-; each R is independently H or C₁-C₆alkyl and n is an integer from 0 to 6.

25 In other embodiments, R⁶ is amindinylalkyl, amidinylalkoxy, amindinylalkylaminy, guanidinylalkyl, guanidinylalkoxy or guanidinylalkylaminy. For example, in some embodiments R⁶ has one of the following structures:



wherein X is a bond, -O- or -NR-; each R is independently H or C₁-C₆alkyl and n is an integer from 0 to 6.

In other embodiments, R⁶ is heterocyclyl, heterocycloxy, heterocyclylalkyloxy, heterocyclylaminy, heterocyclylalkylaminy, heteroaryl, heteroaryloxy, heteroarylalkyloxy, heteroarylaminy or heteroarylalkylaminy. For example, in some embodiments R⁶ has one of the following structures:



wherein X is a bond, -O- or -NR-; each R is independently H or C₁-C₆alkyl and n is an integer from 0 to 6.

15 In some of the foregoing embodiments, X is N. In other of the foregoing embodiments, X is N. In other of the foregoing embodiments, Z is N. In still more embodiments, X is N and Z is N.

In some embodiments, Z is N and Y is N. In other embodiments, X is N, Z is N, Y is CR⁶, wherein R⁶ is H and W is CR⁶, wherein R⁶ is a bond to L¹. In different embodiments, Z is N and Y is CR⁶, wherein R⁶ is H, W is CR⁶, wherein R⁶ is a bond to L¹ and X is CR⁶, wherein R⁶ is cyano, methoxy or amino.

20 In other embodiments, Z is N, X is CR⁶ and R⁶ is cyano, Y is CR⁶, wherein R⁶ is H and W is CR⁶, wherein R⁶ is a bond to L¹.

In other embodiments, Y is N, Z is N, W is CR⁶, wherein R⁶ is a bond to L¹ and X is CR⁶, wherein R⁶ is H.




In other of the foregoing embodiments, Z is a bond.

In certain embodiments, Y is NR⁵. In some of these embodiments, R⁵ is
 5 C₁-C₆alkyl. In other embodiments, R⁵ is H.

In still other embodiments, X or Y is CR⁶. In some of these
 embodiments, R⁶ is, at each occurrence, independently H, cyano, amino, C₁-C₆alkoxy
 or a bond to L¹. In some other of these embodiments, R⁶ is H. In other embodiments,
 R⁶ is C₁-C₆alkoxy. In other embodiments, R⁶ is cyano. In more embodiments, R⁶ is
 10 methoxy. In other embodiments, R⁶ is amino.

In various different embodiments, the compound has one of the
 structures set forth in Table 1 below:

Table 1
 Representative Compounds







No.	Structure	Name	Method	[M+H] ⁺
1		1-(4-(7-chloro-6-(2-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	413.20
2		1-(4-(7-chloro-6-(2-chlorophenyl)quinazolin-4-ylamino)piperidin-1-yl)prop-2-en-1-one	A	427.25
3		1-(4-(6-chloro-5-(2-chlorophenyl)-1H-indazol-3-yl)piperazin-1-yl)prop-2-en-1-one	C	401.20

No.	Structure	Name	Method	[M+H] ⁺
4		1-(4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	413.25
5		1-(4-(7-chloro-6-(3-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	413.20
6		1-(4-(7-chloro-6-(2,4-dichlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	447.20 [#]
7		1-(4-(7-chloro-6-(3,4-dichlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	449.15
8		2-(4-(4-acryloylpiperazin-1-yl)-7-chloroquinazolin-6-yl)benzonitrile	B	404.1
9		1-(4-(7-chloro-6-(2,5-dichlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	448.45

No.	Structure	Name	Method	[M+H] ⁺
10		1-(4-(7-chloro-6-(5-chloro-2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	429.25
11		1-(4-(7-chloro-6-(4-chloro-2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	429.25
12		1-(4-(7-chloro-6-(4-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	395.25
13		1-(4-(7-chloro-6-(4-chloro-2-methoxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	443.30
14		1-(4-(7-chloro-6-(3-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	395.25
15		1-(4-(7-chloro-6-(2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	395.25

No.	Structure	Name	Method	[M+H] ⁺
16		4-(4-(4-acryloylpiperazin-1-yl)-7-chloroquinazolin-6-yl)benzonitrile	B	404.3
17		1-(4-(7-chloro-6-(pyridin-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	380.25
18		1-(4-(7-chloro-6-phenylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	379.25
19		3-(4-(4-acryloylpiperazin-1-yl)-7-chloroquinazolin-6-yl)benzonitrile	B	404.25
20		1-(4-(7-chloro-6-(pyridin-3-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	380.25
21		1-(4-(7-chloro-6-(thiophen-2-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	385.25

No.	Structure	Name	Method	[M+H] ⁺
22		1-(4-(5-(2-chlorophenyl)-4a,7a-dihydrothieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one	H	385.20
23		1-(4-(7-chloro-6-(2-chloro-5-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	431.20
24		1-(4-(6-chloro-7-(2-chlorophenyl)isoquinolin-1-yl)piperazin-1-yl)prop-2-en-1-one	D	412.20
25		(E)-1-(4-(7-chloro-6-(2-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)-4-(dimethylamino)but-2-en-1-one	A	470.35
26		1-(4-(7-chloro-6-(5-methylthiophen-2-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	399.20
27		1-(4-(7-chloro-6-(2-chlorophenyl)quinolin-4-yl)piperazin-1-yl)prop-2-en-1-one	E	412.20







No.	Structure	Name	Method	[M+H] ⁺
28		1-(4-(5-(2-chlorophenyl)-7,7a-dihydro-4aH-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one	J	368.25
29		N-(1-(7-chloro-6-(2-chlorophenyl)quinazolin-4-yl)azetidin-3-yl)acrylamide	B	399.20
30		1-(3-(7-chloro-6-(2-chlorophenyl)quinazolin-4-ylamino)azetidin-1-yl)prop-2-en-1-one	B	399.20
31		1-(4-(6-chloro-5-(2-chlorophenyl)-1H-indazol-3-ylamino)piperidin-1-yl)prop-2-en-1-one	C	413.40 ⁺
32		1-(4-(7-chloro-6-morpholinoquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	L	388.25
33		1-(4-(6-(2-chlorophenyl)-7-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	397.20







No.	Structure	Name	Method	[M+H] ⁺
34		1-(4-(7-chloro-6-(5-chlorothiophen-2-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	419.15
35		1-(4-(8-(2-chlorophenyl)quinazolin-2-yl)piperazin-1-yl)prop-2-en-1-one	I	379.1
36		1-(4-(7-chloro-6-(2-chlorophenyl)quinazolin-4-yl)piperidin-1-yl)prop-2-en-1-one	K	410.35 ⁺
37		1-(4-(6-chloro-7-(4-chlorophenyl)isoquinolin-1-yl)piperazin-1-yl)prop-2-en-1-one	D	412.20
38		1-(4-(6-chloro-7-(4-chloro-2-hydroxyphenyl)isoquinolin-1-yl)piperazin-1-yl)prop-2-en-1-one	D	428.25
39		1-(4-(2-amino-7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	428.3

No.	Structure	Name	Method	[M+H] ⁺
40		1-(4-(6-(4-bromophenyl)-7-chloroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	459.25
41		1-(4-(7-cyclopropyl-6-(4-cyclopropylphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	425.25
42		4-(4-acryloylpiperazin-1-yl)-7-chloro-6-(4-chlorophenyl)quinoline-3-carbonitrile	G	437.25
43		1-(4-(7-chloro-6-(4-chlorophenyl)-2-methoxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	465.30 [*]
44		1-acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carboxamide	A	454.35 ⁺
45		7-chloro-6-(4-chlorophenyl)-4-(4-(vinylsulfonyl)piperazin-1-yl)quinazoline	A	449.25

No.	Structure	Name	Method	[M+H] ⁺
46		1-(4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one	A	443.30
47		1-acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carbonitrile	A	438.25
48		1-acryloyl-4-(7-chloroquinazolin-4-yl)piperazine-2-carbonitrile	A	328.2
49		1-acryloyl-4-(6-bromo-7-chloroquinazolin-4-yl)piperazine-2-carbonitrile	A	408.20
50		1-(4-(7-chloro-6-(4-chlorophenyl)-2-methylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	M	427.35
51		1-acryloyl-4-(7-chloro-6-(thiophen-2-yl)quinazolin-4-yl)piperazine-2-carbonitrile	A	410.30






No.	Structure	Name	Method	[M+H] ⁺
52		1-acryloyl-4-(7-chloro-6-phenylquinazolin-4-yl)piperazine-2-carbonitrile	A	404.35
53		4-(4-acryloyl-3-cyanopiperazin-1-yl)-7-chloroquinazoline-6-carbonitrile	B	353.20
54		(S)-1-acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carboxamide	A	456.30
55		1-acryloyl-4-(7-chloro-6-cyclopropylquinazolin-4-yl)piperazine-2-carbonitrile	B	368.25
56		1-acryloyl-4-(7-chloro-6-(4-chlorophenyl)-2-methylquinazolin-4-yl)piperazine-2-carbonitrile	M	452.30
57		1-acryloyl-4-(quinazolin-4-yl)piperazine-2-carbonitrile	A	294.20

No.	Structure	Name	Method	[M+H] ⁺
58		(R)-1-acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carbonitrile	A	438.20
59		(S)-1-acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carbonitrile	A	438.25
60		1-(4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-((dimethylamino)methyl)piperazin-1-yl)prop-2-en-1-one	A	470.35
61		1-acryloyl-4-(6-chloroisoquinolin-1-yl)piperazine-2-carbonitrile	D	327.20
62		1-(4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-(2-hydroxyethyl)piperazin-1-yl)prop-2-en-1-one	A	457.35
63		(S)-1-(4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one	A	443.30

No.	Structure	Name	Method	[M+H] ⁺
64		(R)-1-acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carboxamide	A	456.30
65		(R)-1-(4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one	A	443.35
66		(E)-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-1-(4-(dimethylamino)but-2-enoyl)piperazine-2-carbonitrile	A	495.40
67		1-(4-(6-chloro-7-phenylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	379.30
68		1-(4-(6-chloro-7-cyclopropylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	343.25
69		2-(1-acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)acetamide	A	470.35

No.	Structure	Name	Method	[M+H] ⁺
70		2-(1-acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)acetonitrile	A	452.35
71		1-(4-(6-(4-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	379.30
72		1-(4-(6-chloro-7-(2-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	413.25
73		1-(4-(6-chloro-7-(3-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	413.3
74		1-(4-(6-chloro-7-(2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	395.25






No.	Structure	Name	Method	[M+H] ⁺
75		1-(4-(6-chloro-7-(3-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	395.25
76		1-(4-(6-chloro-7-phenoxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	L	395.25
77		1-(4-(6-chloro-7-(2-ethylphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	407.75
78		1-(4-(6-chloro-7-(4-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	413.25
79		1-(4-(6-chloro-7-(3-ethylphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	407.30






No.	Structure	Name	Method	[M+H] ⁺
80		1-(4-(6-chloro-7-(piperidin-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	L	387.25
81		1-(4-(6-chloro-7-(2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	397.25
82		(E)-1-(4-(6-chloro-7-phenylquinazolin-4-yl)piperazin-1-yl)-4-(dimethylamino)but-2-en-1-one	A	436.40
83		1-(4-(6-chloro-7-(4-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	397.25
84		1-(4-(6-chloro-7-(3-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	397.25

No.	Structure	Name	Method	[M+H] ⁺
85		2-(1-acryloyl-4-(6-chloro-7-phenylquinazolin-4-yl)piperazin-2-yl)acetonitrile	A	418.30
86		1-(4-(6-cyclopropyl-7-phenylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	385.75
87		1-(4-(7-phenylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	345.20
88		1-(4-(7-chloro-6-phenylisoquinolin-1-yl)piperazin-1-yl)prop-2-en-1-one	D	378.20
89		N-(1-(6-chloro-7-phenylquinazolin-4-yl)piperidin-4-yl)acrylamide	B	393.25

No.	Structure	Name	Method	[M+H] ⁺
90		1-(4-(6-chloro-7-(pyridin-3-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	380.25
91		1-(4-(6-chloro-7-phenylquinolin-4-yl)piperazin-1-yl)prop-2-en-1-one	E	378.20
92		1-(4-(6-chloro-7-(pyridin-2-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	380.25
93		1-(4-(6-ethyl-7-phenylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	373.75
94		1-(4-(6-chloro-2-methoxy-7-phenylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	409.30

No.	Structure	Name	Method	[M+H] ⁺
95		1-(4-(6-chloro-2-methyl-7-phenylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	M	393.70
96		1-(3-(6-chloro-7-phenylquinazolin-4-ylamino)azetidin-1-yl)prop-2-en-1-one	A	365.20
97		1-(4-(6-chloro-7-(2-methoxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	409.7
98		2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)benzamide	B	422.30
99		1-(4-(6-chloro-7-(2-isopropylphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	421.35

No.	Structure	Name	Method	[M+H] ⁺
100		1-(4-(6-chloro-7-(2-(trifluoromethyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	447.80
101		1-(4-(6-chloro-7-(2,5-dichlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	447.25
102		1-(4-(6-chloro-7-(2,4-dichlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	447.30
103		1-(4-(6-chloro-7-(2-(methoxymethyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	423.35
104		1-acryloyl-4-(6-chloro-7-phenylquinazolin-4-yl)piperazine-2-carboxamide	B	422.35





No.	Structure	Name	Method	[M+H] ⁺
105		2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)benzonitrile	B	405.20
106		2-(1-acryloyl-4-(6-chloro-7-(2-fluorophenyl)quinazolin-4-yl)piperazin-2-yl)acetonitrile	B	437.30
107		2-(1-acryloyl-4-(6-chloro-7-(2-ethylphenyl)quinazolin-4-yl)piperazin-2-yl)acetonitrile	B	446.35
108		1-(4-(6-chloro-7-(2-(hydroxymethyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	409.30
109		2-(1-acryloyl-4-(6-chloro-7-(2-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)acetonitrile	B	452.30






No.	Structure	Name	Method	[M+H] ⁺
110		2-(1-acryloyl-4-(6-chloro-7-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)acetonitrile	B	452.25
111		2-(1-acryloyl-4-(6-chloro-7-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)acetonitrile	B	452.25
112		1-(4-(6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	415.0
113		1-(4-(6-chloro-7-(2,5-difluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	415.10
114		1-(4-(6-chloro-7-(4-chloro-2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	431.05

No.	Structure	Name	Method	[M+H] ⁺
115		1-(4-(6-chloro-7-(5-chloro-2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	431.05
116		1-(4-(6-chloro-7-phenylquinazolin-4-yl)-2-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one	B	409.25
117		1-(4-(6-chloro-7-(4-chloro-2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	429.35
118		1-(4-(6-chloro-7-(5-chloro-2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	429.30
119		1-(4-(6-chloro-7-(4-fluoro-2-(trifluoromethyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	465.35

No.	Structure	Name	Method	[M+H] ⁺
120		1-acryloyl-4-(6-chloro-7-(2-fluorophenyl)quinazolin-4-yl)piperazine-2-carboxamide	B	440.30
121		1-acryloyl-4-(6-chloro-7-(2-(trifluoromethyl)phenyl)quinazolin-4-yl)piperazine-2-carboxamide	B	490.40
122		1-(4-(6-chloro-7-(5-fluoro-2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	413.30
123		1-(4-(6-chloro-7-(naphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	429.35
124		1-(4-(6-chloro-7-(2-(trifluoromethyl)phenyl)quinazolin-4-yl)-2-methylpiperazin-1-yl)prop-2-en-1-one	B	461.35

No.	Structure	Name	Method	[M+H] ⁺
125		2-(1-acryloyl-4-(6-chloro-7-(2-(trifluoromethyl)phenyl)quinazolin-4-yl)piperazin-2-yl)acetonitrile	B	486.40
126		1-(4-(6-chloro-7-(2-cyclopropylphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	419.20
127		4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(2-fluorophenyl)quinoline-3-carbonitrile	G	421.30
128		1-(4-(6-chloro-7-(2-chloro-5-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	430.10
129		1-(4-(7-(benzo[d]oxazol-7-yl)-6-chloroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	420.10

No.	Structure	Name	Method	[M+H] ⁺
130		3-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)benzonitrile	B	404.10
131		3-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-2-fluoro-N,N-dimethylbenzamide	B	468.10
132		1-(4-(6-chloro-7-(2,6-difluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	415.3
133		1-(4-(6-chloro-7-(4-fluoro-2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	413.30

No.	Structure	Name	Method	[M+H] ⁺
134		1-(4-(6-chloro-7-(2-hydroxyphenyl)quinazolin-4-yl)-2-methylpiperazin-1-yl)prop-2-en-1-one	B	409.30
135		1-(4-(6-chloro-7-(quinolin-5-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	430.30
136		1-(4-(6-chloro-7-(isoquinolin-5-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	430.35
137		4-(4-acryloylpiperazin-1-yl)-7-(2-fluorophenyl)quinazoline-6-carbonitrile	B	388.30
138		1-(4-(6-chloro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	413.25






No.	Structure	Name	Method	[M+H] ⁺
139		2-(1-acryloyl-4-(6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl)piperazin-2-yl)acetonitrile	B	454.30
140		1-(4-(6-chloro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Q	433.15
141		1-(4-(6-chloro-7-(2-fluoro-5-(trifluoromethoxy)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	481.10
142		3-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-N-cyclopropylbenzamide	B	462.20
143		1-(3-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-4-fluorophenyl)cyclopropanecarbonitrile	B	462.10






No.	Structure	Name	Method	[M+H] ⁺
144		1-(4-(6-chloro-7-(1H-indazol-5-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	419.25
145		1-acryloyl-4-(6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl)piperazine-2-carbonitrile	B	440.30
146		1-acryloyl-4-(6-chloro-7-(2-hydroxyphenyl)quinazolin-4-yl)piperazine-2-carbonitrile	B	420.25
147		1-(4-(6-chloro-7-(5-cyclopropyl-2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	437.10
148		1-(4-(6-chloro-7-(5,6,7,8-tetrahydronaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	433.20





No.	Structure	Name	Method	[M+H] ⁺
149		1-(4-(7-(3-aminobenzo[d]isoxazol-4-yl)-6-chloroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	435.30
150		1-(4-(7-(2-fluorophenyl)-6-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	R	431.30
151		1-(1-acryloylpiperidin-4-yl)-7-chloro-6-(2,4-difluorophenyl)quinoxalin-2(1H)-one	S	430.30
152		1-(4-(6-chloro-7-(1H-indazol-7-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	419.30

No.	Structure	Name	Method	[M+H] ⁺
153		1-(4-(6-chloro-7-(2-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Q	445.10
154		1-(4-(6-chloro-7-(2-ethynylphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	403.25
155		3-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-4-fluorobenzamide	B	440.25
156		1-(4-(6-chloro-7-(2-(cyclopropylmethyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	433.35
157		1-(4-(7-(2-(trifluoromethyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	413.10

No.	Structure	Name	Method	[M+H] ⁺
158		1-(4-(6-chloro-8-fluoro-7-(2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	415.25
159		1-(4-(6-chloro-7-(2-fluorophenyl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one	N	397.25
160		4-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)indolin-2-one	B	434.25
161		2-(2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)phenyl)acetamide	B	436.1
162		1-(4-(6-chloro-7-(1H-indazol-6-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	419.3

No.	Structure	Name	Method	[M+H] ⁺
163		1-(4-(7-(2-fluorophenyl)-6-hydroxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	A	379.25
164		1-(4-(7-(2-aminobenzo[d]oxazol-5-yl)-6-chloroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	435.25
165		1-(4-(7-(1H-benzo[d]imidazol-4-yl)-6-chloroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	419.30
166		1-(4-(6-(2-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one	H	419.10
167		1-(4-(6-chloro-7-(1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	419.30

No.	Structure	Name	Method	[M+H] ⁺
168		2-(2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)phenyl)acetonitrile	B	418.1
169		1-(4-(6-chloro-7-(4-hydroxy-2-(trifluoromethyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	463.30
170		3-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)pyridin-2(1H)-one	B	396.25
171		4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(naphthalen-1-yl)quinoline-3-carbonitrile	P	453.30
172		4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(2,4-difluorophenyl)quinoline-3-carbonitrile	P	439.25






No.	Structure	Name	Method	[M+H] ⁺
173		4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(2-(trifluoromethyl)phenyl)quinoline-3-carbonitrile	P	471.35
174		N-(3-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-4-fluorophenyl)acetamide	B	454.10
175		1-(2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)phenyl)cyclopropanecarbonitrile	B	444.1
176		1-(2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)phenyl)cyclopropanecarboxamide	B	462.2

No.	Structure	Name	Method	[M+H] ⁺
177		1-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-5-chloropyridin-2(1H)-one	T	430.20
178		N-(4-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-5-methylpyrimidin-2-yl)acrylamide	B	464.10
179		1-(4-(7-(2-amino-5-methylpyrimidin-4-yl)-6-chloroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	410.10
180		1-(4-(6-chloro-7,8'-biquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	431.10
181		1-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-4-chloropyridin-2(1H)-one	T	430.10

No.	Structure	Name	Method	[M+H] ⁺
182		4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(2-hydroxyphenyl)quinoline-3-carbonitrile	P	419.15
183		1-(4-(7-(2-(1H-pyrazol-4-yl)phenyl)-6-chloroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	445.20
184		4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(2-chloro-5-hydroxyphenyl)quinoline-3-carbonitrile	P	453.15
185		1-(4-(6-chloro-7-(thiophen-2-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	385.10
186		1-(4-(6-chloro-7-(2-thiazol-2-yl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	U	462.25






No.	Structure	Name	Method	[M+H] ⁺
187		1-(4-(6-chloro-7-(2-(thiazol-5-yl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	U	462.25
188		1-(4-(6-chloro-7-(2-(1H-pyrazol-4-yl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	463.20
189		4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(2-fluorophenyl)quinoline-3-carboxamide	P	439.60
190		1-(4-(7-(2-amino-4-methylpyrimidin-5-yl)-6-chloroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	410.10
191		1-(4-(6-chloro-7-(2-methyl-5-(methylamino)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	422.20

No.	Structure	Name	Method	[M+H] ⁺
192		2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-3-fluorobenzonitrile	B	422.10
193		2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-5-fluorobenzamide	B	440.20
194		1-(4-(6-chloro-7-(2-fluoro-6-methoxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	427.15
195		1-(4-(6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl)-2-ethynylpiperazin-1-yl)prop-2-en-1-one	B	439.15
196		4-(4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(2-fluoro-5-hydroxyphenyl)quinoline-3-carbonitrile	P	437.15

No.	Structure	Name	Method	[M+H] ⁺
197		2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-4-fluorobenzamide	B	440.20
198		1-(4-(7-(benzo[b]thiophen-3-yl)-6-chloroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	435.15
199		1-(4-(6-chloro-7-(2,3-difluoro-6-methoxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	445.1
200		1-(4-(6-chloro-7-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	459.10
201		1-(4-(6-chloro-7-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	437.1






No.	Structure	Name	Method	[M+H] ⁺
202		1-(4-(6-chloro-7-(2-methoxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	459.15
203		1-(4-(6-chloro-7-(2,3-difluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	431.10
204		1-(4-(7-(2,4-difluorophenyl)-6-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	449.15
205		5-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-3,4-dihydroquinolin-2(1H)-one	B	448.15
206		1-(4-(6-chloro-7-(2,4-difluoro-5-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	U	431.10





No.	Structure	Name	Method	[M+H] ⁺
207		1-(4-(7-(2-chloro-5-hydroxyphenyl)-6-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	R	463.15
208		1-(4-(7-(2-fluoro-6-hydroxyphenyl)-6-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	R	447.20
209		1-(4-(6-chloro-8-fluoro-7-(2-(trifluoromethyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	465.15
210		1-(4-(6,8-dichloro-7-(2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	R	431.10
211		2-(4-(4-acryloylpiperazin-1-yl)-6-(trifluoromethyl)quinazolin-7-yl)benzamide	R	456.15





No.	Structure	Name	Method	[M+H] ⁺
212		1-(4-(6-(trifluoromethyl)-7-(2-(trifluoromethyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	R	481.20
213		2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)benzenesulfonamide	B	458.10
214		1-(4-(6-chloro-7-(quinolin-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Q	430.10
215		1-(4-(6-chloro-3-ethynyl-7-(2-fluorophenyl)quinolin-4-yl)piperazin-1-yl)prop-2-en-1-one	G	430.10
216		1-(4-(6-chloro-7-(3,6-difluoro-2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	U	431.15





No.	Structure	Name	Method	[M+H] ⁺
217		1-(4-(6-chloro-7-(2-chloro-5-hydroxyphenyl)-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	447.05
218		1-(4-(7-(2-hydroxynaphthalen-1-yl)-6-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	R	479.20
219		(E)-1-(4-(6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl)piperazin-1-yl)-4-(dimethylamino)but-2-en-1-one	O	472.10
220		4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)quinoline-3-carbonitrile	P	437.15
221		1-(4-(6-chloro-7-(2,4-difluorophenyl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one	N	415.10





No.	Structure	Name	Method	[M+H] ⁺
222		1-(4-(6-chloro-7-(2-(1-methylcyclopropyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	433.20
223		1-(4-(6-chloro-7-(1,2,3,4-tetrahydroquinolin-5-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	434.15
224		1-(4-(6-chloro-7-(2,4-difluorophenyl)-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	433.10
225		1-(4-(6-chloro-7-(2-(trifluoromethyl)phenyl)cinolin-4-yl)piperazin-1-yl)prop-2-en-1-one	N	447.05
226		1-(4-(6-chloro-7-(1-methyl-1H-indazol-3-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	433.05

No.	Structure	Name	Method	[M+H] ⁺
227		1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	431.05
228		(E)-1-(4-(6-chloro-7-(2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)-4-(dimethylamino)but-2-en-1-one	B	454.15
229		(E)-1-(4-(6-chloro-8-fluoro-7-(2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)-4-(dimethylamino)but-2-en-1-one	O	472.15
230		(E)-4-(dimethylamino)-1-(4-(8-fluoro-6,7-bis(2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)but-2-en-1-one	O	532.25
231		1-(4-(6-chloro-7-(2-fluoro-6-hydroxyphenyl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one	N	413.10

No.	Structure	Name	Method	[M+H] ⁺
232		2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-3-fluorobenzamide	Q	440.10
233		1-(4-(6-chloro-7-(2-hydroxy-6-(trifluoromethyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	463.10
234		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	451.1
235		1-(4-(6-chloro-8-fluoro-7-(2-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	463.10

No.	Structure	Name	Method	[M+H] ⁺
236		2-(4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoroquinazolin-7-yl)benzamide	O	440.10
237		1-(4-(7-(5-methyl-1H-indazol-4-yl)-6-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	R	467.20
238		1-(4-(6-chloro-7-(5-methyl-1H-indazol-4-yl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one	N	433.10
239		(E)-ethyl 4-(4-(6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl)piperazin-1-yl)-4-oxobut-2-enoate	O	487.10





No.	Structure	Name	Method	[M+H] ⁺
240		8-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)quinolin-2(1H)-one	U	446.10
241		(E)-2-(4-(6-chloro-7-(2-fluorophenyl)quinazolin-4-yl)piperazine-1-carbonyl)-4-methylpent-2-enenitrile	B	464.10
242		4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(2-fluorophenyl)quinoline-3-carbonitrile	P	439.10
243		2-(1-acryloyl-4-(6-chloro-8-fluoro-7-(2-(trifluoromethyl)phenyl)quinazolin-4-yl)piperazin-2-yl)acetonitrile	O	504.10






No.	Structure	Name	Method	[M+H] ⁺
244		1-(4-(6-chloro-7-(5-methoxy-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	449.10
245		(E)-2-(4-(6-chloro-7-(2-fluorophenyl)quinazolin-4-yl)piperazine-1-carbonyl)-3-(thiazol-5-yl)acrylonitrile	B	505.10
246		4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinoline-3-carbonitrile	P	455.15
247		1-(4-(6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl)piperazin-1-yl)-4-hydroxybut-2-yn-1-one	B	443.1

No.	Structure	Name	Method	[M+H] ⁺
248		1-(4-(6-chloro-8-fluoro-2-(2-hydroxyethylamino)-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	522.30
249		1-(4-(6-chloro-7-(3-methoxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	459.1
250		1-(4-(6-chloro-7-(2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AF	449.10
251		1-(4-(6-chloro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	P	445.10





No.	Structure	Name	Method	[M+H] ⁺
252		1-(4-(6-chloro-8-fluoro-7-(2-ethynylpiperazin-1-yl)prop-2-en-1-one)-2-fluorophenyl)quinazolin-4-yl)-2-ethynylpiperazin-1-yl)prop-2-en-1-one	O	439.10
253		1-(4-(6-chloro-2-(2-(dimethylamino)ethylamino)-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	537.4
254		1-(4-(6-chloro-2-((dimethylamino)methyl)-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AD	508.3
255		1-(4-(6-chloro-7-(5,6-dimethyl-1H-indazol-7-yl)-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Q	465.1
256		1-(4-(6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)-2-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one	O	493.3

No.	Structure	Name	Method	[M+H] ⁺
257		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(methylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	480.2
258		1-(4-(6-chloro-7-(2-hydroxynaphthalen-1-yl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one	N	445.1
259		(E)-2-(4-(6-chloro-7-(2-fluorophenyl)quinazolin-4-yl)piperazine-1-carbonyl)-3-(4-methyloxazol-2-yl)acrylonitrile	B	503.2
260		4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(2-hydroxynaphthalen-1-yl)quinoline-3-carbonitrile	P	469.1
261		(E)-2-(4-(6-chloro-7-(2-fluorophenyl)quinazolin-4-yl)piperazine-1-carbonyl)-5-hydroxy-4,4-dimethylpent-2-enenitrile	B	494.4





No.	Structure	Name	Method	[M+H] ⁺
262		1-(4-(6-chloro-7-(6-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AF	494.3
263		(Z)-4-(4-(6-chloro-7-(2,4-difluorophenyl)quinazolin-4-yl)piperazin-1-yl)-4-oxobut-2-enenitrile	B	440.1
264		1-(4-(6-chloro-7-(5-chloro-1H-indazol-7-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AF	454.1
265		2-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-3-hydroxybenzonitrile	AF	420.1

No.	Structure	Name	Method	[M+H] ⁺
266		1-(4-(6-chloro-7-(6-chloro-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	453.1
267		1-(4-(6-chloro-7-(2-fluoro-5-(2-hydroxypropan-2-yl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	455.1
268		1-(4-(6-chloro-7-(6-methyl-1H-indazol-7-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AF	433.2
269		4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(2-hydroxynaphthalen-1-yl)quinoline-3-carbonitrile	P	487.1
270		4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(5-methyl-1H-indazol-4-yl)quinoline-3-carbonitrile	P	457.1

No.	Structure	Name	Method	[M+H] ⁺
271		1-(4-(8-fluoro-7-(2-fluorophenyl)-6-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	W	449.2
272		1-(4-(6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Q	463.2
273		1-(4-(8-fluoro-7-(2-fluoro-6-hydroxyphenyl)-6-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	W	465.2
274		1-(4-(6-chloro-8-fluoro-7-(6-methyl-1H-indazol-7-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	451.2
275		1-(4-(6-chloro-8-fluoro-7-(4-fluoro-2-(trifluoromethyl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	483.2

No.	Structure	Name	Method	[M+H] ⁺
276		1-(4-(7-(3-(1H-pyrazol-5-yl)phenyl)-6-chloroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Q	445.2
277		1-(4-(6-chloro-7-(3,6-difluoro-2-hydroxyphenyl)-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	449.1
278		1-(4-(6-chloro-8-fluoro-7-(2-(2-hydroxypropan-2-yl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	455.2
279		1-(4-(7-(2-fluoro-6-(trifluoromethyl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one	X	447.2

No.	Structure	Name	Method	[M+H] ⁺
280		1-(4-(6-chloro-7-(2,4-difluoro-6-hydroxyphenyl)-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	449.1
281		1-(4-(6-chloro-8-fluoro-7-(2-fluoro-5-(1H-imidazol-4-yl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	481.2
282		(E)-2-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazine-1-carbonyl)-4-methylpent-2-enenitrile	O	498.2
283		(E)-2-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazine-1-carbonyl)-3-(thiazol-5-yl)acrylonitrile	O	539.2

No.	Structure	Name	Method	[M+H] ⁺
284		(E)-2-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazine-1-carbonyl)-3-(pyridin-2-yl)acrylonitrile	O	533.2
285		4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(2-(trifluoromethyl)phenyl)quinoline-3-carbonitrile	P	489.2
286		1-(4-(6,8-dichloro-7-(2-methoxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	V	494.1
287		1-(4-(6-chloro-8-fluoro-7-(2-methoxy-6-methylphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Q	441.2

No.	Structure	Name	Method	[M+H] ⁺
288		1-(4-(6-chloro-8-fluoro-7-(1H-indol-3-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Q	436.1
289		1-(4-(6-chloro-7-(2-chloro-6-hydroxyphenyl)-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	448.0
290		1-(4-(6-chloro-7-(2-chloro-6-methylphenyl)-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Q	427.1
291		4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinoline-3-carbonitrile	P	487.1
292		1-(4-(7-(2,4-difluorophenyl)-8-fluoro-6-methylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AJ	413.2

No.	Structure	Name	Method	[M+H] ⁺
293		4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinoline-3-carbonitrile	P	475.2
294		2-(1-acryloyl-4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-2-yl)acetonitrile	O	490.2
295		(E)-1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)-4-(dimethylamino)but-2-en-1-one	O	508.2
296		1-(4-(7-(2,4-difluorophenyl)-6,8-difluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Y	417.22
297		1-(4-(6,8-difluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Y	435.3






No.	Structure	Name	Method	[M+H] ⁺
298		1-(4-(6,8-difluoro-7-(6-methyl-1H-indazol-7-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Y	435.3
299		1-(4-(6,8-difluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Y	415.3
300		1-(4-(6-chloro-7-(5-methyl-1H-indazol-4-yl)-2-(tetrahydrofuran-3-yloxy)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	519.3
301		(E)-1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)-4-(dimethylamino)but-2-en-1-one	O	488.2
302		1-(4-(6-chloro-8-methoxy-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Z	463.3

No.	Structure	Name	Method	[M+H] ⁺
303		1-(4-(6,8-dichloro-7-(2-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	V	479.1
304		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(1H-pyrazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AG	517.0
305		1-(4-(7-(5-methyl-1H-indazol-4-yl)-6-(trifluoromethyl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one	X	467.2
306		1-(4-(6-chloro-7-(2,4-difluorophenyl)-8-methoxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Z	445.2
307		1-(4-(6-chloro-7-(5-(difluoromethyl)-2-fluorophenyl)-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	461.2





No.	Structure	Name	Method	[M+H] ⁺
308		4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(6-methyl-1H-indazol-7-yl)quinoline-3-carbonitrile	P	475.1
309		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(1H-pyrazol-5-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AG	517.1
310		(E)-6-chloro-4-(4-(4-(dimethylamino)but-2-enoyl)piperazin-1-yl)-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinoline-3-carbonitrile	P	544.2
311		(E)-4-amino-1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)but-2-en-1-one	O	480.2
312		1-(4-(6-chloro-7-(5-methyl-1H-indazol-4-yl)-2-(methylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	462.3

No.	Structure	Name	Method	[M+H] ⁺
313		1-(4-(6-chloro-7-(2-fluoro-6-hydroxyphenyl)-8-methoxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Z	443.2
314		1-(4-(6-chloro-2-(2-(dimethylamino)ethoxy)-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	520.4
315		(E)-1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)-4-hydroxybut-2-en-1-one	O	481.3
316		1-(4-(6-chloro-7-(5-methyl-1H-indazol-4-yl)-2-(tetrahydro-2H-pyran-3-yloxy)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	533.3
317		(E)-6-chloro-4-(4-(4-(dimethylamino)but-2-enoyl)piperazin-1-yl)-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinoline-3-carbonitrile	P	532.3





No.	Structure	Name	Method	[M+H] ⁺
318		1-(4-(6-chloro-7-(2-fluoro-6-hydroxyphenyl)-5-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AA	481.1
319		1-(4-(2-amino-6-chloro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	448.2
320		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)-2-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one	O	481.2
321		1-(4-(6-chloro-7-(2,4-difluorophenyl)-8-hydroxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Z	431.1
322		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(1-methyl-1H-pyrazol-4-ylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	546.2





No.	Structure	Name	Method	[M+H] ⁺
323		1-(4-(6-chloro-2-(2-(dimethylamino)ethoxy)-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	538.2
324		1-(4-(6-chloro-8-fluoro-7-(3-methyl-1H-indazol-7-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	451.1
325		(E)-1-(4-(6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)-4-(dimethylamino)but-2-en-1-one	O	520.3
326		4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(5-methyl-1H-indazol-4-yl)quinolin-2(1H)-one	AB	448.2
327		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)-2-methylpiperazin-1-yl)prop-2-en-1-one	O	465.2

No.	Structure	Name	Method	[M+H] ⁺
328		(E)-1-(4-(6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)but-2-en-1-one	O	477.2
329		1-(4-(6-chloro-2-(3-(dimethylamino)propoxy)-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	534.3
330		1-(4-(6-chloro-7-(5-methyl-1H-indazol-4-yl)-2-(tetrahydrofuran-3-ylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	518.3
331		1-(4-(6-chloro-8-fluoro-7-(5-fluoro-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Q	455.1
332		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(thiazol-5-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AG	534.1





No.	Structure	Name	Method	[M+H] ⁺
333		(E)-1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(thiazol-5-yl)quinazolin-4-yl)piperazin-1-yl)-4-(dimethylamino)but-2-en-1-one	AG	591.1
334		(R)-1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	451.2
335		(E)-4-amino-1-(4-(6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)but-2-en-1-one	O	492.2
336		4-(4-acryloyl-3-methylpiperazin-1-yl)-6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinoline-3-carbonitrile	P	489.2

No.	Structure	Name	Method	[M+H] ⁺
337		1-(4-(6-chloro-7-(3-(difluoromethyl)naphthalen-1-yl)-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	497.2
338		1-(4-(6-chloro-2-(dimethylamino)-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	494.4
339		1-(4-(6-chloro-2-(3-(dimethylamino)propoxy)-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	552.2
340		1-(4-(6-chloro-8-fluoro-7-(3-fluoro-5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AH	469.1
341		1-(4-(6-chloro-2-(2-(dimethylamino)ethoxy)-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	518.2





No.	Structure	Name	Method	[M+H] ⁺
342		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(2-morpholinoethoxy)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	580.2
343		1-(4-(6-chloro-5-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AD	431.2
344		1-(4-(6-chloro-2-(dimethylamino)-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	506.3
345		1-(4-(6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-(methylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	492.2





No.	Structure	Name	Method	[M+H] ⁺
346		1-(4-(6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)-2-((dimethylamino)methyl)piperazin-1-yl)prop-2-en-1-one	O	520.2
347		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(tetrahydrofuran-3-ylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	536.3
348		1-(4-(6-chloro-7-(3-hydroxynaphthalen-1-yl)-8-methoxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	Z	475.3
349		1-(4-(6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-(1-(2,2,2-trifluoroethyl)pyrrolidin-3-ylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	629.3





No.	Structure	Name	Method	[M+H] ⁺
350		1-(4-(7-(5-methyl-1H-indazol-4-yl)-6-(trifluoromethyl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one	X	467.3
351		1-(4-(7-(3-hydroxynaphthalen-1-yl)-6-(trifluoromethyl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one	X	479.2
352		1-(4-(6-chloro-8-fluoro-2-(2-(1-methyl-1H-imidazol-2-yl)ethylamino)-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	575.2
353		(S)-1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	431.2
354		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(1-(2,2,2-trifluoroethyl)pyrrolidin-3-ylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	617.3



No.	Structure	Name	Method	[M+H] ⁺
355		1-(4-(6-chloro-2-(2-(dimethylamino)ethylamino)-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	549.3
356		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(2,2,2-trifluoroethylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	548.3
357		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(3-morpholinopropoxy)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	594.2
358		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	564.2

No.	Structure	Name	Method	[M+H] ⁺
359		1-(4-(6-chloro-8-fluoro-7-(6-fluoro-3-methyl-1H-indazol-7-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	469.1
360		1-(4-(6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-(1-methylpyrrolidin-3-ylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	561.4
361		1-(4-(6-chloro-2-((2-(dimethylamino)ethyl)(methylamino))-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	563.4
362		1-(4-(6-chloro-7-(2-((dimethylamino)methyl)-6-fluorophenyl)-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	472.3

No.	Structure	Name	Method	[M+H] ⁺
363		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(1-methylpiperidin-4-ylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	563.4
364		1-(4-(6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-(3,3,3-trifluoropropylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	560.30
365		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(tetrahydro-2H-pyran-4-ylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	550.30
366		N-(2-(4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)oxy)ethyl)acetamide	AC	552.35

No.	Structure	Name	Method	[M+H] ⁺
367		1-(4-(6-chloro-2-(2-(dimethylamino)ethoxy)-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)-2-methylpiperazin-1-yl)prop-2-en-1-one	F	552.30
368		1-(4-(6-chloro-8-fluoro-7-(6-fluoro-1H-indazol-7-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	B	455.1
369		1-(4-(6-chloro-8-fluoro-2-(2-(1-methyl-1H-imidazol-2-yl)ethoxy)-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	575.2
370		(R)-1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	O	431.2

No.	Structure	Name	Method	[M+H] ⁺
371		1-(4-(6-chloro-2-((2-(dimethylamino)ethyl)(methylamino)-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	551.35
372		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(1-methylpyrrolidin-3-ylamino)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	AC	549.30
373		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(2-(4-methylpiperazin-1-yl)ethoxy)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	593.30
374		1-(4-(6-chloro-2-(2-(dimethylamino)ethoxy)-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	550.25

No.	Structure	Name	Method	[M+H] ⁺
375		1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(1-methyl-1H-pyrazol-4-yloxy)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one	F	547.25
376		4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazoline-2-carbonitrile	AI	488.15

* [M+Na]⁺+ [M-H]⁻

[M]

5 The compounds in Table 1 were each prepared and analyzed by mass spectrometry and/or ¹H NMR. Experimental mass spectrometry data is included in Table 1 above. Exemplary synthetic procedures are described in more detail below and in the Examples. General methods by which the compounds may be prepared are provided below and indicated in Table 1 above.

10 It is understood that in the present description, combinations of substituents and/or variables of the depicted formulae are permissible only if such contributions result in stable compounds.


 It will also be appreciated by those skilled in the art that in the processes for preparing the compounds described herein the functional groups of intermediate
15 compounds may need to be protected by suitable protecting groups. Such functional groups include, but are not limited to, hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (for

example, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include *t*-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for mercapto include -C(O)-R'' (where R'' is alkyl, aryl or arylalkyl), *p*-methoxybenzyl, trityl and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. Protecting groups are optionally added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P.G.M. Wutz, *Protective Groups in Organic Synthesis* (1999), 3rd Ed., Wiley. As one of skill in the art would appreciate, the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin.

It will also be appreciated by those skilled in the art, although such protected derivatives of compounds of this invention may not possess pharmacological activity as such, they may be administered to a mammal and thereafter metabolized in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". All prodrugs of compounds of this invention are included within the scope of the invention.

Furthermore, all compounds of the invention which exist in free base or acid form can be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid by methods known to one skilled in the art. Salts of the compounds of the invention can be converted to their free base or acid form by standard techniques.

The following General Reaction Schemes illustrate exemplary methods of making compounds of compounds of structure (I):




(I)

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R¹, R^{2a}, R^{3a}, R^{3b}, R^{4a}, R^{4b}, G¹, G², L¹, L², m¹, m², A, B, W, X, Y, Z and E are as defined above. For ease of illustration, many of the schemes which follow illustrate an "R²,"

moiety. The R² moiety is meant to include any one of R^{2a}, R^{2b} or R^{2c}. It is understood that one skilled in the art may be able to make these compounds by similar methods or by combining other methods known to one skilled in the art. It is also understood that one skilled in the art would be able to make, in a similar manner as described below,

5 other compounds of structure (I) not specifically illustrated below by using the appropriate starting components and modifying the parameters of the synthesis as needed. In general, starting components may be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, etc. or synthesized according to sources known to those skilled in the art (see, for

10 example, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition (Wiley, December 2000)) or prepared as described in this invention.




Embodiments of the compound of structure (I) (e.g., compound A-7) can

15 be prepared according to General Reaction Scheme 1 ("Method A"), wherein R¹, R²,

R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein above. As shown in General Reaction Scheme 1, compounds of structure A-1 can be purchased from commercial sources or prepared according to methods familiar to one of ordinary skill in the art. Reaction of A-1 under Suzuki conditions yields A-2. Reaction of

5 compounds of structure A-2 with formamide or other suitable reagents, such as formamidine acetate or trimethyl orthoformate, yields quinazolines of structure A-3. A-3 is chlorinated under appropriate conditions (*e.g.*, SOCl_2 , $\text{POCl}_3/\text{PCl}_5$ or POCl_3) to yield chloroquinazoline A-4. Reaction of A-4 with an appropriately protected heterocycle under basic conditions yields A-5. Appropriate protecting groups include

10 butyloxycarbonyl (BOC) as depicted in General reaction Scheme 1, as well as other protecting groups known in the art. Deprotection of A-5 followed by acylation with an acid chloride (or sulfonyl chloride) or acid and appropriate activating reagents yields A-7.




Alternatively, embodiments of the compound of structure (I) (*e.g.*, compound A-7) can be prepared according to General Reaction Scheme 2 (“Method B”), wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein

20 above. Compounds of structure A-1 are prepared or purchased as described above. Treatment of A-1 with formamide or other suitable reagents, such as formamidine acetate or trimethyl orthoformate, yields quinazolines of structure B-1. B-1 can then be


chlorinated to yield B-2 and reacted with an appropriately protected heterocycle under basic conditions to yield B-3 as described above for Method A. Suzuki coupling then yields A-5 which can be converted to A-7 as described in Method A above.

General Reaction Scheme 3




5

Other embodiments of the compound of structure (I) (e.g., compound C-6) can be prepared according to General Reaction Scheme 3 ("Method C"), wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q, m^1 and m^2 are as defined herein above. As shown in General Reaction Scheme 3, compounds of structure C-1, which can be purchased from commercial sources or prepared according to well-known procedures, are reacted with tosyl hydrazine to yield C-2. Chlorination of C-2 with an appropriate reagent(s), such as thionyl chloride, then yields C-3 which can be reacted under basic conditions with an appropriately protected heterocycle (PG = protecting group or C_1 - C_6 alkyl) to yield indazole C-4. The tosyl group is removed from C-4 by treatment with sodium hydroxide in THF/ H_2O to yield C-5. Removal of the nitrogen protecting group and acylation or thioacylation as described in Method A then yields the desired compound C-6.




- Other embodiments of the compound of structure (I) (*e.g.*, compound D-9) can be prepared according to General Reaction Scheme 4 (“Method D”), wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein above. As shown in General Reaction Scheme 4, benzaldehyde D-1 is treated under reductive amination conditions to yield D-2. Formation of the tosyl-protected amine (D-3) followed by treatment with an appropriate Lewis acid (*e.g.*, $AlCl_3$) yields isoquinoline D-4.
- Oxidation of D-4 with meta-chloroperoxybenzoic acid (*m*CPBA) yields D-5 which can be chlorinated by treatment with an appropriate reagent, such as $POCl_3$. Chloride D-6 is then treated in a manner analogous to that described for Method B to yield D-9.

General Reaction Scheme 5




- Other embodiments of the compound of structure (I) (*e.g.*, compound E-9) can be prepared according to General Reaction Scheme 5 (“Method E”), wherein R¹, R², R^{3a}, R^{3b}, R^{4a}, R^{4b}, R⁹, R¹⁰, Q, m¹ and m² are as defined herein above. As shown in General Reaction Scheme 5, aniline E-1, which can be purchased from commercial sources or prepared via well-known procedures, can be reacted with diethyl 2-(ethoxymethylene)malonate to yield E-2. E-2 can then be cyclized by heating in an appropriate high-boiling solvent (*e.g.*, Ph₂O) to yield quinolone E-3. Saponification of E-3 followed by decarboxylation yields E-4 and E-5, respectively. E-5 is then treated in a manner analogous to that described for Method B to yield E-9.


General Reaction Scheme 6




- Other embodiments of the compound of structure (I) (e.g., compound F-6) can be prepared according to General Reaction Scheme 6 (“Method F”), wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein above. As shown in General Reaction Scheme 6, A-1 is cyclized to quinazolinone F-1 by treatment with urea. Chlorination of F-1 by treatment with POCl_3 followed by reaction with a protected heterocycle yield F-2 and F-3, respectively. The R^6 substituent is installed by $\text{S}_{\text{N}}\text{Ar}$ reaction of G-3 with $\text{LG}-\text{R}^6$, wherein LG is an appropriate leaving group. For example, where R^6 is cyano or alkoxy, LG is sodium or another appropriate action. The general procedures described above with respect to Method B can then be employed to yield F-6.




- Other embodiments of the compound of structure (I) (*e.g.*, compound G-4) can be prepared according to General Reaction Scheme 7 (“Method G”), wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein above. As shown in General Reaction Scheme 7, aniline E-1 is treated under Suzuki conditions to install the R^1 substituent. G-1 is then heated in toluene with an appropriately substituted unsaturated ester to yield G-2. Cyclization of G-2 to hydroxyquinoline G-3 is accomplished by heating in a high boiling solvent (*e.g.*, Ph_2O) for an appropriate amount of time. Following the general procedures outlined in Method A then yields G-4.



Other embodiments of the compound of structure (I) (*e.g.*, compound H-3) can be prepared according to General Reaction Scheme 8 (“Method H”), wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein above. Referring to General Reaction Scheme 8, thienopyrimidine H-1 can be prepared according to well-known procedures or purchased from commercial sources. H-1 is treated with an appropriately protected heterocycle under basic conditions to yield H-2. Deprotection followed by acylation or thioacylation according to the procedures described above then yields H-3.




Other embodiments of the compound of structure (I) (*e.g.*, compound I-4) can be prepared according to General Reaction Scheme 9 (“Method I”), wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein above. Referring to General Reaction Scheme 9, quinazoline I-1 can be prepared according to well-known procedures or purchased from commercial sources. I-1 is treated with an appropriately protected heterocycle under basic conditions to yield I-2. Suzuki reaction of I-2 with an appropriate reagent to install the R^1 moiety results in I-3. I-3 is then deprotected and acylated (or thioacylated) according to the procedures described above to yield I-4.




Other embodiments of the compound of structure (I) (*e.g.*, compound J-6) can be prepared according to General Reaction Scheme 10 (“Method J”), wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q, m^1 and m^2 are as defined herein above. Referring to General Reaction Scheme 10, pyrrolopyrimidinone J-1 can be prepared according to well-known procedures or purchased from commercial sources. J-1 is chlorinated with an appropriate reagent (*e.g.*, POCl_3) to yield J-2 which is then iodinated with an appropriate reagent, such as N-iodosuccinimide (NIS) to yield J-3. Protection of J-3 followed by Suzuki reaction yields J-5. J-5 is then treated according to the procedures described above to yield J-6.

General Reaction Scheme 11



- Other embodiments of the compound of structure (I) (*e.g.*, compound K-5) can be prepared according to General Reaction Scheme 11 (“Method K”), wherein R¹, R², R^{3a}, R^{3b}, R^{4a}, R^{4b}, R⁹, R¹⁰, Q, m¹ and m² are as defined herein above. Referring to General Reaction Scheme 11, quinazoline K-1 can be prepared according to well-known procedures or purchased from commercial sources. K-1 is reacted with an appropriate ester under basic conditions to form the requisite carbon-carbon bond. K-2 is then decarboxylated to yield K-3. Suzuki reaction, deprotection and acylation or thioacylation are then carried out as described in the above schemes to yield K-5.


General Reaction Scheme 12



Other embodiments of the compound of structure (I) (*e.g.*, compound L-2) can be prepared according to General Reaction Scheme 12 (“Method L”), wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein above.

Specifically, compounds wherein R^1 is a N-heterocycle can be efficiently prepared according to Method L. Referring to General Reaction Scheme 12, compound B-3 is prepared according to Method B and treated under Buchwald conditions (where R^1 -H is a N-heterocycle or alkylaminy) to yield L-1. Methods for Buchwald reactions are well-known in the art. L-1 is then converted to L-2 according to the above general procedures.

10




15

Other embodiments of the compound of structure (I) (*e.g.*, compound M-3) can be prepared according to General Reaction Scheme 13 (“Method M”), wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^6 , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein above.


Referring to General Reaction Scheme 13, compound A-1 is reacted an appropriate nitrile ($R^6\text{CN}$) to form compound M-1. In this regard, R^6 may be any of the R^6 moieties described herein, for example alkyl. M-1 is chlorinated by reaction with an appropriate reagent such as thionyl chloride. Compound M-3 is then prepared according to the general procedures outlined herein, for example the procedures of General Reaction Scheme 2.

20



- Embodiments of the compound of structure (I) (*e.g.*, compound N-7) can
- 5 be prepared according to General Reaction Scheme 14 (“Method N”), wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q, m^1 and m^2 are as defined herein above. As shown in General Reaction Scheme 14, compounds of structure N-1 can be purchased from commercial sources or prepared according to methods familiar to one of ordinary skill in the art. Compound N-1 is reacted with methylnitrile to form compound N-2.
- 10 Reaction of N-2 with sodium nitrite under acidic conditions yields cinnolines of structure N-3. N-3 is chlorinated under appropriate conditions (*e.g.*, SOCl_2 , $\text{POCl}_3/\text{PCl}_5$ or POCl_3) to yield the chlorocinnoline N-4. Reaction of N-4 with an appropriately protected heterocycle under basic conditions yields N-5. Appropriate protecting groups include butyloxycarbonyl (BOC) as depicted in General reaction Scheme 1, as well as
- 15 other protecting groups known in the art. Suzuki reaction of N-5 with an appropriate reagent to install the R^1 moiety results in N-6. Deprotection of N-6 followed by acylation with an acid chloride (or sulfonyl chloride) or acid and appropriate activating reagents yields N-7.

General Reaction Scheme 15




Embodiments of the compound of structure (I) (e.g., compound O-11)

- 5 can be prepared according to General Reaction Scheme 15 ("Method O"), wherein R^1 , R^{2b} , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein above. As shown in General Reaction Scheme 15, compounds of structure O-1 can be purchased from commercial sources or prepared according to methods familiar to one of ordinary skill in the art. Compound O-1 is reduced to form compound O-2. Reaction of O-2 with
- 10 2,2,2-trichloroethane-1,1-diol under acidic conditions, then hydroxylamine hydrochloride, yields O-3. O-3 is cyclized in the presence of acid to yield O-4. O-4 is reacted in the presence H_2O_2 under basic conditions to yield O-5. O-5 is chlorinated using N-chlorosuccinimide to yield O-6. Reaction of O-6 with formamide or other suitable reagents such as formamidine acetate or trimethyl orthoformate yields the


quinazolin-4(3H)-one, O-7. O-7 is chlorinated under appropriate conditions (*e.g.*, SOCl_2 , $\text{POCl}_3/\text{PCl}_5$ or POCl_3) to yield the chloroquinazoline, O-8. Reaction of O-8 with an appropriately protected heterocycle under basic conditions yields O-9.

Appropriate protecting groups include butyloxycarbonyl (BOC) as depicted in General reaction Scheme 1, as well as other protecting groups known in the art. Suzuki reaction of O-9 with an appropriate reagent to install the R^1 moiety results in O-10. Deprotection of O-10 followed by acylation with an acid chloride (or sulfonyl chloride) or acid and appropriate activating reagents yields O-11.



Embodiments of the compound of structure (I) (*e.g.*, compound P-10) can be prepared according to General Reaction Scheme 16 (“Method P”), wherein R^1 , R^{2b} , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein above. As shown in General Reaction Scheme 16, compound O-2 is chlorinated using N-chlorosuccinimide to yield P-1. Reaction of P-1 with diethyl-2-(ethoxymethylene)malonate yields P-2. P-2 is then cyclized by heating in an appropriate high-boiling solvent (*e.g.* Ph_2O) to yield the quinolone, P-3. P-3 is chlorinated under appropriate conditions (*e.g.*, $SOCl_2$, $POCl_3/PCl_5$ or $POCl_3$) to yield the chloroquinolone, P-4. Reaction of P-4 with an appropriately protected heterocycle under basic conditions yields P-5. Appropriate protecting groups include butyloxycarbonyl (BOC) as depicted in General reaction Scheme 1, as well as other protecting groups known in the art. Saponification of P-5 followed by amidation yields P-6 and P-7, respectively. Suzuki reaction of P-7 with an appropriate reagent to install the R^1 moiety results in P-8. Deprotection of P-8 followed by acylation with an acid chloride (or sulfonyl chloride) or acid and appropriate activating reagents yields P-9. Reaction of P-9 in the presence of acid yielded P-10.

General Reaction Scheme 17




Embodiments of the compound of structure (I) (*e.g.*, compound Q-2) can be prepared according to General Reaction Scheme 16 (“Method Q”), wherein R^1 , R^{2b} , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^9 , R^{10} , Q , m^1 and m^2 are as defined herein above. As shown in General Reaction Scheme 17, deprotection of compound O-9 followed by acylation with an acid chloride (or sulfonyl chloride) or acid and appropriate activating reagents

yields Q-1. Suzuki reaction of Q-1 with an appropriate reagent to install the R¹ moiety results in Q-2.

Additional General synthetic methods are provided in the Examples. It will be apparent to one of ordinary skill in the art that all compounds of structure (I) can be prepared according to one or more of the methods described herein or otherwise known in the art. It will also be apparent that in some instances it will be necessary to use a differently substituted starting material and/or protecting groups to arrive at the desired compound when following the general procedures described herein. Various substituents may also be added at various points in the synthetic scheme to prepare the desired compound.

Further, one skilled in the art will recognize that certain modifications to the above schemes and those provided in the examples are possible to prepare different embodiments of compounds of structure (I). For example, for ease of illustration, most of the general procedures depict preparation of compounds of structure (I) wherein L¹ is a bond. However, one of ordinary skill in the art will readily recognize that compounds wherein L¹ is NR⁷ can be prepared by substituting a heterocycle having the following structure (see e.g., Method C):



where R is H, a protecting group or C₁-C₆alkyl.

20 Pharmaceutical Compositions

Other embodiments are directed to pharmaceutical compositions. The pharmaceutical composition comprises any one (or more) of the foregoing compounds and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is formulated for oral administration. In other embodiments, the pharmaceutical composition is formulated for injection. In still more embodiments, the pharmaceutical compositions comprise a compound as disclosed herein and an additional therapeutic agent (*e.g.*, anticancer agent). Non-limiting examples of such therapeutic agents are described herein below.

Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration. In addition, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.

In certain embodiments, a compound as described herein is administered in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in a depot preparation or sustained release formulation. In specific embodiments, long acting formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Furthermore, in other embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with organ-specific antibody. In such embodiments, the liposomes are targeted to and taken up selectively by the organ. In yet other embodiments, the compound as described herein is provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation. In yet other embodiments, the compound described herein is administered topically.

The compounds according to the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that are used in some embodiments. An exemplary dosage is 10 to 30 mg per day. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.

In some embodiments, a compound of the invention is administered in a single dose. Typically, such administration will be by injection, e.g., intravenous injection, in order to introduce the agent quickly. However, other routes are used as appropriate. A single dose of a compound of the invention may also be used for treatment of an acute condition.

In some embodiments, a compound of the invention is administered in multiple doses. In some embodiments, dosing is about once, twice, three times, four times, five times, six times, or more than six times per day. In other embodiments, dosing is about once a month, once every two weeks, once a week, or once every other day. In another embodiment a compound of the invention and another agent are administered together about once per day to about 6 times per day. In another embodiment the administration of a compound of the invention and an agent continues for less than about 7 days. In yet another embodiment the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous dosing is achieved and maintained as long as necessary.

Administration of the compounds of the invention may continue as long as necessary. In some embodiments, a compound of the invention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, a compound of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, a compound of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.

In some embodiments, the compounds of the invention are administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention may be found by routine experimentation in light of the instant disclosure.

In some embodiments, the compounds described herein are formulated into pharmaceutical compositions. In specific embodiments, pharmaceutical compositions are formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any pharmaceutically acceptable techniques, carriers, and excipients are used as suitable to formulate the pharmaceutical compositions described herein: Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack

Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999).

5 Provided herein are pharmaceutical compositions comprising a compound of structure (I) and a pharmaceutically acceptable diluent(s), excipient(s), or carrier(s). In certain embodiments, the compounds described are administered as pharmaceutical compositions in which compounds of structure (I) are mixed with other active ingredients, as in combination therapy. Encompassed herein are all combinations
10 of actives set forth in the combination therapies section below and throughout this disclosure. In specific embodiments, the pharmaceutical compositions include one or more compounds of structure (I).

A pharmaceutical composition, as used herein, refers to a mixture of a compound of structure (I) with other chemical components, such as carriers, stabilizers,
15 diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. In certain embodiments, the pharmaceutical composition facilitates administration of the compound to an organism. In some embodiments, practicing the methods of treatment or use provided herein, therapeutically effective amounts of compounds of structure (I) provided herein are administered in a pharmaceutical composition to a mammal having
20 a disease, disorder or medical condition to be treated. In specific embodiments, the mammal is a human. In certain embodiments, therapeutically effective amounts vary depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. The compounds described herein are used singly or in combination with one or more therapeutic agents as components of
25 mixtures.

In one embodiment, one or more compounds of structure (I) is formulated in an aqueous solution. In specific embodiments, the aqueous solution is selected from, by way of example only, a physiologically compatible buffer, such as Hank's solution, Ringer's solution, or physiological saline buffer. In other
30 embodiments, one or more compound of structure (I) is/are formulated for transmucosal administration. In specific embodiments, transmucosal formulations include penetrants

that are appropriate to the barrier to be permeated. In still other embodiments wherein the compounds described herein are formulated for other parenteral injections, appropriate formulations include aqueous or nonaqueous solutions. In specific embodiments, such solutions include physiologically compatible buffers and/or
5 excipients.

In another embodiment, compounds described herein are formulated for oral administration. Compounds described herein are formulated by combining the active compounds with, e.g., pharmaceutically acceptable carriers or excipients. In various embodiments, the compounds described herein are formulated in oral dosage
10 forms that include, by way of example only, tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like.

In certain embodiments, pharmaceutical preparations for oral use are obtained by mixing one or more solid excipient with one or more of the compounds described herein, optionally grinding the resulting mixture, and processing the mixture
15 of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium
20 carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. In specific embodiments, disintegrating agents are optionally added. Disintegrating agents include, by way of example only, cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

25 In one embodiment, dosage forms, such as dragee cores and tablets, are provided with one or more suitable coating. In specific embodiments, concentrated sugar solutions are used for coating the dosage form. The sugar solutions, optionally contain additional components, such as by way of example only, gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide,
30 lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs and/or pigments are also optionally added to the coatings for identification purposes.

Additionally, the dyestuffs and/or pigments are optionally utilized to characterize different combinations of active compound doses.

In certain embodiments, therapeutically effective amounts of at least one of the compounds described herein are formulated into other oral dosage forms. Oral dosage forms include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In specific embodiments, push-fit capsules contain the active ingredients in admixture with one or more filler. Fillers include, by way of example only, lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In other embodiments, soft capsules, contain one or more active compound that is dissolved or suspended in a suitable liquid. Suitable liquids include, by way of example only, one or more fatty oil, liquid paraffin, or liquid polyethylene glycol. In addition, stabilizers are optionally added.

In other embodiments, therapeutically effective amounts of at least one of the compounds described herein are formulated for buccal or sublingual administration. Formulations suitable for buccal or sublingual administration include, by way of example only, tablets, lozenges, or gels. In still other embodiments, the compounds described herein are formulated for parental injection, including formulations suitable for bolus injection or continuous infusion. In specific embodiments, formulations for injection are presented in unit dosage form (e.g., in ampoules) or in multi-dose containers. Preservatives are, optionally, added to the injection formulations. In still other embodiments, the pharmaceutical compositions are formulated in a form suitable for parenteral injection as sterile suspensions, solutions or emulsions in oily or aqueous vehicles. Parenteral injection formulations optionally contain formulatory agents such as suspending, stabilizing and/or dispersing agents. In specific embodiments, pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. In additional embodiments, suspensions of the active compounds (e.g., compounds of structure (I)) are prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles for use in the pharmaceutical compositions described herein include, by way of example only, fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl

oleate or triglycerides, or liposomes. In certain specific embodiments, aqueous injection suspensions contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension contains suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, in other embodiments, the active ingredient is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

In still other embodiments, the compounds of structure (I) are administered topically. The compounds described herein are formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments. Such pharmaceutical compositions optionally contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

In yet other embodiments, the compounds of structure (I) are formulated for transdermal administration. In specific embodiments, transdermal formulations employ transdermal delivery devices and transdermal delivery patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive. In various embodiments, such patches are constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. In additional embodiments, the transdermal delivery of the compounds of structure (I) is accomplished by means of iontophoretic patches and the like. In certain embodiments, transdermal patches provide controlled delivery of the compounds of structure (I). In specific embodiments, the rate of absorption is slowed by using rate-controlling membranes or by trapping the compound within a polymer matrix or gel. In alternative embodiments, absorption enhancers are used to increase absorption. Absorption enhancers or carriers include absorbable pharmaceutically acceptable solvents that assist passage through the skin. For example, in one embodiment, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

In other embodiments, the compounds of structure (I) are formulated for administration by inhalation. Various forms suitable for administration by inhalation include, but are not limited to, aerosols, mists or powders. Pharmaceutical compositions of any of compound of structure (I) are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant (*e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In specific embodiments, the dosage unit of a pressurized aerosol is determined by providing a valve to deliver a metered amount. In certain embodiments, capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator are formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

In still other embodiments, the compounds of structure (I) are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.

In certain embodiments, pharmaceutical compositions are formulated in any conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any pharmaceutically acceptable techniques, carriers, and excipients are optionally used as suitable. Pharmaceutical compositions comprising a compound of structure (I) are manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.

Pharmaceutical compositions include at least one pharmaceutically acceptable carrier, diluent or excipient and at least one compound of structure (I),

described herein as an active ingredient. The active ingredient is in free-acid or free-base form, or in a pharmaceutically acceptable salt form. In addition, the methods and pharmaceutical compositions described herein include the use of N-oxides, crystalline forms (also known as polymorphs), as well as active metabolites of these compounds
5 having the same type of activity. All tautomers of the compounds described herein are included within the scope of the compounds presented herein. Additionally, the compounds described herein encompass unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the compounds presented herein are also considered to be disclosed herein. In
10 addition, the pharmaceutical compositions optionally include other medicinal or pharmaceutical agents, carriers, adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, buffers, and/or other therapeutically valuable substances.

Methods for the preparation of compositions comprising the compounds
15 described herein include formulating the compounds with one or more inert, pharmaceutically acceptable excipients or carriers to form a solid, semi-solid or liquid. Solid compositions include, but are not limited to, powders, tablets, dispersible granules, capsules, cachets, and suppositories. Liquid compositions include solutions in which a compound is dissolved, emulsions comprising a compound, or a solution
20 containing liposomes, micelles, or nanoparticles comprising a compound as disclosed herein. Semi-solid compositions include, but are not limited to, gels, suspensions and creams. The form of the pharmaceutical compositions described herein include liquid solutions or suspensions, solid forms suitable for solution or suspension in a liquid prior to use, or as emulsions. These compositions also optionally contain minor amounts of
25 nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and so forth.

In some embodiments, pharmaceutical composition comprising at least one compound of structure (I) illustratively takes the form of a liquid where the agents are present in solution, in suspension or both. Typically when the composition is
30 administered as a solution or suspension a first portion of the agent is present in solution and a second portion of the agent is present in particulate form, in suspension

in a liquid matrix. In some embodiments, a liquid composition includes a gel formulation. In other embodiments, the liquid composition is aqueous.

In certain embodiments, useful aqueous suspensions contain one or more polymers as suspending agents. Useful polymers include water-soluble polymers such as cellulosic polymers, e.g., hydroxypropyl methylcellulose, and water-insoluble polymers such as cross-linked carboxyl-containing polymers. Certain pharmaceutical compositions described herein comprise a mucoadhesive polymer, selected for example from carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.

Useful pharmaceutical compositions also, optionally, include solubilizing agents to aid in the solubility of a compound of structure (I). The term “solubilizing agent” generally includes agents that result in formation of a micellar solution or a true solution of the agent. Certain acceptable nonionic surfactants, for example polysorbate 80, are useful as solubilizing agents, as can ophthalmically acceptable glycols, polyglycols, e.g., polyethylene glycol 400, and glycol ethers.

Furthermore, useful pharmaceutical compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.

Additionally, useful compositions also, optionally, include one or more salts in an amount required to bring osmolality of the composition into an acceptable range. Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.

Other useful pharmaceutical compositions optionally include one or more preservatives to inhibit microbial activity. Suitable preservatives include

mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.

Still other useful compositions include one or more surfactants to
5 enhance physical stability or for other purposes. Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.

Still other useful compositions include one or more antioxidants to
10 enhance chemical stability where required. Suitable antioxidants include, by way of example only, ascorbic acid and sodium metabisulfite.

In certain embodiments, aqueous suspension compositions are packaged in single-dose non-reclosable containers. Alternatively, multiple-dose reclosable containers are used, in which case it is typical to include a preservative in the
15 composition.

In alternative embodiments, other delivery systems for hydrophobic pharmaceutical compounds are employed. Liposomes and emulsions are examples of delivery vehicles or carriers useful herein. In certain embodiments, organic solvents such as N-methylpyrrolidone are also employed. In additional embodiments, the
20 compounds described herein are delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials are useful herein. In some embodiments, sustained-release capsules release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent,
25 additional strategies for protein stabilization are employed.

In certain embodiments, the formulations described herein comprise one or more antioxidants, metal chelating agents, thiol containing compounds and/or other general stabilizing agents. Examples of such stabilizing agents, include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v
30 methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to

about 0.02% w/v polysorbate 80, (g) 0.001% to about 0.05% w/v. polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (l) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.

5 In some embodiments, the concentration of one or more compounds provided in the pharmaceutical compositions of the present invention is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%,
10 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w/w, w/v or v/v.

In some embodiments, the concentration of one or more compounds of the invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%,
15 19.50%, 19.25% 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25% 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25% 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25% 7%, 6.75%, 6.50%, 6.25% 6%, 5.75%,
20 5.50%, 5.25% 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 1.25% , 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w/w, w/v, or v/v.

25 In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40 %, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05%
30 to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%,

approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w/w, w/v or v/v.

In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w/w, w/v or v/v.

In some embodiments, the amount of one or more compounds of the invention is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g.

In some embodiments, the amount of one or more compounds of the invention is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g, , 0.15 g, 0.2 g, , 0.25 g, 0.3 g, , 0.35 g, 0.4 g, , 0.45 g, 0.5 g, 0.55 g, 0.6 g, , 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5g, 7 g, 7.5g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g.

In some embodiments, the amount of one or more compounds of the invention is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.

Kits/Articles of Manufacture

5 For use in the therapeutic applications described herein, kits and articles of manufacture are also provided. In some embodiments, such kits comprise a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein. Suitable containers include, for
10 example, bottles, vials, syringes, and test tubes. The containers are formed from a variety of materials such as glass or plastic.

 The articles of manufacture provided herein contain packaging materials. Packaging materials for use in packaging pharmaceutical products include those found in, e.g., U.S. Pat. Nos. 5,323,907, 5,052,558 and 5,033,252. Examples of
15 pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment. For example, the container(s) includes one or more compounds described herein, optionally in a composition or in combination with
20 another agent as disclosed herein. The container(s) optionally have a sterile access port (for example the container is an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). Such kits optionally comprising a compound with an identifying description or label or instructions relating to its use in the methods described herein.

25 For example, a kit typically includes one or more additional containers, each with one or more of various materials (such as reagents, optionally in concentrated form, and/or devices) desirable from a commercial and user standpoint for use of a compound described herein. Non-limiting examples of such materials include, but not limited to, buffers, diluents, filters, needles, syringes; carrier, package, container, vial
30 and/or tube labels listing contents and/or instructions for use, and package inserts with

instructions for use. A set of instructions will also typically be included. A label is optionally on or associated with the container. For example, a label is on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself, a label is associated with a container when it is present
5 within a receptacle or carrier that also holds the container, e.g., as a package insert. In addition, a label is used to indicate that the contents are to be used for a specific therapeutic application. In addition, the label indicates directions for use of the contents, such as in the methods described herein. In certain embodiments, the pharmaceutical composition is presented in a pack or dispenser device which contains one or more unit
10 dosage forms containing a compound provided herein. The pack for example contains metal or plastic foil, such as a blister pack. Or, the pack or dispenser device is accompanied by instructions for administration. Or, the pack or dispenser is accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals,
15 which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, is the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. In some embodiments, compositions containing a compound provided herein formulated in a compatible pharmaceutical carrier are prepared, placed in an
20 appropriate container, and labeled for treatment of an indicated condition.

Methods

The present invention provides a method of inhibiting RAS-mediated cell signaling comprising contacting a cell with an effective amount of one or more compounds disclosed herein. Inhibition of RAS-mediated signal transduction can be
25 assessed and demonstrated by a wide variety of ways known in the art. Non-limiting examples include a showing of (a) a decrease in GTPase activity of RAS; (b) a decrease in GTP binding affinity or an increase in GDP binding affinity; (c) an increase in K_{off} of GTP or a decrease in K_{off} of GDP; (d) a decrease in the levels of signaling transduction molecules downstream in the RAS pathway, such as a decrease in pMEK
30 level; and/or (e) a decrease in binding of RAS complex to downstream signaling

molecules including but not limited to Raf. Kits and commercially available assays can be utilized for determining one or more of the above.

The invention also provides methods of using the compounds or pharmaceutical compositions of the present invention to treat disease conditions, including but not limited to conditions implicated by G12C KRAS, HRAS or NRAS mutation, G12C HRAS mutation and/or G12C NRAS mutation (*e.g.*, cancer).

In some embodiments, a method for treatment of cancer is provided, the method comprising administering an effective amount of any of the foregoing pharmaceutical compositions comprising a compound of structure (I) to a subject in need thereof. In some embodiments, the cancer is mediated by a KRAS, HRAS or NRAS G12C mutation. In other embodiments, the cancer is pancreatic cancer, colon cancer, MYH associated polyposis, colorectal cancer or lung cancer.

In some embodiments the invention provides method of treating a disorder in a subject in need thereof, wherein the said method comprises determining if the subject has a KRAS, HRAS or NRAS G12C mutation and if the subject is determined to have the KRAS, HRAS or NRAS G12C mutation, then administering to the subject a therapeutically effective dose of at least one compound of structure (I) or a pharmaceutically acceptable salt, ester, prodrug, tautomer, solvate, hydrate or derivative thereof.

The disclosed compounds strongly inhibit anchorage-independent cell growth and therefore have the potential to inhibit tumor metastasis. Accordingly, in another embodiment the disclosure provides a method for inhibiting tumor metastasis, the method comprising administering an effective amount a pharmaceutical composition of comprising any of the compounds disclosed herein and a pharmaceutically acceptable carrier to a subject in need thereof.

KRAS, HRAS or NRAS G12C mutations have also been identified in hematological malignancies (*e.g.*, cancers that affect blood, bone marrow and/or lymph nodes). Accordingly, certain embodiments are directed to administration of a disclosed compounds (*e.g.*, in the form of a pharmaceutical composition) to a patient in need of treatment of a hematological malignancy. Such malignancies include, but are not limited to leukemias and lymphomas. For example, the presently disclosed compounds

can be used for treatment of diseases such as Acute lymphoblastic leukemia (ALL), Acute myelogenous leukemia (AML), Chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Chronic myelogenous leukemia (CML), Acute monocytic leukemia (AMoL) and/ or other leukemias. In other embodiments, the
5 compounds are useful for treatment of lymphomas such as all subtypes of Hodgkins lymphoma or non-Hodgkins lymphoma.

Determining whether a tumor or cancer comprises a G12C KRAS, HRAS or NRAS mutation can be undertaken by assessing the nucleotide sequence encoding the KRAS, HRAS or NRAS protein, by assessing the amino acid sequence of
10 the KRAS, HRAS or NRAS protein, or by assessing the characteristics of a putative KRAS, HRAS or NRAS mutant protein. The sequence of wild-type human KRAS, HRAS or NRAS is known in the art, (e.g. Accession No. NP203524).

Methods for detecting a mutation in a KRAS, HRAS or NRAS nucleotide sequence are known by those of skill in the art. These methods include, but
15 are not limited to, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assays, polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) assays, real-time PCR assays, PCR sequencing, mutant allele-specific PCR amplification (MASA) assays, direct sequencing, primer extension reactions, electrophoresis, oligonucleotide ligation assays,
20 hybridization assays, TaqMan assays, SNP genotyping assays, high resolution melting assays and microarray analyses. In some embodiments, samples are evaluated for G12C KRAS, HRAS or NRAS mutations by real-time PCR. In real-time PCR, fluorescent probes specific for the KRAS, HRAS or NRAS G12C mutation are used. When a mutation is present, the probe binds and fluorescence is detected. In some
25 embodiments, the KRAS, HRAS or NRAS G12C mutation is identified using a direct sequencing method of specific regions (e.g., exon 2 and/or exon 3) in the KRAS, HRAS or NRAS gene. This technique will identify all possible mutations in the region sequenced.

Methods for detecting a mutation in a KRAS, HRAS or NRAS protein
30 are known by those of skill in the art. These methods include, but are not limited to, detection of a KRAS, HRAS or NRAS mutant using a binding agent (e.g., an antibody)

specific for the mutant protein, protein electrophoresis and Western blotting, and direct peptide sequencing.

Methods for determining whether a tumor or cancer comprises a G12C KRAS, HRAS or NRAS mutation can use a variety of samples. In some embodiments, the sample is taken from a subject having a tumor or cancer. In some embodiments, the sample is taken from a subject having a cancer or tumor. In some embodiments, the sample is a fresh tumor/cancer sample. In some embodiments, the sample is a frozen tumor/cancer sample. In some embodiments, the sample is a formalin-fixed paraffin-embedded sample. In some embodiments, the sample is processed to a cell lysate. In some embodiments, the sample is processed to DNA or RNA.

The invention also relates to a method of treating a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof. In some embodiments, said method relates to the treatment of cancer such as acute myeloid leukemia, cancer in adolescents, adrenocortical carcinoma childhood, AIDS-related cancers (e.g. Lymphoma and Kaposi's Sarcoma), anal cancer, appendix cancer, astrocytomas, atypical teratoid, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, bronchial tumors, burkitt lymphoma, carcinoid tumor, atypical teratoid, embryonal tumors, germ cell tumor, primary lymphoma, cervical cancer, childhood cancers, chordoma, cardiac tumors, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative disorders, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, extrahepatic ductal carcinoma in situ (DCIS), embryonal tumors, CNS cancer, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, ewing sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, eye cancer, fibrous histiocytoma of bone, gall bladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (GIST), germ cell tumor, gestational trophoblastic tumor, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors, pancreatic neuroendocrine tumors, kidney cancer,

laryngeal cancer, lip and oral cavity cancer, liver cancer, lobular carcinoma in situ (LCIS), lung cancer, lymphoma, metastatic squamous neck cancer with occult primary, midline tract carcinoma, mouth cancer multiple endocrine neoplasia syndromes, multiple myeloma/plasma cell neoplasm, mycosis fungoides, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, multiple myeloma, merkel cell carcinoma, malignant mesothelioma, malignant fibrous histiocytoma of bone and osteosarcoma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-hodgkin lymphoma, non-small cell lung cancer (NSCLC), oral cancer, lip and oral cavity cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pleuropulmonary blastoma, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach (gastric) cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, T-Cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, trophoblastic tumor, unusual cancers of childhood, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, or Viral-Induced cancer. In some embodiments, said method relates to the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e. g., psoriasis), restenosis, or prostate (e. g., benign prostatic hypertrophy (BPH)).

In certain particular embodiments, the invention relates to methods for treatment of lung cancers, the methods comprise administering an effective amount of any of the above described compound (or a pharmaceutical composition comprising the same) to a subject in need thereof. In certain embodiments the lung cancer is a non-small cell lung carcinoma (NSCLC), for example adenocarcinoma, squamous-cell lung carcinoma or large-cell lung carcinoma. In other embodiments, the lung cancer is a small cell lung carcinoma. Other lung cancers treatable with the disclosed compounds include, but are not limited to, glandular tumors, carcinoid tumors and undifferentiated carcinomas.

Subjects that can be treated with compounds of the invention, or pharmaceutically acceptable salt, ester, prodrug, solvate, tautomer, hydrate or derivative of said compounds, according to the methods of this invention include, for example, subjects that have been diagnosed as having acute myeloid leukemia, acute myeloid leukemia, cancer in adolescents, adrenocortical carcinoma childhood, AIDS-related cancers (e.g. Lymphoma and Kaposi's Sarcoma), anal cancer, appendix cancer, astrocytomas, atypical teratoid, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, bronchial tumors, burkitt lymphoma, carcinoid tumor, atypical teratoid, embryonal tumors, germ cell tumor, primary lymphoma, cervical cancer, childhood cancers, chordoma, cardiac tumors, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative disorders, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, extrahepatic ductal carcinoma in situ (DCIS), embryonal tumors, CNS cancer, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, ewing sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, eye cancer, fibrous histiocytoma of bone, gall bladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (GIST), germ cell tumor, gestational trophoblastic tumor, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors, pancreatic neuroendocrine tumors, kidney cancer, laryngeal cancer, lip and oral cavity cancer, liver cancer, lobular carcinoma in situ (LCIS), lung cancer, lymphoma, metastatic squamous neck cancer with occult primary, midline tract carcinoma, mouth cancer multiple endocrine neoplasia syndromes, multiple myeloma/plasma cell neoplasm, mycosis fungoides, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, multiple myeloma, merkel cell carcinoma, malignant mesothelioma, malignant fibrous histiocytoma of bone and osteosarcoma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-hodgkin lymphoma, non-small cell lung cancer (NSCLC), oral cancer, lip and oral cavity cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pleuropulmonary

blastoma, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach (gastric) cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, T-Cell lymphoma, testicular cancer, throat cancer, 5 thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, trophoblastic tumor, unusual cancers of childhood, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, or Viral-Induced cancer. In some embodiments subjects that are treated with the compounds of the invention include subjects that have been diagnosed as having a non-cancerous hyperproliferative 10 disorder such as benign hyperplasia of the skin (e. g., psoriasis), restenosis, or prostate (e. g., benign prostatic hypertrophy (BPH)).

The invention further provides methods of modulating a G12C Mutant KRAS, HRAS or NRAS protein activity by contacting the protein with an effective amount of a compound of the invention. Modulation can be inhibiting or activating 15 protein activity. In some embodiments, the invention provides methods of inhibiting protein activity by contacting the G12C Mutant KRAS, HRAS or NRAS protein with an effective amount of a compound of the invention in solution. In some embodiments, the invention provides methods of inhibiting the G12C Mutant KRAS, HRAS or NRAS protein activity by contacting a cell, tissue, organ that express the protein of interest. In 20 some embodiments, the invention provides methods of inhibiting protein activity in subject including but not limited to rodents and mammal (e.g., human) by administering into the subject an effective amount of a compound of the invention. In some embodiments, the percentage modulation exceeds 25%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. In some embodiments, the percentage of inhibiting exceeds 25%, 30%, 25 40%, 50%, 60%, 70%, 80%, or 90%.

In some embodiments, the invention provides methods of inhibiting KRAS, HRAS or NRAS G12C activity in a cell by contacting said cell with an amount of a compound of the invention sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in said cell. In some embodiments, the invention provides methods of 30 inhibiting KRAS, HRAS or NRAS G12C activity in a tissue by contacting said tissue with an amount of a compound of the invention sufficient to inhibit the activity of

KRAS, HRAS or NRAS G12C in said tissue. In some embodiments, the invention provides methods of inhibiting KRAS, HRAS or NRAS G12C activity in an organism by contacting said organism with an amount of a compound of the invention sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in said organism. In some
5 embodiments, the invention provides methods of inhibiting KRAS, HRAS or NRAS G12C activity in an animal by contacting said animal with an amount of a compound of the invention sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in said animal. In some embodiments, the invention provides methods of inhibiting KRAS, HRAS or NRAS G12C activity in a mammal by contacting said mammal with an
10 amount of a compound of the invention sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in said mammal. In some embodiments, the invention provides methods of inhibiting KRAS, HRAS or NRAS G12C activity in a human by contacting said human with an amount of a compound of the invention sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in said human. The present invention
15 provides methods of treating a disease mediated by KRAS, HRAS or NRAS G12C activity in a subject in need of such treatment.

The present invention also provides methods for combination therapies in which an agent known to modulate other pathways, or other components of the same pathway, or even overlapping sets of target enzymes are used in combination with a
20 compound of the present invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, tautomer, hydrate or derivative thereof. In one aspect, such therapy includes but is not limited to the combination of one or more compounds of the invention with chemotherapeutic agents, therapeutic antibodies, and radiation treatment, to provide a synergistic or additive therapeutic effect.

25 Many chemotherapeutics are presently known in the art and can be used in combination with the compounds of the invention. In some embodiments, the chemotherapeutic is selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-
30 hormones, angiogenesis inhibitors, and anti-androgens.

Non-limiting examples are chemotherapeutic agents, cytotoxic agents, and non-peptide small molecules such as Gleevec® (Imatinib Mesylate), Velcade® (bortezomib), Casodex (bicalutamide), Iressa® (gefitinib), and Adriamycin as well as a host of chemotherapeutic agents. Non-limiting examples of chemotherapeutic agents

5 include alkylating agents such as thiotepa and cyclophosphamide (CYTOXANTM); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramidate, triethylenethiophosphoramidate and trimethylolomelamine;

10 nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine,

15 bleomycins, cactinomycin, calicheamicin, carabycin, carminomycin, carzinophilin, CasodexTM, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex,

20 zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, androgens such as calusterone,

25 dromostanolone propionate, epitiostanol, mepitiothane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone;

30 mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK.RTM.; razoxane; sizofiran; spirogermanium;

tenuazonic acid; triaziquone; 2,2',2''-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes, e.g. paclitaxel (TAXOL™, Bristol-Myers Squibb Oncology, Princeton, N.J.) and docetaxel (TAXOTERETM, Rhone-Poulenc Rorer, Antony, France); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included as suitable chemotherapeutic cell conditioners are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, (Nolvadex™), raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; camptothecin-11 (CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO). Where desired, the compounds or pharmaceutical composition of the present invention can be used in combination with commonly prescribed anti-cancer drugs such as Herceptin®, Avastin®, Erbitux®, Rituxan®, Taxol®, Arimidex®, Taxotere®, ABVD, AVICINE, Abagovomab, Acridine carboxamide, Adecatumumab, 17-N-Allylamino-17-demethoxygeldanamycin, Alpharadin, Alvocidib, 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone, Amonafide, Anthracenedione, Anti-CD22 immunotoxins, Antineoplastic, Antitumorigenic herbs, Apaziquone, Atiprimod, Azathioprine, Belotecan, Bendamustine, BIBW 2992, Biricodar, Brostallicin, Bryostatins, Buthionine sulfoximine, CBV (chemotherapy), Calyculin, cell-cycle nonspecific antineoplastic agents, Dichloroacetic acid, Discodermolide, Elsamitrucin, Enocitabine, Epothilone, Eribulin, Everolimus, Exatecan, Exisulind, Ferruginol, Forodesine, Fosfestrol, ICE chemotherapy regimen, IT-101, Imexon, Imiquimod, Indolocarbazole, Irofulven, Laniquidar, Larotaxel, Lenalidomide, Lucanthone, Lurtotecan, Mafosfamide, Mitozolomide, Nafoxidine, Nedaplatin, Olaparib, Ortataxel, PAC-1, Pawpaw,

Pixantrone, Proteasome inhibitor, Rebeccamycin, Resiquimod, Rubitecan, SN-38, Salinosporamide A, Sapacitabine, Stanford V, Swainsonine, Talaporfin, Tariquidar, Tegafur-uracil, Temodar, Tesetaxel, Triplatin tetranitrate, Tris(2-chloroethyl)amine, Troxacitabine, Uramustine, Vadimezan, Vinflunine, ZD6126 or Zosuquidar.

5 This invention further relates to a method for using the compounds or pharmaceutical compositions provided herein, in combination with radiation therapy for inhibiting abnormal cell growth or treating the hyperproliferative disorder in the mammal. Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein. The
10 administration of the compound of the invention in this combination therapy can be determined as described herein.

 Radiation therapy can be administered through one of several methods, or a combination of methods, including without limitation external-beam therapy, internal radiation therapy, implant radiation, stereotactic radiosurgery, systemic
15 radiation therapy, radiotherapy and permanent or temporary interstitial brachytherapy. The term “brachytherapy,” as used herein, refers to radiation therapy delivered by a spatially confined radioactive material inserted into the body at or near a tumor or other proliferative tissue disease site. The term is intended without limitation to include exposure to radioactive isotopes (e.g. At-211, I-131, I-125, Y-90, Re-186, Re-188, Sm-
20 153, Bi-212, P-32, and radioactive isotopes of Lu). Suitable radiation sources for use as a cell conditioner of the present invention include both solids and liquids. By way of non-limiting example, the radiation source can be a radionuclide, such as I-125, I-131, Yb-169, Ir-192 as a solid source, I-125 as a solid source, or other radionuclides that emit photons, beta particles, gamma radiation, or other therapeutic rays. The
25 radioactive material can also be a fluid made from any solution of radionuclide(s), e.g., a solution of I-125 or I-131, or a radioactive fluid can be produced using a slurry of a suitable fluid containing small particles of solid radionuclides, such as Au-198, Y-90. Moreover, the radionuclide(s) can be embodied in a gel or radioactive micro spheres.

 Without being limited by any theory, the compounds of the present
30 invention can render abnormal cells more sensitive to treatment with radiation for purposes of killing and/or inhibiting the growth of such cells. Accordingly, this

invention further relates to a method for sensitizing abnormal cells in a mammal to treatment with radiation which comprises administering to the mammal an amount of a compound of the present invention or pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof, which amount is effective is sensitizing abnormal
5 cells to treatment with radiation. The amount of the compound, salt, or solvate in this method can be determined according to the means for ascertaining effective amounts of such compounds described herein.

The compounds or pharmaceutical compositions of the invention can be used in combination with an amount of one or more substances selected from anti-
10 angiogenesis agents, signal transduction inhibitors, antiproliferative agents, glycolysis inhibitors, or autophagy inhibitors.

Anti-angiogenesis agents, such as MMP-2 (matrix-metalloproteinase 2) inhibitors, MMP-9 (matrix-metalloprotenase 9) inhibitors, and COX-11 (cyclooxygenase 11) inhibitors, can be used in conjunction with a compound of the
15 invention and pharmaceutical compositions described herein. Anti-angiogenesis agents include, for example, rapamycin, temsirolimus (CCI-779), everolimus (RAD001), sorafenib, sunitinib, and bevacizumab. Examples of useful COX-II inhibitors include CELEBREXTM (alecoxib), valdecoxib, and rofecoxib. Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published October
20 24,1996), WO 96/27583 (published March 7,1996), European Patent Application No. 97304971.1 (filed July 8,1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO 98/07697 (published February 26,1998), WO 98/03516 (published January 29,1998), WO 98/34918 (published August 13,1998), WO 98/34915 (published August 13,1998), WO 98/33768 (published August 6,1998), WO 98/30566
25 (published July 16, 1998), European Patent Publication 606,046 (published July 13,1994), European Patent Publication 931, 788 (published July 28,1999), WO 90/05719 (published May 31,1990), WO 99/52910 (published October 21,1999), WO 99/52889 (published October 21, 1999), WO 99/29667 (published June 17,1999), PCT International Application No. PCT/IB98/01113 (filed July 21,1998), European Patent
30 Application No. 99302232.1 (filed March 25,1999), Great Britain Patent Application No. 9912961.1 (filed June 3, 1999), United States Provisional Application No.

60/148,464 (filed August 12,1999), United States Patent 5,863, 949 (issued January 26,1999), United States Patent 5,861, 510 (issued January 19,1999), and European Patent Publication 780,386 (published June 25, 1997), all of which are incorporated herein in their entireties by reference. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP-2 and/or AMP-9 relative to the other matrix-metalloproteinases (i. e., MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP- 7, MMP-8, MMP-10, MMP-11, MMP-12, andMMP-13). Some specific examples of MMP inhibitors useful in the invention are AG-3340, RO 32-3555, and RS 13-0830.

Autophagy inhibitors include, but are not limited to chloroquine, 3-methyladenine, hydroxychloroquine (Plaquenil™), bafilomycin A1, 5-amino-4-imidazole carboxamide riboside (AICAR), okadaic acid, autophagy-suppressive algal toxins which inhibit protein phosphatases of type 2A or type 1, analogues of cAMP, and drugs which elevate cAMP levels such as adenosine, LY204002, N6-mercaptopurine riboside, and vinblastine. In addition, antisense or siRNA that inhibits expression of proteins including but not limited to ATG5 (which are implicated in autophagy), may also be used.

The invention also relates to a method of and to a pharmaceutical composition for treating a cardiovascular disease in a mammal which comprises an amount of a compound of the invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, tautomer, hydrate or derivative thereof, or an isotopically-labeled derivative thereof, and an amount of one or more therapeutic agents use for the treatment of cardiovascular diseases.

Exemplary agents for use in cardiovascular disease applications are anti-thrombotic agents, e.g., prostacyclin and salicylates, thrombolytic agents, e.g., streptokinase, urokinase, tissue plasminogen activator (TPA) and anisoylated plasminogen-streptokinase activator complex (APSAC), anti-platelets agents, e.g., acetyl-salicylic acid (ASA) and clopidrogel, vasodilating agents, e.g., nitrates, calcium channel blocking drugs, anti-proliferative agents, e.g., colchicine and alkylating agents, intercalating agents, growth modulating factors such as interleukins, transformation growth factor-beta and congeners of platelet derived growth factor, monoclonal

antibodies directed against growth factors, anti-inflammatory agents, both steroidal and non-steroidal, and other agents that can modulate vessel tone, function, arteriosclerosis, and the healing response to vessel or organ injury post intervention. Antibiotics can also be included in combinations or coatings comprised by the invention. Moreover, a
 5 coating can be used to effect therapeutic delivery focally within the vessel wall. By incorporation of the active agent in a swellable polymer, the active agent will be released upon swelling of the polymer.

In some embodiments, the compounds described herein are formulated or administered in conjunction with liquid or solid tissue barriers also known as
 10 lubricants. Examples of tissue barriers include, but are not limited to, polysaccharides, polyglycans, seprafilm, interceed and hyaluronic acid.

In some embodiments, medicaments which are administered in conjunction with the compounds described herein include any suitable drugs usefully delivered by inhalation for example, analgesics, e.g. codeine, dihydromorphine,
 15 ergotamine, fentanyl or morphine; anginal preparations, e.g. diltiazem; antiallergics, e.g. cromoglycate, ketotifen or nedocromil; anti-infectives, e.g. cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines or pentamidine; antihistamines, e.g. methapyrilene; anti-inflammatories, e.g. beclomethasone, flunisolide, budesonide, tipredane, triamcinolone acetonide or fluticasone; antitussives, e.g. noscapine;
 20 bronchodilators, e.g. ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutalin, isoetharine, tulobuterol, orciprenaline or (-)-4-amino-3,5-dichloro- α -[[[6-[2-(2-pyridinyl)ethoxy]hexyl]-amino]methyl]benzenemethanol; diuretics, e.g. amiloride; anticholinergics e.g. ipratropium, atropine or oxitropium;
 25 hormones, e.g. cortisone, hydrocortisone or prednisolone; xanthines e.g. aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; and therapeutic proteins and peptides, e.g. insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments are used in the form of salts (e.g. as alkali metal or amine salts or as acid addition salts) or as esters (e.g. lower alkyl esters) or as solvates
 30 (e.g. hydrates) to optimize the activity and/or stability of the medicament.

Other exemplary therapeutic agents useful for a combination therapy include but are not limited to agents as described above, radiation therapy, hormone antagonists, hormones and their releasing factors, thyroid and antithyroid drugs, estrogens and progestins, androgens, adrenocorticotrophic hormone; adrenocortical
 5 steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones, insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas, agents affecting calcification and bone turnover: calcium, phosphate, parathyroid hormone, vitamin D, calcitonin, vitamins such as water-soluble vitamins, vitamin B complex, ascorbic acid, fat-soluble vitamins, vitamins A, K, and E,
 10 growth factors, cytokines, chemokines, muscarinic receptor agonists and antagonists; anticholinesterase agents; agents acting at the neuromuscular junction and/or autonomic ganglia; catecholamines, sympathomimetic drugs, and adrenergic receptor agonists or antagonists; and 5-hydroxytryptamine (5-HT, serotonin) receptor agonists and antagonists.

15 Therapeutic agents can also include agents for pain and inflammation such as histamine and histamine antagonists, bradykinin and bradykinin antagonists, 5-hydroxytryptamine (serotonin), lipid substances that are generated by biotransformation of the products of the selective hydrolysis of membrane phospholipids, eicosanoids, prostaglandins, thromboxanes, leukotrienes, aspirin, nonsteroidal anti-inflammatory
 20 agents, analgesic-antipyretic agents, agents that inhibit the synthesis of prostaglandins and thromboxanes, selective inhibitors of the inducible cyclooxygenase, selective inhibitors of the inducible cyclooxygenase-2, autacoids, paracrine hormones, somatostatin, gastrin, cytokines that mediate interactions involved in humoral and cellular immune responses, lipid-derived autacoids, eicosanoids, β -adrenergic agonists,
 25 ipratropium, glucocorticoids, methylxanthines, sodium channel blockers, opioid receptor agonists, calcium channel blockers, membrane stabilizers and leukotriene inhibitors.

Additional therapeutic agents contemplated herein include diuretics, vasopressin, agents affecting the renal conservation of water, rennin, angiotensin,
 30 agents useful in the treatment of myocardial ischemia, anti-hypertensive agents,

angiotensin converting enzyme inhibitors, β -adrenergic receptor antagonists, agents for the treatment of hypercholesterolemia, and agents for the treatment of dyslipidemia.

Other therapeutic agents contemplated include drugs used for control of gastric acidity, agents for the treatment of peptic ulcers, agents for the treatment of gastroesophageal reflux disease, prokinetic agents, antiemetics, agents used in irritable bowel syndrome, agents used for diarrhea, agents used for constipation, agents used for inflammatory bowel disease, agents used for biliary disease, agents used for pancreatic disease. Therapeutic agents used to treat protozoan infections, drugs used to treat Malaria, Amebiasis, Giardiasis, Trichomoniasis, Trypanosomiasis, and/or Leishmaniasis, and/or drugs used in the chemotherapy of helminthiasis. Other therapeutic agents include antimicrobial agents, sulfonamides, trimethoprim-sulfamethoxazole quinolones, and agents for urinary tract infections, penicillins, cephalosporins, and other, β -lactam antibiotics, an agent comprising an aminoglycoside, protein synthesis inhibitors, drugs used in the chemotherapy of tuberculosis, mycobacterium avium complex disease, and leprosy, antifungal agents, antiviral agents including nonretroviral agents and antiretroviral agents.

Examples of therapeutic antibodies that can be combined with a compound of the invention include but are not limited to anti-receptor tyrosine kinase antibodies (cetuximab, panitumumab, tRAStuzumab), anti CD20 antibodies (rituximab, tositumomab), and other antibodies such as alemtuzumab, bevacizumab, and gemtuzumab.

Moreover, therapeutic agents used for immunomodulation, such as immunomodulators, immunosuppressive agents, tolerogens, and immunostimulants are contemplated by the methods herein. In addition, therapeutic agents acting on the blood and the blood-forming organs, hematopoietic agents, growth factors, minerals, and vitamins, anticoagulant, thrombolytic, and antiplatelet drugs.

For treating renal carcinoma, one may combine a compound of the present invention with sorafenib and/or avastin. For treating an endometrial disorder, one may combine a compound of the present invention with doxorubicin, taxotere (taxol), and/or cisplatin (carboplatin). For treating ovarian cancer, one may combine a compound of the present invention with cisplatin (carboplatin), taxotere, doxorubicin,

topotecan, and/or tamoxifen. For treating breast cancer, one may combine a compound of the present invention with taxotere (taxol), gemcitabine (capecitabine), tamoxifen, letrozole, tarceva, lapatinib, PD0325901, avastin, herceptin, OSI-906, and/or OSI-930. For treating lung cancer, one may combine a compound of the present invention with
5 taxotere (taxol), gemcitabine, cisplatin, pemetrexed, Tarceva, PD0325901, and/or avastin.

Further therapeutic agents that can be combined with a compound of the invention are found in Goodman and Gilman's "The Pharmacological Basis of Therapeutics" Tenth Edition edited by Hardman, Limbird and Gilman or the
10 Physician's Desk Reference, both of which are incorporated herein by reference in their entirety.

The compounds described herein can be used in combination with the agents disclosed herein or other suitable agents, depending on the condition being treated. Hence, in some embodiments the one or more compounds of the invention will
15 be co-administered with other agents as described above. When used in combination therapy, the compounds described herein are administered with the second agent simultaneously or separately. This administration in combination can include simultaneous administration of the two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. That is, a
20 compound described herein and any of the agents described above can be formulated together in the same dosage form and administered simultaneously. Alternatively, a compound of the invention and any of the agents described above can be simultaneously administered, wherein both the agents are present in separate formulations. In another alternative, a compound of the present invention can be
25 administered just followed by and any of the agents described above, or vice versa. In some embodiments of the separate administration protocol, a compound of the invention and any of the agents described above are administered a few minutes apart, or a few hours apart, or a few days apart.

The examples and preparations provided below further illustrate and
30 exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited

in any way by the scope of the following examples and preparations. In the following examples, and throughout the specification and claims, molecules with a single chiral center, unless otherwise noted, exist as a racemic mixture. Those molecules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of

5 diastereomers. Single enantiomers/diastereomers may be obtained by methods known to those skilled in the art.


EXAMPLES

The following examples are provided for exemplary purposes. Other compounds of structure (I) were prepared according to the following general procedures as indicated in Table 1.

5

EXAMPLE 1

SYNTHESIS OF 1-(4-(7-CHLORO-6-(2-CHLOROPHENYL)QUINAZOLIN-4-YL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (**1**)



10 Compound 1 was prepared according to Method A as described below:

Methyl 2-amino-5-(2-chlorophenyl)-4-chlorobenzoate

A mixture of methyl 2-amino-5-bromo-4-chlorobenzoate (1.2 g, 4.54 mmol), 2-chlorophenylboronic acid (0.85 g, 5.44 mmol), Na₂CO₃ (1.44 g, 13.61 mmol), and Pd(PPh₃)₄ (0.52 g, 0.45 mmol) in 1,4-dioxane (30 mL) and water (6 mL) was stirred at 75°C under argon for 16 h. The mixture was allowed to cool to room temperature (RT), and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (ethyl acetate / petroleum = 8 : 1) to afford the desired product (1.22 g, 91% yield) as a yellow solid.

7-Chloro-6-(2-chlorophenyl)quinazolin-4-ol

A mixture of methyl 2-amino-5-(2-chlorophenyl)-4-chlorobenzoate (342 mg, 1.16 mmol), CH(OMe)₃ (306 mg, 2.89 mmol), and NH₄OAc (223 mg, 2.89 mmol) in MeOH (1 mL) in a sealed tube was stirred at 130°C for 4.5 h. The mixture was allowed to cool to RT, and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel eluting with DCM and MeOH (40 : 1) to yield the desired product (277 mg, 82% yield) as a white solid. ESI-MS *m/z*: 289.2 [M - H]⁻.

4,7-Dichloro-6-(2-chlorophenyl)quinazoline

A mixture of 7-chloro-6-(2-chlorophenyl)quinazolin-4-ol (277 mg, 0.95 mmol), PCl₅ (397 mg, 1.90 mmol) and POCl₃ (16 mL) was stirred at reflux for 20 h. The mixture was allowed to cool to RT, and then concentrated *in vacuo* to yield the crude product (1.19 g) as a dark oil which was used directly in next step without further purification.

***tert*-Butyl-4-(7-chloro-6-(2-chlorophenyl)quinazolin-4-yl)piperazine-1-carboxylate**

The above obtained crude 4,7-dichloro-6-(2-chlorophenyl)quinazoline (1.19 g) was added to the mixture of *tert*-butyl piperazine-1-carboxylate (5 g, 26.9 mmol) and Et₃N (7.76 g, 76.8 mmol) in DCM (200 mL) at 0 °C and the resulting mixture was stirred at the same temperature for 1 h. The mixture was poured into water (500 mL) and brine (100 mL), and then dichloromethane (DCM) (200 mL) was added. The mixture was filtered through filter paper. The organic layer was separated, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel eluting with DCM and MeOH (30 : 1) to yield the desired

product (184 mg, 42% yield, 2 steps) as a light yellow oil. ESI-MS m/z : 459.3 $[M + H]^+$.

1-(4-(7-Chloro-6-(2-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one


A mixture of tertbutyl-4-(7-chloro-6-(2-chlorophenyl)quinazolin-4-yl)piperazine-1-carboxylate (184 mg, 0.40 mmol) and HCl in MeOH (20 mL) was stirred at RT for 1 h. The mixture was concentrated *in vacuo* to yield the crude product (176 mg) as a yellow solid which was used directly in next step without further purification.

1-(4-(7-Chloro-6-(2-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

10 (1)

The above obtained crude 1-(4-(7-chloro-6-(2-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one (176 mg) was dissolved in Et₃N (450 mg, 4.45 mmol) and DCM (30 mL) and cooled to 0°C, acryloyl chloride (44 mg, 0.49 mmol) in DCM (50 mL) was added to the mixture. The resulting mixture was allowed to warm to RT and stirred at RT for 1.5 h. The reaction mixture was quenched with saturated NaHCO₃ aqueous solution, and then extracted with ethyl acetate. The organic layer was washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel eluting with DCM and MeOH (30 : 1) to yield the desired product (82 mg, 50% yield, 2 steps) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ : 8.75 (s, 1H), 8.03 (s, 1H), 7.96 (s, 1H), 7.62-7.49 (m, 4H), 6.81 (dd, J = 10.4, 16.4 Hz, 1H), 6.15 (dd, J = 16.4, 2.4 Hz, 1H), 5.71 (dd, J = 10.4, 2.0 Hz, 1H), 3.87-3.72 (m, 8H). ESI-MS m/z : 413.2 $[M + H]^+$.

EXAMPLE 2

SYNTHESIS OF 1-(4-(7-CHLORO-6-PHENYLQUINAZOLIN-4-YL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (**18**)

Compound 18 was prepared according to Method B as described below:

6-Bromo-7-chloroquinazolin-4-ol

A mixture of methyl 2-amino-5-bromo-4-chlorobenzoate (1 g, 3.95 mmol) and NH_2CHO (20 mL) was stirred at 200°C for 3 h. The mixture was allowed to cool to RT and quenched with water. The solid precipitate was collected by filtration and dried *in vacuo* to yield the desired product (669 mg, 66% yield) as a brown solid.

6-Bromo-4,7-dichloroquinazoline

A mixture of 6-bromo-7-chloroquinazolin-4-ol (669 mg, 2.59 mmol), PCl_5 (1.6 g, 7.78 mmol) and POCl_3 (15 mL) was stirred at reflux for 16 h. The mixture was allowed to cool to RT and then concentrated *in vacuo* to yield the desired product as a dark oil which was used directly in next step without further purification.

***tert*-Butyl 4-(6-bromo-7-chloroquinazolin-4-yl)piperazine-1-carboxylate**

The above obtained crude 6-bromo-4,7-dichloroquinazoline was added to the mixture of *tert*-butyl piperazine-1-carboxylate (4.82 g, 25.9 mmol) and Et₃N (2.62 g, 25.9 mmol) in DCM (70 mL). The resulting mixture was stirred at RT for 2 h and then was quenched with saturated NaHCO₃ aqueous solution. The mixture was extracted with DCM, washed with saturated NaHCO₃ aqueous solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel eluting with ethyl acetate and petroleum ether (4: 1) to yield the desired product (631 mg, 57% yield, 2 steps) as a yellow solid. ESI-MS *m/z* : 429.3 [M + H]⁺.


***tert*-Butyl 4-(7-chloro-6-phenylquinazolin-4-yl)piperazine-1-carboxylate**

A mixture of *tert*-butyl 4-(6-bromo-7-chloroquinazolin-4-yl)piperazine-1-carboxylate (200 mg, 0.47 mmol), phenylboronic acid (115 mg, 0.94 mmol), Na₂CO₃ solution (2.0 M, 0.71 mL, 1.41 mmol), Pd(PPh₃)₄ (109 g, 0.094 mmol) in 1,4-dioxane (10 mL) was stirred at reflux under argon for 16 h. The mixture was allowed to cool to RT, diluted with ethyl acetate, and then washed with H₂O and brine. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel eluting with ethyl acetate and petroleum ether (1 : 4) to yield the desired product (120 mg, 60% yield) as a yellow oil. ESI-MS *m/z* : 425.4 [M + H]⁺.

1-(4-(7-Chloro-6-phenylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from *tert*-butyl 4-(7-chloro-6-phenylquinazolin-4-yl)piperazine-1-carboxylate in two steps following the procedure described in Example 1. ¹H NMR (400 MHz, CDCl₃) δ: 8.74 (s, 1H), 8.15 (s, 1H), 7.83 (s, 1H), 7.50-7.45 (m, 5H), 6.58 (dd, *J* = 16.8, 10.4 Hz, 1H), 6.36 (dd, *J* = 16.4, 1.6 Hz, 1H), 5.77 (dd, *J* = 10.4, 2.0 Hz, 1H), 3.92-3.81 (m, 8H). ESI-MS *m/z*: 379.3 [M + H]⁺.

EXAMPLE 3

SYNTHESIS OF 1-(4-(6-CHLORO-5-(2-CHLOROPHENYL)-1H-INDAZOL-3-YLAMINO)PIPERIDIN-1-YL)PROP-2-EN-1-ONE (**31**)

Compound 31 was prepared according to Method C as described below:

4-Methyl-N'-(2',4,6-trichlorobiphenylcarbonyl)benzenesulfonohydrazide

To a stirred solution of 2',4,6-trichlorobiphenyl-3-carbonyl chloride (5.5 g) in toluene at RT, NH₂NHTs (3.8 g, 20.3 mmol) was added and the resulting mixture was stirred at 75°C overnight. The mixture was allowed to cool to RT. The solid was collected by filtration and dried *in vacuo* to afford the desired product (6 g, 75% yield) as a white solid.

2',4,6-Trichloro-N'-tosylbiphenyl-3-carbohydrazonoyl chloride

A solution of 4-methyl-N'-(2',4,6-trichlorobiphenylcarbonyl)benzenesulfonohydrazide (2.3 g, 4.5 mmol) in SOCl₂ (5.8 g, 45 mmol) was stirred at 75°C for 4 h. The mixture was allowed to cool to RT, and then petroleum ether was added. The resulting mixture was stirred at 0°C for 1 h. The precipitate was collected by filtration and dried *in vacuo* to afford the desired product (1.6 g, 67% yield) as a white solid.

tert-Butyl 4-((6-chloro-5-(2-chlorophenyl)-1-tosyl-1H-indazol-3-yl)(4-methoxybenzyl)amino) piperidine-1-carboxylate

To a stirred solution of 2',4,6-trichloro-N'-tosylbiphenyl-3-carbohydrazonoyl chloride (1.6 g, 3.4 mmol) in 100 mL of NMP at RT, tert-butyl 4-(4-methoxybenzylamino)piperidine-1-carboxylate (1.1 g, 3.4 mmol) was added followed by K₂CO₃ (1.4 g, 10.2 mmol). The reaction mixture was stirred at 40°C overnight. The mixture was allowed to cool to RT, and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (1 - 20% ethyl acetate / petroleum ether) to afford the desired product (550 mg, 23% yield) as a white solid.

tert-Butyl 4-((6-chloro-5-(2-chlorophenyl)-1H-indazol-3-yl)(4-methoxybenzyl)amino) piperidine-1-carboxylate

To a stirred solution of tert-butyl 4-((6-chloro-5-(2-chlorophenyl)-1-tosyl-1H-indazol-3-yl)(4-methoxybenzyl)amino) piperidine-1-carboxylate (550 mg, 0.75 mmol) in THF (20 mL) and water (5 mL) at RT, NaOH (75 mg, 1.87 mmol) was added, and the resulting mixture was stirred at reflux overnight. The reaction mixture was cooled to RT and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (1 - 10% ethyl acetate / petroleum ether) to afford the desired product (100 mg, 23% yield) as a white solid. ESI-MS *m/z*: 581.5 [M + H]⁺.


6-Chloro-5-(2-chlorophenyl)-N-(piperidin-4-yl)-1H-indazol-3-amine

A solution of tert-butyl 4-((6-chloro-5-(2-chlorophenyl)-1H-indazol-3-yl)(4-methoxybenzyl)amino) piperidine-1-carboxylate (100 mg, 0.17 mmol) in 5 mL of TFA was stirred at reflux for 2 h. The reaction mixture was allowed to cool to RT and then partitioned between saturated NaHCO₃ aqueous solution and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to afford the desired product (62 mg) as a yellow solid. The crude product was used directly in the next step without further purification.

1-(4-(6-Chloro-5-(2-chlorophenyl)-1H-indazol-3-ylamino)piperidin-1-yl)prop-2-en-1-one

To a stirred solution of acrylic acid (12.4 mg, 0.17 mmol) in 5 mL of DMF at RT, 6-chloro-5-(2-chlorophenyl)-N-(piperidin-4-yl)-1H-indazol-3-amine (62 mg, 0.17 mmol), HOBT (30 mg, 0.22 mmol), EDCI (42 mg, 0.22 mmol), and TEA (52 mg, 0.51 mmol) were added sequentially. The reaction mixture was stirred at RT overnight. The mixture was partitioned between brine and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by prep-HPLC to give the desired product (2 mg, 3% yield) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ: 11.67 (s, 1H), 7.73 (s, 1H), 7.56-7.58 (m, 1H), 7.41-7.47 (m, 2H), 7.42 (s, 1H), 7.36-7.39 (m, 1H), 6.80-6.87 (m, 1H), 6.07 (dd, *J* = 2.5, 16.7 Hz, 1H), 6.04 (d, *J* = 7.3 Hz, 1H), 5.65 (dd, *J* = 2.4, 10.4 Hz, 1H), 4.23 (d, *J* = 12.3 Hz, 1H), 3.98 (d, *J* = 13.6 Hz, 1H), 3.76-3.80 (m, 1H), 3.26 (t, *J* = 13.0 Hz, 1H), 2.97 (t, *J* = 10.2 Hz, 1H), 2.06 (m, 2H), 1.38 (m, 2H). ESI-MS *m/z*: 415.1 [M + H]⁺.

EXAMPLE 4

SYNTHESIS OF 1-(4-(6-CHLORO-7-(2-CHLOROPHENYL)ISOQUINOLIN-1-YL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (**24**)

Compound 24 was prepared according to Method D as described below:

N-(3-Bromo-4-chlorobenzyl)-2,2-diethoxyethanamine

To a solution of 3-bromo-4-chlorobenzaldehyde (10.0 g, 45 mmol) and
 10 2,2-diethoxyethanamine (6.68 g, 50 mmol) in 200 mL of DCM at RT, 0.5 mL of AcOH
 was added and the resulting mixture was stirred at RT for 30 min. To this mixture,
 NaCNBH₃ (8.1 g, 135 mmol) was added in portions and then stirred at RT overnight.
 The reaction mixture was portioned between water and DCM. The organic layer was
 washed with water (80 mL x 2) and brine, dried over anhydrous Na₂SO₄, filtered and

concentrated *in vacuo* to afford the desired product (11 g, 72% yield) as an oil. The crude product obtained was used directly in the next step without further purification.

N-(3-Bromo-4-chlorobenzyl)-2,2-diethoxy-N-tosylethanamine

To a solution of N-(3-bromo -4-chlorobenzyl)-2,2-diethoxyethanamine
5 (11 g, 33 mmol) in 100 mL of DCM, pyridine (10 mL) was added and the resulting mixture was cooled to 0 °C. To this mixture, a solution of 4-methylbenzene-1-sulfonyl chloride (6.8 g, 36 mmol) in 50 mL of DCM was added dropwise. The reaction mixture was allowed to warm to RT and stirring was continued until conversion was completed. The reaction mixture was washed twice with HCl aqueous solution (2 M), sodium
10 bicarbonate solution and brine. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (5-20% ethyl acetate / petroleum ether) to afford the desired product (12.5 g, 78% yield). **ESI-MS** *m/z*: 490.2 [M+H]⁺.

7-Bromo-6-chloroisoquinoline

15 AlCl₃ (14.9 g) was suspended in DCM at RT, a solution of N-(3-bromo-4-chlorobenzyl)-2,2-diethoxy-N-tosylethanamine (11.0 g, 22.5 mmol) in 75 mL of DCM was added and the resulting mixture was stirred overnight. The mixture was poured into ice water, and extracted with DCM. The combined organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified
20 by flash column chromatography on silica gel (10-40% ethyl acetate / petroleum ether) to afford the desired product (5 g, 92.5% yield) as a white solid. **ESI-MS** *m/z*: 242 [M+H]⁺.

7-Bromo-6-chloroisoquinoline2-oxide


To a solution of 7-bromo-6-chloroisoquinoline (5.5 g, 22.8 mmol) in 100
25 mL of DCM at RT, was added m-chloroperbenzoic acid (70%, 5.88 g, 34.2 mmol) and the resulting mixture was stirred at RT overnight. The precipitate was filtered off and rinsed with DCM. The filtrate was washed with sodium bicarbonate solution. The layers were separated and the aqueous layer was extracted with DCM. The combined organic layer was dried with anhydrous Na₂SO₄ and concentrated *in vacuo* to afford the
30 desired product (4.6 g, 79% yield). The crude product was used directly in the next step without further purification. **ESI-MS** *m/z*: 258.2 [M+H]⁺.

1-(4-(6-chloro-7-(2-chlorophenyl)isoquinolin-1-yl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from 7-Bromo-6-chloroisoquinoline2-oxide in five steps following the procedure described in Example 1. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.22-8.21 (m, 2H), 8.00 (s, 1H), 7.65-7.47 (m, 5 H), 6.87 (dd, *J* = 16.9, 10.5 Hz, 1H), 6.16 (dd, *J* = 16.7, 1.7 Hz, 1H), 5.72 (dd, *J* = 10.3, 2.1 Hz, 1H), 3.83 (m, 4H), 3.37 (m, 4H). **ESI-MS** *m/z*: 412.2 [M+H]⁺.

EXAMPLE 5

SYNTHESIS OF 1-(4-(7-CHLORO-6-(2-CHLOROPHENYL)QUINOLIN-4-YL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (27)



10

Compound 27 was prepared according to Method E as described below:

Diethyl 2-((3-chloro-4-iodophenylamino)methylene)malonate

3-Chloro-4-iodoaniline (3.0 g, 11.8 mmol) and diethyl 2-(ethoxymethylene)malonate (12.78 g, 59.2 mmol) were mixed in a 100 mL single neck flask, and the resulting mixture was heated to 120°C and stirred for 2.5 h. The mixture
5 was allowed to cool to RT and purified by flash column chromatography on silica gel (10-20% ethyl acetate / petroleum ether) to afford the desired product (3.93 g) as a white solid. ESI-MS m/z : 422.1 $[M - H]^-$.

Ethyl 7-chloro-4-hydroxy-6-iodoquinoline-3-carboxylate

(E)-diethyl 2-(((3-chloro-4-iodophenyl)imino)methyl) malonate (2.0 g, 4.73 mmol) was suspended in 30 mL of Ph₂O. The mixture was stirred at 250 °C for 4
10 h. The mixture was allowed to cool to RT and then 100 mL of petroleum ether was added. The white solid was collected by filtration and rinsed with petroleum ether (100 mL) to afford the desired product (1.20 g) as a white solid.

7-Chloro-4-hydroxy-6-iodoquinoline-3-carboxylic acid

Ethyl 7-chloro-4-hydroxy-6-iodoquinoline-3-carboxylate (1.2 g, 3.18 mmol) was suspended in 10% NaOH aqueous solution (50 mL). The mixture was stirred at reflux for 3.5 h. The white solid was slowly dissolved in NaOH solution. After the mixture turned to a colorless phase, it was kept heating for additional 1 h. The mixture was allowed to cool to RT, and the white solid was separated out. The mixture
20 was acidified with con. HCl to adjust the pH to 2. The white precipitate was collected by filtration and rinsed with petroleum ether to afford the desired product (1.13 g) as a white solid.

7-Chloro-6-iodoquinolin-4-ol

7-Chloro-4-hydroxy-6-iodoquinoline-3-carboxylic acid (1.134 g, 3.25 mmol) was suspended in 40 mL of Ph₂O. The mixture was stirred at 250°C for 3.5 h. The mixture was allowed to cool to RT and 100 mL of petroleum ether was added. The solid was collected by filtration, and rinsed with petroleum ether to afford the desired product (0.92 g) as a white solid.

4,7-Dichloro-6-iodoquinoline

7-Chloro-6-iodoquinolin-4-ol (591 mg, 1.94 mmol) was dissolved in 40 mL of POCl₃ and the mixture was stirred at reflux for 3 h. The mixture was allowed to
30

cool to RT and concentrated *in vacuo*. The residue was poured into a solution of Et₃N (2.93 g, 29.03 mmol, 15 eq.) in 40 mL of DCM at 0°C. The mixture was partitioned between ethyl acetate and brine. The organic layer was dried and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (40% ethyl acetate / petroleum ether) to afford the desired product (895 mg) as a solid. ESI-MS *m/z*: 323.9 [M + H]⁺.

tert-Butyl 4-(7-chloro-6-iodoquinolin-4-yl)piperazine-1-carboxylate

4,7-Dichloro-6-iodoquinoline (200 mg, 0.62 mmol) was mixed with tert-butyl piperazine-1-carboxylate (172 mg, 0.93 mmol) and Et₃N (250 mg, 2.47 mmol) in 15 mL DMSO. The resulting mixture was stirred at 80°C under argon for 16 h. The mixture was poured into 250 mL of water and 50 mL of brine, and then extracted with ethyl acetate. The combined organic layer was washed with brine, dried over Na₂SO₄, and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (20-30% ethyl acetate / petroleum ether) to afford the desired product (132 mg). ESI-MS *m/z*: 374.2 [M + H]⁺.

tert-Butyl 4-(7-chloro-6-(2-chlorophenyl)quinolin-4-yl)piperazine-1-carboxylate

tert-Butyl 4-(7-chloro-6-iodoquinolin-4-yl)piperazine-1-carboxylate (130 mg, 0.28 mmol) was mixed with (2-chlorophenyl)boronic acid (109 mg, 0.33 mmol), Pd(PPh₃)₄ (32 mg, 0.028 mmol) and Na₂CO₃ (88 mg, 0.83 mmol) in 1,4-dioxane (20 mL) and water (4 mL). The mixture was stirred at 70°C under argon for 4 h. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (30-40% ethyl acetate / petroleum ether) to afford the desired (100 mg). ESI-MS *m/z*: 458.3 [M + H]⁺.


1-(4-(7-Chloro-6-(2-chlorophenyl)quinolin-4-yl)piperazin-1-yl)prop-2-en-1-one

tert-butyl 4-(7-chloro-6-(2-chlorophenyl)quinolin-4-yl)piperazine-1-carboxylate (100 mg, 0.22 mmol) was dissolved in 20% MeOH-HCl solution (20 mL). The mixture was stirred at RT for 1 h. The mixture was concentrated *in vacuo* to yield a yellow solid salt (124 mg). The yellow salt (124 mg, 0.32 mmol) was dissolved in 30 mL of DCM in the presence of Et₃N (191 mg, 1.89 mmol). The mixture was cooled to 0°C and then a solution of acryloyl chloride (32 mg, 0.35 mmol) in DCM (2 mL) was added dropwise. The mixture was stirred at 0°C for 30 min. The mixture was

concentrated *in vacuo* and the residue was purified by flash column chromatography on silica gel (50-100% ethyl acetate / petroleum ether) to afford the desired product (35 mg). ¹H NMR (300 MHz, DMSO-*d*₆) δ: 8.78-8.79 (m, 1H), 8.17 (s, 1H), 7.96 (s, 1H), 7.65-7.51 (m, 4H), 7.10-7.09 (m, 1H), 6.87 (dd, *J* = 16.4, 10.4 Hz, 1H), 6.15 (d, *J* = 16.4 Hz, 1H), 5.71 (d, *J* = 10.4 Hz, 1H), 3.81 (br s, 4H), 3.22 (br s, 4H). ESI-MS *m/z*: 412.2 [M + H]⁺.

5

EXAMPLE 6

SYNTHESIS OF 4-(4-ACRYLOYLPIPERAZIN-1-YL)-7-CHLORO-6-(4-CHLOROPHENYL)QUINOLINE-3-CARBONITRILE (**42**)

5

Compound **42** was prepared according to Method G as described below:

3-Chloro-4-(4-chlorophenyl)benzenamine

A mixture of 3-chloro-4-iodobenzaniline (500 mg, 1.97 mmol), 4-chlorophenylboronic acid (324 mg, 2.07 mmol), Na_2CO_3 (627 mg, 5.92 mmol) and $\text{Pd(PPh}_3)_4$ (228 mg, 0.20 mmol) in 1,4-dioxane (21 mL) and H_2O (4 mL) was stirred at 80°C under argon for 16 h. The mixture was allowed to cool to RT and concentrated *in*

vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate / petroleum ether = 5/1) to afford the desired product (424 mg, 91% yield) as a yellow solid.

(E)-Ethyl 3-(3-chloro-4-(4-chlorophenyl)-phenylamino)-2-cyanoacrylate

5 A mixture of 3-chloro-4-(4-chlorophenyl)benzenamine (250 mg, 1.05 mmol) and (E)-ethyl 2-cyano-3-ethoxyacrylate (186 mg, 1.10 mmol) was stirred at 100°C for 2 h and then at 130°C for 4 h. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was triturated with ethyl acetate to afford the desired product (219 mg, 55% yield) as a white solid. ESI-MS *m/z*: 359.1 [M-H]⁻.

10 **7-chloro-6-(4-chlorophenyl)-4-hydroxyquinoline-3-carbonitrile**


 A mixture of (E)-Ethyl-3-(3-chloro-4-(4-chlorophenyl)-phenylamino)-2-cyanoacrylate (219 mg, 0.608 mmol) in Ph₂O (8 mL) was stirred at 253°C for 4 h. The mixture was cooled to RT and poured into petroleum ether (20 mL). The precipitate was collected by filtration and washed with petroleum ether (50 mL x 2) to yield the
15 desired product (65 mg, 34% yield) as a brown solid.

4-(4-acryloylpiperazin-1-yl)-7-chloro-6-(4-chlorophenyl)quinoline-3-carbonitrile

 The title compound was prepared from 7-chloro-6-(4-chlorophenyl)quinolin-4-ol in four steps according to the procedure described in Example 1. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.84 (s, 1H), 8.21 (s, 1H), 8.05 (s, 1H),
20 7.66-7.59 (m, 4H), 6.88 (dd, *J* = 16.8, 10.4 Hz, 1H), 6.17 (dd, *J* = 16.8, 2.0 Hz, 1H), 5.74 (dd, *J* = 10.4, 2.0 Hz, 1H), 3.83-3.74 (m, 8H). ESI-MS *m/z* : 437.2 [M + H]⁺.

EXAMPLE 7

SYNTHESIS OF 1-(4-(5-(4-CHLOROPHENYL)THIENO[2,3-D]PYRIMIDIN-4-YL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (**22**)



5 Compound 22 was prepared according to Method H as described below:

tert-Butyl 4-(5-(4-chlorophenyl)thieno[2,3-d]pyrimidin-4-yl)piperazine-1-carboxylate

A solution of 4-chloro-5-(4-chlorophenyl)thieno[2,3-d]pyrimidine (180
10 mg, 0.64 mmol), tert-butyl piperazine-1-carboxylate (119 mg, 0.64 mmol) and diisopropyl amine in THF (6 mL) was stirred at RT overnight. The mixture was partitioned between DCM and water. The organic layer was dried over Na₂SO₄, filtered and concentrated *in vacuo* to afford the desired product which was used directly in the next step without further purification.

5-(4-Chlorophenyl)-4-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride


To a suspension of tert-butyl 4-(5-(4-chlorophenyl)thieno[2,3-
d]pyrimidin-4-yl)piperazine-1-carboxylate obtained from the previous step in 1,4-
dioxane (10 mL) and MeOH (5 mL), was added a solution of HCl in 1,4-dioxane (4 M,
1.0 mL). The mixture was stirred at RT overnight. The mixture was concentrated *in*
20 *vacuo* and the residue was used directly in the next step without further purification.

1-(4-(5-(4-Chlorophenyl)thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

To a solution of 5-(4-Chlorophenyl)-4-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride obtained above in DCM (10 mL) at 0°C, Et₃N (0.2 mL) was added followed by acryloyl chloride. The resulting mixture was allowed to warm to RT and stirred for 1 h. The mixture was partitioned between DCM and water. The organic layer was dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified via Isolera One (silica cartridge, 0-60% ethyl acetate / hexanes) to afford the desired product (27.5 mg). ¹H NMR (300 MHz, CDCl₃), δ: 8.64 (s, 1H), 7.35-7.48 (m, 4H), 7.30 (s, 1H), 6.42-6.60 (m, 1H), 6.26 (d, *J* = 24 Hz, 1H), 5.69 (d, *J* = 10.5 Hz, 1H), 3.10-3.35 (m, 8 H). ESI-MS *m/z*: 385.0 [M+H]⁺

EXAMPLE 8

SYNTHESIS OF 1-(4-(8-(2-CHLOROPHENYL)QUINAZOLIN-2-YL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (35)



Compound 35 was prepared according to Method I as described below:

tert-Butyl 4-(8-bromoquinazolin-2-yl)piperazine-1-carboxylate

The title compound was prepared from 8-bromo-2-chloroquinazoline according to the procedure described in step 1 in Example 7.

tert-Butyl 4-(8-(2-chlorophenyl)quinazolin-2-yl)piperazine-1-carboxylate

5 A mixture of tert-Butyl 4-(8-bromoquinazolin-2-yl)piperazine-1-carboxylate


(250 mg, 0.64 mmol), 2-chlorophenylbromic acid (110 mg, 1.1 mmol) and Pd(dppf)Cl₂.CH₂Cl₂ (50 mg) in a mixture of 1,4-dioxane (6 mL) and sat. NaHCO₃ solution (3 mL) was stirred at 100°C for 1 h. The mixture was allowed to cool to RT, and partitioned between water and ethyl acetate. The organic layer was dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified via Isolera One (silica cartridge, 0-60% ethyl acetate /hexanes) to afford the desired product.

1-(4-(8-(2-Chlorophenyl)quinazolin-2-yl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from tert-Butyl 4-(8-(2-chlorophenyl)quinazolin-2-yl)piperazine-1-carboxylate according to the procedure described in steps 2 and 3 in Example 7. ¹H NMR (300 MHz, CDCl₃) δ: 9.07 (s, 1H), 7.74 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.67 (dd, *J* = 6.8, 1.2 Hz, 1H), 7.46-7.56 (m, 1H), 7.39-7.42 (m, 4H), 6.58 (dd, *J* = 16.8, 10.8 Hz, 1H), 6.32 (dd, *J* = 16.8, 2.0 Hz, 1H), 5.71 (dd, *J* = 10.6, 1.9 Hz, 1H), 3.8-3.9 (br., 4H), 3.68-3.78 (br., 2H), 3.55-3.62 (br., 2H).

20 **ESI-MS** *m/z*: 379.1 [M+H]⁺.

EXAMPLE 9

SYNTHESIS OF 1-(4-(5-(2-CHLOROPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (**28**)

5

Compound **28** was prepared according to Method J as described below:

4-Chloro-7H-pyrrolo[2,3]pyrimidine

A mixture of 1H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (2.5 g, 18.6 mmol) in 46 mL of POCl₃ was stirred at reflux for 5 h. The mixture was allowed to cool to RT and then concentrated *in vacuo* to remove the excess amount of POCl₃. Ice was added to the residue and the mixture was stirred at RT for 10 min. The aqueous layer was extracted with diethyl ether. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo* to afford the desired product (1.5 g, 54% yield) as an off-white solid.

15

4-Chloro-5-iodo-7H-pyrrolo[2,3]pyrimidine

4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (1.8 g 11.9 mmol) and *N*-iodosuccinamide (3g, 13.1 mmol) were mixed in a round bottomed flask. The flask was dried under high vacuum for 5 h and then back-filled with argon. To this mixture, dry
5 DMF (100 mL) was added and the resulting mixture was stirred in the dark for 20 h. The reaction was quenched with methanol and concentrated *in vacuo*. The residue was diluted with 150 mL of DCM and washed with water (200 mL), saturated aqueous sodium sulfite (200 mL), and brine (100 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by flash column
10 chromatography on silica gel (50% ethyl acetate / hexanes) to afford the desired product (3.1 g, 95% yield) as a white solid. ESI-MS *m/z*: 279.5 [M + H]⁺.

4-Chloro-5-iodo-7benzenesulfonyl-pyrrolo[2,3-d]pyrimidine

To a solution of 4-chloro-5-iodo-7H-pyrrolo[2,3]pyrimidine (280 mg, 1 mmol) in DMF (5 mL) at 0°C, NaH (60%, 52 mg, 1.3 mmol) was added and the
15 resulting mixture was stirred at 0°C for 30 min. To this mixture, benzenesulfonyl chloride (194 mg, 1.1 mmol) was added. The mixture was then stirred at RT for 2 h. The mixture was partitioned between ethyl acetate and water. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel to afford the desired product (300 mg,
20 71.6% yield).

4-Chloro-5-(2-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidine

To a solution of 4-chloro-5-iodo-7benzenesulfonyl-pyrrolo[2,3-d]pyrimidine (300 mg, 0.71 mmol) and 2-chlorophenylboronic acid (167 mg, 1.07 mmol) in 1,4-dioxane (15 mL) and water (3 mL), Pd(PPh₃)₄ (60 mg) and Na₂CO₃ (227
25 mg, 2.14 mmol) were added. The mixture was stirred at 80°C overnight. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel to afford the desired product (120 mg, 63% yield). ESI-MS *m/z*: 262.2 [M - H]⁻.

tert-butyl-4-(5-(2-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazine-1-carboxylate


To a solution of 4-chloro-5-(2-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidine (120 mg, 0.45 mmol) and tert-butyl piperazine-1-carboxylate (254 mg, 1.36 mmol) in 1,4-dioxane (15 mL), DIEA (293 mg, 2.27 mmol) was added. The mixture was stirred at 100°C overnight. The mixture was concentrated *in vacuo* and the residue was purified by flash column chromatography on silica gel to afford the desired product (120 mg, 64% yield).

1-(4-(5-(2-Chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from tert-butyl-4-(5-(2-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazine-1-carboxylate in two steps according to the procedure described in Example 1. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.5 (s, 1H), 7.5 (m, 1H), 7.4 (m, 3H), 7.3 (s, 2H), 6.5 (m, 1H), 6.3 (m, 1H), 5.7 (m, 1H), 3.4 (m, 8H). ESI-MS *m/z*: 368.3 [M + H]⁺.

EXAMPLE 10

SYNTHESIS OF 1-(4-(2-AMINO-7-CHLORO-6-(4-CHLOROPHENYL)QUINAZOLIN-4-
YL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (**39**) AND 1-(4-(7-CHLORO-6-(4-CHLOROPHENYL)-
2-METHOXYQUINAZOLIN-4-YL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (**43**)



5

Compounds **39** and **43** were prepared according to Method F as described below:

6-Bromo-7-chloroquinazoline-2,4-diol

10

A mixture of methyl 2-amino-5-bromo-4-chlorobenzoate (3.0 g, 11.34 mmol) and urea (1.36 g, 22.68 mmol, 2eq.) was stirred at 200°C for 3 h. The mixture

was allowed to cool to RT, triturated with ethyl acetate and dried to afford the desired product (2.39 g) as a brown solid.

6-Bromo-2,4,7-trichloroquinazoline

The mixture of 6-bromo-7-chloroquinazoline-2,4-diol (1.1 g, 6.79 mmol) in 30 mL of POCl₃ was stirred at reflux for 2 days. The mixture was allowed to cool to RT and concentrated *in vacuo* to remove POCl₃. The residue was poured into a solution of Et₃N (13.7 g, 20 eq.) in 30 mL of DCM at 0°C. The mixture was partitioned between ethyl acetate and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash chromatography on silica gel (5-10% ethyl acetate / petroleum ether) to afford the desired product (474 mg) as a yellow solid.

tert-Butyl-4-(6-bromo-2,7-dichloroquinazolin-4-yl)piperazine-1-carboxylate

To a solution of tert-butyl piperazine-1-carboxylate (123 mg, 0.66 mmol) in DMF (10 mL) at RT, DIEA (94 mg, 0.72 mmol) was added followed by 6-bromo-2,4,7-trichloroquinazoline (206 mg, 0.66 mmol). The resulting mixture was stirred at 50°C for 40 min. The mixture was allowed to cool to RT and partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (5% ethyl acetate / petroleum ether) to afford the desired product (222 mg) as a yellow solid. ESI-MS *m/z* : 463.2 [M + H]⁺.

tert-Butyl 4-(6-bromo-7-chloro-2-methoxyquinazolin-4-yl)piperazine-1-carboxylate

To a solution of NaOMe (26 mg, 0.476 mmol) in MeOH (20 mL), tert-butyl-4-(6-bromo-2,7-dichloroquinazolin-4-yl)piperazine-1-carboxylate (110 mg, 0.238 mmol) was added. The mixture was stirred at 60°C under argon for 40 min. The mixture was quenched by water (1.0 mL) and then concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (10-20% ethyl acetate / petroleum ether) to afford the desired product (55 mg) as a yellow solid. ESI-MS *m/z* : 459.2 [M + H]⁺.

tert-Butyl-4-(7-chloro-6-(4-chlorophenyl)-2-methoxyquinazolin-4-yl)piperazine-1-carboxylate

The mixture of tert-butyl 4-(6-bromo-7-chloro-2-methoxyquinazolin-4-yl)piperazine-1-carboxylate (85 mg, 0.19 mmol), (4-chlorophenyl)boronic acid (35 mg, 0.22 mmol), Pd(PPh₃)₄ (22 mg, 0.019 mmol), Na₂CO₃ (60 mg, 0.56 mmol) in dioxane (20 mL) and water (2 mL) was stirred at 80°C under argon for 16 h. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (10-20% ethyl acetate / petroleum ether) followed by Prep-TLC to afford the desired product (100 mg) as a white solid. ESI-MS *m/z*: 489.4 [M + H]⁺.

1-(4-(7-Chloro-6-(4-chlorophenyl)-2-methoxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

tert-Butyl-4-(7-chloro-6-(4-chlorophenyl)-2-methoxyquinazolin-4-yl)piperazine-1-carboxylate (100 mg, 0.20 mmol) was dissolved in 20 mL of 20% HCl methanol solution. The mixture was stirred at RT for 1 h and then concentrated *in vacuo* to yield a yellow solid salt (90 mg).

The above yellow solid (90 mg, 0.21 mmol) was dissolved in 30 mL of DCM with Et₃N (129 mg, 1.27 mmol). The mixture was cooled to 0°C and then added dropwise to a solution of acryloyl chloride (23 mg, 0.25 mmol) in DCM (2 mL). The resulting mixture was stirred at 0°C for 30 min. The mixture was poured into H₂O (100 mL), sat. NaHCO₃ (50 mL) and brine (50 mL), and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by Prep-TLC followed by Prep-HPLC to afford the desired product (8 mg) as a white solid. ESI-MS *m/z*: 443.2 [M + H]⁺.

tert-Butyl-4-(2-amino-6-bromo-7-chloroquinazolin-4-yl)piperazine-1-carboxylate

The mixture of tert-butyl 4-(6-bromo-2,7-dichloroquinazolin-4-yl)piperazine-1-carboxylate in sat. NH₃-EtOH (4 mL) in a sealed tube was stirred at 100°C for 16 h. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (20-30% ethyl acetate / petroleum ether) to afford the desired product (70 mg) as a white solid.

tert-Butyl-4-(2-amino-7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-1-carboxylate

The mixture of tert-butyl-4-(2-amino-6-bromo-7-chloroquinazolin-4-yl)piperazine-1-carboxylate (70 mg, 0.16 mmol), (4-chlorophenyl)boronic acid (29 mg, 0.19 mmol), Pd(PPh₃)₄ (18 mg, 0.019 mmol), and Na₂CO₃ (50 mg, 0.48 mmol) in dioxane (20 mL) and water (2 mL) was stirred at 80 °C under argon for 16 h. The mixture was allowed to cool to RT and then concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (10-20% ethyl acetate / petroleum ether) followed by Prep-TLC to afford the desired product (70 mg) as a red solid. ESI-MS *m/z* : 474.5[M + H]⁺.


1-(4-(2-Amino-7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

tert-Butyl-4-(2-amino-7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-1-carboxylate (70 mg, 0.15 mmol) was dissolved in 20% HCl methanol solution (20 mL) and the resulting mixture was stirred at RT for 1 h. The mixture was concentrated to afford the desired product (70 mg) as a yellow solid salt.

The mixture of above obtained yellow solid (70 mg, 0.21 mmol), acrylic acid (18 mg, 0.25 mmol), EDCI (73 mg, 0.381mmol) and HOBt(52mg, 0.381mmol) in 10 mL of DMF at 0°C, a solution of Et₃N (120 mg, 1.2 mmol) in DCM (2 mL) was added dropwise. The resulting mixture was stirred at 0°C for 30 min and at RT for 1.5h. The mixture was poured into water (100 mL), sat. NaHCO₃ (50 mL) and brine (50 mL), and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel to yield the desired product (5 mg) as a gray solid. ESI-MS *m/z*: 428.3 [M + H]⁺.

EXAMPLE 11

SYNTHESIS OF 1-(4-(7-CHLORO-6-(2-CHLOROPHENYL)QUINAZOLIN-4-YL)PIPERIDIN-1-YL)PROP-2-EN-1-ONE (36)



5

Compound 36 was prepared according to Method K as described below:

1-tert-Butyl 4-methyl 4-(6-bromo-7-chloroquinazolin-4-yl)piperidine-1,4-dicarboxylate

10 To a stirred solution of tert-butyl methyl piperidine-1,4-dicarboxylate (3.3 g, 13.5 mmol) in anhydrous THF (30 mL) at 0°C under nitrogen, LiHMDS (15 mL, 15 mmol) was added and the resulting mixture was stirred at 0°C for 1 h. To this mixture, a solution of 6-bromo-4,7-dichloroquinazoline (748 mg, 2.7 mmol) in THF (5 mL) was added and the resulting mixture was stirred at room temperature for 4 h. The mixture was quenched with ice-water and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (1-10% ethyl

15

acetate / petroleum ether) to afford the desired product (580 mg, 37% yield) as a white solid.

tert-Butyl 4-(6-bromo-7-chloroquinazolin-4-yl)piperidine-1-carboxylate

To a solution of 1-tert-butyl 4-methyl 4-(6-bromo-7-chloroquinazolin-4-yl)piperidine- 1,4-dicarboxylate (483 mg, 1.2 mmol) in DMSO (10 mL), LiCl (103 mg, 2.4 mmol) and water (65 mg, 3.6 mmol) were added, and the rusting mixture was stirred at 110°C for 16 h. The mixture was allowed to cool to room temperature and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (1-20% ethyl acetate/petroleum ether) to afford the desired product (170 mg, 33% yield) as a white solid.


tert-Butyl 4-(7-chloro-6-(2-chlorophenyl)quinazolin-4-yl)piperidine-1-carboxylate

A mixture of tert-butyl 4-(6-bromo-7-chloroquinazolin-4-yl)piperidine-1- carboxylate (230 mg, 0.59 mmol), 2-chlorophenylboronic acid (138 mg, 0.88 mmol), Pd(PPh₃)₄ (69 mg, 0.06 mmol) and Na₂CO₃ (188 mg, 106 mmol) in 1,4-dioxane (10 mL) under argon was stirred at 100°C for 16 h. The mixture was allowed to cool to room temperature, and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (1-20% ethyl acetate/petroleum ether) to afford the desired product (160 mg, 65% yield) as a white solid.

1-(4-(7-Chloro-6-(2-chlorophenyl)quinazolin-4-yl)piperidin-1-yl)prop-2-en-1-one (45)

The title compound was prepared from tert-butyl 4-(7-chloro-6-(2-chlorophenyl) quinazolin-4-yl)piperidine-1-carboxylate according to the procedure described in steps 5 and 6 in Example 1. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 9.28 (s, 1H), 8.55 (s, 1H), 8.27 (s, 1H), 7.70 (m, 2H), 7.53-7.68 (m, 2H), 6.82-6.88 (m, 1H), 6.10 (dd, *J* = 2.5, 16.8 Hz, 1H), 5.68 (dd, *J* = 2.3, 10.3 Hz, 1H), 4.55 (d, *J* = 12.2 Hz, 1H), 4.09-4.16 (m, 2H), 3.32 (t, *J* = 12.2 Hz, 1H), 2.89 (t, *J* = 12.1 Hz, 1H), 1.72-1.93 (m, 4H). ESI-MS *m/z*: 410.35 [M-H]⁻.

EXAMPLE 12

SYNTHESIS OF 7-CHLORO-6-(4-CHLOROPHENYL)-4-(4-(VINYL SULFONYL)PIPERAZIN-1-YL)QUINAZOLINE (**45**)

10

The title compound was prepared from tert-butyl 4-(6-bromo-7-chloroquinazolin-4-yl)piperazine-1-carboxylate and 4-chlorophenylboronic acid according to the procedure described in step 4 in Example 2.

tert-Butyl 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-1-carboxylate

15


A solution of tert-butyl 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-1-carboxylate (500 mg, 1.09 mmol) in HCl/MeOH (10 mL, 28.6 mmol) was stirred at room temperature for 30 min. The mixture was concentrated *in vacuo* to afford the crude product.

7-Chloro-6-(4-chlorophenyl)-4-(4-(vinylsulfonyl)piperazin-1-yl)quinazoline

The above obtained crude product was dissolved with DCM (15 mL) and cooled to 0°C. To this mixture, 2-chloroethanesulfonyl chloride (213.2 mg, 1.31 mmol) and Et₃N (1.5 mL, 10.9 mmol) were added and the resulting mixture was stirred at 0°C for 10 min. The mixture was quenched with ice-water and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by prep-HPLC to afford the desired product (3 mg, 0.6% yield). ¹H-NMR(400 M Hz, CDCl₃) δ: 8.78 (s, 1H), 8.08 (s, 1H), 7.75 (s, 1H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.42 (d, *J* = 8.4 Hz, 2H), 6.46 (dd, *J* = 10, 16.8 Hz, 1H), 6.31 (d, *J* = 16.8 Hz, 1H), 6.11 (d, *J* = 9.6 Hz, 1H), 3.91 (t, *J* = 4.8 Hz, 4H), 3.35 (t, *J* = 4.8 Hz, 4H). **ESI-MS** *m/z*: 449.25 [M+H]⁺.

EXAMPLE 13

SYNTHESIS OF 1-(4-(7-CHLORO-6-(4-CHLOROPHENYL)QUINAZOLIN-4-YL)-2-(HYDROXYMETHYL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (46)



5

Compound 46 was prepared according to the general procedures of Method A as described below:

4,7-Dichloro-6-(4-chlorophenyl)quinazoline

10 The title compound was prepared from 2-amino-5-bromo-4-chlorobenzoate according to the procedure described in steps 1, 2 and 3 in Example 1.

tert-Butyl 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-(hydroxymethyl)piperazine-1-carboxylate

15 The above obtained crude 4,7-dichloro-6-(4-chlorophenyl)quinazoline (200 mg, 0.464 mmol) was added to the mixture of tert-butyl 2-(hydroxymethyl)piperazine-1-carboxylate (210 mg, 0.968 mmol) and DIEA (418 mg, 3.24 mmol) in 1,4-dioxane (20 mL) at room temperature and the resulting mixture was stirred at 80°C for 3 h. The mixture was allowed to cool to room temperature and then

concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (DCM/MeOH = 30 :1) to afford the desired product (110 mg, 35% yield) as a light yellow oil. **ESI-MS** *m/z*: 498.9 [M+H]⁺.

(4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)methanol


5 hydrochloride

A mixture of 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-(hydroxymethyl)piperazine-1-carboxylate (110 mg, 0.225 mmol) and HCl in MeOH (10 mL, 28.6 mmol) was stirred at room temperature for 1 h. The mixture was concentrated *in vacuo* to afford the crude product (106 mg) as a yellow solid which was used directly
10 in next step without further purification.

1-(4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one

To a stirred solution of above obtained yellow solid (106 mg, 0.225 mmol) in DMF (5 mL) at room temperature, acrylic acid (19 mg, 0.27 mmol), BOP
15 (149 mg, 0.338 mmol) and DIEA (203 mg, 1.58 mmol) were added and the resulting mixture was stirred at room temperature for 30 min. The mixture was poured into saturated aqueous NaHCO₃ solution (50 mL), and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel
20 (DCM/MeOH = 20:1) to afford the desired product (20 mg, 20% yield, 2 steps) as a solid. **¹H NMR** (400 MHz, DMSO-*d*₆) δ : 8.7 (s, 1H), 8.2 (d, *J* = 2.8 Hz, 1H), 8.0 (s, 1H), 7.5 (m, 4H), 6.8 (dd, *J* = 10.4, 16.4 Hz, 1H), 6.1 (d, *J* = 17 Hz, 1H), 5.7 (dd, *J* = 2.4, 10.4 Hz, 1H), 5.0 (m, 1H), 4.3 (m, 2H), 4.2 (m, 2H), 3.6 (m, 3H), 2.5 (s, 2H). **ESI-MS** *m/z*: 443.30 [M+H]⁺.

EXAMPLE 14

SYNTHESIS OF 1-ACRYLOYL-4-(7-CHLORO-6-(4-CHLOROPHENYL)QUINAZOLIN-4-
YL)PIPERAZINE-2-CARBONITRILE (**47**)

5

Compound **47** was prepared according to the general procedures of Method A as described below:

4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carboxamide

10

The crude 4,7-dichloro-6-(4-chlorophenyl)quinazoline (310 mg, 1 mmol) was added to the mixture of piperazine-2-carboxamide (249 mg, 1.5 mmol) and DIEA (645 mg, 5 mmol) in 1,4-dioxane (20 mL) at room temperature and the resulting mixture was stirred at 80°C for 2 h. The mixture was allowed to cool to room

temperature and then concentrated *in vacuo*. The residue was used in the next step without further purification. **ESI-MS** m/z : 402.3 $[M+H]^+$.

tert-Butyl 2-carbamoyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-1-carboxylate

5 To a solution of the above obtained crude product 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carboxamide in DCM (20 mL) at room temperature, Et₃N (152 mg, 1.5 mmol) and di-tert-butyl dicarbonate (262 mg, 1.2 mmol) were added. The mixture was stirred at room temperature for 3 h. The mixture was concentrated *in vacuo* and the residue was purified by flash column
10 chromatography on silica gel (DCM/MeOH = 30:1) to afford the desired product (60 mg, 12% yield) as a solid. **ESI-MS** m/z : 502.4 $[M+H]^+$.

tert-Butyl 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-cyanopiperazine-1-carboxylate


To a solution of tert-butyl 2-carbamoyl-4-(7-chloro-6-(4-
15 chlorophenyl)quinazolin-4-yl)piperazine-1-carboxylate (60 mg, 0.12 mmol) and Et₃N (48 mg, 0.48 mmol) in DCM (20 mL) at 0°C, TFAA (50 mg, 0.24 mmol) and the resulting mixture was stirred at room temperature for 1 h. The reaction mixture was quenched with saturated NaHCO₃ solution, and then extracted with DCM. The organic layer was washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄ and
20 concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (DCM/MeOH = 50:1) to afford the desired product (50 mg, 86% yield) as a solid. **ESI-MS** m/z : 484.4 $[M+H]^+$.

1-Acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carbonitrile

The title compound was prepared from tert-butyl 4-(7-chloro-6-(4-
25 chlorophenyl)quinazolin-4-yl)-2-cyanopiperazine-1-carboxylate according to the procedure described in steps 5 and 6 in Example 1. **¹H NMR** (400 MHz, DMSO-*d*₆) δ : 8.7 (s, 1H), 8.1 (s, 1H), 8.0 (d, J = 2.0 Hz, 1H), 7.5 (m, 4H), 6.8 (dd, J = 10.4, 16.8 Hz, 1H), 6.3 (dd, J = 1.6, 16.8 Hz, 1H), 5.8 (dd, J = 1.6, 10.4 Hz, 1H), 4.6 (m, 1H), 4.3 (m, 3H), 3.6 (m, 2H), 3.4 (s, 1H). **ESI-MS** m/z : 438.25 $[M+H]^+$.

30

EXAMPLE 15

SYNTHESIS OF 1-(4-(7-CHLORO-6-(4-CHLOROPHENYL)-2-METHYLQUINAZOLIN-4-
YL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (50)

5

Compound 50 was prepared according to the general procedures of Method M as described below:

6-Bromo-7-chloro-2-methylquinazolin-4-ol

10 To a solution of methyl 2-amino-5-bromo-4-chlorobenzoate (1.0 g, 3.781 mmol) in MeCN (35 mL) at RT, *dry hydrogen chloride* was added *continuously* for 20 min. The resulting mixture was stirred at reflux for 2 h. The mixture was allowed to cool to RT and poured into saturated NaHCO₃ solution. The white solid was filtered, and the filtrate was extracted with ethyl acetate. The filtrate cake and organic layer was
15 combined and dried over Na₂SO₄, concentrated *in vacuo* to afford the crude product (1.62 g) as a white solid. **ESI-MS** *m/z* : 273.3 [M + H]⁺.

6-Bromo-4,7-dichloro-2-methylquinazoline

The mixture of 6-bromo-7-chloro-2-methylquinazolin-4-ol (500 mg, 1.828 mmol) in 30 mL of SOCl₂ was stirred at reflux for 16 h. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was purified through silica chromatography (5-10 % ethyl acetate/petroleum ether) to afford the desired product (180 mg, 34 % yield) as a yellow solid.

tert-Butyl 4-(6-bromo-7-chloro-2-methylquinazolin-4-yl)piperazine-1-carboxylate


To a solution of tert-butyl piperazine-1-carboxylate (76 mg, 0.410 mmol) in *i*-PrOH (10 mL) at RT, 6-bromo-4,7-dichloro-2-methylquinazoline (60 mg, 0.205 mmol) was added. The resulting mixture was stirred at reflux for 40 min. The mixture was allowed to cool to RT and partitioned between water and ethyl acetate. The organic layer was washed with saturated NaHCO₃ and brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (5 % ethyl acetate/petroleum ether) to afford the desired product (53 mg, 59 % yield) as a yellow solid.

1-(4-(7-Chloro-6-(4-chlorophenyl)-2-methylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from tert-butyl 4-(6-bromo-7-chloro-2-methylquinazolin-4-yl)piperazine-1-carboxylate in three steps according to the procedure described in **Example 2**. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.92 (s, 2H), 7.59 (m, 4H), 6.84-6.77 (dd, *J* = 10.4, 16.8 Hz, 1H), 6.17-6.36 (m, 1H), 5.74-5.71 (m, 1H), 3.85-3.72 (m, 8H), 2.54 (s, 3H). **ESI-MS** *m/z*: 428.3 [M+H]⁺.

EXAMPLE 16

SYNTHESIS OF 1-ACRYLOYL-4-(7-CHLORO-6-(4-CHLOROPHENYL)-2-METHYLQUINAZOLIN-4-YL)PIPERAZINE-2-CARBONITRILE (56)



5

Compound 56 was prepared according to the general procedures of Method M as described below:

1-tert-butyl 2-methyl 4-(6-Bromo-7-chloro-2-methylquinazolin-4-yl)piperazine-1,2-dicarboxylate

To a solution of 6-bromo-4,7-dichloro-2-methylquinazoline (435 mg, 1.49 mmol) and 1-tert-butyl 2-methyl piperazine-1,2-dicarboxylate (437 mg, 1.79 mmol) in 1,4-dioxane (30 mL), DIEA (769 mg, 5.96 mmol) was added. The mixture was stirred at 80°C for 1.5 h. The mixture was allowed to cool to RT and partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (5-50 % ethyl acetate/petroleum ether) to afford the desired product (224 mg, 30 % yield) as a yellow solid.

4-(6-Bromo-7-chloro-2-methylquinazolin-4-yl)-1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid

To a solution of 1-tert-butyl 2-methyl 4-(6-bromo-7-chloro-2-methylquinazolin-4-yl)piperazine-1,2-dicarboxylate (224 mg, 0.448 mmol) in THF (15 mL) and H₂O (5 mL), LiOH.H₂O (114 mg, 2.690 mmol) was added and the resulting mixture was stirred at RT for 1 h. The mixture was diluted with H₂O, acidified with HCl to adjust pH to 4 and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo* to afford the desired product (211 mg, 97 % yield) as a yellow solid.

tert-Butyl 4-(6-bromo-7-chloro-2-methylquinazolin-4-yl)-2-carbamoylpiperazine-1-carboxylate

To a solution of 4-(6-bromo-7-chloro-2-methylquinazolin-4-yl)-1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid (221 mg, 0.435 mmol) and Et₃N (176 mg, 1.738 mmol) in THF (35 mL) at -5°C, ethyl chloroformate (51 mg, 0.465 mmol) was added. The mixture was stirred at -5°C for 40 min and NH₃.H₂O (30 %, 507mg, 4.346 mmol) was added. The resulting mixture was kept stirring for 5 min at 0°C. The mixture was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (3 % methanol/dichloromethane) to afford the desired product (179 mg, 85 % yield) as a yellow solid. **ESI-MS** *m/z*: 484.3 [M + H]⁺.

tert-Butyl 2-carbamoyl-4-(7-chloro-6-(4-chlorophenyl)-2-methylquinazolin-4-yl)piperazine-1-carboxylate

A mixture of tert-butyl 4-(6-bromo-7-chloro-2-methylquinazolin-4-yl)-2-carbamoylpiperazine-1-carboxylate (179 mg, 0.371 mmol), (4-chlorophenyl)boronic acid (67 mg, 0.426 mmol), Pd(PPh₃)₄ (51 mg, 0.0445 mmol) and Na₂CO₃ (118 mg, 1.113 mmol) in 1,4-dioxane (25 mL) was stirred at 85°C for 16 h under argon. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (3 % methanol/dichloromethane) to afford the desired product (181 mg, 95 % yield) as a brown solid. **ESI-MS** *m/z*: 517.4 [M + H]⁺.

tert-Butyl 4-(7-chloro-6-(4-chlorophenyl)-2-methylquinazolin-4-yl)-2-cyanopiperazine-1-carboxylate

To a solution of tert-butyl 2-carbamoyl-4-(7-chloro-6-(4-chlorophenyl)-2-methylquinazolin-4-yl)piperazine-1-carboxylate (100 mg, 0.194 mmol) and Et₃N (78 mg, 0.775 mmol) in DCM (30 mL) at 0°C, TFAA (162 mg, 0.776 mmol) was added and the resulting mixture was stirred at RT for 1 h. The reaction mixture was quenched with saturated NaHCO₃ solution, and then extracted with dichloromethane. The organic layer was washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (petroleum ether/ethyl acetate = 2:1) to afford the desired product (58 mg, 60 % yield) as a yellow solid. **ESI-MS** *m/z*: 499.4[M+H]⁺.

1-Acryloyl-4-(7-chloro-6-(4-chlorophenyl)-2-methylquinazolin-4-yl)piperazine-2-carbonitrile


tert-Butyl 4-(7-chloro-6-(4-chlorophenyl)-2-methylquinazolin-4-yl)-2-cyanopiperazine-1-carboxylate (100 mg, 0.194 mmol) was dissolved in 20 mL of 20 % HCl/Et₂O solution. The mixture was stirred at RT for 30 min and then concentrated *in vacuo* to yield a solid salt (44 mg, 87 % yield). The above solid (44 mg, 0.101 mmol) was dissolved in 25 mL of DCM with Et₃N (51 mg, 0.505 mmol). The mixture was cooled to 0°C and then a solution of acryloyl chloride (10 mg, 0.111 mmol) in dichloromethane (2 mL) was added. The resulting mixture was stirred at 0°C for 40 min. The mixture was extracted with ethyl acetate. The organic layer was washed with

saturated NaHCO_3 and brine, dried over Na_2SO_4 and concentrated. The residue was purified with silica chromatography (petroleum ether/ethyl acetate = 2:1) to afford the desired product (24 mg, 52 % yield) as a white solid. $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ : 8.01 (d, $J = 6.4$ Hz, 2H), 7.63 (q, $J = 8.4, 20.4$ Hz, 4H), 6.90 (dd, $J = 10.4, 16.4$ Hz, 1H), 6.30 (m, 1H), 5.68 (s, 1H), 4.60 (m, 1H), 4.32 (m, 2H), 3.57 (m, 2H), 2.59 (s, 3H), 3.36 (m, 1H). **ESI-MS** m/z : 453.3 $[\text{M} + \text{H}]^+$.

EXAMPLE 17

SYNTHESIS OF 1-(4-(7-CHLORO-6-(4-CHLOROPHENYL)QUINAZOLIN-4-YL)-2-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (62)

10



Compound 62 was prepared according to the general procedures of Method A as described below:

15

Methyl 2-(3-oxopiperazin-2-yl)acetate

To a solution of dimethyl maleate (4.0 g, 27.78 mmol) in propan-2-ol (40 mL) at RT, ethane-1,2-diamine (1.167 g, 27.78 mmol) was added. The resulting mixture was stirred at 55°C for 16 h and concentrated *in vacuo*. The residue was washed
5 by a mixture of ethyl acetate/petroleum ether = 1:1 to afford the desired product (2.8 g, 59% yield) as a white solid.

2-(Piperazin-2-yl)ethanol

To a solution of methyl 2-(3-oxopiperazin-2-yl)acetate (1.82 g, 10.58 mmol) in THF (150 mL) at 0°C, LiAlH₄ (2.01 g, 52.9 mmol) was added. The resulting
10 mixture was stirred at reflux for 16 h. Then the mixture was cooled to RT. It was quenched with 10H₂O.Na₂SO₄ and filtered, washed with ethyl acetate. The filtrate was dried over Na₂SO₄ and concentrated *in vacuo* to afford the desired product (674 mg, 49% yield) as a yellow oil.

2-(4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)ethanol

15 A mixture of 4,7-dichloro-6-(4-chlorophenyl)quinazoline (150 mg, 0.48 mmol), 2-(piperazin-2-yl)ethanol (187 mg, 1.44 mmol), Et₃N (0.33 mL, 2.4 mmol), in 1,4-dioxane (5 mL) was stirred at 80°C for 30 min. The mixture was allowed to cool to RT, quenched with saturated NaHCO₃ solution and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated
20 *in vacuo*. The residue was purified by flash column chromatography on silica gel (methanol/dichloroethane = 1:30) to afford the desired product (121 mg, 63% yield) as a colorless oil. **ESI-MS** *m/z*: 403.3 [M + H]⁺.

1-(4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-(2-hydroxyethyl)piperazin-1-yl)prop-2-en-1-one


25 To a solution of 2-(4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)ethanol (123 mg, 0.305 mmol), acrylic acid (24 mg, 0.336 mmol), BOP (270 mg, 0.61 mmol) in DMF (5 mL) at -30°C, DIEA (157 mg, 1.22 mmol) was added. The resulting mixture was warmed to 0°C over 1 h, quenched with saturated NaHCO₃ solution, and then extracted with ethyl acetate. The organic layer was washed
30 with saturated NaHCO₃ solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by Pre-HPLC to afford the desired product (16 mg,

12% yield) as a light-yellow oil. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.64 (s, 1H), 8.01 (s, 1H), 7.99 (s, 1H), 7.64-7.57 (m, 4H), 6.89-6.78 (m, 1H), 6.17-6.13 (m, 1H), 5.72 (dd, *J* = 2.4, 10.4 Hz, 1H), 4.72-4.58 (m, 2H), 4.38-4.29 (m, 4H), 4.06-3.99 (m, 1H), 3.67-3.60 (m, 2H), 1.79-1.68 (m, 2H). ESI-MS *m/z*: 457.4 [M + H]⁺.

5

EXAMPLE 18

SYNTHESIS OF 2-(1-ACRYLOYL-4-(7-CHLORO-6-(4-CHLOROPHENYL)QUINAZOLIN-4-
YL)PIPERAZIN-2-YL)ACETONITRILE (70)



10

Compound 70 was prepared according to the general procedures of Method A as described below:

Dibenzyl 2-(2-hydroxyethyl)piperazine-1,4-dicarboxylate

5 To a solution of 2-(piperazin-2-yl)ethanol (2.0 g, 15.4 mmol) in THF (48 mL), H₂O (32 mL) and saturated NaHCO₃ (32 mL) at 0°C, Cbz-Cl (5.5 g, 32.3 mmol) was added dropwise. The mixture was stirred at 0°C for 2 h and at RT for 16 h. The mixture was diluted with brine, extracted with dichloromethane. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by
10 flash column chromatography on silica gel (25 %-50 % ethyl acetate/petroleum ether) to afford the desired product (1.454 g, 23 % yield) as a colorless oil. **ESI-MS** *m/z*: 399.4 [M+H]⁺.

2-(1,4-Bis((benzyloxy)carbonyl)piperazin-2-yl)acetic acid

To a solution of dibenzyl 2-(2-hydroxyethyl)piperazine-1,4-
15 dicarboxylate (515 mg, 1.294 mmol) in acetone (30 mL), Jones reagent (1.48 mL, 3.88 mmol, 2.6 M) was added dropwise at 0°C, which was stirred at RT for 1 h. The mixture was quenched with *i*-PrOH (2 mL) and filtered through celite. The filtrate was extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated to afford the crude product (545 mg) as a colorless oil. **ESI-**
20 **MS** *m/z*: 413.2 [M + H]⁺.

Dibenzyl 2-(2-amino-2-oxoethyl)piperazine-1,4-dicarboxylate

To a solution of 2-(1,4-bis((benzyloxy)carbonyl)piperazin-2-yl)acetic acid (545 mg, 1.323 mmol) and Et₃N (535 mg, 5.292 mmol) in THF (20 mL), ethyl chloroformate (154 mg, 1.415 mmol) was added at -10 °C and stirred at this
25 temperature for 40 min. Then the mixture was added NH₃.H₂O (1.984 g, 15.87 mmol) at -10°C and stirred for 20 min at -10°C. The mixture was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (2 % methanol/dichloromethane) to afford the desired product (393 mg, 72 % yield) as a
30 colorless oil. **ESI-MS** *m/z*: 412.3[M+H]⁺.

2-(Piperazin-2-yl)acetamide

A mixture of dibenzyl 2-(2-amino-2-oxoethyl)piperazine-1,4-dicarboxylate (385 mg, 0.937 mmol), Pd/C (10%, 40 mg) and MeOH (30 mL) was stirred at 40°C for 2.5 h under H₂ (1 atm). The mixture was filtered through celite and concentrated to afford the crude product (188 mg) as a colorless oil.

2-(4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)acetamide

A mixture of 4,7-dichloro-6-(4-chlorophenyl)quinazoline (313 mg, 1.315 mmol), 2-(piperazin-2-yl)acetamide (188 mg, 1.315 mmol), DIEA (848 mg, 6.575 mmol) and 1,4-dioxane (30 mL) at 100°C for 5 h. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (5-20 % methanol/dichloromethane) to afford the desired product (78 mg, 14% yield) as a brown solid. **ESI-MS** *m/z*: 417.3 [M+H]⁺.

2-(1-Acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)acetamide

A mixture of 2-(4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)acetamide (78 mg, 0.1875 mmol), Et₃N (76 mg, 0.750 mmol) and dichloromethane (30 mL) at 0°C, a solution of acryloyl chloride (21 mg, 0.225 mmol) in dichloromethane (2 mL) was added dropwise. The resulting mixture was stirred at 0°C for 40 min. The mixture was quenched with saturated NaHCO₃ and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified with column chromatography on silica gel (2.5-4% methanol in dichloromethane) to afford the desired product (32 mg, 36% yield) as a white solid. **¹H NMR** (400 MHz, DMSO-*d*₆) δ: 8.74 (s, 1H), 8.07 (s, 1H), 7.80 (s, 1H), 7.50-7.42 (dd, *J* = 8.8, 14.4 Hz, 1H), 6.79-6.24 (m, 3H), 5.83 (m, 1H), 5.36-5.14 (m, 2H), 4.72-4.49 (m, 2H), 4.32 (m, 1H), 3.99-3.49 (m, 3H), 3.07-2.44 (m, 3H). **ESI-MS** *m/z*: 470.2 [M+H]⁺.

2-(1-Acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)acetonitrile

To a solution of 2-(1-acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)acetamide (25 mg, 0.0533 mmol) and Et₃N (27 mg, 0.267 mmol) in DCM (10 mL) at 0°C, TFAA (46 mg, 0.214 mmol) and the resulting mixture was

stirred at RT for 20 min. The reaction mixture was quenched with saturated NaHCO₃ solution, and then extracted with dichloromethane. The organic layer was washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*.

The residue was purified by flash column chromatography on silica gel (2.5 % methanol in dichloromethane) to afford the desired product (21 mg, 87% yield) as a white solid.


¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.67 (s, 1H), 8.06 (m, 2H), 7.70 (s, 4H), 6.88 (m, 1H), 6.20 (d, *J* = 10.0 Hz, 1H), 5.76 (s, 1H), 4.97 (m, 1H), 4.30 (m, 4H), 3.75 (m, 2H), 2.99 (m, 2H). ESI-MS *m/z*: 453.3 [M+H]⁺.

10

EXAMPLE 19

SYNTHESIS OF 4-(4-ACRYLOYL-3-CYANOPIPERAZIN-1-YL)-7-CHLOROQUINAZOLINE-6-

CARBONITRILE (53)



Compound 53 was prepared according to the general procedures of Method B as described below:

1-tert-Butyl 2-methyl 4-(6-bromo-7-chloroquinazolin-4-yl)piperazine-1,2-dicarboxylate

A mixture of 6-bromo-4,7-dichloroquinazoline (300 mg, 1.08 mmol), tert-butyl methyl piperazine-1,2-dicarboxylate (395 mg, 1.62 mmol), DIEA (836 mg, 6.48 mmol) in 1,4-dioxane (8 mL) was stirred at 80°C for 1 h. The mixture was allowed to cool to RT, quenched with saturated NaHCO₃ solution and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (ethyl acetate/petroleum ether = 1:5) to afford the desired product (367 mg, 70% yield) as a white solid.

1-(tert-Butoxycarbonyl)-4-(6-bromo-7-chloroquinazolin-4-yl)piperazine-2-carboxylic acid

To a solution of 1-tert-butyl 2-methyl 4-(6-bromo-7-chloroquinazolin-4-yl)piperazine-1,2-dicarboxylate (100 mg, 0.206 mmol) in THF (2 mL), MeOH (2 mL) and water (2 mL), LiOH.H₂O (165 mg, 4.12 mmol) was added and the resulting mixture was stirred at RT for 1 h. The mixture was washed with 20% ethyl acetate/petroleum ether. The aqueous layer was acidified with aqueous HCl (1 N) to adjust pH to 5 and extracted with ethyl acetate. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo* to afford the desired product (65 mg, 67% yield).

tert-Butyl 4-(6-bromo-7-chloroquinazolin-4-yl)-2-carbamoylpiperazine-1-carboxylate

To a mixture of 1-(tert-butoxycarbonyl)-4-(6-bromo-7-chloroquinazolin-4-yl)piperazine-2-carboxylic acid (65 mg, 0.14 mmol), Et₃N (0.11 mL, 0.77 mmol) in THF (4 mL) and DMF (2 mL) at 0°C, ethyl chloroformate (83 mg, 0.77 mmol) was added. The resulting mixture was stirred at 0°C for 1 h and NH₃.H₂O (1 mL, 15 N) was added. Then the mixture was warmed to RT and stirred for another 1 h. It was quenched with saturated NaHCO₃ solution and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo* to afford the crude product (77 mg) as a yellow solid. ESI-MS *m/z*: 471.4 [M + H]⁺.

tert-Butyl 2-carbamoyl-4-(7-chloro-6-cyanoquinazolin-4-yl)piperazine-1-carboxylate

A mixture of tert-butyl 4-(6-bromo-7-chloroquinazolin-4-yl)-2-carbamoylpiperazine-1-carboxylate (200 mg, 0.43 mmol), PdCl₂(dppf) (31 mg, 0.043 mmol), Zn(CN)₂ (80 mg, 0.68 mmol) and DMF (20 mL) was stirred at reflux for 5 h. The mixture was allowed to cool to room temperature, and partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (1-2% methanol/dichloromethane) to afford the desired product (140 mg, 79% yield) as a solid. ESI-MS *m/z*: 417.3 [M + H]⁺.

4-(7-Chloro-6-cyanoquinazolin-4-yl)piperazine-2-carboxamide

A solution of tert-butyl 2-carbamoyl-4-(7-chloro-6-cyanoquinazolin-4-yl)piperazine-1-carboxylate (140 mg, 0.34 mmol) in dichloromethane (20 mL) at RT, TFA (2 mL) was added. The resulting mixture was stirred at RT for 2 h. The mixture was concentrated *in vacuo* to afford the crude product (100 mg) which was used directly in the next step without further purification.

1-Acryloyl-4-(7-chloro-6-cyanoquinazolin-4-yl)piperazine-2-carboxamide


A mixture of 4-(7-chloro-6-cyanoquinazolin-4-yl)piperazine-2-carboxamide (100 mg, 0.32 mmol), Et₃N (96 mg, 0.96 mmol) in dichloromethane (10 mL) at 0°C, acryloyl chloride (35 mg, 0.384 mmol) was added. The resulting mixture was stirred at RT for 0.5 h, poured into water and then extracted with dichloromethane. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (1-2% methanol/dichloromethane) to afford the desired product (50 mg, 43 % yield) as a solid. ESI-MS *m/z*: 371.3 [M + H]⁺.

4-(4-Acryloyl-3-cyanopiperazin-1-yl)-7-chloroquinazoline-6-carbonitrile

A mixture of 1-acryloyl-4-(7-chloro-6-cyanoquinazolin-4-yl)piperazine-2-carboxamide (50 mg, 0.14 mmol) and Et₃N (82 mg, 0.81 mmol) in DCM (10 mL) at RT, trifluoroacetic anhydride (117.6 mg, 0.56 mmol) was added. The resulting mixture was stirred at RT for 0.5 h and poured into water and then extracted with dichloromethane. The organic layer was washed with brine, dried over Na₂SO₄ and

concentrated. The residue was purified by flash column chromatography on silica gel (1-3% methanol/dichloromethane) to afford the desired product (15 mg, 32% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.79 (s, 1H), 8.77 (s, 1H), 8.16 (s, 1H), 6.92-6.85 (m, 1H), 6.32-6.28 (m, 1H), 5.91-5.88 (m, 1H), 5.68 (s, 1H), 4.73-4.70 (d, *J* = 14 Hz, 1H), 4.46-4.43 (d, *J* = 13.2 Hz, 1H), 4.25-4.22 (d, *J* = 12.8 Hz, 1H), 3.82-3.74 (m, 2H), 3.59-3.56 (m, 1H). ESI-MS *m/z*: 353.2 [M + H]⁺.

EXAMPLE 20

SYNTHESIS OF 1-ACRYLOYL-4-(7-CHLORO-6-CYCLOPROPYLQUINAZOLIN-4-
YL)PIPERAZINE-2-CARBONITRILE (55)

Compound 55 was prepared according to the general procedures of Method B as described below:

***tert*-Butyl 2-carbamoyl-4-(7-chloro-6-cyclopropylquinazolin-4-yl)piperazine-1-carboxylate**

A mixture of *tert*-butyl 4-(6-bromo-7-chloroquinazolin-4-yl)-2-carbamoylpiperazine-1-carboxylate (200 mg, 0.414 mmol), cyclopropylboronic acid (44 mg, 0.51 mmol), K₃PO₄·3H₂O (270 mg, 1.272 mmol), Pd(OAc)₂ (18 mg, 0.08 mmol)

and tricyclohexyl phosphine (22 mg, 0.08 mmol) in toluene (10 mL) and water (1 mL) was stirred at reflux under argon for 16 h. The solvent was removed, and the residue was purified by flash column chromatography on silica gel (dichloromethane/methanol = 50:1) to afford the desired product (100 mg, 56% yield) as a solid. **ESI-MS** m/z :

5 432.4 $[M + H]^+$.


Acryloyl-4-(7-chloro-6-cyclopropylquinazolin-4-yl)piperazine-2-carboxamide

The title compound was prepared from tert-butyl 2-carbamoyl-4-(7-chloro-6-cyclopropylquinazolin-4-yl)piperazine-1-carboxylate in two steps following the procedure described in **Example 1**.

10 **Acryloyl-4-(7-chloro-6-cyclopropylquinazolin-4-yl)piperazine-2-carboxamide**

To a solution of 1-acryloyl-4-(7-chloro-6-cyclopropylquinazolin-4-yl)piperazine-2-carboxamide (17 mg, 0.044 mmol) and Et₃N (18 mg, 0.176 mmol) in DCM (5 mL) at 0°C, TFAA (18 mg, 0.088 mmol) was added and the resulting mixture was stirred at RT for 1 h. The reaction mixture was quenched with saturated NaHCO₃ solution, and then extracted with dichloromethane. The organic layer was washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*.
 15 The residue was purified by flash column chromatography on silica gel (dichloromethane/methanol = 50:1) to afford the desired product (10 mg, 62% yield) as a solid. **¹H NMR** (400 MHz, CDCl₃) δ : 8.8 (s, 1H), 8.0 (s, 1H), 7.7 (s, 1H), 6.6 (dd, J = 10.0, 16.4 Hz, 1H), 6.5 (d, J = 16.4 Hz, 1H), 6.0 (dd, J = 2.0, 10.4 Hz, 1H), 6.0-5.9 (m, 1H), 4.4 (dd, J = 2, 13.2 Hz, 1H), 4.3-4.1 (m, 2H), 3.9-3.8 (m, 1H), 3.3-3.1 (m, 2H), 2.4-2.3 (m, 1H), 1.2-1.1 (m, 2H), 1.0-0.9 (m, 2H). **ESI-MS** m/z : 368.3 $[M + H]^+$.
 20

EXAMPLE 21

SYNTHESIS OF (S)-1-ACRYLOYL-4-(7-CHLORO-6-(4-CHLOROPHENYL)QUINAZOLIN-4-
YL)PIPERAZINE-2-CARBOXAMIDE (54)

5

Compound 54 was prepared according to the general procedures of Method A as described below:

(S)-Methyl piperazine-2-carboxylate hydrochloride

10

A mixture of (S)-tert-butyl methyl piperazine-1,3-dicarboxylate (366 mg, 1.5 mmol) and HCl in MeOH (20 mL, 2.9 M) was stirred at RT for 1 h. The mixture was concentrated *in vacuo* to yield the crude product (270 mg) as a yellow solid which was used directly in next step without further purification.

(S)-1-tert-Butyl 2-methyl 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-1,2-dicarboxylate

To the mixture of above obtained crude (S)-methyl piperazine-2-carboxylate hydrochloride, 4,7-dichloro-6-(4-chlorophenyl)quinazoline (310 mg, 1 mmol), DIEA (1.29 g, 10 mmol) and 1,4-dioxane (20 mL) was stirred for 1 h at 80°C. Then mixture was cooled to RT and di-tert butyl dicarbonate (327 mg, 1.5 mmol) was added. The mixture was stirred for 16 h and quenched with saturated NaHCO₃ solution and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (methanol/dichloroethane = 1:50) to afford the desired product (300 mg, 58% yield, 2 steps) as a solid oil. **ESI-MS** *m/z*: 517.5 [M + H]⁺.

(S)-1-(tert-Butoxycarbonyl)-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carboxylic acid

To a solution of (S)-1-tert-butyl 2-methyl 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-1,2-dicarboxylate (300 mg, 0.58 mmol) in mixture of 1:1 tetrahydrofuran and water (20 mL) at RT, LiOH.H₂O (49 mg, 1.16 mmol) were added and the resulting mixture was stirred for 1 h and then acidified with aqueous HCl (1 N) to adjust the pH to 3-5. The mixture was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to afford the crude product (230 mg) which was used directly in the next step without further purification.

(S)-tert-Butyl 2-carbamoyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-1-carboxylate

To a mixture of (S)-1-(tert-butoxycarbonyl)-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carboxylic acid (230 mg, 0.46 mmol), Et₃N (139 mmg, 1.37 mmol) in THF (5 mL) at 0°C, ethyl chloroformate (148 mg, 1.37 mmol) was added. The resulting mixture was stirred at 0°C for 1 h, then Ammonium hydroxide (1 mL, 15 N) was added and kept stirring for another 1 h at RT. The mixture was extracted with ethyl acetate dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel


(dichloromethane/methanol = 50:1) to afford the desired product (150 mg, 65% yield) as a solid. **ESI-MS** m/z : 502.4 $[M+H]^+$.

(S)-1-Acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carboxamide

5 The title compound was prepared from (S)-tert-butyl 2-carbamoyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-1-carboxylate in 2 steps according to the procedure described in **Example 1**. **^1H NMR** (400 MHz, DMSO- d_6) δ : 8.7 (s, 1H), 8.3 (d, $J = 8.0$ Hz, 1H), 8.0 (s, 1H), 7.8-7.5 (m, 5H), 7.4-7.2 (m, 1H), 6.9-6.6 (m, 1H), 6.2 (d, $J = 2.4, 17.6$ Hz, 1H), 5.8-5.7 (m, 1H), 5.0-4.8 (m, 1H), 4.7 (d, $J = 13.2$ Hz, 1H), 4.2-4.0 (m, 2H), 3.9-3.8 (m, 1H), 3.7-3.5 (m, 1H), 3.5-3.4 (m, 1H). **ESI-MS** m/z : 456.3 $[M+H]^+$.

EXAMPLE 22

SYNTHESIS OF (S)-1-ACRYLOYL-4-(7-CHLORO-6-(4-CHLOROPHENYL)QUINAZOLIN-4-
15 YL)PIPERAZINE-2-CARBONITRILE (59)



Compound 59 was prepared according to the general procedures of Method A as described below:

20


(S)-1-Acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carbonitrile

To a solution of (S)-1-acryloyl-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carboxamide (23 mg, 0.05 mmol) and Et₃N (20 mg, 0.2 mmol) in DCM (5 mL) at 0°C, trifluoroacetic anhydride (21 mg, 0.1 mmol) and the resulting mixture was stirred at RT for 1 h. The reaction mixture was quenched with saturated NaHCO₃ solution, and then extracted with dichloromethane. The organic

layer was washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (dichloromethane/methanol = 50:1) to afford the desired product (15 mg, 68% yield) as a solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.7 (s, 1H), 8.1 (s, 1H), 8.0 (s, 1H), 7.5 (m, 4H), 6.8 (dd, *J* = 10.4, 16.4 Hz, 1H), 6.3 (dd, *J* = 2.0, 17.2 Hz, 1H), 5.8 (dd, *J* = 2.0, 10.8 Hz, 1H), 5.7 (m, 1H), 4.6 (d, *J* = 14.0 Hz, 3H), 4.3 (m, 2H), 3.6 (m, 2H). ESI-MS *m/z*: 438.3 [M+H]⁺.

EXAMPLE 23

10 SYNTHESIS OF (S)-1-(4-(7-CHLORO-6-(4-CHLOROPHENYL)QUINAZOLIN-4-YL)-2-(HYDROXYMETHYL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (63)



Compound 63 was prepared according to the general procedures of Method A as described below:

(S)-tert-Butyl 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-(hydroxymethyl)piperazine-1-carboxylate

To a solution of (S)-1-tert-butyl 2-methyl 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-1,2-dicarboxylate (200 mg, 0.387 mmol) in EtOH (10 mL) was added CaCl₂ (215 mg, 1.933 mmol) and NaBH₄ (74 mg, 1.933


mmol) at 0°C. The mixture was stirred at RT for 16 h. The mixture was filtered, and washed by ethylanol. The mixture was concentrated *in vacuo*, and the residue was purified by flash column chromatography on silica gel (dichloromethane/methanol = 50:1) to afford the desired product (80 mg, 42% yield) as a solid. **ESI-MS** *m/z*: 489.4
5 [M+H]⁺.

1-((S)-4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from (S)-tert-butyl 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-(hydroxymethyl)piperazine-1-carboxylate in two steps
10 according to the procedure described in **Example 13**. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.7 (s, 1H), 8.3-8.1 (m, 1H), 8.0 (s, 1H), 7.7-7.5 (m, 4H), 6.8 (dd, *J* = 10.4, 16.4 Hz, 1H), 6.1 (d, *J* = 16 Hz, 1H), 5.8 (dd, *J* = 2, 10.4 Hz, 1H), 5.1-4.9 (m, 1H), 4.3-4.1 (m, 4H), 4.2 (m, 2H), 3.7-3.5 (m, 4H). **ESI-MS** *m/z*: 443.3 [M+H]⁺.

EXAMPLE 24

SYNTHESIS OF 1-(4-(6-CHLORO-7-PHENYLQUINAZOLIN-4-YL)PIPERAZIN-1-YL)PROP-2-EN-



- 5 Compound 67 was prepared according to the general procedures of Method B as described below:

7-Bromo-6-chloroquinazolin-4-ol

- To a solution of 2-amino-4-bromo-5-chlorobenzoic acid (500 mg, 2mmol) in EtOH (20 mL) at RT, formamidine acetate (620 mg, 6 mmol) was added. The mixture was reflux for 16 hour. The mixture was concentrated *in vacuo*, and the residue was washed by saturated NaHCO₃ aqueous solution, and a mixture of ethyl acetate/petroleum ether = 1:2. The solid was dried *in vacuo* to get the product (520 mg, 100% yield) which was used directly in next step without further purification. **ESI-MS**
- 15 *m/z*: 259.0 [M+H]⁺.

7-Bromo-4,6-dichloroquinazoline

To a solution of 7-bromo-6-chloroquinazolin-4-ol (520 mg, 2 mmol) in thionyl chloride (15 mL) was added one drop of DMF. The mixture was reflux for 16 h. The mixture was concentrated *in vacuo*, the residue was used directly in next step


5 without further purification .

1-(4-(6-Chloro-7-phenylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from 7-bromo-4,6-dichloroquinazoline in four steps according to the procedure described in **Example 2**. ¹H NMR (400 MHz, DMSO) δ : 8.7 (s, 1H), 8.2 (s, 1H), 7.8 (s, 1H), 7.6-7.4 (m, 5H), 6.85 (dd, $J = 10.8, 16.8$ Hz, 1H), 6.2 (d, $J = 16.8$ Hz, 1H), 5.75 (d, $J = 10$ Hz, 1H), 3.9-3.7 (m, 8H). ESI-MS m/z : 379.3 [M + H]⁺.

EXAMPLE 25**SYNTHESIS OF 1-(4-(7-CHLORO-6-(4-CHLOROPHENYL)QUINAZOLIN-4-YL)-2-**

15 **((DIMETHYLAMINO)METHYL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE (60)**



Compound 60 was prepared according to the general procedures of Method A as described below:

di-tert-Butyl 2-(dimethylcarbamoyl)piperazine-1,4-dicarboxylate

5 A mixture of 1,4-bis(tert-butoxycarbonyl)piperazine-2-carboxylic acid (5 g, 15.13 mmol), dimethylamine hydrochloride (1.3 g, 15.13 mmol), EDCI (4.3 g, 22.7 mmol), HOBt (3.1 g, 22.7 mmol) and DMF (100 mL) at 0°C, Et₃N (4.6 g, 45.39 mmol) was added. The mixture was then warmed to RT and kept stirring for 2 h. The reaction mixture was poured into water, extracted with ethyl acetate, the combined organic layer
10 was washed with NaHCO₃ solution, brine and dried over Na₂SO₄ and concentrated. The residue was washed with petroleum ether to afford the desired product (3.64 g, 67% yield).

N,N-Dimethylpiperazine-2-carboxamide dihydrochloride

A mixture of the above obtained crude of di-tert-butyl 2-(dimethylcarbamoyl)piperazine-1,4-dicarboxylate, HCl in MeOH (50 mL, 2.9 M) was
15 stirred at RT for 1 h, evaporated the solvent to afford the crude product (2.4 g).

N,N-Dimethyl-1-(piperazin-2-yl)methanamine

A mixture of the above obtained crude of N,N-dimethylpiperazine-2-carboxamide dihydrochloride (2.4 g, 10.43 mmol) and THF (50 mL) at -40°C, LiAlH₄
20 (1.6 g, 41.73 mmol) was added slowly. The mixture was heated to reflux for 3 h and cooled to RT. It was quenched with 10H₂O.Na₂SO₄ and filtered, washed with ethyl acetate. The filtrate was dried over Na₂SO₄ and concentrated *in vacuo* to afford the desired product (693 mg, 47% yield).

1-(4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)-N,N-dimethylmethanamine
25

A mixture of N,N-dimethyl-1-(piperazin-2-yl)methanamine (200 mg, 0.68 mmol), 4,7-dichloro-6-(4-chlorophenyl)quinazoline (111 mg, 0.77 mmol), DIEA (397 mg, 3.08 mmol) and dioxane (10 mL) was stirred at 80°C for 30 min. The mixture was allowed to cool to RT, quenched with saturated NaHCO₃ solution and then
30 extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column


chromatography on silica gel (methanol/ dichloroethane = 1 : 20) to afford the desired product (78 mg, 30% yield). **ESI-MS** m/z: 416.3 [M+H]⁺.

**1-(4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)-2-
((dimethylamino)methyl)piperazin-1-yl)prop-2-en-1-one**

- 5 A mixture of 1-(4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazin-2-yl)-N,N-dimethylmethanamine (78 mg, 0.19 mmol), Et₃N (58 mg, 0.57 mmol) and dichloromethane (15 mL) at 0°C, acryloyl chloride (20 mg, 0.22 mmol) was added. The reaction was stirred at RT for 30 min and quenched with water, extracted with dichloromethane. The organic layer was washed with water and brine, anhydrous
- 10 sodium sulfate, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (dichloromethane/methanol = 30:1) to afford the desired product (32 mg, 36% yield). **¹H NMR** (400 MHz, DMSO-*d*₆) δ: 8.70 (s, 1H), 8.57-8.56 (bs, 1H), 8.03 (s, 1H), 7.61-7.53 (m, 4H), 6.83-6.80 (m, 1H), 6.17-6.13(m, 1H), 5.75-5.72(m, 1H), 4.76-4.74(m, 0.5 H) ,4.70-4.57 (m, 1H), 4.36-3.29 (m, 2H),
- 15 4.11-4.08 (m, 0.5H), 3.46 (m, 1H), 3.27-3.11 (m, 2H), 2.93-2.84 (m, 1H), 1.99-1.94 (m, 1H), 1.87 (s, 6H). **ESI-MS** m/z: 470.4 [M+H]⁺.

EXAMPLE 26

SYNTHESIS OF 1-ACRYLOYL-4-(6-CHLOROISOQUINOLIN-1-YL)PIPERAZINE-2-CARBONITRILE (61)



5

Compound 61 was prepared according to the general procedures of Method D as described below:

6-Chloroisoquinoline 2-oxide

10 To a stirred solution 6-chloroisoquinoline (1.0 g, 6.1 mmol) in dichloromethane (20 mL) at RT, 3-chlorobenzoperoxoic acid (1.57 g, 9.2 mmol) was added. The reaction mixture was stirred at RT for 2 h. The precipitate was filtered off and washed with dichloromethane, the filtrate was washed twice with NaHCO₃ solution. The organic layer was dried with Na₂SO₄ and concentrated *in vacuo* to afford

15 the desired product (1.05 g, 96% yield) as a white solid. **ESI-MS** *m/z*: 180.2 [M + H]⁺.

1,6-Dichloroisoquinoline

A mixture of 6-chloroisoquinoline 2-oxide (1.0 g, 5.58 mmol) and POCl₃ (10 mL) was heated to reflux for 4 h. After cooled down to RT, the reaction mixture was poured into ice-water, and extracted with dichloromethane. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to afford the desired crude product which was used in the next step without further purification.

4-(6-Chloroisoquinolin-1-yl)piperazine-2-carboxamide

To a stirred solution of 1,6-dichloroisoquinoline (500 mg, 2.56 mmol) in DMSO (5 mL) at RT, piperazine-2-carboxamide (425.6 mg, 2.56 mmol) and K₂CO₃ (1.05 g, 7.68 mmol). The reaction mixture was heated at 80°C for 5 h. The reaction mixture was diluted with ethyl acetate and washed with brine. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (ethyl acetate/petroleum ether = 1:5) to afford the desired product (80 mg, 12% yield). **ESI-MS** *m/z*: 291[M + H]⁺.

15 Acryloyl-4-(6-chloroisoquinolin-1-yl)piperazine-2-carboxamide

To a mixture of 4-(6-chloroisoquinolin-1-yl)piperazine-2-carboxamide (50 mg, 0.172 mmol), triethylamine (52.1 mg, 0.51 mmol) in dichloromethane (20 mL), acryloyl chloride (15.6 mg, 0.172 mmol) in dichloromethane (1 mL) was added dropwise. The reaction mixture was stirred at RT for 30 min, poured into water, and extracted with dichloromethane. The organic layer was washed with water and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (dichloromethane/methanol = 100:1) to afford the desired product (45 mg, 76.3% yield). **ESI-MS** *m/z*: 345 [M+H]⁺.

Acryloyl-4-(6-chloroisoquinolin-1-yl)piperazine-2-carbonitrile


To a mixture of 1-acryloyl-4-(6-chloroisoquinolin-1-yl)piperazine-2-carboxamide (40 mg, 0.116 mmol), triethylamine (46.8 mg, 0.46 mmol) in DCM (5 mL) at 0°C, trifluoroacetic anhydride (50 mg, 0.233 mmol) was added. The reaction mixture was warmed to RT over 1 h, poured into water and extracted with dichloromethane. The organic layer was washed with water and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (dichloromethane/methanol = 100:1) to afford the desired

product (20 mg, 53% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.25 (m, 1H), 8.22 (m, 1H), 8.11 (s, 1H), 7.71 (m, 1H), 7.52 (m, 1H), 6.96 (dd, *J* = 10.5, 16.9 Hz, 1H), 6.32 (dd, *J* = 1.7, 16.7 Hz, 1H), 5.90 (dd, *J* = 1.7, 16.7 Hz, 1H), 5.79 (m, 1H), 4.34 (m, 1H), 3.99 (m, 1H), 3.79 (m, 1H), 3.66 (m, 1H), 3.16 (m, 1H), 2.97 (m, 1H). ESI-MS *m/z*:

5 327 [M+H]⁺.

EXAMPLE 27

SYNTHESIS OF (E)-4-(7-CHLORO-6-(4-CHLOROPHENYL)QUINAZOLIN-4-YL)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PIPERAZINE-2-CARBONITRILE (66)



10

Compound 66 was prepared according to the general procedures of Method A as described below:

15 4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carboxamide

A mixture of 4,7-dichloro-6-(4-chlorophenyl)quinazoline (769 mg, 2.48 mmol), piperazine-2-carboxamide dihydrochloride (498 mg, 2.48 mmol), DIPEA (3.2 g, 24.8 mmol) and 1,4-dioxane (20mL) was stirred at 80°C for 16 h. The mixture was allowed to cool to RT, quenched with saturated NaHCO₃ solution and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (methanol/dichloroethane = 1:20) to afford the desired product (486 mg, 48.7% yield).

20

(E)-4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)-1-(4-(dimethylamino)but-2-enoyl)piperazine-2-carboxamide

To a mixture of 4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)piperazine-2-carboxamide (100 mg, 0.26 mmol), BOP (256.6 mg, 0.58 mmol), (E)-4-(dimethylamino)but-2-enoic acid (48 mg, 0.58 mmol) in dichloromethane (10 ml) at RT, DIEA (108.6 mg, 0.78 mmol) was added. The mixture was stirred for 30 min, extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (methanol/dichloroethane = 1:10) to afford the desired product (50 mg, 39% yield). ESI-MS *m/z*: 513.3 [M+H]⁺


(E)-4-(7-Chloro-6-(4-chlorophenyl)quinazolin-4-yl)-1-(4-(dimethylamino)but-2-enoyl)piperazine-2-carbonitrile

To a solution of (E)-4-(7-chloro-6-(4-chlorophenyl)quinazolin-4-yl)-1-(4-(dimethylamino)but-2-enoyl)piperazine-2-carboxamide (50 mg, 0.10 mmol) and Et₃N (0.05 mL, 0.40 mmol) in DCM (10 mL) at 0°C, TFAA (51 mg, 0.20 mmol) and the resulting mixture was stirred at RT for 1 h. The reaction mixture was quenched with saturated NaHCO₃ solution, and then extracted with dichloromethane. The organic layer was washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (dichloromethane/methanol = 20:1) to afford the desired product (14 mg, 29% yield) as a solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.76 (s, 1H), 8.08 (d, *J* = 16 Hz, 2H), 7.61 (dd, *J* = 8, 24 Hz, 4H), 6.78-6.72 (m, 2H), 5.67 (s, 1H), 4.62 (d, *J* = 14.4 Hz, 1H), 4.36-4.26 (m, 2H), 3.63 (d, *J* = 12.4 Hz, 1H), 3.21 (s, 2H), 3.03 (d, *J* = 6.4 Hz, 2H), 2.26 (s, 1H). ESI-MS *m/z*: 495.4 [M+H]⁺.

25

EXAMPLE 28

SYNTHESIS OF 1-(4-(7-(2-FLUOROPHENYL)-6-HYDROXYQUINAZOLIN-4-YL)PIPERAZIN-1-YL)PROP-2-EN-1-ONE



5 Example 28 is an exemplary preparation according to General Synthetic Method B.

1-Bromo-2-fluoro-4-methyl-5-nitrobenzene

HNO₃ (9 mL) was added into a solution of 1-bromo-2-fluoro-4-methylbenzene (5.35 g, 28.30 mmol) in H₂SO₄ (25 mL) while it was kept at -20 °C and
 10 the resulting mixture was stirred at 0 °C for 10 min. The mixture was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with saturated NaHCO₃ aqueous solution and brine, dried over Na₂SO₄ and concentrated in vacuo to yield the product as a yellow solid (5.3g, 80 % yield).

1-Bromo-2-methoxy-4-methyl-5-nitrobenzene

15 Na (351 mg, 15.28 mmol) was added into CH₃OH (20 mL) and the resulting mixture was stirred at 0 °C for 30 min. 1-Bromo-2-fluoro-4-methyl-5-nitrobenzene (3.25 g, 13.89 mmol) was added to the mixture and then stirred at 30 °C for 2 h. The solvent was removed and the residue was dissolved in H₂O, extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and
 20 concentrated in vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate/petroleum ether = 1:50) to yield the product as a white solid (3.0 g, 87.8% yield).

4-Bromo-5-methoxy-2-nitrobenzaldehyde

A mixture of 1-bromo-2-methoxy-4-methyl-5-nitrobenzene (3.7 g, 15.04 mmol) and DMF-DMA (5.41 g, 45.12 mmol) in DMF (40 mL) was stirred at 140 °C for 16 h. The mixture was allowed to cool to RT and concentrated in vacuo. The residue
5 was dissolved in DMF (40 mL) and added into a solution of NaIO₄ (19.22 g, 90.24 mmol) in DMF (120 mL) and H₂O (30 mL) at 0°C. The resulting mixture was stirred at 30°C for 16 h, quenched with H₂O, and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated in vacuo, the residue was purified by column chromatography on silica gel (acetate/petroleum ether = 1:20)
10 to yield the product as an off-white solid (1.52 g, 38.9% yield).

4-Bromo-5-methoxy-2-nitrobenzoic acid

A mixture of 4-bromo-5-methoxy-2-nitrobenzoic acid (1.52 g, 5.84 mmol) and KMnO₄ (5.53 g, 35.04 mmol) in CH₃CN (40 mL) was stirred at reflux for 2 h. The mixture was allowed to cool to RT, quenched with H₂O, adjusted pH to 3-4 with
15 1N HCl, and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated in vacuo to yield the product as an off-white solid (1.24 g, 77.4% yield).

methyl 4-bromo-5-methoxy-2-nitrobenzoate

A mixture of 4-bromo-5-methoxy-2-nitrobenzoic acid (1.24 g, 4.52
20 mmol) and SOCl₂ (5 mL) in CH₃OH (10 mL) was stirred at reflux for 2 h, Then solvent was removed and the residue was dissolved in H₂O, extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated to yield the product as an off-white solid (1.3 g, 99% yield).

Methyl 2-amino-4-bromo-5-methoxybenzoate

25 A mixture of methyl 4-bromo-5-methoxy-2-nitrobenzoate (1.3 g, 4.48 mmol) and Fe (1.25 g, 22.4 mmol) in acetic acid (10 mL) and H₂O (10 mL) was stirred at reflux for 16 h. The mixture was allowed to cool to RT and quenched with saturated NaHCO₃ aqueous solution. The mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated NaHCO₃ aqueous solution and brine, dried
30 over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash column


chromatography on silica gel (ethyl acetate/petroleum ether = 1:4) to yield the desired product (1.1 g, 94% yield) as a yellow solid.

7-Bromo-6-methoxyquinazolin-4(1H)-one

The product was made from methyl 2-amino-4-bromo-5-methoxybenzoate in 6 steps followed the procedure described in **Example 2**. ESI-MS m/z : 393.8 $[M + H]^+$.

1-(4-(7-(2-Fluorophenyl)-6-hydroxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

BBr₃ (127 mg, 0.51 mmol) was added into a solution of 1-(4-(7-(2-fluorophenyl)-6-methoxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one (20 mg, 0.051 mmol) in dichloromethane (5 mL) at -78 °C and stirred at 40 °C for 1 h. Then it was cooled to -78 °C, quenched with saturated NaHCO₃ aqueous solution extracted with dichloromethane. The organic layer was washed with saturated NaHCO₃ aqueous solution and brine, dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by Prep-HPLC to yield the desired product (7 mg, 36 % yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.44 (bs, 1H), 8.57 (s, 1H), 7.69 (s, 1H), 7.51-7.46 (m, 3H), 7.33-7.29 (m, 1H), 6.87 (dd, J = 10.4, 16.4 Hz, 1H), 6.18 (dd, J = 2.0, 16.4 Hz, 1H) 5.75 (dd, J = 2.4, 10.4 Hz, 1H), 3.82-3.68 (m, 8H). ESI-MS m/z : 379.3 $[M + H]^+$.

EXAMPLE 29**Synthesis of 1-(4-(6-chloro-7-(5-methyl-1H-indazol-4-yl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one**

- 5 Example 29 provides and exemplary preparation according to General Synthetic Method N

5-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole

- 10 To a solution of 5-methyl-1H-indazol-4-yl-4-boronic acid (300 mg, 1.7 mmol) in THF (20 mL), pinacol (249 mg, 2.1 mmol) and MgSO₄ (614 mg, 5.1 mmol) were added, and the resulting mixture was stirred at 45 °C for 3 h. The mixture was filtered and rinsed with brine, dried over Na₂SO₄ and concentrated in vacuo to afford the desired product (330 mg, 75% yield).

1-(2-Amino-4-bromo-5-chlorophenyl)ethanone

- 15 To a stirred solution of BCl₃ (51 mL, 51 mmol) in toluene at 0 °C, 3-bromo-4-chlorobenzaniline (10 g, 48.4 mmol) in CH₃CN (90 mL) was added dropwise over 20 min. To this suspension, AlCl₃ (7.1 g, 53.2 mmol) was added in three portions. The mixture was stirred at reflux for 16 h. The mixture was cooled to 0 °C, HCl (4 N, 100 mL) was added and the resulting mixture was stirred at reflux for 2 h.
- 20 The mixture was allowed to cool to RT and extracted with ethyl acetate. The organic layer was washed with 2 N HCl and brine, dried over Na₂SO₄, and concentrated in

vacuo. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate = 4 : 1) to afford the desired product (1.6 g, 11% yield).

7-Bromo-6-chlorocinnolin-4(1H)-one

To a mixture of concentrated HCl (20 mL) and 1-(2-amino-4-bromo-5-chlorophenyl)ethanone (1.6 g, 6.44 mmol) at 0 °C, sodium nitrite (466 mg, 6.76 mmol) in water (1 mL) was slowly added (over 30 min). The mixture was stirred at 0 °C for 30 min and then stirred at 60 °C for 2 h. The mixture was allowed to cool to RT and poured into water. The solid was collected by filtration to afford the desired product (1.4 g, 84% yield).

7-Bromo-4,6-dichlorocinnoline

Thionyl chloride (10 mL) and DMF (3 drops) was added to 7-bromo-6-chlorocinnolin-4(1H)-one (1.4 g, 5.4 mmol), and the resulting mixture was stirred at reflux for 2 h. The mixture was concentrated in vacuo to afford the crude product (1.5 g) which was used in next step without further purification.

tert-Butyl 4-(7-bromo-6-chlorocinnolin-4-yl)piperazine-1-carboxylate

A mixture of 7-bromo-4,6-dichlorocinnoline (1.5 g, 5.4 mmol), tert-butyl piperazine-1-carboxylate (1.51 g, 8.1 mmol), DIEA (2.1 g, 16.2 mmol) and 1,4-dioxane (20 mL) was stirred at reflux for 16 h. The mixture was allowed to cool to RT, poured into ice water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate = 1: 1) to afford the desired product (1.8 g, 78% yield). **ESI-MS** *m/z*: 429.05 [M+H]⁺.

tert-Butyl 4-(6-chloro-7-(5-methyl-1H-indazol-4-yl)cinnolin-4-yl)piperazine-1-carboxylate

To a solution of tert-butyl 4-(7-bromo-6-chlorocinnolin-4-yl)piperazine-1-carboxylate (138 mg, 0.32 mmol) and 5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (250 mg, 0.97 mmol) in 1,4-dioxane (10 mL) and water (2 mL), Pd(PPh₃)₄ (37 mg, 0.0325 mmol) and Na₂CO₃ (136 mg, 1.28 mmol) were added. The mixture was stirred at 100 °C for 16 h. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was purified by flash column


chromatography on silica gel (dichloromethane / methanol = 20:1) to afford the desired product (140 mg, 91% yield).

1-(4-(6-Chloro-7-(5-methyl-1H-indazol-4-yl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one

5 The mixture of 4-(6-chloro-7-(5-methyl-1H-indazol-4-yl)cinnolin-4-yl)piperazine-1-carboxylate (140 mg, 0.29 mmol) in HCl/MeOH (20 mL, 2.8 N) was stirred for 1 h. The mixture was concentrated *in vacuo* and the residue was dissolved in DCM (5 mL) and Et₃N (88 mg, 0.87 mmol). This mixture was cooled to – 60 °C, acryloyl chloride (26 mg, 0.29 mmol) was added slowly. The reaction mixture was
10 stirred at RT for 1 h. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by Prep-HPLC to afford the desired product (12 mg, 10% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 13.18 (s, 1H), 9.08 (s, 1H), 8.34 (m, 2H), 7.57 (m, 2H), 7.39 (d, *J* = 8.4 Hz, 1H), 6.90 (dd, *J* = 10.8, 16.4 Hz, 1H),
15 6.20 (d, *J* = 16.4 Hz, 1H), 5.77 (d, *J* = 10.4 Hz, 1H), 3.91-3.88 (m, 4H), 3.51 (m, 4H), 2.20 (s, 3H). ESI-MS *m/z*: 433.1 [M+H]⁺.

EXAMPLE 30

Synthesis of 1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



Example 30 provides an exemplary preparation according to General Synthetic Method O

3-Bromo-2-fluorobenzenamine

To a mixture of 1-bromo-2-fluoro-3-nitrobenzene (13.75 g, 62.76 mmol), HOAc (26.36 g, 439 mmol), EtOH (150 mL) and H₂O (60 mL) at room temperature, iron powder (9.14 g, 163 mmol) was added portion-wise. The resulting mixture was stirred at room temperature for 16 h and then was neutralized with NaOH (5 N) solution. Then the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate = 10 : 1) to afford the desired product (7.77 g, 65% yield) as a brown oil.

10 N-(3-Bromo-2-fluorophenyl)-2-(hydroxyimino)acetamide

A mixture of 2,2,2-trichloroethane-1,1-diol (8.09 g, 49.33 mmol) and Na₂SO₄ (53 g, 370 mol) was dissolved in water and warmed to 35 °C. 3-Bromo-2-fluorobenzenamine (7.77 g, 41.11 mmol) in water was added, followed by 35% aqueous HCl solution (4.6 mL) and hydroxylamine hydrochloride (9.08 g, 131.6 mmol). The resulting mixture was stirred at 90 °C for 16 h and yellow precipitate was formed. The mixture was cooled to room temperature. The solid was collected by filtration, rinsed with water, and dried in the air to afford the desired product (6.5 g, 61% yield).

6-Bromo-7-fluoroindoline-2,3-dione

To the concentrated sulfuric acid (20 mL), N-(3-bromo-2-fluorophenyl) - 2-(hydroxyimino)acetamide (1.82 g, 7.03 mmol) was added at 60 °C. The temperature was raised to 90 °C and maintained for 3 h. The reaction mixture was cooled to room temperature and poured into ice. The yellow precipitate was collected by filtration and dried to afford the desired product (1.41 g, 82% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 11.75 (s, 1H), 7.39 (dd, *J* = 5.7, 7.9 Hz, 1H), 7.31 (d, *J* = 8.2 Hz, 1H).

25 2-Amino-4-bromo-3-fluorobenzoic acid

To a solution of 6-bromo-7-fluoroindoline-2,3-dione (1.41 g, 5.80 mmol) in 2 N NaOH (15 mL), H₂O₂ solution (30%, 3 mL) was added at 0 °C and the resulting mixture was stirred at 0 °C for 30 min. After stirring at room temperature for 16 h, the mixture was poured into ice-water, and the solution was acidified with conc. HCl solution. The precipitate was collected by filtration and dried in the air to afford the desired product (1.2 g, 89% yield) as a white solid.

2-Amino-4-bromo-5-chloro-3-fluorobenzoic acid

To a solution of 2-amino-4-bromo-3-fluorobenzoic acid (234 mg, 1.00 mmol) in DMF (10 mL), NCS (134 mg, 1 mmol) was added at room temperature and the resulting mixture was stirred at 70 °C for 16 h. The mixture was poured into ice-
5 water. The precipitate was collected by filtration, rinsed with water and dried to afford the desired product (209 mg, 78% yield) as a white solid. **ESI-MS** m/z : 269.8 $[M + H]^+$.

7-Bromo-6-chloro-8-fluoroquinazolin-4(3H)-one

To a solution of 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid (1.07 g, 3.98 mmol) in EtOH (15 mL), formamidine acetate (4.92 g, 47.76 mmol) was added
10 at room temperature and the resulting mixture was stirred at reflux for 16 h. The mixture was allowed to cool to room temperature and then concentrated *in vacuo*. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (dichloromethane / methanol = 100 : 1 to 50 : 1) to
15 afford the desired product (600 mg, 55% yield) as a white solid. **ESI-MS** m/z : 278.9 $[M + H]^+$.

7-Bromo-4,6-dichloro-8-fluoroquinazoline

A mixture of 7-bromo-6-chloro-8-fluoroquinazolin-4(3H)-one (600 mg, 2.16 mmol), SOCl₂ (30 mL) and DMF (3 drops) was stirred at reflux for 16 h. The
20 mixture was allowed to cool to room temperature and then concentrated *in vacuo* to afford the crude product (639 mg), which was used directly in the next step.

tert-Butyl 4-(7-bromo-6-chloro-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate

To a solution of 7-bromo-4,6-dichloro-8-fluoroquinazoline (639 mg, 2.16 mmol) in 1,4-dioxane (20 mL), tert-butyl piperazine-1-carboxylate (1.21 g, 6.48
25 mmol) and DIPEA (1.39 g, 10.8 mmol) were added at room temperature. The resulting mixture was stirred at 50 °C for 3 h. The mixture was allowed to cool to room temperature and concentrated *in vacuo*. The residue was partitioned between ethyl acetate and saturated NaHCO₃ solution. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column
30 chromatography on silica gel (dichloromethane / methanol = 100 : 1) to afford the desired product (950 mg, 98% yield) as a yellow solid. **ESI-MS** m/z : 446.1 $[M + H]^+$.

tert-Butyl 4-(6-chloro-8-fluoro-7-(2-fluoro-6-methoxyphenyl)quinazolin-4-yl)piperazine-1-carboxylate

A mixture of tert-butyl 4-(7-bromo-6-chloro-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate (45 mg, 0.1 mmol), 2-fluoro-6-methoxyphenylboronic acid
 5 (85 mg, 0.5 mmol), Pd(PPh₃)₄ (6 mg, 0.05 mmol) and Na₂CO₃ (53 mg, 0.5 mmol) in 1,4-dioxane/H₂O (8 mL/2 mL) was stirred at 85 °C under an argon atmosphere for 16 h. The mixture was allowed to cool to room temperature and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (dichloromethane / methanol = 100 :1) to afford the desired product (46 mg, 92 % yield) as a yellow solid.
 10 **ESI-MS *m/z***: 491.2 [M + H]⁺.

1-(4-(6-Chloro-8-fluoro-7-(2-fluoro-6-methoxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

A mixture of tert-butyl 4-(6-chloro-8-fluoro-7-(2-fluoro-6-methoxyphenyl)quinazolin-4-yl)piperazine-1-carboxylate (136 mg, 0.277 mmol) and
 15 HCl in MeOH (6 mL, 2.8 N) was stirred at room temperature for 1 h. The mixture was concentrated *in vacuo* to yield the crude product (118 mg) as a yellow solid which was used directly in the next step.

Acryloyl chloride (30 mg, 0.33 mmol) was added to the mixture of the above obtained crude 6-chloro-8-fluoro-7-(2-fluoro-6-methoxyphenyl)-4-(piperazin-1-yl)quinazoline
 20 (118 mg, 0.277 mmol) in Et₃N (140 mg, 1.38 mmol) and dichloromethane (15 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 2 h. The mixture was quenched with saturated NaHCO₃ solution, and then extracted with ethyl acetate. The organic layer was washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on
 25 silica gel (dichloromethane / methanol = 80:1) to yield the desired product (61 mg, 49% yield) as a solid.


1-(4-(6-Chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

To a solution of 1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-methoxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one (61 mg, 0.137 mmol)
 30 in dichloromethane (10 mL) at -78 °C under nitrogen atmosphere, BBr₃ (343 mg, 1.37

mmol) was added and the resulting mixture was stirred at room temperature for 3 h. The mixture was quenched with saturated NaHCO₃ solution at -30 °C and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by pre-TLC to afford the desired product (45 mg, 76% yield) as a solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 10.30 (s, 1H), 8.70 (s, 1H), 8.04 (s, 1H), 7.34-7.40 (m, 1H), 6.80-6.87 (m, 3H), 6.16-6.20 (m, 1H), 5.73-5.76 (m, 1H), 3.77-3.93 (m, 8H). ESI-MS *m/z*: 431.1 [M + H]⁺.

EXAMPLE 31

Synthesis of 4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinoline-3-carbonitrile



Example 31 provides an exemplary preparation according to General Synthetic Method

15 P

3-Bromo-4-chloro-2-fluorobenzaniline

To a solution of 3-bromo-2-fluorobenzaniline (1.9 g, 10 mmol) in DMF (10 mL) at room temperature, NCS (1.4 g, 10.5 mmol) was added and the resulting mixture was stirred at room temperature for 16 h. The mixture was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column

chromatography on silica gel (petroleum ether / ethyl acetate = 30 : 1) to afford the desired product (1.15 g, 51% yield) as a solid. **ESI-MS** m/z : 225.9 $[M + H]^+$.

Diethyl 2-((3-bromo-4-chloro-2-fluorophenylamino)methylene)malonate

A mixture of 3-bromo-4-chloro-2-fluorobenzenamine (2.3 g, 10.2 mmol) and diethyl 2 - (ethoxymethylene)malonate (2.42 g, 11.22 mmol) was stirred at 120 °C for 3 h. The mixture was allowed to cool to room temperature, and then petroleum ether was added. The mixture was stirred at room temperature for 1 h. The precipitate was collected by filtration and dried to afford the desired product (2.76 g, 68.7% yield) as a solid. **ESI-MS** m/z : 395.9 $[M + H]^+$.

Ethyl 7-bromo-6-chloro-8-fluoro-4-hydroxyquinoline-3-carboxylate

Diethyl 2-((3-bromo-4-chloro-2-fluorophenylamino)methylene)malonate (2.76 g, 6.99 mmol) was suspended in Ph₂O (20 mL). The mixture was stirred at 250 °C for 2 h. The mixture was allowed to cool to room temperature and then 100 mL of petroleum ether was added. The white solid was collected by filtration and rinsed with petroleum ether (100 mL) to afford the desired product (1.85 g, 76% yield) as a solid. **ESI-MS** m/z : 349.9 $[M + H]^+$.

Ethyl 7-bromo-4,6-dichloro-8-fluoroquinoline-3-carboxylate

A mixture of ethyl 7-bromo-6-chloro-8-fluoro-4-hydroxyquinoline-3-carboxylate (1.85 g, 5.31 mmol) and POCl₃ (10 mL) was stirred at reflux for 4 h. The mixture was allowed to cool to room temperature and concentrated *in vacuo* to afford the crude product (1.41 g).

Ethyl 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-7-bromo-6-chloro-8-fluoroquinoline-3-carboxylate

A mixture of ethyl 7-bromo-4,6-dichloro-8-fluoroquinoline-3-carboxylate (1.41 g, 3.84 mmol), tert-butyl piperazine-1-carboxylate (1.43 g, 7.68 mmol), Et₃N (1.55 g, 15.36 mmol) and DMSO (20 mL) was stirred at 80 °C under an argon atmosphere for 2 h. The mixture was allowed to cool to room temperature and poured into ice-water. The mixture was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over Na₂SO₄, and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (petroleum

ether / ethyl acetate = 3 : 1) to afford the desired product (1.96 g, 98% yield) as a solid. **ESI-MS** m/z : 518.1 $[M + H]^+$.

4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-7-bromo-6-chloro-8-fluoroquinoline-3-carboxylic acid

5 To a solution of ethyl 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-7-bromo-6-chloro-8-fluoroquinoline-3-carboxylate (517 mg, 1 mmol) in EtOH/H₂O (16 mL/8 mL), LiOH·H₂O (126 mg, 3 mmol) was added. The mixture was stirred at room temperature for 16 h and poured into ice-water. The mixture was acidified with 1N HCl solution and extracted with ethyl acetate. The organic layer was washed with brine,
10 dried over Na₂SO₄ and concentrated *in vacuo* to afford the desired product (489 mg, 100% yield) as a solid. **ESI-MS** m/z : 489.1 $[M + H]^+$.

tert-Butyl 4-(7-bromo-3-carbamoyl-6-chloro-8-fluoroquinolin-4-yl)piperazine-1-carboxylate

A mixture of 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-7-bromo-6-chloro-8-fluoroquinoline-3-carboxylic acid (290 mg, 0.59 mmol), HOBt (121 mg, 0.89 mmol), NH₄Cl (63 mg, 1.18 mmol), DIPEA (306 mg, 2.37 mmol) in DMF (16 ml) at room temperature, BOP (393 mg, 0.89 mmol) was added and the resulting mixture was stirred at room temperature for 16 h. The mixture was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with brine, dried over
15 Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (dichloromethane / methanol = 15:1) to afford the desired product (160 mg, 55% yield) as a white solid. **ESI-MS** m/z : 533.2 $[M + H]^+$.

tert-Butyl 4-(3-carbamoyl-6-chloro-8-fluoro-7-(2-fluoro-6-methoxyphenyl)quinolin-4-yl)piperazine-1-carboxylate

25 A mixture of tert-butyl 4-(7-bromo-3-carbamoyl-6-chloro-8-fluoroquinolin-4-yl)piperazine-1-carboxylate (100 mg, 0.21 mmol), 2-fluoro-6-methoxyphenylboronic acid (174 mg, 1.025 mmol), Pd(PPh₃)₄ (12 mg, 0.01 mmol) and Na₂CO₃ (109 mg, 1.02 mmol) in 1,4-dioxane/H₂O (12 mL/3 mL) was stirred at 100 °C under an argon atmosphere for 16 h. The mixture was allowed to cool to room
30 temperature and concentrated *in vacuo*. The residue was purified by pre-TLC to afford the desired product (71 mg, 65% yield) as a white solid.

4-(4-Acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(2-fluoro-6-methoxyphenyl)quinoline-3-carboxamide

A mixture of tert-butyl 4-(3-carbamoyl-6-chloro-8-fluoro-7-(2-fluoro-6-methoxyphenyl)quinolin-4-yl)piperazine-1-carboxylate (71 mg, 0.13 mmol) and HCl in
5 MeOH (8 mL, 2.8 N) was stirred at room temperature for 1 h. The mixture was concentrated *in vacuo* to afford the crude 6-chloro-8-fluoro-7-(2-fluoro-6-methoxyphenyl)-4-(piperazin-1-yl)quinoline-3-carboxamide hydrochloride.

The above obtained crude compound was dissolved in Et₃N (40 mg, 0.40 mmol) and dichloromethane (15 mL) and cooled to 0°C, acryloyl chloride (14 mg, 0.16
10 mmol) was added to the mixture. The resulting mixture was stirred at 0 °C for 2 h. The reaction mixture was quenched with saturated NaHCO₃ aqueous solution, and then extracted with ethyl acetate. The organic layer was washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by pre-TLC to afford the desired product (62 mg, 95% yield) as a white solid.
15 **ESI-MS** *m/z*: 487.2 [M + H]⁺.

4-(4-Acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinoline-3-carboxamide

To a solution of 4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(2-fluoro-6-methoxyphenyl)quinoline-3-carboxamide (62 mg, 0.13 mmol) in
20 dichloromethane (10 mL) at -78 °C under nitrogen atmosphere, BBr₃ (317 mg, 1.27 mmol) was added and the resulting mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with saturated NaHCO₃ at -30 °C, and the aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo* to afford the desired product as a yellow
25 solid (60 mg, 100% yield).


4-(4-Acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinoline-3-carbonitrile

A mixture of 4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinoline-3-carboxamide, TEA (64 mg, 0.635 mmol) in
30 dichloromethane (10 mL) at 0 °C, TFAA (80 mg, 0.38 mmol) was added. The mixture was stirred at 0 °C for 2 h and then poured into saturated NaHCO₃ solution. The mixture

was extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by pre-TLC to afford the desired product (15 mg, 26% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 10.33 (s, 1H), 8.89 (s, 1H), 8.08 (d, *J* = 0.4, 1H), 7.35-7.41 (m, 1H), 6.81-6.94 (m, 3H), 6.17-6.22 (m, 1H), 5.74-5.77 (m, 1H), 3.85-3.89 (m, 4H), 3.73 (m, 4H). ESI-MS *m/z*: 455.2 [M + H]⁺.

EXAMPLE 32

Synthesis of 1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



Example 32 provides an exemplary preparation according to General Synthetic Method Q

1-(4-(7-Bromo-6-chloro-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

tert-Butyl 4-(7-bromo-6-chloro-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate (300 mg, 0.67 mmol) was dissolved in TFA and DCM (50% TFA, 5 mL) and the resulting mixture was stirred at room temperature for 30 min. The mixture was concentrated *in vacuo*. The residue was dissolved in DCM and washed with sat. NaHCO₃ solution. The organic layer was dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was dissolved in DCM at 0 °C, iPr₂NEt (262 mg, 2 mmol) was added, followed by acryloyl chloride (122 mg, 1.35 mmol). The mixture was stirred at 0 °C for 30 min. The mixture was concentrated *in vacuo*, and the residue was purified via Isolera One (MeOH/DCM = 0 – 3%) to afford the desired product (250 mg, 93% yield).

1-(4-(6-Chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one


A mixture of 1-(4-(7-bromo-6-chloro-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one (30 mg, 0.075 mmol), (5-methyl-1H-indazol-4-yl)boronic acid

(20 mg, 0.113 mmol) and Tetrakis (43 mg, 0.038 mmol) in co-solvent of 1,4-dioxane (3 mL) and 1 M Na₂CO₃ (0.5 mL) was heated in microwave reactor at 120 °C for 15 min. The mixture was partitioned between DCM and water. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified via Isolar One (MeOH/DCM = 0 - 10%) followed by prep-TLC (MeOH/DCM = 10%) to afford the desired product (9 mg, 26.6% yield). ¹H NMR (500 MHz, CDCl₃) δ: 8.86 (s, 1H), 9.08 (s, 1H), 7.90 (s, 1H), 7.59 (s, 1H), 7.54 (d, *J* = 8.5 Hz, 1H), 7.40 (d, *J* = 8.5 Hz, 1H), 6.62 (dd, *J* = 10.5, 17 Hz, 1H), 6.40 (dd, *J* = 1.5, 17 Hz, 1H), 5.80 (dd, *J* = 1.5, 10.5 Hz, 1H), 3.78-4.02 (m, 8H), 2.25 (s, 3H). ESI-MS *m/z*: 451.1 [M+H]⁺.

10

EXAMPLE 33

Synthesis of 1-(4-(7-(2-fluorophenyl)-6-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



15 Example 33 provides an exemplary preparation according to General Synthetic Method R

Methyl 2-amino-4-chloro-5-iodobenzoate

To a mixture of I₂ (6.8 g, 27.0 mmol) and Ag₂SO₄ (8.4 g, 27.0 mmol) in EtOH (250 mL), methyl 2-amino-4-chlorobenzoate (5.0 g, 27.0 mmol) was added and the resulting mixture was stirred at RT for 45 min. The solid was filtered off and washed with dichloromethane, and the filtrate was concentrated *in vacuo*. The residue

was extracted with dichloromethane and washed with brine. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo* to afford the desired product (6.4 g, 76% yield) as a white solid. **ESI-MS** *m/z*: 311.9 [M + H]⁺.

Methyl 2-acetamido-4-chloro-5-iodobenzoate

5 A mixture of methyl 2-amino-4-chloro-5-iodobenzoate (8.4 g, 0.027 mol), pyridine (6.4 g, 0.081 mol) in dichloromethane (250 mL) at 0 °C, acetyl chloride (2.5 g, 0.032 mol) was added. The mixture was stirred at RT for 16 h. The reaction mixture was washed with brine. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column
10 chromatography on silica gel (ethyl acetate/petroleum ether = 1:5) to afford the desired product (7.6 g, 80% yield). **ESI-MS** *m/z*: 353.9 [M + H]⁺.

Methyl 2-amino-4-chloro-5-(trifluoromethyl)benzoate

To a stirred solution of methyl 2-acetamido-4-chloro-5-iodobenzoate (2.5 g, 7.08 mmol) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (2.72 g, 14.2
15 mmol) in NMP (30 mL) at RT, CuI (0.4 g, 2.12 mmol) was added and the resulting mixture was stirred at 80 °C for 16 h. The mixture was quenched with water and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (ethyl acetate/petroleum ether = 1:5) to
20 afford the desired product (1.8 g, 90% yield) as a light yellow oil. **ESI-MS** *m/z*: 296.4 [M+H]⁺.

Methyl 2-amino-4-chloro-5-(trifluoromethyl)benzoate

A mixture of methyl 2-amino-4-chloro-5-(trifluoromethyl)benzoate (800 mg, 2.71 mmol) in HCl/MeOH (2.85 mol/L, 10 mL) was stirred at 80 °C for 1.5 h. The
25 reaction mixture was concentrated *in vacuo* to afford the desired product which was used in the next step without further purification.

2-Amino-4-chloro-5-(trifluoromethyl)benzoic acid

To a mixture of methyl 2-amino-4-chloro-5-(trifluoromethyl)benzoate (600 mg, 2.55 mmol) in THF (10 mL) and water (2.5 mL) at RT, LiOH.H₂O (408 mg,
30 10.21 mmol) was added and the resulting mixture was stirred at 80 °C for 3 h. The mixture was diluted with H₂O, acidified with HCl to adjust pH to 4 and then extracted

with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo* to afford the desired product (500 mg, 82 % yield) as a solid.

7-Chloro-6-(trifluoromethyl)quinazolin-4-ol

A mixture of 2-amino-4-chloro-5-(trifluoromethyl)benzoic acid (500 mg, 2.09 mmol) and formamidine acetate (430 mg, 4.18 mmol) in 2-ethoxyethanol (15 mL) was stirred at reflux for 16 h. The mixture was concentrated *in vacuo* and extracted with dichloromethane. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated to afford the desired product (500 mg, 96% yield) which was used in the next step without further purifications. **ESI-MS** *m/z*: 249.3 [M+H]⁺.

4,7-Dichloro-6-(trifluoromethyl)quinazoline

To a suspension of 7-chloro-6-(trifluoromethyl)quinazolin-4-ol (500 mg, 0.016 mol) in SOCl₂ (20 mL), DMF (one drop) was added and the resulting mixture was stirred at reflux for 3 h. The mixture was concentrated *in vacuo* to afford the crude product which was used in the next step without further purification

tert-Butyl 4-(7-chloro-6-(trifluoromethyl)quinazolin-4-yl)piperazine-1-carboxylate.

To a solution of 4,7-dichloro-6-(trifluoromethyl)quinazoline (500 mg, 1.88 mmol) and Et₃N (3.33 g, 33 mmol) in dichloromethane (20 mL) at RT, tert-butyl piperazine-1-carboxylate (3.07 g, 16.5 mmol) was added. The resulting mixture was stirred at RT for 16 h. The mixture was washed with saturated NH₄Cl solution and brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (50% ethyl acetate/petroleum ether) to afford the desired product (650 mg, 83 % yield) as a yellow solid. **ESI-MS** *m/z*: 417.0 [M+H]⁺.

tert-Butyl 4-(6-(trifluoromethyl)-7-(2-fluorophenyl)quinazolin-4-yl)piperazine-1-carboxylate

The mixture of 4-(7-chloro-6-(trifluoromethyl)quinazolin-4-yl)piperazine-1-carboxylate (200 mg, 0.48 mmol), 2-fluorophenylboronic acid (132.6 mg, 0.96 mmol), PdCl₂(dppf) (35 mg, 0.048 mmol), Na₂CO₃ (254 mg, 2.4 mmol) in dioxane (20 mL) and water (2 mL) was stirred at 100 °C under argon for 16 h. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (50% ethyl acetate / petroleum ether) to afford the desired product (100 mg, 44% yield) as a white solid.


1-(4-(6-(Trifluoromethyl)-7-(2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from tert-butyl 4-(6-(trifluoromethyl)-7-(2-fluorophenyl)quinazolin-4-yl)piperazine-1-carboxylate according to the procedure described in steps 5 and 6 in **Example 1**. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 9.74 (s, 1H), 8.43 (s, 1H), 7.78 (s, 1H), 7.58-7.53 (m, 1H), 7.44-7.32 (m, 3H), 6.87-6.80 (dd, *J* = 11.0, 16.4 Hz, 1H), 6.21 (dd, *J* = 2.4, 16.8 Hz, 1H), 5.77 (dd, *J* = 2.1, 10.0 Hz, 1H), 4.06-4.00 (m, 4H), 3.05-3.77 (m, 4H). ESI-MS *m/z*: 431.2 [M+H]⁺.

10

EXAMPLE 34

Synthesis of 1-(1-acryloylpiperidin-4-yl)-7-chloro-6-(2,4-difluorophenyl)quinoxalin-2(1H)-one



Example 34 provides an exemplary preparation according to General Synthetic Method S

15

tert-Butyl 4-(2-chloroacetamido)piperidine-1-carboxylate

To a mixture of tert-butyl 4-aminopiperidine-1-carboxylate (5 g, 25 mmol), Et₃N (4.5 mL, 32.3 mmol) in dichloromethane (50 mL) at 0 °C, 2-chloroacetyl chloride (3.4 g, 30 mmol) was added dropwise. The reaction mixture was allowed to warm to RT and stirring was continued until conversion was completed. The reaction mixture was washed with NaHCO₃ aqueous solution and brine. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was

20

purified by flash column chromatography on silica gel (20-50% ethyl acetate / petroleum ether) to afford the desired product (4 g, 57.8% yield).

5-Bromo-4-chloro-2-iodobenzenamine

A mixture of 3-bromo-4-chlorobenzenamine (15 g, 72.6 mmol) in HOAc (100 mL), NIS (19.6 g, 87.1 mmol) was added and the resulting mixture was stirred at RT for 6 h. The mixture was quenched with water, and extracted with ethyl acetate. The organic layer washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (5% petroleum ether/ethyl acetate) to afford the desired product (5.2 g, 21.6% yield).

N-(5-Bromo-4-chloro-2-iodophenyl)methanesulfonamide

A mixture of 5-bromo-4-chloro-2-iodobenzenamine (5.2 g, 15.6 mmol), Et₃N (4.7 g, 46.8 mmol) in dichloromethane (60 mL) at 0 °C, methanesulfonyl chloride (2.2 g, 18.8 mmol) was added dropwise. The resulting mixture was stirred at RT for 10 h. The mixture was quenched with water, and extracted with dichloromethane. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (10% petroleum ether/ethyl acetate) to afford the desired product (5 g, 78.1% yield).

tert-Butyl 4-(2-(N-(5-bromo-4-chloro-2-iodophenyl)methylsulfonamido)acetamido)piperidine-1-carboxylate

A mixture of 5-bromo-4-chloro-2-iodo-N-methanesulfonybenzenamine (1.6 g, 3.9 mmol), tert-butyl 4-(2-chloroacetamido)piperidine-1-carboxylate (1.08 g, 3.9 mmol), CuI (74 mg, 0.39 mmol), 1,10-phenanthroline (141 mg, 0.78 mmol), K₂CO₃ (1.1 g, 7.58 mmol) in dioxane (20 mL) was stirred at reflux under argon for 12 h. The mixture was allowed to cool to RT, quenched with water, and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (30% petroleum ether/ethyl acetate) to afford the desired product (1.5 g, 59% yield).

tert-Butyl

4-(6-bromo-7-chloro-2-oxoquinoxalin-1(2H)-yl)piperidine-1-carboxylate

A mixture of tert-butyl 4-(2-(N-(5-bromo-4-chloro-2-iodophenyl)methylsulfonamido)acetamido)piperidine-1-carboxylate (1.5 g, 2.31 mmol),

CuI (44 mg, 0.231 mmol), 1,10-phenanthroline (83 mg, 0.462 mmol), Cs₂CO₃ (1.9 g, 5.78 mmol) in dioxane (10 mL) was stirred at reflux under argon for 12 h. The mixture was allowed to cool to RT, quenched with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (30% petroleum ether/ethyl acetate) to afford the desired product (55 mg, 5.4% yield).


1-(1-Acryloylpiperidin-4-yl)-7-chloro-6-(2,4-difluorophenyl)quinoxalin-2(1H)-one

The title compound was prepared from tert-butyl 4-(6-bromo-7-chloro-2-oxoquinoxalin-1(2H)-yl)piperidine-1-carboxylate in three steps following the procedure described in **Example 2**. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.24 (s, 1H), 7.86 (s, 1H), 7.66 (s, 1H), 7.37-7.31 (m, 1H), 7.05-6.95 (m, 2H), 6.71-6.64 (m, 1H), 6.38 (dd, *J* = 2, 16.8 Hz, 1H), 5.74 (dd, *J* = 2.0, 10.8 Hz, 1H), 4.97 (m, 1H), 4.27 (m, 1H), 3.28 (m, 1H), 2.84 (m, 3H), 1.89 (m, 2H), 1.66 (m, 1H) ESI-MS *m/z*: 430.3 [M+1]⁺.

15

EXAMPLE 35

Synthesis of 1-(4-(4-acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-5-chloropyridin-2(1H)-one



Example 35 provides an exemplary preparation according to General Synthetic Method

20 T

6-Fluoroquinazolin-4(1H)-one

A mixture of 2-amino-5-fluorobenzoic acid (8.0 g, 51.6 mmol) and formamidine acetate (10.6 g, 103 mmol) in EtOH (150 mL) was stirred at reflux for 16 h. The mixture was concentrated *in vacuo* and extracted with dichloromethane. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated in vacuo to afford the desired product (7.8 g, 92% yield) which was used in the next step without further purification.

6-Fluoro-7-nitroquinazolin-4(1H)-one

6-Fluoroquinazolin-4(1H)-one (4.3 g, 26.2 mmol) was added to a mixture of concentrated H₂SO₄ (10 mL) and fuming HNO₃ (5 mL) at 0 °C. The resulting mixture was stirred at RT for 1 h and then stirred at 110 °C for 2 h. The mixture was cooled to RT and poured into ice-water. The precipitate was collected by filtration and dried to afford the desired product (2.3 g, 42.6% yield) as a yellow solid. **ESI-MS** *m/z*: 210.3 [M+H]⁺.

4-Chloro-7-fluoro-6-nitroquinazoline

A suspension of 6-fluoro-7-nitroquinazolin-4(1H)-one (2.3 g, 0.011 mol) in SOCl₂ (10 mL) was stirred at reflux for 3 h. The mixture was allowed to cool to RT, and concentrated in vacuo to afford the crude product (2.5 g) which was used in the next step without further purification.

tert-Butyl 4-(7-fluoro-6-nitroquinazolin-4-yl)piperazine-1-carboxylate

To a solution of 4-chloro-7-fluoro-6-nitroquinazoline (2.5 g, 11.0 mmol) in dichloromethane (50 mL) and Et₃N (3.33 g, 33 mmol) at RT, tert-butyl piperazine-1-carboxylate (3.07 g, 16.5 mmol) was added, and the resulting mixture was stirred at RT for 16 h. The mixture was washed with saturated NH₄Cl solution and brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (50 % ethyl acetate/petroleum ether) to afford the desired product (1.8 g, 44 % yield) as a yellow solid. **ESI-MS** *m/z*: 378.0 [M+H]⁺.

tert-Butyl 4-(7-(5-chloro-2-oxopyridin-1(2H)-yl)-6-nitroquinazolin-4-yl)piperazine-1-carboxylate

To a solution of 5-chloropyridin-2-ol (213 mg, 1.39 mmol) in DMF (5 mL) at RT, NaH (55.6 mg, 1.39 mmol) was added and the resulting mixture was stirred

for 30 min. To this mixture, tert-butyl 4-(7-fluoro-6-nitroquinazolin-4-yl)piperazine-1-carboxylate (350 mg, 0.928 mmol) was added and the resulting mixture was stirred at 50 °C for 1.5 h. The mixture was allowed to cool to RT and partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (5 % ethyl acetate/petroleum ether) to afford the desired product (400 mg, 88 % yield) as a yellow solid. **ESI-MS** *m/z*: 487.2 [M+H]⁺.

tert-Butyl 4-(6-amino-7-(5-chloro-2-oxopyridin-1(2H)-yl)quinazolin-4-yl)piperazine-1-carboxylate

10 A mixture of 4-(7-(5-chloro-2-oxopyridin-1(2H)-yl)-6-nitroquinazolin-4-yl)piperazine-1-carboxylate (400 mg, 0.818 mmol), ammonium chloride (520 mg, 9.82 mmol), Zn powder (265.8 mg, 4.09 mmol) in EtOH (20 mL) and water (4 mL) was stirred at 70 °C for 2 h. The mixture was concentrated in vacuo and extracted with dichloromethane. The organic layer was washed with NaHCO₃ and brine, dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (30 % ethyl acetate/petroleum ether) to afford the desired product (300 mg, 80.4% yield) as a solid. **ESI-MS** *m/z*: 457.2 [M+H]⁺.

tert-Butyl 4-(6-chloro-7-(5-chloro-2-oxopyridin-1(2H)-yl)quinazolin-4-yl)piperazine-1-carboxylate

20 To a mixture of tert-Butyl nitrite (135.5 mg, 1.32 mmol) and cupric chloride (280 mg, 1.65 mmol) in CH₃CN (10 mL), tert-butyl 4-(6-amino-7-(5-chloro-2-oxopyridin-1(2H)-yl)quinazolin-4-yl)piperazine-1-carboxylate (300 mg, 0.658 mmol) in CH₃CN (5 mL) was added and the resulting mixture was stirred at RT for 2 h. The mixture was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel (50 % ethyl acetate/petroleum ether) to afford the desired product (110 mg, 38 % yield).

1-(4-(4-Acryloylpiperazin-1-yl)-6-chloroquinazolin-7-yl)-5-chloropyridin-2(1H)-one


30 The title compound was prepared from tert-butyl 4-(6-chloro-7-(5-chloro-2-oxopyridin-1(2H)-yl)quinazolin-4-yl)piperazine-1-carboxylate according to

the procedure described in steps 5 and 6 in **Example 1**. ^1H NMR (400 MHz, DMSO-*d*6) δ : 8.71 (s, 1H), 8.29 (s, 1H), 8.10 (s, 1H), 7.95 (d, 1H), 7.75 (d, 1H), 6.87-6.80 (dd, J = 12.0, 12.0 Hz, 1H), 6.46 (dd, J = 8.0, 1H), 6.20 (d, J = 2.6, 16.8 Hz, 1H), 5.76 (dd, J = 2.2, 10.0 Hz, 1H), 3.91-3.77 (m, 8H). ESI-MS m/z : 430.4 $[\text{M}+\text{H}]^+$.

5

EXAMPLE 36

Synthesis of 1-(4-(6-chloro-7-(2-(thiazol-2-yl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



10 Example 36 provides an exemplary preparation according to General Synthetic Method U

tert-Butyl 4-(7-(tributylstannyl)-6-chloroquinazolin-4-yl)piperazine-1-carboxylate

A mixture of tert-butyl 4-(7-bromo-6-chloroquinazolin-4-yl)piperazine-1-carboxylate (1.5 g, 3.51 mmol), 1,1,1,2,2,2-hexabutyldistannane (2.6 g, 4.56 mmol), Pd(PPh₃)₄ (203 mg, 0.18 mmol) in toluene (40 mL) was stirred at reflux under argon for 16 h. The mixture was allowed to cool to RT, quenched with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (40% petroleum ether/ethyl acetate) to afford the desired product (542 mg, 24% yield).

20

tert-Butyl 4-(6-chloro-7-(2-(thiazol-2-yl)phenyl)quinazolin-4-yl)piperazine-1-carboxylate

A mixture of tert-butyl 4-(7-(tributylstannyl)-6-chloroquinazolin-4-yl)piperazine-1-carboxylate (150 mg, 0.24 mmol), 2-(2-bromophenyl)thiazole (68 mg, 0.28 mmol), Pd(PPh₃)₄ (28 mg, 0.024 mmol), CsF (73 mg, 0.48 mmol) and CuI (9 mg, 0.048 mmol) in DMF (10 mL) was stirred at 80 °C under argon for 16 h. Then reaction mixture was allowed to cool to room temperature, quenched with water, extracted with

25

ethyl acetate. The organic layer was washed with brine, dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (dichloromethane/methanol = 25:1) to afford the desired product (38 mg, 31.1% yield).


5 **1-(4-(6-Chloro-7-(2-(thiazol-2-yl)phenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one**

A mixture of 4-(6-chloro-7-(2-(thiazol-2-yl)phenyl)quinazolin-4-yl)piperazine-1-carboxylate (38 mg, 0.075 mmol) in HCl/MeOH (2.86 M, 5 mL) was stirred at RT for 1 h. The mixture was concentrated *in vacuo* to afford the crude product. The crude product was dissolved in dichloromethane (5 mL) at RT, acryloyl chloride (8 mg, 0.090 mmol) and Et_3N (23 mg, 0.225 mmol) were added and the resulting mixture was stirred at RT for 1 h. The mixture was partitioned between dichloromethane and water. The organic layer was washed brine, dried over MgSO_4 , filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (dichloromethane/methanol = 20:1) to afford the desired product (8 mg, 23% yield, 2 steps). $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ : 8.69 (s, 1H), 8.15 (d, $J = 2.4$ Hz, 1H), 8.13 (s, 1H), 7.82 (s, 1H), 7.76 (d, $J = 3.2$ Hz, 1H), 7.67-7.60 (m, 3H), 7.43-7.41 (m, 1H), 6.87-6.81 (m, 1H), 6.18 (dd, $J = 2.0, 16.8$ Hz, 1H), 5.75 (dd, $J = 2.0, 10.0$ Hz, 1H), 3.92-3.78 (m, 8H). **ESI-MS** m/z : 462.3 $[\text{M}+1]^+$.

20

EXAMPLE 37

Synthesis of 1-(4-(6,8-dichloro-7-(2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



Example 37 provides an exemplary preparation according to General Synthetic Method V

2-Bromo-6-nitroaniline

5 A mixture of 1-bromo-2-fluoro-3-nitrobenzene (6.0 g, 27.27 mmol) and NH₃ in CH₃OH (7 M, 20 mL) was stirred in a sealed tube at 100 °C for 16 h. The solvent was removed and the residue was dissolved in H₂O, and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate/petroleum ether = 1:100) to afford the product as a yellow solid (5.4 g, 91.3%
10 yield).

1-Bromo-2-chloro-3-nitrobenzene

A mixture of 2-bromo-6-nitroaniline (3.0 g, 13.84 mmol), tert-butyl nitrite (2.85 g 27.68 mmol) and CuCl₂ (3.7 g, 27.68 mmol) in CH₃CN (60 mL) was
15 stirred at 60 °C under argon for 1 h. The mixture was allowed to cool to RT, quenched with H₂O, and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate/petroleum ether = 1:100) to yield the product as an off-white solid (2.7 g, 82.7% yield).

20 3-Bromo-2-chloroaniline

A mixture of 1-bromo-2-chloro-3-nitrobenzene (2.7 g, 11.44 mmol) and SnCl₂ (12.97 g, 57.20 mmol) in CH₃CH₂OH (60 mL) was stirred at reflux for 3 h. The mixture was allowed to cool to RT, quenched with H₂O, and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated.
25 The residue was purified by column chromatography on silica gel (ethyl acetate/petroleum ether = 1:50) to yield the product as an off-white solid (1.3 g, 55.2% yield).

1-(4-(6,8-Dichloro-7-(2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one


30 The title compound was prepared from 3-bromo-2-chloroaniline according to the procedure described in **Example 30**. ¹H NMR (400 MHz, DMSO-*d*6)

δ : 8.76 (s, 1H), 8.20 (s, 1H), 7.61-7.57 (m, 1H), 7.45-7.40 (m, 3H), 6.83 (dd, $J = 10.4$, 16.8, 1H), 6.18 (dd, $J = 2.4$, 16.8, 1H), 5.75 (dd, $J = 2.4$, 10.4, 1H), 3.93-3.76 (m, 8H).
ESI-MS m/z : 430.1 $[M + H]^+$.

5

EXAMPLE 38

Synthesis of 1-(4-(8-fluoro-7-(2-fluorophenyl)-6-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



Example 38 provides an exemplary preparation according to General Synthetic Method

10 W

2-Amino-4-chloro-3-fluorobenzoic acid

The title compound was prepared from 3-chloro-2-fluorobenzaniline according to the procedure described in **Example 30**.

15 **Methyl 2-amino-4-chloro-3-fluorobenzoate**

To a solution of 2-amino-4-chloro-3-fluorobenzoic acid (7.0 g, 35.0 mmol) in MeOH (100 mL) at 0 °C, thionyl chloride (8.37 g, 70 mmol) was added dropwise. The mixture was warmed stirred at RT for 30 min, and then stirred at reflux for 16 h. The mixture was concentrated *in vacuo*. The residue was extracted with dichloromethane and washed with brine. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on

20

silica gel (10% ethyl acetate / petroleum ether) to afford the desired product (4.0 g, 56% yield) as a white solid.


1-(4-(8-Fluoro-6-(trifluoromethyl)-7-(2-fluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

5 The title compound was prepared from methyl 2-amino-4-chloro-3-fluorobenzoate according to the procedure described in **Example 32**. ¹HNMR (400 MHz, DMSO-*d*₆) δ: 8.78 (s, 1H), 8.32 (s, 1H), 7.61 (m, 1H), 7.49-7.37 (m, 3H), 6.87-6.80 (dd, *J* = 11.0, 16.4 Hz, 1H), 6.21-6.16 (dd, *J* = 2.4, 16.8 Hz, 1H), 5.775.73 (dd, *J* = 2.1, 10.0 Hz, 1H), 4.06-4.00 (m, 4H), 3.85-3.72 (m, 4H). ESI-MS *m/z*: 449.2 [M+H]⁺.

10

EXAMPLE 39

Synthesis of 1-(4-(7-(2-fluoro-6-hydroxyphenyl)-6-(trifluoromethyl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one



15 Example 39 provides an exemplary preparation according to General Synthetic Method X

1-(4-Chloro-2-nitrophenyl)ethanone

To a stirred solution of 4-chloro-2-nitrobenzoic acid (15.0 g, 75 mmol) in THF (250 mL) at 0 °C, oxalyl chloride (13 mL, 150 mmol) was added followed by DMF (2 drops). The mixture was stirred at 0 °C for 10 min and then stirred at reflux 2

h. The mixture was concentrated in vacuo to dryness to afford 4-chloro-2-nitrobenzoyl chloride.

To a solution of diethyl malonate (12.0 g, 75 mmol) in THF (250 mL), NaH (3.6 g, 90 mmol) was added in portions and the resulting mixture was stirred at RT for 20 min. A solution of 4-chloro-2-nitrobenzoyl chloride in THF (100 mL) was added dropwise to the reaction mixture at 0 °C. The resulting mixture was stirred at RT for 30 min and then stirred at 80 °C for 2 h. The mixture was quenched with water and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was dissolved in AcOH (25 mL) and 20% H₂SO₄ (25 mL) and the resulting mixture was stirred at 80°C for 6 h. The mixture was extracted with ethyl acetate, washed with brine, water and NaHCO₃ solution. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (ethyl acetate/petroleum ether = 1:5) to afford the desired product (5.0 g, 33% yield) as a light yellow solid.

1-(2-Amino-4-chlorophenyl)ethanone

A mixture of methyl 1-(4-chloro-2-nitrophenyl)ethanone (5.0 g, 25 mmol) and Fe (5.6 g, 100 mmol) in CH₃COOH (50 mL) and H₂O (50 mL) was stirred at reflux for 16 h. The mixture was allowed to cool to RT and quenched with saturated NaHCO₃ aqueous solution. The mixture was extracted with ethyl acetate. The organic layer was washed with saturated NaHCO₃ aqueous solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (ethyl acetate/petroleum ether= 1:4) to afford the desired product (3.8 g, 89% yield) as a yellow solid.

1-(2-Amino-4-chloro-5-iodophenyl)ethanone

To a mixture of I₂ (4.5 g, 17.7 mmol) and Ag₂SO₄ (5.5 g, 17.7 mmol) in EtOH (100 mL), 1-(2-amino-4-chlorophenyl)ethanone (3.0 g, 17.7 mmol) was added and the resulting mixture was stirred at RT for 45 min. The solid was filtered off and washed with dichloromethane, and the filtrate was concentrated *in vacuo*. The residue was extracted with dichloromethane. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo* to afford the desired product (2.0 g, 38% yield) as a white solid. **ESI-MS** *m/z*: 295.3 [M + H]⁺.

N-(2-Acetyl-5-chloro-4-iodophenyl)acetamide

To a stirred solution of methyl 2-amino-4-chloro-3-fluoro-5-iodobenzoate (2.0 g, 6.8 mmol) and pyridine (1.6 g, 20.3 mmol) in DCM (50 mL) at 0 °C, acetyl chloride (634 mg, 8.14 mmol) was added. The mixture was stirred at RT for 16 h. The reaction mixture was washed with brine. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (ethyl acetate/petroleum ether = 1:5) to afford the desired product (1.4 g, 61% yield). **ESI-MS** *m/z*: 338.4 [M + H]⁺.

N-(2-Acetyl-5-chloro-4-(trifluoromethyl)phenyl)acetamide

To a stirred solution of N-(2-acetyl-5-chloro-4-iodophenyl)acetamide (1.4 g, 4.2 mmol) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (1.6 g, 8.3 mmol) in NMP (20 mL) at RT, CuI (235 mg, 1.24 mmol) was added and the resulting mixture was stirred at 90 °C for 16 h. The mixture was quenched with water and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (ethyl acetate/petroleum ether = 1:5) to afford the desired product (1.0 g, 87% yield) as oil. **ESI-MS** *m/z*: 280.1 [M+H]⁺.

1-(2-Amino-4-chloro-5-(trifluoromethyl)phenyl)ethanone

The mixture of 2-acetamido-4-chloro-3-fluoro-5-(trifluoromethyl)benzoic acid (1.0 g, 3.58 mmol) in HCl/MeOH (2.85 M, 10 mL) was stirred at 60 °C for 1.5 h. The reaction mixture was concentrated *in vacuo* to afford the desired product (900 mg) which was used in the next step without further purification.

7-Chloro-6-(trifluoromethyl)cinnolin-4(1H)-one

Concentrated HCl (10 mL) was added to 1-(2-amino-4-chloro-5-(trifluoromethyl)phenyl)ethanone (900 mg, 3.58 mmol). After the mixture was cooled to 0 °C, a solution of sodium nitrite (259 mg, 3.76 mmol) in water (2 mL) was added over 30 min. The mixture was stirred at 0 °C for 30 min and then stirred at 60 °C for 2 h. The mixture was cooled and poured into water. The solid was collected by filtration to afford the desired crude product (680 mg, 77% yield).


1-(4-(7-(2-Fluoro-6-hydroxyphenyl)-6-(trifluoromethyl)cinnolin-4-yl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from 7-chloro-6-(trifluoromethyl)cinnolin-4(1H)-one according to the procedure described in **Example 29**. ¹HNMR (400 MHz, CDCl₃) δ: 9.06 (s, 1H), 8.47 (s, 1H), 8.45 (s, 1H), 6.84 (m, 1H), 6.69-6.62 (dd, *J* = 14.0, 12.0 Hz, 1H), 6.44 (dd, *J* = 2.6, 14.5 Hz, 1H), 5.85 (dd, *J* = 2.2, 10.0 Hz, 1H), 5.38 (m, 1H), 4.05-3.96 (m, 4H), 3.54-3.52 (m, 4H). ESI-MS *m/z*: 447.2 [M+H]⁺.

10

EXAMPLE 40

Synthesis of 1-(4-(7-(2,4-difluorophenyl)-8-fluoro-6-methylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



Example 40 provides an exemplary preparation according to General Synthetic Method AJ

15

3-Amino-2,2',4'-trifluoro-[1,1'-biphenyl]-4-carboxylic acid

A mixture of 2-amino-4-bromo-3-fluorobenzoic acid (400 mg, 1.71 mmol), (2,4-difluorophenyl)boronic acid (405 mg, 1.5 mmol), Pd(PPh₃)₄ (197 mg, 0.171 mmol) and Na₂CO₃ (725 mg, 6.84 mmol) in 1,4-dioxane/H₂O (10 mL/2 mL) was stirred at 100 °C under argon for 16 h. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (dichloromethane / methanol = 20:1) to yield the desired product (374 mg, 81.9% yield) as an off-white solid. ESI-MS *m/z*: 268.1 [M + H]⁺.

20

3-Amino-6-bromo-2,2',4'-trifluoro-[1,1'-biphenyl]-4-carboxylic acid

A mixture of 3-amino-2,2',4'-trifluoro-[1,1'-biphenyl]-4-carboxylic acid (374 mg, 1.4 mmol) and NBS (249 mg, 1.4 mmol) in DMF (4 mL) was stirred at RT for 2 h. The reaction mixture was quenched with H₂O, and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (Petroleum ether / ethyl acetate = 2:1) to yield the desired product (330 mg, 67.9% yield) as a gray solid. **ESI-MS** *m/z*: 345.9 [M + H]⁺.

6-Bromo-7-(2,4-difluorophenyl)-8-fluoroquinazolin-4-ol

A mixture of 3-amino-6-bromo-2,2',4'-trifluoro-[1,1'-biphenyl]-4-carboxylic acid (330 mg, 0.95 mmol) and formimidamide acetate (790 mg, 7.6 mmol) was stirred at reflux for 16 h. The mixture was allowed to cool to RT, and quenched with water. The solid precipitate was collected by filtration and rinsed with a mixture of petroleum ether-ethyl acetate-MeOH (100:10:5) and dried *in vacuo* to yield the crude product (320 mg, 94.8% yield) as a brown solid. **ESI-MS** *m/z*: 354.9 [M + H]⁺.

6-Bromo-4-chloro-7-(2,4-difluorophenyl)-8-fluoroquinazoline

A mixture of 6-bromo-7-(2,4-difluorophenyl)-8-fluoroquinazolin-4-ol (320 mg, 0.901 mmol), SOCl₂ (3 mL) and DMF (cat.) was stirred at reflux for 1 h. The mixture was allowed to cool to RT and then concentrated *in vacuo* to yield the desired product as a brown solid which was used directly in next step without further purification.

tert-Butyl-4-(6-bromo-7-(2,4-difluorophenyl)-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate

The above obtained crude 6-bromo-4-chloro-7-(2,4-difluorophenyl)-8-fluoroquinazoline was added to the mixture of tert-butyl piperazine-1-carboxylate (344 mg, 1.80 mmol) and DIPEA (585 mg, 4.50 mmol) in dioxane (10 mL). The resulting mixture was stirred at reflux for 16 h and then was quenched with saturated NaHCO₃ aqueous solution. The mixture was extracted with dichloromethane. The organic layer was washed with saturated NaHCO₃ aqueous solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on

silica gel (ethyl acetate/petroleum ether = 2: 1) to yield the desired product (410 mg, 87% yield, 2 steps) as an off-white solid. **ESI-MS** m/z : 523.1 $[M + H]^+$.

tert-Butyl-4-(7-(2,4-difluorophenyl)-8-fluoro-6-methylquinazolin-4-yl)piperazine-1-carboxylate


5 To a solution of tert-butyl-4-(6-bromo-7-(2,4-difluorophenyl)-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate (200 mg, 0.382 mmol) and $Pd(PPh_3)_4$ (44 mg, 0.0382 mmol) in THF (4 mL) at RT under nitrogen atmosphere, dimethylzinc (1.147 mL, 1.147 mmol, 1.0 M in THF) was added. The resulting mixture was stirred at RT for 30 min and then stirred at 50 °C overnight. The mixture was allowed to cool to
10 RT, quenched with saturated NH_4Cl aqueous solution, and extracted with ethyl acetate. The organic layer was washed with saturated $NaHCO_3$ solution and brine, dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by Prep-HPLC to yield the desired product (90 mg, 51.3% yield) as an off-white solid. **ESI-MS** m/z : 459.2 $[M + H]^+$.

15 **1-(4-(7-(2,4-Difluorophenyl)-8-fluoro-6-methylquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one**

 The title compound was prepared from tert-butyl-4-(7-(2,4-difluorophenyl)-8-fluoro-6-methylquinazolin-4-yl)piperazine-1-carboxylate in two steps according to the procedure described in **Example 2**. **^1H NMR** (400 MHz, DMSO-
20 d_6) δ : 8.67 (s, 1H), 7.83 (s, 1H), 7.57-7.47 (m, 2H), 7.32-7.29 (m, 1H), 6.84 (dd, J = 10.4, 16.8, 1H), 6.18 (dd, J = 2.4, 16.8, 1H), 5.75 (dd, J = 2.0, 10.4, 1H), 3.87-3.77 (m, 8H), 2.26 (s, 3H). **ESI-MS** m/z : 413.2 $[M + H]^+$.

EXAMPLE 41

Synthesis of 1-(4-(7-(2,4-difluorophenyl)-6,8-difluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



5 Example 41 provides an exemplary preparation according to General Synthetic Method
Y

2-Bromo-1,3-difluoro-4-nitrobenzene

10 KNO_3 (5.20 g, 51.80 mmol) was added into a solution of 2-bromo-1,3-difluorobenzene (5.0 g, 26.0 mmol) in H_2SO_4 (30 mL) at) 0 °C and stirred at 25 °C for 18 h. The mixture was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with saturated NaHCO_3 aqueous solution and brine, dried over Na_2SO_4 and concentrated to yield the product as a yellow solid (5.0 g, 81% yield).

15 **3-Bromo-2,4-difluoroaniline**

To a mixture of 2-bromo-1,3-difluoro-4-nitrobenzene (5 g, 21.01 mmol), AcOH (5.70 g, 94.53 mmol), EtOH (100 mL) and H₂O (60 mL) at RT, iron powder (5.30 g, 94.53 mmol) was added in portions and the resulting mixture was stirred at RT for 16 h. The mixture was neutralized with NaOH (5 N) solution and then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (petroleum) to afford the desired product (1.60 g, 37% yield) as a brown oil.

N-(3-Bromo-2,4-difluorophenyl)-2-(hydroxyimino)acetamide


To a mixture of 3-bromo-2,4-difluoroaniline (1.60 g, 7.69 mmol), Na₂SO₄ (9.8 g, 68.77 mmol), 2,2,2-trichloroethane-1,1-diol (1 g, 5.82 mmol) and hydroxylamine hydrochloride (1.1 g, 15.87 mmol), the concentrated sulfuric acid (4 mL) was added. The resulting mixture was stirred at 130 °C for 2 h and yellow precipitate was formed. The mixture was cooled to RT. The solid was collected by filtration, rinsed with water, and dried in the air to afford the desired product (1.3 g, 61% yield).

1-(4-(6,8-Difluoro-7-(2,4-difluorophenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from N-(3-bromo-2,4-difluorophenyl)-2-(hydroxyimino)acetamide according to the procedure described in **Example 30**.
¹H NMR (400 MHz, CDCl₃) δ: 8.83 (s, 1H), 7.49-7.44 (m, 2H), 7.09-7.00 (m, 2H), 6.63 (dd, *J* = 10.5, 16.9 Hz, 1H), 6.39 (dd, *J* = 1.3, 16.8 Hz, 1H), 5.80 (dd, *J* = 1.4, 10.4 Hz, 1H), 3.91-3.86 (m, 8 H). **ESI-MS** *m/z*: 417.2 [M + H]⁺.

EXAMPLE 42

Synthesis of 1-(4-(6-chloro-7-(2,4-difluorophenyl)-8-hydroxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



20

Example 42 provides an exemplary preparation according to General Synthetic Method Z

tert-Butyl4-(7-bromo-6-chloro-8-methoxyquinazolin-4-yl)piperazine-1-carboxylate

To a solution of tert-butyl 4-(7-bromo-6-chloro-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate (45 mg, 0.10 mmol) in THF (8 mL) at RT, CH₃ONa (17 mg, 0.15 mmol) was added and the resulting mixture was stirred for 16 h. The mixture was poured into ice-water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by Prep-TLC to afford the desired product as a white solid (32 mg, 70% yield). **ESI-MS** *m/z*: 459.1 [M + H]⁺.

tert-Butyl4-(6-chloro-7-(2,4-difluorophenyl)-8-methoxyquinazolin-4-yl)piperazine-1-carboxylate

A mixture of tert-butyl4-(7-bromo-6-chloro-8-methoxyquinazolin-4-yl)piperazine-1-carboxylate (65 mg, 0.14 mmol), 2,4-difluorophenylboronic acid (25 mg, 0.15 mmol), Pd(PPh₃)₄ (16 mg, 0.014 mmol) and Na₂CO₃ (45 mg, 0.42 mmol) in 1,4-dioxane/H₂O (8 mL/2 mL) was stirred at 100 °C under argon for 16 h. The mixture was allowed to cool to RT and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (1% methanol/dichloromethane) to afford the desired product (17 mg, 25% yield) as a white solid. **ESI-MS** *m/z*: 491.2 [M + H]⁺.

6-Chloro-7-(2,4-difluorophenyl)-8-methoxy-4-(piperazin-1-yl)quinazoline

To a solution of tert-butyl4-(6-chloro-7-(2,4-difluorophenyl)-8-methoxyquinazolin-4-yl)piperazine-1-carboxylate (22 mg, 0.044 mmol) in dichloromethane (5 mL) at RT, TFA (1 mL) was added and the resulting mixture was stirred at RT for 1 h. The mixture was concentrated *in vacuo*. The resultant was quenched with NaHCO₃ solution, and the aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo* to afford the desired product as a white solid (17 mg, 100% yield).

1-(4-(6-Chloro-7-(2,4-difluorophenyl)-8-methoxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

To a solution of the above obtained crude 6-chloro-7-(2,4-difluorophenyl)-8-methoxy-4-(piperazin-1-yl)quinazoline (17 mg, 0.0448 mmol) in dichloromethane (10 mL) and Et₃N (14 mg, 0.134 mmol) at 0 °C, acryloyl chloride (5


mg, 0.05 mmol) was added and the resulting mixture was stirred at 0 °C for 2 h. The mixture was quenched with saturated NaHCO₃ aqueous solution, and then extracted with ethyl acetate. The organic layer was washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by Prep-TLC to yield the desired product (9 mg, 47% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ: 8.82 (s, 1H), 7.77 (s, 1H), 7.29-7.33 (m, 1H), 6.97-7.06 (m, 2H), 6.61-6.67 (m, 1H), 6.37-6.42 (m, 1H), 5.79-5.82 (m, 1H), 3.96 (s, 3H), 3.82-3.92 (m, 8H). **ESI-MS** m/z: 445.2 [M + H]⁺.

1-(4-(6-Chloro-7-(2,4-difluorophenyl)-8-hydroxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

To a solution of 1-(4-(6-chloro-7-(2,4-difluorophenyl)-8-methoxyquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one (53 mg, 0.119 mmol) in dichloromethane (10 mL) at -78 °C under nitrogen, BBr₃ (298 mg, 1.19 mmol) was added and the resulting mixture was stirred from at -78 °C to RT for 3 h. The mixture was cooled to -30°C, and NaHCO₃ solution was added. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by prep-TLC to afford the desired product as a white solid (17 mg, 33% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.70 (s, 1H), 7.61 (s, 1H), 7.37-7.46 (m, 2H), 7.20-7.24 (m, 1H), 6.80-6.87 (m, 1H), 6.15-6.20 (m, 1H), 5.72-5.76 (m, 1H), 3.76-3.86 (m, 8H). **ESI-MS** m/z: 431.1 [M + H]⁺.

EXAMPLE 43

Synthesis of 1-(4-(6-chloro-7-(2-fluoro-6-hydroxyphenyl)-5-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



- 5 Example 43 provides an exemplary preparation according to General Synthetic Method AA

5-Bromo-2-methyl-1-nitro-3-(trifluoromethyl)benzene

- 2-Methyl-1-nitro-3-(trifluoromethyl)benzene (1 g, 4.87 mmol) was dissolved in concentrated sulfuric acid (15 mL), 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (836 mg, 2.92 mmol) was added in portions and the resulting mixture was stirred at RT for 2 h. The reaction mixture was poured into ice water, stirred for 10 min, and then extracted with ethyl acetate. The combined organic layer was washed with water, saturated NaHCO₃ solution and brine, dried over Na₂SO₄, and concentrated *in vacuo* to afford the crude product (1.1 g).

5-Bromo-2-(bromomethyl)-1-nitro-3-(trifluoromethyl)benzene

- NBS (12.6 g, 70.61 mmol) was added into a solution of 5-bromo-2-methyl-1-nitro-3-(trifluoromethyl)benzene (19 g, 67.25 mmol) and BPO (1.63 g, 6.73 mmol) in CCl₄ (200 mL). The mixture was stirred at reflux under argon for 18 h. The resulting mixture was concentrated and the residue was purified by column chromatography eluting with petroleum ether to yield the product (14 g, 58% yield).

4-Bromo-2-nitro-6-(trifluoromethyl)benzaldehyde

To a mixture of 5-bromo-2-(bromomethyl)-1-nitro-3-(trifluoromethyl)benzene (14 g, 38.88 mmol) and 4 Å molecular sieves (25 g) in MeCN (120 mL) at RT, N-methylmorpholine N-oxide (9.2 g, 82.14 mmol) was added and the
5 resulting mixture was stirred under argon for 1.5 h. The mixture was diluted with ethyl acetate and filtered. The filtrate was washed with H₂O, 1 N HCl and brine, dried over Na₂SO₄ and concentrated *in vacuo* to give the desired product (4.1 g, 37% yield) which was used in the next step without further purification.

4-Bromo-2-fluoro-6-nitrobenzoic acid

To a solution of 4-bromo-2-nitro-6-(trifluoromethyl)benzaldehyde (4.1 g, 13.75 mmol) in a mixture of THF, H₂O and t-BuOH at -5 °C, NaClO₂ (4.97 g, 55.03 mmol) and NaH₂PO₄ (6.6 g, 55.03 mmol) were added. The mixture was treated with 2-methylbut-2-ene (6.75 g, 96.25 mmol) dropwise. The reaction was stirred at 0 °C for 1.5 h and concentrated *in vacuo*. The residue was diluted with water, acidified with 2 N
10 HCl to pH 4-5 and then extracted with ethyl acetate. The organic layer was washed with water and brine, dried over Na₂SO₄, and concentrated to afford crude product (4.4 g) which used in next step directly.

2-Amino-4-bromo-6-(trifluoromethyl)benzoic acid

To a solution of 4-bromo-2-fluoro-6-nitrobenzoic acid (4.4 g, 12.9 mmol) in a mixture of AcOH (40 mL) and H₂O (20 mL), Fe (3.6 g, 64.5 mmol) was added and the resulting mixture was stirred at RT for 2 h. The mixture was poured into water, and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na₂SO₄, and concentrated *in vacuo* to afford the target product (3.1 g) without further purification.

Methyl 2-amino-4-bromo-6-(trifluoromethyl)benzoate

Cs₂CO₃ (4.82 g, 14.79 mmol) was added into a solution of 2-amino-4-bromo-6-(trifluoromethyl)benzoic acid (2.8 g, 9.86 mmol) in DMF (30 mL), and the resulting mixture was stirred at RT for 40 min. To this mixture, CH₃I (1.4 g, 9.86 mmol) was added dropwise and stirring was continued at RT for 16 h. The mixture was
25 poured into water and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified

by flash column chromatography on silica gel (ethyl acetate/petroleum ether = 1:10) to yield the desired product (2.9 g, 97% yield) as a yellow solid.

Methyl 6-amino-4-bromo-3-chloro-2-(trifluoromethyl)benzoate

To a solution of methyl 2-amino-4-bromo-6-(trifluoromethyl)benzoate (2.8 g, 9.39 mmol) in isopropyl alcohol (45 mL) at RT, NCS (1.51 g, 11.28 mmol) was added in portions and the resulting mixture was stirred at reflux for 16 h. The mixture was allowed to cool to RT and the residue was purified by flash column chromatography on silica (ethyl acetate/petroleum ether = 1:20) to afford the desired product (860 mg, 27% yield).

1-(4-(6-Chloro-7-(2-fluoro-6-hydroxyphenyl)-5-(trifluoromethyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one


The title compound was prepared from methyl 6-amino-4-bromo-3-chloro-2-(trifluoromethyl)benzoate according to the procedure described in **Example 30**.

¹H NMR (400 MHz, DMSO-*d*₆) δ: 10.29 (s, 1H), 8.50 (s, 1H), 7.93 (s, 1H), 7.35-7.33 (m, 1H), 6.91-6.89 (m, 1H), 6.83-6.76 (m, 1H), 6.17-6.12 (dd, *J* = 2.0, 16.8 Hz, 1H), 5.74-5.70 (dd, *J* = 2.4, 10.4 Hz, 1H), 3.88 (s, 4H), 3.66-3.64 (m, 2H), 3.46 (m, 2H).
ESI-MS *m/z*: 481.3 [M + H]⁺.

20

EXAMPLE 44

Synthesis of 4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(5-methyl-1H-indazol-4-yl)quinolin-2(1H)-one



Example 44 provides an exemplary preparation according to General Synthetic Method AB

7-Bromo-4,6-dichloroquinoline N-oxide

5 To a stirred solution of 7-bromo-4,6-dichloroquinoline (500 mg, 1.82 mmol) in DC under argon, UHP (359 mg, 3.82 mmol) was added. The mixture was cooled to 0 °C, and TFA (415 mg, 3.64 mmol) was added. The resulting mixture was stirred at RT for 16 h. The mixture was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to afford the desired product (450 mg, 85%
10 yield). **ESI-MS** *m/z*: 292.3 [M + H]⁺.

7-Bromo-2,4,6-trichloroquinoline

The mixture of 7-bromo-2,4,6-trichloroquinolin N-oxide (450 mg, 1.55 mmol) in POCl₃ (20 mL) was stirred at reflux for 1 h. The mixture was concentrated to dryness and the residue was partitioned between water and ethyl acetate. The organic
15 layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (ethyl acetate/petroleum ether = 1:5) to afford the desired product (400 mg, 84% yield) as solid. **ESI-MS** *m/z*: 310.1 [M+H]⁺.

7-Bromo-4,6-dichloroquinolin-2(1H)-one

20 The mixture of 7-bromo-2,4,6-trichloroquinolin (400 mg, 1.29 mmol) in 20% H₂SO₄ (10 mL) and dioxane (10 mL) was stirred at 140 °C for 8 h. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to afford the desired product (250 mg, 66% yield) as solid. **ESI-MS** *m/z*: 292.1[M+H]⁺.

25 tert-Butyl 4-(7-bromo-6-chloro-1,2-dihydro-2-oxoquinolin-4-yl)piperazine-1-carboxylate

A mixture of 7-bromo-4,6-dichloroquinolin-2(1H)-one (250 mg, 0.856 mmol) and tert-butyl piperazine-1-carboxylate (796 mg, 4.28 mmol) in n-BuOH (10 mL) was stirred at 150 °C in a sealed tube for 24 h. The mixture was quenched with
30 water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column


chromatography on silica gel (dichloromethane/MeOH = 30:1) to afford the desired product (180 mg, 47% yield) as solid. **ESI-MS** m/z : 442.1[M+H]⁺.

4-(4-Acryloylpiperazin-1-yl)-6-chloro-7-(5-methyl-1H-indazol-4-yl)quinolin-2(1H)-one

5 The title compound was prepared from tert-butyl 4-(7-bromo-6-chloro-1,2-dihydro-2-oxoquinolin-4-yl)piperazine-1-carboxylate according to the procedure described in **Examples 2**. ¹H NMR (400 MHz, DMSO-*d*₆) δ : 13.15 (s, 1H), 11.60 (s, 1H), 7.86 (s, 1H), 7.55 (m, 1H), 7.52 (s, 1H), 7.35 (m, 1H), 7.25 (s, 1H), 6.90-6.84 (dd, J = 12.0, 16.4 Hz, 1H), 6.20-6.15 (dd, J = 2.4, 16.8 Hz, 1H), 6.02 (s, 1H), 5.77-5.74 (dd, J = 2.1, 10.0 Hz, 1H), 3.86-3.83 (m, 4H), 3.13 (m, 4H), 2.17(s, 3H). **ESI-MS** m/z : 450.2 [M+H]⁺.

EXAMPLE 45

15 **Synthesis of 1-(4-(6-chloro-2-(2-(dimethylamino)ethylamino)-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one**



Example 44 provides an exemplary preparation according to General Synthetic Method

20 AC

7-Bromo-6-chloro-8-fluoroquinazoline-2,4(1H,3H)-dione

A mixture of methyl 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid (10.0 g, 39.9 mmol) and urea (12 g, 199.6 mmol) was stirred at 200 °C for 3 h. The mixture was allowed to cool to RT, triturated with ethyl acetate and dried to afford the
5 crude product (13g) as a brown solid.

7-Bromo-2,4,6-trichloro-8-fluoroquinazoline

The mixture of 7-bromo-6-chloro-8-fluoroquinazoline-2,4(1H,3H)-dione (13 g, 44.5 mmol) in POCl₃ (200 mL) and DIPEA (20 mL) was stirred at reflux for 16 h. The mixture was allowed to cool to RT and concentrated *in vacuo* to remove POCl₃.
10 The residue was purified by flash chromatography on silica gel (5% ethyl acetate / petroleum ether) and then washed by HCl (1M) to afford the product (10.4 g, 74% yield) as a yellow solid.

4-(7-Bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate

To a solution of 7-bromo-2,4,6-trichloro-8-fluoroquinazoline (10.4 g, 33.3 mmol) and DIEA (29 mL, 167 mmol) in 1,4-dioxane (100 mL) at RT, tert-butyl piperazine-1-carboxylate (6.2 g, 33.3 mmol) was added. The resulting mixture was stirred at 50 °C for 20 min. The mixture was allowed to cool to RT and partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on
20 silica gel (MeOH/dichloromethane =1:200) to afford the desired product (6 g, 40% yield) as a yellow solid. ESI-MS *m/z*: 447.2 [M + H]⁺.

tert-Butyl 4-(2-(2-(dimethylamino)ethylamino)-7-bromo-6-chloro-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate

To a stirred solution of tert-butyl 4-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl) piperazine-1-carboxylate (300 mg, 0.63 mmol) in propan-2-ol (10 mL), DIEA (243 mg, 1.88 mmol) and *N*¹, *N*¹-dimethylethane-1,2-diamine (166 mg, 1.88 mmol) were added and the resulting mixture was stirred at 95 °C overnight. The mixture was allowed to cool to RT, and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*.
30 The residue was purified by flash column chromatography on silica gel (1 - 5% MeOH

/dichloromethane) to afford the desired product (230 mg, 69% yield) as a white solid.

ESI-MS m/z : 531.3 $[M+H]^+$.


1-(4-(2-(2-(Dimethylamino)ethylamino)-6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

- 5 The title compound was prepared from tert-butyl 4-(2-(2-(dimethylamino)ethylamino) - 6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazine-1-carboxylate in three steps following the procedure described in **Example 2**.

^1H NMR (400 MHz, DMSO- d_6) δ : 13.16 (s, 1H), 7.81 (s, 1H), 7.56-7.58 (m, 2H), 7.37-7.39 (m, 1H), 6.96-7.32 (m, 1H), 6.82-6.89 (m, 1H), 6.17 (dd, $J = 2.2$, 16.5 Hz, 1H), 5.74 (dd, $J = 2.1$, 10.3 Hz, 1H), 3.72-3.84 (m, 8H), 3.45 (m, 2H), 2.42-2.45 (m, 2H), 2.17-2.21 (m, 9H). ESI-MS m/z : 537.4 $[M + H]^+$.

EXAMPLE 46

Synthesis of 1-(4-(6-chloro-2-((dimethylamino)methyl)-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



Example 46 provides an exemplary preparation according to General Synthetic Method AD

Methyl 2-amino-4-bromo-5-chloro-3-fluorobenzoate

A mixture of 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid (1.0 g, 3.746 mmol) in CH₃OH (30 mL), SOCl₂ (4.457g, 37.46 mmol) was added dropwise and the resulting mixture was stirred at 100 °C for 16 h. The solvent was removed and the residue was dissolved in ethyl acetate. The organic layer was washed with saturated NaHCO₃ aqueous solution and brine, dried over Na₂SO₄ and concentrated. The residue

was purified by column chromatography (ethyl acetate/petroleum ether = 1:10) to afford the product as a pink solid (848 mg, 81% yield).

7-Bromo-6-chloro-2-(chloromethyl)-8-fluoroquinazolin-4-ol

A mixture of methyl 2-amino-4-bromo-5-chloro-3-fluorobenzoate (500 mg, 1.779 mmol) and 2-chloroacetonitrile (667 mg, 8.895 mmol) in dioxane (30 mL) was bubbled with HCl gas at RT for 1 h, and the resulting mixture was stirred at 80 °C for 16 h. The mixture was allowed to cool to RT and then Et₂O (20 mL) was added to it. After stirring for 1 h, the mixture was filtered and the white solid was collected. The white solid was dissolved in ethyl acetate and washed with saturated NaHCO₃ aqueous solution and brine. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo* to afford the product as a white solid (605 mg, 104% yield).

7-Bromo-4,6-dichloro-2-(chloromethyl)-8-fluoroquinazoline

A mixture of 7-bromo-6-chloro-2-(chloromethyl)-8-fluoroquinazolin-4-ol (300 mg, 0.925 mmol) and DIEA (3 mL) in POCl₃ (30 mL) was stirred at 130 °C for 16 h. The mixture was concentrated *in vacuo* and azeotroped with toluene. The residue was purified by column chromatography on silica gel (ethyl acetate/petroleum ether = 1:6) to afford the product as an orange color solid (320 mg, 100% yield).

tert-Butyl-4-(7-bromo-6-chloro-2-(chloromethyl)-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate

A mixture of 7-bromo-4,6-dichloro-2-(chloromethyl)-8-fluoroquinazoline (320 mg, 0.936 mmol) and tert-butyl piperazine-1-carboxylate (260 mg, 1.397 mmol) in *i*-PrOH (30 mL) was stirred at 75 °C for 1 h. The mixture was concentrated *in vacuo*. The residue was dissolved in ethyl acetate, washed with saturated NaHCO₃ aqueous solution and brine, dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate/petroleum ether = 1:4) to afford the product as a yellow solid (422 mg, 92% yield). ESI-MS *m/z*: 495.2 [M+H]⁺.

tert-Butyl-4-(7-bromo-6-chloro-2-((dimethylamino)methyl)-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate

A mixture of 7-bromo-4,6-dichloro-2-(chloromethyl)-8-fluoroquinazoline (422 mg, 0.857 mmol) and dimethylamine (2.0 M in THF, 4.7 mL)

was stirred at 80 °C for 16 h. The mixture was diluted with ethyl acetate, washed with saturated NaHCO₃ aqueous solution and brine, dried over Na₂SO₄ and concentrated.

The residue was purified by column chromatography on silica gel

(dichloromethane/MeOH = 30:1) to afford the product as an orange color thick oil (437

5 mg, 100% yield). ESI-MS *m/z*: 504.2 [M+H]⁺.


1-(4-(6-Chloro-2-((dimethylamino)methyl)-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from tert-butyl-4-(7-bromo-6-chloro-2-((dimethylamino)methyl)-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate in three steps according to the procedure described in **Example 2**. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 13.24 (s, 1H), 8.15 (s, 1H), 7.62 (m, 2H), 7.42 (m, 1H), 6.88 (dd, *J*₁ = 10.4 Hz, *J*₂ = 16.8 Hz, 1H), 6.22 (dd, *J*₁ = 2.4 Hz, *J*₂ = 17.2 Hz, 1H), 5.78 (dd, *J*₁ = 2.4 Hz, *J*₂ = 10.4 Hz, 1H), 4.33 (s, 2H), 4.05 (m, 8H), 2.82 (s, 6H), 2.17 (s, 3H). ESI-MS *m/z*: 508.2[M + H]⁺.

15

EXAMPLE 47

Synthesis of 1-(4-(6-chloro-5-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



Example 47 provides an exemplary preparation according to General Synthetic Method AE

5-Bromo-2-methyl-1,3-dinitrobenzene

5 To a solution of 2-methyl-1,3-dinitrobenzene (10 g, 54.91 mmol) in concentrated sulfuric acid (150 mL), 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (9.42 g, 32.94 mmol) was added and the resulting mixture was stirred at RT for 2 h. The mixture was poured into ice-water, stirred for 10 min, and then extracted with ethyl acetate. The combined organic layer was washed with water, saturated NaHCO₃ solution and brine, dried over Na₂SO₄, concentrated to afford the crude product (15 g).

5-Bromo-2-methyl-3-nitroaniline

To a mixture of 5-bromo-2-methyl-1,3-dinitrobenzene (11.2 g, 42.91 mmol) and pyridine (15.6 g, 197.47 mmol) in EtOH (230 mL), (NH₄)₂S (39 g, 22% in water) was added dropwise over 1 h. The mixture was concentrated *in vacuo*. The residue was diluted with water and stirred at 0 °C for 10 min. The solid was collected by filtration, rinsed with water, and dried under vacuum to afford 10.5 g crude product.

5-Bromo-1-fluoro-2-methyl-3-nitrobenzene

To a mixture of 5-bromo-2-methyl-3-nitroaniline (9.5 g, 41.12 mmol) and BF₃-Et₂O (8.7 g, 61.67 mmol) in THF (30 mL) and dichloromethane (60 mL) at -10 °C, tert-butyl nitrite (5.1 g, 49.34 mmol) was added dropwise and the resulting mixture was stirred at 0 °C for 1.5 h. The mixture was diluted with dichloromethane (200 mL) and stirred for 5 min. The solid was collected by filtration and dried *in vacuo*. The crude product was mixed with sand and heated to 120 °C for 40 min. The mixture was allowed to cool to RT, and then rinsed with dichloromethane. The organic layer was concentrated *in vacuo* and the residue was purified by column chromatography on silica gel (petroleum ether) to yield the product (3.6 g, 37.5% yield).

5-Bromo-2-(bromomethyl)-1-fluoro-3-nitrobenzene

To a solution of 5-bromo-1-fluoro-2-methyl-3-nitrobenzene (11.2 g, 47.86 mmol) and BPO (1.2 g, 4.79 mmol) in CCl₄ (150 mL), NBS (10.2 g, 57.43 mmol) was added and the resulting mixture was stirred at reflux under argon for 18 h. The

mixture was concentrated *in vacuo* and the residue was purified by column chromatography on silica gel (petroleum ether) to yield the product (11.7 g, 78% yield).

4-Bromo-2-fluoro-6-nitrobenzaldehyde

To a mixture of 5-bromo-2-(bromomethyl)-1-fluoro-3-nitrobenzene (10 g, 41.28 mmol) and 4 Å molecular sieves (25 g) in MeCN (120 mL) at RT, N-methylmorpholine N-oxide (9.2 g, 82.14 mmol) was added and the resulting mixture was stirred under argon for 1.5 h. The mixture was diluted with ethyl acetate and filtered. The filtrate was washed with H₂O, 1 N HCl and brine. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo* to afford the product (6.82 g, 67%) which was used in the next step without further purification.

4-Bromo-2-fluoro-6-nitrobenzoic acid

To a solution of 4-bromo-2-fluoro-6-nitrobenzaldehyde (4 g, 16.13 mmol) in THF-H₂O-t-BuOH at -5 °C, NaClO₂ (5.83 g, 64.51 mmol) and NaH₂PO₄ (7.74 g, 64.51 mmol) were added followed by addition of 2-methylbut-2-ene (7.92 g, 112.91 mmol) dropwise. The mixture was stirred at 0 °C for 1.5 h and concentrated *in vacuo*. The residue was diluted with water and acidified with 2 N HCl to pH 4-5. The mixture was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over Na₂SO₄, and concentrated *in vacuo* to afford the crude product (4.8 g) which was used in the next step directly.

2-Amino-4-bromo-6-fluorobenzoic acid

To a solution of 4-bromo-2-fluoro-6-nitrobenzoic acid (4.8 g, 18.18 mmol) in AcOH (40 mL) and H₂O (20 mL), Fe (5.1 g, 90.9 mmol) was added and the resulting mixture was stirred at RT for 2 h. The mixture was poured into water, and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over Na₂SO₄, and concentrated *in vacuo* to afford the crude product (2.75 g) which was used in the next step without further purification.

Methyl 2-amino-4-bromo-6-fluorobenzoate

To a solution of 2-amino-4-bromo-6-fluorobenzoic acid (2.75 g, 11.75 mmol) in DMF (40 mL), Cs₂CO₃ (5.74 g, 17.63 mmol) was added and the resulting mixture was stirred at RT for 40 min. To this mixture, CH₃I (1.75 g, 12.33 mmol) was added dropwise and the resulting mixture was stirred at RT for 16 h. The mixture was

poured into water and extracted with ethyl acetate. The organic layer was washed with water and brine, dried Na_2SO_4 , and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (ethyl acetate/petroleum ether = 1:15) to yield the desired product (2.32 g, 80% yield) as a yellow solid.

5 **Methyl 6-amino-4-bromo-3-chloro-2-fluorobenzoate**

To a solution of methyl 2-amino-4-bromo-6-fluorobenzoate (3.8 g, 15.48 mmol) in isopropyl alcohol (45 mL) at RT, NCS (2.2 g, 16.25 mmol) was added in portions and the resulting mixture was stirred at reflux for 4 h. The mixture was concentrated *in vacuo* and the residue was purified by flash column chromatography on
10 silica gel (ethyl acetate/petroleum ether = 1:30) to yield the desired product (1.68 g, 38% yield).

6-Amino-4-bromo-3-chloro-2-fluorobenzoic acid


To a solution of methyl 6-amino-4-bromo-3-chloro-2-fluorobenzoate (200 mg, 0.71 mmol) in a mixture of THF (5 mL), H_2O (2 mL) and MeOH (1 mL),
15 $\text{LiOH}\cdot\text{H}_2\text{O}$ (297 mg, 7.08 mmol) was added. The resulting mixture was stirred at RT for 2 h. The mixture was concentrated *in vacuo*. The residue was diluted with water and acidified with 2 N HCl to pH 4-5. The mixture was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over Na_2SO_4 , and concentrated *in vacuo* to afford the desired product (189 mg, 100% yield).

20 **1-(4-(6-Chloro-5-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one**

The title compound was prepared from 6-amino-4-bromo-3-chloro-2-fluorobenzoic acid according to the procedure described in **Example 30**. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 10.22 (s, 1H), 8.66 (s, 1H), 7.65 (s, 1H), 7.31-7.37 (m, 1H), 6.88-
25 6.79 (m, 3H), 6.19-6.14 (dd, $J = 2.0, 16.8$ Hz, 1H), 5.75-5.72 (dd, $J = 2.4, 10.4$ Hz, 1H), 3.78-3.70 (m, 8H). **ESI-MS** m/z : 431.4 $[\text{M} + \text{H}]^+$.

EXAMPLE 48

Synthesis of 1-(4-(6-chloro-7,8'-biquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



Example 48 provides an exemplary preparation according to General Synthetic Method

5 AF

(4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-6-chloroquinazolin-7-yl)boronic acid

The mixture of tert-butyl 4-(7-bromo-6-chloroquinazolin-4-yl)piperazine-1-carboxylate (1.45 g, 1.0 eq), bis(pinacolato)diboron (2.02 g, 2.3 eq.), and potassium acetate (1.66 g, 5.0 eq) in dioxane was degassed via nitrogen gas. After adding PdCl₂(dppf) (306 mg, 0.11 eq.), the reaction mixture was degassed again via nitrogen gas. The resulting mixture was stirred at 120 °C for 2 h. The mixture was allowed to cool to RT, diluted with EtOAc, washed with water, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel to afford the desired product in 43% yield.

tert-Butyl 4-(6-chloro-[7,8'-biquinazolin]-4-yl)piperazine-1-carboxylate

To a solution of (4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-6-chloroquinazolin-7-yl)boronic acid (108 mg, 1.0 eq.) in dioxane (4 mL) in the sealed tube, 8-bromoquinazoline (79 mg, 1.3 eq.), PdCl₂(dppf) (26 mg, 0.1 eq.) and aqueous Na₂CO₃ (1M, 2 mL) we added. The resulting mixture was stirred at 120 °C for 5 min in the Microwave Reactor. After cooling down, it was filtered and partitioned between EtOAc and water. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was used directly in the next step.


1-(4-(6-chloro-[7,8'-biquinazolin]-4-yl)piperazin-1-yl)prop-2-en-1-one

TFA (1 mL) was added into above obtained tert-butyl 4-(6-chloro-[7,8'-biquinazolin]-4-yl)piperazine-1-carboxylate (131 mg, 1.0 eq.) in DCM (10 mL). The reaction mixture was stirred at RT for 1 h. The mixture was concentrated *in vacuo*.

To a solution of above obtained crude compound in Et₃N (0.5 mL, 13.0 eq) and dichloromethane (10 mL), acryloyl chloride (0.062 mL, 2.8 eq.) was added and the resulting mixture was stirred at RT for 1.5 h. The mixture was concentrated *in vacuo* to remove the DCM. The residue was dissolved in EtOAc. It was washed with water,
 5 dried over Na₂SO₄ and concentrated *in vacuo*. After column purification, the desired product was obtained in 44% yield over three steps from (4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-6-chloroquinazolin-7-yl)boronic acid. ¹H NMR (500 MHz, DMSO-*d*₆) δ: 9.73 (s, 1H), 9.26 (s, 1H), 8.700 (s, 1H), 8.32 (dd, *J* = 8, 1.5 Hz, 1H), 8.20 (s, 1H), 8.09 (dd, *J* = 7, 1.5 Hz, 1H), 7.92 (t, *J* = 8 Hz, 1H), 7.891 (s, 1H),
 10 6.84 (dd, , *J* = 17, 10.5Hz, 1H), 6.18 (dd, *J* = 17, 2.5 Hz, 1H), 5.75 (dd, *J* = 10.5, 2.5Hz, 1H), 3.92-3.79 (m, 8H). ESI-MS *m/z*: 431.1 [M + H]⁺.

EXAMPLE 49

Synthesis of 1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(thiazol-5-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



Example 49 provides an exemplary preparation according to General Synthetic Method AG

20

tert-Butyl 4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(thiazol-5-yl)quinazolin-4-yl)piperazine-1-carboxylate

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-thiazole (67 mg, 1.1 eq.) and tetrakis (158 mg, 0.5 eq.) were added into *tert*-butyl 4-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate (133 mg, 1.0 eq.) in dioxane (6 mL)
 25 and aqueous Na₂CO₃ (1 M, 3 mL) in the sealed tube. The reaction mixture was stirred at 120 °C in the Microwave Reactor for 15 min. After cooling down, into this mixture (5-methyl-1H-indazol-4-yl)boronic acid (267 mg, 5.1 eq.), tetrakis (164 mg, 0,5 eq.), 4 mL


of dioxane, and 2 mL of aqueous Na₂CO₃ (1M) were added. The resulting mixture was stirred at 120 °C in the Microwave Reactor for 45 min. After cooling down, it was filtered and partitioned between EtOAc and water. The organic layer was dried over Na₂SO₄, and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (dichloromethane / methanol = 10 : 1) to afford the desired product (88 mg, 55% yield) as a solid. **ESI-MS** *m/z*: 580 [M + H]⁺.

1-(4-(6-Chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(thiazol-5-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

The title compound was prepared from tert-butyl 4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-(thiazol-5-yl)quinazolin-4-yl)piperazine-1-carboxylate in two steps according to the procedure described in **Example 46**. ¹H NMR (500MHz, DMSO-*d*₆) δ: 13.19 (s, 1H), 9.22 (s, 1H), 8.70 (s, 1H), 8.12 (s, 1H), 7.60 (d, *J* = 8.5 Hz, 1H), 7.59 (s, 1H), 7.41 (d, *J* = 8.5 Hz, 1H), 6.84 (dd, *J* = 17, 10.5 Hz, 1H), 6.18 (dd, *J* = 17, 2.5 Hz, 1H), 5.76 (dd, *J* = 10.5, 2.5Hz, 1H), 4.06-3.82 (m, 8H), 2.18 (s, 3H). **ESI-MS** *m/z*: 534.1 [M + H]⁺.

EXAMPLE 50

Synthesis of 1-(4-(6-chloro-8-fluoro-7-(3-fluoro-5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one



Example 50 provides an exemplary preparation according to General Synthetic Method AH

1-(4-(6-chloro-8-fluoro-7-(3-fluoro-5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one


A mixture of 1-(4-(6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one (45.1 mg, 0.1 mmol) and Selectfluor

(53 mg, 0.15 mmol) in acetonitrile (5 mL) was stirred at 120 °C for 2 h. The mixture was allowed to cool to RT and partitioned between DCM and water. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel via Isolera One (MeOH/DCM = 0- 5%) to afford the
 5 desired product (4.4 mg). ¹H NMR (500 MHz, CDCl₃) δ: 1H NMR (CDCl₃): 8.84 (s, 1H), 7.88 (s, 1H), 7.40-7.46 (m, 2H), 6.63 (dd, J = 8.4, 13.2 Hz, 1H), 6.40 (d, J = 13.6 Hz, 1H), 5.78 (d, J = 8.4 Hz, 1H), 3.75-4.01 (m, 8H), 2.24 (s, 1H). ESI-MS *m/z*: 469.1 [M+H]⁺.

10

EXAMPLE 51

Synthesis of 4-(4-acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazoline-2-carbonitrile



tert-Butyl 4-(2-(acetoxymethyl)-7-bromo-6-chloro-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate
 15

A mixture of tert-butyl 4-(7-bromo-6-chloro-2-(chloromethyl)-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate (288 mg, 0.59 mmol) in DMSO (10 mL), NaOAc (143 mg, 1.75 mmol) was added and the resulting mixture was stirred at 80 °C for 2 h. The mixture was partitioned between ethyl acetate and water. The
 20 organic layer was washed with sat. NaHCO₃ and brine, dried over Na₂SO₄ and

concentrated in vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate/petroleum ether = 1:2) to afford the product (306 mg, 100% yield).

ESI-MS m/z : 519.2 $[M+H]^+$.

tert-Butyl 4-(7-bromo-6-chloro-8-fluoro-2-(hydroxymethyl)quinazolin-4-yl)piperazine-1-carboxylate

A mixture of tert-butyl 4-(2-(acetoxymethyl)-7-bromo-6-chloro-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate (306 mg, 0.59 mmol), LiOH.H₂O (99 mg, 2.64 mmol) in THF (30 mL) and H₂O (10 mL) was stirred at RT for 1 h. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated in vacuo to afford the product (286 mg, 100% yield). **ESI-MS** m/z : 477.2 $[M+H]^+$.

tert-Butyl 4-(7-bromo-6-chloro-8-fluoro-2-formylquinazolin-4-yl)piperazine-1-carboxylate

A mixture of tert-butyl 4-(7-bromo-6-chloro-8-fluoro-2-(hydroxymethyl)quinazolin-4-yl)piperazine-1-carboxylate (286 mg, 0.60 mmol) and MnO₂ (523 mg, 6.01 mmol) in dichloromethane (30 mL) was stirred at 60 °C for 16 h. The mixture was purified by column chromatography on silica gel (ethyl acetate/petroleum ether = 1:1) to afford the product as an orange color solid (212 mg, 74.5% yield). **ESI-MS** m/z : 505.2 $[M+H]^+$.

7-Bromo-4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-6-chloro-8-fluoroquinazoline-2-carboxylic acid

To a mixture of tert-butyl 4-(7-bromo-6-chloro-8-fluoro-2-formylquinazolin-4-yl) piperazine-1-carboxylate (212 mg, 0.45 mmol) in THF (10 mL), t-BuOH (10 mL), DCM (5 mL) and H₂O (10 mL) at 0 °C, NaH₂PO₄ (215 mg, 1.79 mmol) and NaClO₂ (162 mg, 1.79 mmol) were added and resulting mixture was stirred at 0 °C for 1 h. To this mixture, 2-methylbut-2-ene (219 mg, 3.13 mmol) was added and stirring was continued for 1 h. The mixture was concentrated *in vacuo* and the residue was diluted with 1M HCl (30 mL) and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo* to afford the crude product as a yellow solid (257 mg) which was used in the next step directly without purification. **ESI-MS** m/z : 489.1 $[M+H]^+$.

tert-Butyl 4-(7-bromo-2-carbamoyl-6-chloro-8-fluoroquinazolin-4-yl)piperazine-1-carboxylate

To a mixture of 7-bromo-4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-6-chloro-8-fluoroquinazoline-2-carboxylic acid (257 mg, 0.53 mmol), NH₄Cl (112 mg, 2.10 mmol), BOP (464 mg, 1.05 mmol) in DMF (10 mL) at RT, DIEA (271 mg, 2.10 mmol) in DCM (5 mL) was added dropwise. The mixture was stirred for 1 h. The mixture was extracted with ethyl acetate, washed with sat.NaHCO₃ and brine. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH = 40:1) to afford the product as a yellow solid (163 mg, 63.5% yield). **ESI-MS** *m/z*: 490.1 [M+H]⁺.

tert-Butyl 4-(2-carbamoyl-6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazine-1-carboxylate

A mixture of tert-butyl 4-(7-bromo-2-carbamoyl-6-chloro-8-fluoroquinazolin-4-yl) piperazine-1-carboxylate (80 mg, 0.16 mmol), (3-hydroxynaphthalen-1-yl)boronic acid (34 mg, 0.18 mmol), Na₂CO₃ (86 mg, 0.82 mmol), Pd(PPh₃)₄ (19 mg, 0.016 mmol) in dioxane (15 mL) and H₂O (5 mL) was stirred at 100 °C for 16 h. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with sat.NaHCO₃ and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (dichloromethane / MeOH = 30 : 1) to afford the product as a yellow solid (35 mg, 40.2% yield). **ESI-MS** *m/z*: 552.2 [M+H]⁺.

4-(4-Acryloylpiperazin-1-yl)-6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazoline-2-carboxamide

A mixture of tert-butyl-4-(2-carbamoyl-6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazine-1-carboxylate (35 mg, 0.066 mmol) in dichloromethane (10 mL) and CF₃COOH (2 mL) was stirred at R.T. for 0.5 h. The mixture was concentrated *in vacuo*. The residue was dissolved in dichloromethane (20 mL) and Et₃N (32 mg, 0.317 mmol). The mixture was stirred at -78 °C and acryloyl chloride (5.4 mg, 0.063 mmol) in dichloromethane (0.8 mL) was added dropwise. The mixture was stirred at -78 °C for 5 min and quenched with sat.NaHCO₃. The mixture


was extracted with dichloromethane. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (dichloromethane / MeOH = 40 : 1 to 15 : 1) to afford the product as a white solid (33 mg). **ESI-MS** *m/z*: 506.2 [M+H]⁺.

5 **4-(4-Acryloylpiperazin-1-yl)-6-chloro-7-(3-hydroxynaphthalen-1-yl)quinazoline-2-carbonitrile**

To a stirred mixture of 4-(4-acryloylpiperazin-1-yl)-6-chloro-7-(3-hydroxynaphthalen-1-yl) quinazoline-2-carboxamide (33 mg, 0.065 mmol) and Et₃N (33 mg, 0.326 mmol) in dichloromethane (20 mL) at RT, (CF₃CO)₂O (68 mg, 0.326 mmol) was added and the resulting mixture was stirred for 0.5 h. The mixture was quenched with sat.NaHCO₃ and extracted with dichloromethane. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (dichloromethane /MeOH = 40:1) to afford the product as a white solid (6 mg, 18.8% yield). **¹H NMR** (400 MHz, DMSO-*d*₆) δ: 10.11 (s, 1H), 8.21 (s, 1H), 7.84 (m, 2H), 7.48-7.10 (m, 5H), 6.86 (dd, *J* = 10.4 Hz, *J* = 16.8 Hz, 1H), 6.22 (dd, *J* = 2.0 Hz, *J* = 16.4 Hz, 1H), 5.78 (dd, *J* = 2.4 Hz, *J* = 10.8 Hz, 1H), 4.10 (m, 4H), 3.89 (m, 4H). **ESI-MS** *m/z*: 488.2 [M +H]⁺.

EXAMPLE 52

20 **Synthesis of 1-(4-(6-chloro-8-fluoro-7-(2-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one**



25 **1-(4-(6-Chloro-8-fluoro-7-(2-methoxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one**

(2-Methoxynaphthalen-1-yl)boronic acid (904 mg, 98%, 5.88 eq.) and tetrakis (431 mg, 0.5 eq.) were added into a mixture of 1-(4-(7-bromo-6-chloro-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one (297 mg, 1.0 eq.) in 1,4-dioxane

(12 mL) and aqueous Na₂CO₃ (1M, 6 mL) in the sealed tube. The reaction mixture was heated at 120 °C in the Microwave Reactor for 15 min. After cooling down, it was filtered. The filtrate was diluted with ethyl acetate, and washed with water. The separated organic layer was dried over Na₂SO₄, and concentrated *in vacuo*. The residue
 5 was used directly in the next step.

1-(4-(6-Chloro-8-fluoro-7-(2-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one

To a solution of above obtained 1-(4-(6-chloro-8-fluoro-7-(2-methoxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one in
 10 dichloromethane (10 mL) at -78 °C, BBr₃ in DCM (1M, 4.7 ml, 7 eq.) was added dropwise and the resulting mixture was stirred from -78 °C to room temperature overnight. The reaction was quenched with saturated aqueous NaHCO₃ solution at 0 °C. The mixture was partitioned between dichloromethane and water. The organic layer was dried with Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash
 15 column chromatography on silica gel (MeOH/DCM = 1-10%) to afford the desired product (100 mg, 29% yield in 2 steps) as a white solid. ¹H NMR (500 MHz, DMSO-*d*₆) δ: 9.98 (s, 1H), 8.71 (s, 1H), 8.9 (s, 1H), 7.95 (d, *J* = 9 Hz, 1H), 7.90 (d, *J* = 9.0 Hz, 1H), 7.34 (m, 3 H), 7.11 (d, *J* = 8.0 Hz, 1H), 6.84 (dd, , *J* = 17, 10.5 Hz, 1H), 6.18 (dd, , *J* = 17, 2.5 Hz, 1H), 6.18 (dd, , *J* = 10.5, 2.5 Hz, 1H), 3.96-3.79 (m, 8H). ESI-MS *m/z*:
 20 463.1 [M + H]⁺.

EXAMPLE 53

BIOCHEMICAL ASSAY OF THE COMPOUNDS

Test compounds were prepared as 10 mM stock solutions in DMSO (Fisher cat# BP-231-100). KRAS G12C 1-169, his-tagged protein, GDP-loaded was
 25 diluted to 2 μM in buffer (20mM Hepes, 150mM NaCl, 1mM MgCl₂). Compounds were tested for activity as follows:

Compounds were diluted to 50X final test concentration in DMSO in 96-well storage plates. Compound stock solutions were vortexed before use and observed carefully for any sign of precipitation. Dilutions were as follow:

- For 100 μ M final compound concentration, compounds were diluted to 5000 μ M (5 μ l 10mM compound stock + 5 μ l DMSO and mixed well by pipetting.
 - For 30 μ M final compound concentration, compounds were diluted to 1500 μ M (3 μ l 10mM compound stock + 17 μ l DMSO) and mixed well by pipetting.
 - For 10 μ M final compound concentration, compounds were diluted to 500 μ M (2 μ l 10mM compound stock + 38 μ l DMSO) and mixed well by pipetting.
- 49 μ l of the stock protein solution was added to each well of a 96-well PCR plate (Fisher cat# 1423027). 1 μ l of the diluted 50X compounds were added to appropriate wells in the PCR plate using 12-channel pipettor. Reactions were mixed carefully and thoroughly by pipetting up/down with a 200 μ l multi-channel pipettor. The plate was sealed well with aluminum plate seal, and stored in drawer at room temperature for 30 min, 2 hour or 24hrs. 5 μ l of 2% formic acid (Fisher cat# A117) in DI H₂O was then added to each well followed by mixing with a pipette. The plate was then resealed with aluminum seal and stored on dry ice until analyzed as described below.

The above described assays were analyzed by mass spectrometry according to the following procedure:

- The MS instrument is set to positive polarity, 2 GHz resolution, and low mass (1700) mode and allowed to equilibrate for 30 minutes. The instrument is then calibrated, switched to acquisition mode and the appropriate method loaded.

- After another 30 minute equilibration time, a blank batch (*i.e.*, buffer) is run to ensure equipment is operating properly. The samples are thawed at 37°C for 10 minutes, briefly centrifuged, and transfer to the bench top. Wells A1 and H12 are spiked with 1 μ L 500 μ M internal standard peptide, and the plates centrifuged at 2000 x g for 5 minutes. The method is then run and masses of each individual well recorded.

- The masses (for which integration data is desired) for each well are pasted into the platemap and exported from the analysis. Masses for the internal standards are exported as well. The data at 50 ppm is extracted for the +19 charge state, and identity of well A1 is assigned using the internal standard spike and integrated.

Peak data is exported as a TOF list and the above steps are repeated individually, for the +20, 21, 22, 23, 24, and 25 charge states.

Other in vitro analyses are as follows:

5 Inhibition of Cell Growth:

The ability of the subject compounds to inhibit RAS-mediated cell growth is assessed and demonstrated as follows. Cells expressing a wildtype or a mutant RAS are plated in white, clear bottom 96 well plates at a density of 5,000 cells per well. Cells are allowed to attach for about 2 hours after plating before a compound
10 disclosed herein is added. After certain hours (e.g., 24 hours, 48 hours, or 72 hours of cell growth), cell proliferation is determined by measuring total ATP content using the Cell Titer Glo reagent (Promega) according to manufacturer's instructions. Proliferation EC50s is determined by analyzing 8 point compound dose responses at half-log intervals decreasing from 100 μ M.

15

Inhibition of RAS-mediated signaling transduction:

The ability of the compounds disclosed herein in inhibiting RAS-mediated signaling is assessed and demonstrated as follows. Cells expressing wild type or a mutant RAS (such as G12C, G12V, or G12A) are treated with or without (control
20 cells) a subject compound. Inhibition of RAS signaling by one or more subject compounds is demonstrated by a decrease in the steady-state level of phosphorylated MEK, and/or Raf binding in cells treated with the one or more of the subject compounds as compared to the control cells.

25 Inhibition of RAS-mediated signaling transduction:

The ability of the compounds disclosed herein in inhibiting RAS-mediated signaling is assessed and demonstrated as follows. Cells expressing wild type or a mutant RAS (such as G12C, G12V, or G12A) are treated with or without (control
30 cells) a subject compound. Inhibition of RAS signaling by one or more subject compounds is demonstrated by percentage binding of compound to the G12C mutated

RAS protein in cells treated with the one or more of the subject compounds as compared to the control cells.

Inhibition of RAS-mediated signaling transduction:

- 5 The ability of the compounds disclosed herein in inhibiting RAS-mediated signaling is assessed and demonstrated as follows. Cells expressing wild type or a mutant RAS (such as G12C, G12V, or G12A) are treated with or without (control cells) a subject compound. Inhibition of RAS signaling by one or more subject compounds is demonstrated by a decrease in binding of RAS complex to downstream
10 signaling molecules (for example Raf) in cells treated with the one or more of the subject compounds as compared to the control cells.

- Each of the compounds in Table 1 were tested according to the above methods and found to covalently bind to KRAS G12C to the extent of at least about 5% (*i.e.*, at least about 5% of the protein present in the well was found to be covalently
15 bound to test compound).

Table 2
Activity of Representative Compounds*

No.	Binding %	No.	Binding %	No.	Binding %	No.	Binding %
1	+++	2	+	3	+	4	++++
5	+++	6	+++	7	++++	8	++
9	+++	10	++	11	++++	12	+
13	++	14	++	15	+++	16	++
17	+	18	++	19	++	20	+
21	+++	22	+	23	++	24	+
25	++	26	++	27	++	28	+
29	+	30	+	31	+	32	+
33	++	34	+++	35	+	36	+
37	++	38	++	39	+	40	+++
41	+	42	+++	43	+++	44	+++
45	+	46	++++	47	++++	48	++++
49	++++	50	+	51	++++	52	++++
53	++++	54	++	55	++++	56	++++
57	+	58	+++	59	++++	60	+
61	+	62	+	63	+	64	++
65	+	66	++++	67	+++	68	+
69	+	70	+++	71	+	72	++
73	++	74	+++	75	+	76	+

No.	Binding %	No.	Binding %	No.	Binding %	No.	Binding %
77	+++	78	+	79	+	80	+
81	+++	82	+	83	++	84	++
85	+++	86	+	87	+	88	+
89	+	90	+	91	++	92	+
93	+	94	++	95	++	96	+
97	++	98	+	99	+++	100	+++
101	+++	102	+++	103	++	104	+++
105	+	106	++++	107	++++	108	++
109	++++	110	+++	111	+++	112	+++
113	+++	114	+++	115	+++	116	++
117	+++	118	+++	119	+++	120	+++
121	++++	122	++	123	++++	124	+++
125	++++	126	++++	127	++++	128	+++
129	+	130	+	131	+	132	+++
133	++	134	++	135	+	136	++
137	+	138	++++	139	++++	140	+++
141	+	142	+	143	+++	144	+
145	++++	146	++++	147	++	148	+++
149	+	150	++++	151	+	152	+++
153	++++	154	++	155	++	156	++
157	+	158	++++	159	+++	160	+
161	++	162	+	163	+	164	+
165	N/A	166	+	167	+	168	++
169	+++	170	+	171	+++	172	+++
173	++++	174	++	175	+++	176	+++
177	+	178	+	179	+	180	+
181	+	182	+++	183	+++	184	++++
185	++	186	+++	187	+++	188	+++
189	++	190	+	191	+++	192	++
193	++	194	++++	195	++++	196	++++
197	++	198	++++	199	N/A	200	++
201	+++	202	+++	203	++++	204	+++
205	+	206	+++	207	++++	208	++++
209	++++	210	++++	211	+	212	++++
213	++	214	+	215	++	216	+
217	+++	218	+++	219	+	220	+++
221	++	222	+++	223	+	224	+++
225	++	226	+	227	++++	228	+
229	++	230	+	231	+++	232	+
233	+++	234	++++	235	+++	236	+++
237	++++	238	+++	239	+++	240	+++
241	+	242	++++	243	++++	244	+
245	+	246	++++	247	+++	248	N/A
249	+	250	++	251	++++	252	++++
253	++++	254	+++	255	+++	256	+++

No.	Binding %	No.	Binding %	No.	Binding %	No.	Binding %
257	++++	258	++	259	+++	260	++
261	+	262	+	263	+	264	++
265	+	266	+++	267	+	268	+++
269	+++	270	+++	271	+++	272	++++
273	++++	274	++++	275	++	276	+
277	+	278	++	279	+++	280	+++
281	++	282	+++	283	++	284	++++
285	+++	286	+	287	++	288	++
289	+++	290	+++	291	++++	292	+
293	++++	294	++++	295	+	296	+
297	+	298	++	299	+	300	++
301	++	302	+++	303	++	304	++
305	++	306	++	307	++	308	+++
309	+++	310	++++	311	+++	312	++++
313	+++	314	++++	315	+	316	++
317	N/A	318	+	319	++	320	++
321	+	322	+++	323	+++	324	+
325	++	326	+	327	++	328	+
329	++	330	++	331	++	332	++
333	+	334	++++	335	++++	336	+++
337	+	338	++	339	++++	340	++++
341	++++	342	++++	343	+++	344	+++
345	++++	346	++++	347	++++	348	++++
349	+++	350	++++	351	++++	352	++++
353	++++	354	++++	355	++++	356	+++
357	++++	358	++++	359	++++	360	++++
361	++++	362	++	363	++++	364	++++
365	++++	366	++++	367	++++	368	++++
369	++++	370	+	371	++	372	+++
373	+++	374	+++	375	+++	376	N/A

* Binding for compounds 1-47 was measured at 24 h; binding for compounds 48-246 was measured at 2 h; binding for compounds 247-375 was measured at 30 min. N/A = results pending

+ indicates binding activity from 5% to 25%

5

++ indicates binding activity greater than 25% and up to 50%

+++ indicates binding activity greater than 50% and up to 75%

++++ indicates binding activity greater than 75%

All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications


referred to in this specification or the attached Application Data Sheet are incorporated herein by reference, in their entirety to the extent not inconsistent with the present description.

U.S. provisional patent application Serial No. 61/889,460 filed October
5 10, 2013, U.S. provisional patent application Serial No. 62/034,619 filed August 7, 2014, U.S. provisional patent application Serial No. 62/052,366 filed on September 18, 2014, Jordanian patent application Serial No. 289/2014 filed on October 9, 2014 and Taiwan patent application entitled "INHIBITORS OF KRAS G12C" filed on October 9, 2014 are incorporated herein by reference, in their entirety.

10 From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

1. A compound having the following structure (I):



(I)

or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:

A is CR¹, CR^{2b}, NR⁷ or S;

B is a bond, CR¹ or CR^{2c}

G¹ and G² are each independently N or CH;

W, X and Y are each independently N, NR⁵ or CR⁶;

Z is a bond, N or CR^{6a} or Z is NH when Y is C=O;

L¹ is a bond or NR⁷;

L² is a bond or alkylene;

R¹ is heterocyclyl, heteroaryl or aryl;

R^{2a}, R^{2b} and R^{2c} are each independently H, halo, hydroxyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₃-C₈ cycloalkyl, heteroaryl or aryl;

R^{3a} and R^{3b} are, at each occurrence, independently H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalklyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R^{3a} and R^{3b} join to form a carbocyclic or heterocyclic ring; or R^{3a} is H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalklyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R^{3b} joins with R^{4b} to form a carbocyclic or heterocyclic ring;

R^{4a} and R^{4b} are, at each occurrence, independently H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalklyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R^{4a} and R^{4b} join to form a carbocyclic or heterocyclic ring; or R^{4a} is H, -OH, -NH₂, -CO₂H, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkynyl, hydroxylalklyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl,

aminylcarbonylalkyl or aminylcarbonyl, and R^{4b} joins with R^{3b} to form a carbocyclic or heterocyclic ring;

R^5 is, at each occurrence, independently H, C_1 - C_6 alkyl or a bond to L^1 ;

R^6 is, at each occurrence, independently H, oxo, cyano, cyanoalkyl, amino, aminylalkyl, aminylalkylaminyl, aminylcarbonyl, aminylsulfonyl, $-CO_2NR^aR^b$, wherein R^a and R^b , are each independently H or C_1 - C_6 alkyl or R^a and R^b join to form a carbocyclic or heterocyclic ring, alkylaminyl, haloalkylaminyl, hydroxylalkylaminyl, amindinylalkyl, amidinylalkoxy, amindinylalkylaminyl, guanidinylalkyl, guanidinylalkoxy, guanidinylalkylaminyl, C_1 - C_6 alkoxy, aminylalkoxy, alkylaminylalkoxy, alkylcarbonylaminylalkoxy, C_1 - C_6 alkyl, heterocyclyl, heterocyclyoxy, heterocyclylalkyloxy, heterocyclylaminyl, heterocyclylalkylaminyl, heteroaryl, heteroaryloxy, heteroarylalkyloxy, heteroarylaminyl, heteroarylalkylaminyl, aryl, aryloxy, arylaminyl, arylalkylaminyl, arylalkyloxy or a bond to L^1 ;

R^{6a} is H, alkyl or a bond to L^1 ;

R^7 is H or C_1 - C_6 alkyl

m^1 and m^2 are each independently 1, 2 or 3;


==== indicates a single or double bond such that all valences are satisfied; and

E is an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS, HRAS or NRAS G12C mutant protein,

wherein at least one of W, X, Y or Z is CR^6 where R^6 is a bond to L^1 or at least one of W, X or Y is NR^5 , wherein R^5 is a bond to L^1 , and

provided that least one of R^{2a} , R^{2b} or R^{2c} is not H when R^1 is pyridyl.


2. The compound of claim 1, wherein the compound has the following structure (I'):



(I'),

wherein R' is R^1 and R'' is R^{2c} or R' is H and R'' is R^1 .

3. The compound of any one of claims 1 or 2, wherein the compound has the following structure (I'a):



(I'a)

wherein:

$\equiv$ represents a double or triple bond;

Q is $-C(=O)-$, $-C(=NR^{8'})-$, $-NR^8C(=O)-$, $-S(=O)_2-$ or $-NR^8S(=O)_2-$;

R^8 is H, C_1-C_6 alkyl or hydroxylalkyl;


$R^{8'}$ is H, $-OH$, $-CN$ or C_1-C_6 alkyl;

when $\equiv$ is a double bond then R^9 and R^{10} are each independently H, cyano, carboxyl, C_1-C_6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, heteroaryl or hydroxylalkyl or R^9 and R^{10} join to form a carbocyclic or heterocyclic ring;


when $\equiv$ is a triple bond then R^9 is absent and R^{10} is H, C_1-C_6 alkyl, aminylalkyl, alkylaminylalkyl or hydroxylalkyl; and

R' is R^1 and R'' is R^{2c} or R' is H and R'' is R^1 .


4. The compound of claim 3, wherein the compound has one of the following structures (I'b), (I'c), (I'd) or (I'e):




(I'b)



(I'c)




(I'd)




(I'e)


5. The compound of claim 4, wherein the compound has one of the following structures (I'f), (I'g), (I'h) or (I'i):




(I'f)



(I'g)




(I'h)




(I'i)


6. The compound of claim 5, wherein the compound has one of the following structures (I'j), (I'k), (I'l) or (I'm):



(I'j)



(I'k)




when $\equiv$ is a double bond then R^9 and R^{10} are each independently H, cyano, carboxyl, C_1 - C_6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, heteroaryl or hydroxylalkyl or R^9 and R^{10} join to form a carbocyclic or heterocyclic ring;


when $\equiv$ is a triple bond then R^9 is absent and R^{10} is H, C_1 - C_6 alkyl, aminylalkyl, alkylaminylalkyl or hydroxylalkyl; and


R' is R^1 and R'' is R^{2c} or R' is H and R'' is R^1 .

9. The compound of claim 8, wherein the compound has one of the following structures (I''b), (I''c), (I''d) or (I''e):




10. The compound of claim 9, wherein the compound has one of the following structures (I''f), (I''g), (I''h) or (I''i):






(I'h)




(I'i)


11. The compound of claim 9, wherein the compound has one of the following structures (I'j), (I'k), (I'l) or (I'm):




(I'j)



(I'k)




(I'l)



(I'm)


12. The compound of claim 1, wherein the compound has the following structure (I'''):



(I''')

wherein A is NH or S.

13. The compound of any one of claims 1 or 12, wherein the compound has the following structure (I'''a):



wherein:

$\equiv$ represents a double or triple bond;

Q is $-\text{C}(=\text{O})-$, $-\text{C}(=\text{NR}^8)-$, $-\text{NR}^8\text{C}(=\text{O})-$, $-\text{S}(=\text{O})_2-$ or $-\text{NR}^8\text{S}(=\text{O})_2-$;

R^8 is H, C_1 - C_6 alkyl or hydroxylalkyl;



$\text{R}^{8'}$ is H, $-\text{OH}$, $-\text{CN}$ or C_1 - C_6 alkyl; and



when $\equiv$ is a double bond then R^9 and R^{10} are each independently H, cyano, carboxyl, C_1 - C_6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, heteroaryl or hydroxylalkyl or R^9 and R^{10} join to form a carbocyclic or heterocyclic ring;

when $\equiv$ is a triple bond then R^9 is absent and R^{10} is H, C_1 - C_6 alkyl, aminylalkyl, alkylaminylalkyl or hydroxylalkyl; and



A is NH or S.

14. The compound of claim 13, wherein the compound has one of the following structures (I'''b), (I'''c), (I'''d) or (I'''e):





15. The compound of claim 14, wherein the compound has one of the following structures (I'''f), (I'''g), (I'''h) or (I'''i):



16. The compound of any one of claims 1-15, wherein R¹ is aryl.


17. The compound of claim 16, wherein R¹ is phenyl.


18. The compound of claim 16, wherein R¹ is naphthyl.

19. The compound of any one of claims 16-18, wherein R¹ is unsubstituted

20. The compound of any one of claims 16-18, wherein R¹ is substituted with one or more substituents.

23. The compound of any one of claims 1-22, wherein R¹ has one of the following structures:





24. The compound of any one of claims 1-15, wherein R¹ is heteroaryl.

25. The compound of claim 24, wherein R¹ comprises oxygen, sulfur, nitrogen or combinations thereof.

26. The compound of claim 24, wherein R¹ is thiophenyl, pyridinyl, pyridinonyl, pyrimidinyl, benzooxazolyl, benzoisoxazolyl, benzodioxazolyl, benzoimidazolyl, quinolinyl, quinolinonyl, dihydroquinolinonyl, tetrahydroquinolinyl, quinazolinyl, indazolyl, indolinonyl, benzothiophenyl or dihydrobenzodioxinyl.


27. The compound of any one of claims 24-26, wherein R¹ is unsubstituted.


28. The compound of any one of claims 24-26, wherein R¹ is substituted with one or more substituents.

29. The compound of claim 28, wherein the substituents are selected from halo, C₁-C₆alkyl, C₁-C₆alkoxy, or C₂-C₆alkenylcarbonylaminy.

30. The compound of claim 29, wherein the substituents are selected from fluoro, chloro, amino and methyl.

31. The compound of any one of claims 24-30, wherein R¹ has one of the following structures:






39. The compound of any one of claims 1-37, wherein R^{2b} and R^{2c} , when present, are each independently halo.
40. The compound of any one of claims 1-37, wherein R^{2b} , when present, is halo.
41. The compound of any one of claims 1-37, wherein R^{2c} , when present, is halo.
42. The compounds of any one of claims 39-41, wherein halo is chloro or fluoro.
43. The compound of any one of claims 5-42, wherein Q is $-C(=O)-$.
44. The compound of any one of claims 5-42, wherein Q is $-S(=O)_2-$.
45. The compound of any one of claims 5-42, wherein Q is $-NR^8C(=O)-$.
46. The compound of any one of claims 5-42, wherein Q is $-NR^8S(=O)_2-$.
47. The compound of any one of claims 45 or 46, wherein R^8 is H.
48. The compound of any one of claims 45 or 46, wherein R^8 is hydroxylalkyl.
49. The compound of claim 48, wherein hydroxylalkyl is 2-hydroxylalkyl.
50. The compound of any one of claims 5-49, wherein at least one of R^9 or R^{10} is H.
51. The compound of claim 50, wherein each of R^9 and R^{10} are H.

52. The compound of any of one of claims 5-50, wherein R¹⁰ is alkylaminylalkyl.

53. The compound of claim 52, wherein R¹⁰ has the following structure:




54. The compound of any of one of claims 5-50, wherein R¹⁰ is hydroxylalkyl.

55. The compound of claim 54, wherein hydroxylalkyl is 2-hydroxylalkyl

56. The compound of any one of claims 5-49, wherein R⁹ and R¹⁰ join to form a carbocyclic ring.

57. The compound of claim 56, wherein the carbocyclic ring is a cyclopentene, cyclohexene or phenyl ring.

58. The compound of any one of claims 1-57, wherein E has one of the following structures:



59. The compound of any one of claims 1-58, wherein L^1 is a bond.

60. The compound of any one of claims 1-58, wherein L^1 is $-NR^7-$.

61. The compound of claim 60, wherein L^1 is $-NH-$.


62. The compound of any one of claims 1-61, wherein L^2 is a bond.

63. The compound of any one of claims 1-61, wherein L^2 is alkylene.

64. The compound of claim 63, wherein L^2 is $-CH_2-$ or $-CH_2CH_2-$.

65. The compound of any one of claims 1-64, wherein R^{3a} , R^{3b} , R^{4a} and R^{4b} are H.

66. The compound of any one of claims 1-64, wherein R^{3a} or R^{4a} is aminylcarbonyl.

67. The compound of claim 66, wherein aminylcarbonyl is .

68. The compound of any one of claims 1-64, wherein R^{3a} or R^{4a} is cyano.

69. The compound of any one of claims 1-68 wherein Z is N.

70. The compound of claim 69, wherein X is N.

71. The compound of claim 69, wherein Y is N.

72. The compound of claim 70, wherein Y is CR^6 , wherein R^6 is H and W is CR^6 , wherein R^6 is a bond to L^1 .

73. The compound of claim 69, wherein Y is CR^6 , wherein R^6 is H, W is CR^6 , wherein R^6 is a bond to L^1 and X is CR^6 , wherein R^6 is cyano, methoxy or amino.

74. The compound of claim 73, wherein X is CR^6 and R^6 is cyano.

75. The compound of claim 71, wherein W is CR^6 , wherein R^6 is a bond to L^1 and X is CR^6 , wherein R^6 is H.

76. The compound of claim 1, wherein Z is a bond.

77. The compound of claim 1 or 76, wherein Y is NR^5 .

78. The compound of claim 77, wherein R^5 is H.

79. The compound of claim 1, wherein X or Y is CR^6 .

80. The compound of claim 79, wherein R^6 is cyano, methoxy or amino.

81. The compound of claim 1, wherein the compound is selected from a compound in Table 1.

82. A pharmaceutical composition comprising a compound of any one of claims 1-81 and a pharmaceutically acceptable carrier.

83. The pharmaceutical composition of claim 82, wherein the pharmaceutical composition is formulated for oral administration.

84. The pharmaceutical composition of claim 83, wherein the pharmaceutical composition is formulated for injection.

85. A method for treatment of cancer, the method comprising administering an effective amount of the pharmaceutical composition of claim 82 to a subject in need thereof.

86. The method of claim 85, wherein the cancer is mediated by a KRAS G12C, HRAS G12C or NRAS G12C mutation.

87. The method of claim 85, wherein the cancer is a hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer or lung cancer.

88. A method for regulating activity of a KRAS, HRAS or NRAS G12C mutant protein, the method comprising reacting the KRAS G12C mutant protein with the compound of any one of claims 1-81.

89. A method for inhibiting proliferation of a cell population, the method comprising contacting the cell population with the compound of any one of claims 1-81.

90. The method of claim 89, wherein inhibition of proliferation is measured as a decrease in cell viability of the cell population.

91. A method for treating a disorder mediated by a KRAS G12C, HRAS G12C or NRAS G12C mutation in a subject in need thereof, the method comprising:
determining if the subject has a KRAS, HRAS or NRAS G12C mutation; and
if the subject is determined to have the KRAS, HRAS or NRAS G12C mutation, then administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 82.
92. The method of claim 91 wherein the disorder is a cancer.
93. The method of claim 92, wherein the cancer is a hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer or lung cancer.
94. A method for preparing a labeled KRAS, HRAS or NRAS G12C mutant protein, the method comprising reacting the KRAS, HRAS or NRAS G12C mutant with a compound of any one of claims 1-81, to result in the labeled KRAS, HRAS or NRAS G12C protein.
95. A method for inhibiting tumor metastasis, the method comprising administering an effective amount of the pharmaceutical composition of claim 82 to a subject in need thereof.






FIG. 1



Oncogene	Tumor Type	Cumulative Mutation Frequency (All Tumors)
Bcr-Abl	90% CML	<1%
EGFR	10% NSCLC	<5%
ALK	5% NSCLC	<1%
B-Raf	66% Melanoma	<5%
Flt3	25% AML	<1%
PI3k α	25% Breast; 25% Endometrial; 15% CRC	15-20%
K-Ras	>80% Pancreatic; >40% colon >20% lung	~20%

FIG. 3



Oncogene	Tumor Type	Cumulative Mutation Frequency (All Tumors)
Bcr-Abl	90% CML	<1%
EGFR	10% NSCLC	<5%
ALK	5% NSCLC	<1%
B-Raf	66% Melanoma	<5%
Flt3	25% AML	<1%
PI3k α	25% Breast; 25% Endometrial; 15% CRC	15–20%
K-Ras	>80% Pancreatic; >40% colon >20% lung	~20%

FIG. 3